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Abstract 
Objective. To develop an outcome prediction score for patients with obstructive lung 
disease considered for admission to critical care. 
Design. Prospective cohort study using multivariate logistic regression for model 
building followed by score development and bootstrapping to adjust for over fitting. 
Setting. Critical care and respiratory high dependency units in England Wales and 
Northern Ireland. 
Participants. Patients aged 45 years and older with a clinical diagnosis of breathlessness, 
respiratory failure or change in mental status due to an exacerbation of COPD, asthma or 
a combination of COPD and asthma. 
Main outcome measures. The primary outcome was survival at 180 days and the model 
was constructed to predict this. The secondary outcomes were the accuracy of clinicians' 
predictions at the time of critical care admission and 180-day health-related quality of life 
Results. Ninety two critical care units and three respiratory high dependency units took 
part. Eight hundred and thirty two patients were recruited and the 651 patients without 
treatment limitations were used to develop the outcome score. Of the 651 patients 450 
were intubated and 107 (16.4%) died in critical care, another 66 (10.1%) died in hospital 
and a further 47 (7.2%) had died by 180 days follow-up, giving a cumulative 180-day 
mortality of 33.8% (220 deaths). 420 of 518 (81.1%) survivors provided quality of life 
data and 400 (96.4%) would want ICU again under similar circumstances. A score using 
length of stay, age, sex, acute physiology , 
functional capacity, mid-arm circumference, 
atrial fibrillation, intubation status and diagnosis had an area under the receiver operating 
characteristic curve of 0.75 after bootstrapping and was well calibrated. Clinicians' 
predictions had an ROC area of 0.71 and were less well calibrated with a tendency 
towards pessimism. 
Conclusions. This study has produced an outpome prediction score with reasonable 
discrimination and good calibration that has the potential to support clinicians in 
understanding the prognosis of patients with obstructive lung disease considered for 
critical care. 
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Chapter 1 Introduction 
The aim of this study is to develop a prognostic model to predict the 180-day survival 
and quality of life of patients with Chronic Obstructive Pulmonary Disease (COPD) 
admitted to hospital with an exacerbation of sufficient severity that they may require 
intubation. The introduction explains why estimates of prognosis are important for these 
patients. It identifies the current problems that clinicians face in planning care for these 
patients and the potential for a prognostic model to improve things. 
1.1 What is chronic obstructive pulmonary disease? 
Chronic obstructive pulmonary disease (COPD) is a chronic slowly progressive disorder 
that results in the lungs becoming damaged and unable to support normal activity. 
COPD encompasses a number of related conditions including chronic bronchitis, 
emphysema, chronic obstructive airways disease (COAD), chronic airflow limitation 
and some cases of chronic asthma 12 . Healthy lungs allow oxygen to be transported from 
the air into the blood and carbon dioxide to be cleared from the blood into the air. 
Normal lungs at sea level will produce an oxygen partial pressure in arterial blood of 
around l2kPa and a carbon dioxide partial pressure less than 6kPa. In healthy lungs gas 
is drawn into the lungs via the connecting tubes of the airways and into alveoli which 
form a delicate honeycomb structure in which the air passes close to a plentiful blood 
supply. The interface between the air inside the alveoli and their blood supply 
comprises an exchange membrane which has a surface area similar to the size of a 
tennis court. In COPD the airways carrying air in and out of the chest become narrowed 
and this is often accompanied by damage to the honeycomb exchange membrane (lung 
parenchyma). In COPD it is usually cigarette smoking that damages the lung and 
typically the first objective measure of this damage will be narrowing of the airways 
demonstrated by a Forced Expiratory Volume (FEVI) less than 80% predicted, and 
breathlessness on exertion. 
There can be confusion in the terminology applied to COPD, with some patients and 
GPs using the term asthma to describe their breathing problems. This may be because 
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asthma seems to be better known and also because it does not carry the stigma of a 
smoking related disease. However investigations can be used to distinguish pure 
asthma from pure COPD, because in asthma, though airway narrowing occurs, it is 
reversible, whereas in COPD airway narrowing is permanent. In some asthmatics, 
particularly those who smoke, there may be some reversible airway narrowing 
superimposed on fixed obstruction, and these patients may be considered to have a 
mixture of asthma and COPD. Often when older patients are admitted as emergencies 
and old notes are not available it can be difficult to distinguish between asthma, COPD 
and patients with a mixture of asthma (reversible airway narrowing) and COPD (fixed 
airway narrowing). 
1.2 The need for prognostic estimates in patients with COPD 
As smokers age and lung damage progresses, airway narrowing will increase and as the 
FEV, continues to fall and the delicate honeycomb exchange membrane is damaged, 
sufferers will typically experience breathlessness on even trivial exertion. The oxygen 
in the blood may fall and the carbon dioxide rise. Patients admitted to hospital with 
COPD span a continuum from those with only mildly impaired lung fimction to those 
with severe lung damage. In the most badly affected patients the sufferer can be 
considered to have terminal respiratory failure, in that only the slightest additional 
deterioration will lead to death. For the milder COPD patients, though infections might 
impair lung function so that temporary organ support in the form of ventilation in 
critical care is required, the patient is able to recover sufficiently to breathe 
independently and enjoy an acceptable quality of life. For COPD patients with severely 
damaged lungs temporary lung support in the Intensive Care Unit (ICU) is likely to be 
attended by difficulties in weaning from support and an early death either in the ICU or 
shortly afterward. Non-invasive ventilation (NIV) provides respiratory support via a 
3 mask and can provide an alternative to intubation in selected patients . The recent 
NICE guidance recommended that NIV should be used as the first line treatment for 
COPD patients with respiratory failure, but in recognition of the fact that some patients 
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will fail NIV and will require intubating in order to survive, the guidance recommends 
that: 
"When patients are started on non-invasive ventilation there should be a clear plan 
covering what to do in the event of deterioration and ceilings of therapy should be 
agreed. "A . 
Decisions about ceilings of therapy involve identifying which patients are likely to 
benefit from intubation, a judgment that must weigh up the interaction between the 
current acute illness and the patient's position on the continuum of deterioration 
associated with chronic progressive disease. The General Medical Council guidance on 
withholding and withdrawing life sustaining therapy suggests that "prolonging life will 
usually be in the best interests of the patient, provided that the treatment is not 
considered excessively burdensome or disproportionate in relation to the expected 
benefits" 5. 
Decision making typically involves clinicians assessing patients who have been 
admitted to hospital but not yet admitted to ICU, and estimating the patients' prognosis 
with the various potential treatment modalities available. The clinician is interested in 
both the possibility of survival and the quality of life that a surviving patient will enjoy. 
Clinicians use information about the patient's condition in the period of stability prior to 
the onset of the current exacerbation, and also their assessment of the severity of the 
current episode gleaned from clinical examination and the results of any tests such as x- 
rays and blood tests carried out since admission6. This process will be carried out at the 
bedside by clinicians who are usually under time pressure because of involvement in the 
care of other recently admitted medical patients. 
13 How often are prognostic decisions required in clinical practice? 
Large numbers of patients are admitted to hospital each year with COPD and many of 
them die. In England in 2000/1 there were over 100 000 hospital admissions for COPD 
and there are over 30 000 deaths from COPD in the UK each year7, with COPD being 
the fifth most common cause of death in England and Wales (top four causes: coronary 
heart disease, pneumonia, stroke and lung cancer). Patients with COPD comprise 
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around 2.5% of ICU admissions in the UK 1. Ninety-eight consultants, comprising 82% 
of all consultants providing acute care for emergency admissions in the eight hospitals 
of the UK Heart of England Critical Care Network, stated that they had made a median 
(IQR) of 10 (6.0 - 20.0) end of life/intubation decisions for COPD patients in the 
previous 12 months (2001-2002)8, The large number of hospital admissions with COPD 
and the large number of these patients who require treatment plans based in part upon 
estimates of prognosis indicate the importance of prognosis in the management of this 
patient group. In a recent vignette-based questionnaire study involving 381 intensive 
care specialists in Switzerland, more than 80% identified the prognosis of the acute and 
underlying disease as important or very important for making critical care gatekeeping 
decisions9. There is literature that suggests that clinicians find prognostication difficultlo 
and given the importance of prognosis in this patient group it is useful to review what is 
known about clinicians' prognostic performance for patients with COPD. 
1.4 How good are clinicians at predicting the prognosis of patients with COPD? 
Pearlman used paper-based cases to understand how 205 American physicians 
formulated prognoses for patients with COPD and the impact of those prognoses on 
treatment decisions". He showed that estimates of survival for identical patients were 
quite variable and influenced treatment recommendations. Investigations of decision- 
making using paper cases may be criticised because the decision making process is 
divorced from real life. However in real life different clinicians do not make decisions 
about the same patient in sufficient numbers to allow decision making to be studied. 
The recent Heart of England Critical Care Network study, mentioned above, exploited 
the fact that in the UK consultants on call will occasionally be asked to make decisions 
about patient management on the basis of information about the patient relayed by 
phone8. In this study of ICU gatekeeping consultants were contacted by telephone as 
though they were on call and the investigator, who was an experienced clinician, 
described the characteristics of COPD patients who required intubation, and asked the 
consultant to estimate the prognosis of the patient with intubation and make a decision 
as to whether intubation should occur. 
_7 
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This study showed that clinicians differed in their treatment limitation decisions for 
identical patients with identical preferences under conditions of identical resource 
availability. In addition intubaters and non-intubaters formulated markedly different 
prognostic estimates despite identical patient characteristics. In figure 1.4.1 the outcome 
predictions for admitters, (who would intubate) and non-admitters (who would not 
intubate) are shown for the second patient that was considered in the simulation study. 
This was a 75 year old female COPI) patient and it was explained that the patient would 
die if not intubated. The predicted probability of survival given the patients 
characteristics was calculated using the Study to Understand Prognoses and Preferences 
for Outcomes and Risks of Treatments (SUPPORT) model 12 and are shown on the 
figure. It can be seen that 64% of the consultants would intubate and 36% would not. 
Also the predictions of survival with intubation for intubaters versus non-intubaters 
differed significantly whether for ICU survival (47% vs. 19% p<0.0001), hospital 
survival (38% vs. 12% p<0.0001) or 180-day survival (32% vs. 8% p<0.0001). Indeed, 
estimated 180-day survival rate among intubaters was greater than critical care survival 
rate among non-intubaters. 
Figure 1.4.1 Outcome predictions -for -a 75 year old female with COPD who 
required intubation in order to avoid death. 
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The Heart of England Critical Care Network study suggests that clinicians differ 
markedly in their prognostic estimates for identical patients, and that compared to an 
objective outcome prediction model their estimates may be pessimistic. The suggestion 
from the SUPPORT model that UK clinicians are pessimistic should be treated with 
caution since the model was produced in the USA and Justice points out the dangers in 
applying outcome prediction models in different health care systems 13 .A separate study 
also carried out in West Midlands critical care units and again involving consultants 
making prognostic estimates for patients with COPD suggested that consultants differ in 
the way they interpreted patient's characteristics when attempting to formulate 
prognoses and these differences lead to different interpretations of prognosis for 
identical patientS6. 
In the SUPPORT study mentioned above an outcome prediction model for COPD 
patients was developed in five US hospitals using a model development set of 600 
COPD patients and then tested in 416 subsequent patients. This study used observations 
made on day three of the hospital admission and only 526 patients were admitted to 
critical care. The COPD model had an area under the ROC curve of 0.731 and 
clinicians 0.722, with the model being better calibrated and clinicians tending to be 
pessimistic 12 . Figure 1.4.2 (below) is taken from the SUPPORT study and shows the 
calibration curves for clinicians and the SUPPORT COPD model. In this study the best 
performance was seen when clinicians supplemented the model predictions with their 
own judgement with an area under the ROC curve of 0.749 and improved calibration. 
The SUPPORT study suggests that objective estimates of outcome can support and 
improve clinical decisions. 
1.5 What are the likely explanations for the variability in clinicians' prognostic 
estimates? 
Prognostication is a difficult task for clinicians, in that it demands that predictive 
characteristics be correctly identified, noted and weighted in the light of information 
about outcome. Prognostication requires clinicians to use evidence about outcomes from 
the literature and/or from their own experience. Chapter 3 Figure Fig 3.3.1 (All studies 
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reporting hospital mortality for 10 or more intubated patients) shows that individual 
studies report very different hospital mortality for COPD patients, so that using the 
literature to understand outcomes may not be easy. 
Figure 1.4.2 Calibration curves for the SUPPORT COPD model and clinicians 
taken from the SUPPORT study 12 . 
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Research on cognitive biases in decision making suggests that decisions tend to be 
unduly influenced by patients who are particularly memorable 14 . In this respect an 
intubated COPD patient who was difficult to wean from the ventilator and who was 
reviewed on many ward rounds over a number of weeks is more likely to lodge in a 
clinician's memory than the uncomplicated patient who was quickly weaned and 
discharged. Learning from experience is also hampered by the difficulty of accurately 
remembering all of a patient's characteristics. The clinician may not know the outcome 
at hospital discharge for all patients upon whom decisions are made, and it is likely that 
this information will be even less complete for follow-up periods in the region of 6 
months. In addition the authors of the Heart of England Critical Care Network 
hypothesised that in a health care system where historically ICU beds have been in short 
supply, the confident identification of futility in patients with COPD and respiratory 
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failure may have eased the cognitive dissonance otherwise experienced when ICT beds 
were unavailable". The habitual identification of' futility resulting in certain groups of 
patients being rarely admitted to ICU might result in a self-fulfilling prophecy leading 
to the development of a tacit folklore of' pessimism about outcomes for that patient 
group. 
1.6 What characteristics would a prognostic model require to improve COPI) 
decision making? 
The 1*0regoing suggests that given the evidence of' difficulties in decision-making for 
COIID patients and the cognitive challenges Caced by an individual clinician who 
wishes to make better decisions, there may be a role for prognostic models in supporting 
decision making. This asserlion is consistent with the improved di. %Lnmination and 
calibration %Len when American clinicians supplemented their clinical judgement with 
the St JPPORT model'2. An understanding of' the information required to make a 
decision is very important when considering the potential I'M a decision aid to support 
decisions making. Pr(wJucing a decision aid that distinguishes a patient with a 5% nsk 
From a patient with 7% risk ol'death or an aid that is required to identify patients certain 
to have no (0%) chance ol'survival is much more dillicult than producing a model that 
identifies patients above a given risk threshold. such as atx)ve 3(Y! 1o. Clinicians in the 
I leart of' Frigland Critical Care Network were asked at what predicted probability of' 
hospital survival they would move From intubating to not intubating a COPD patient in 
their rnid seventies, given that the patient would die it'not intubated 8. The distribution 
of' the clinician's responses is shown in figure 1.6.1. Out of 120 clinicians making 
intubation decisions in the network, 82% responded and 94% ol'these (93 clinicians) 
were able to suggest a survival probability below which they would withhold 
intubation. The mean (SD) predicted hospital survival threshold with intuhation belo% 
which the consultants would move 1rom intubating to not intuba-ling a patient was 22% 
( 13.2%), so that a prognostic ni(xiel that could reliably identify patients with a greater 
than 22% chance of' hospital survival would have the potential to supporl decision 
making. In other words IJK decision making did not require the identification of' 
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patients with a 0% chance of survival with treatment and nor did decision making turn 
on making fine distinctions between patients for example differentiating between a 5% 
or a 7% chance of survival. However clinicians clearly vary in their thresholds, and if 
this is seen as a justifiable element of their clinical discretion, the model would have to 
be reasonably accurate over a range of risk thresholds, say from 10% to 40%. 
Figure 1.6.1 Predicted probability of survival with aggressive treatment below 
which consultants would withhold treatment in patients with COPD 
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Note Five (5.4%) of study participants felt unable to provide a threshold survival probability below which they would withhold 
aggressive treatment. 
As highlighted in section 1.2 above, decision making typically involves clinicians under 
time pressure, and occurs at the bedside using the information obtained from history, 
clinical examination and the results of readily available emergency investigations. Any 
prognostic model that supports this process would need to be quick and easy to use and 
the sort of model that might be summarised on a single page of the Oxford Handbook of 
Medicine that most junior doctors carry in their pockets. 
It is important to bear in mind that models make predictions for groups of patients with 
certain characteristics. They can indicate for example what proportion of 100 patients 
with these characteristics will be dead at a defined time point. Ninety-five percent 
confidence intervals can be calculated for that prediction, but these intervals will be for 
the group, not the individual. Any given individual can only live or die. On occasions 
it has been suggested that since the prediction of the model only applies to groups of 
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patients rather than to the individual patient and since the uncertainty for the individual 
must be greater than for the group" it is wrong to use the model to support decision 
making. Though the limitations of group predictions for individual patients cannot be 
disputed the response to the recognition of limitations is often to reject the model and 
fall back upon clinical judgement. However as outlined above there is evidence in the 
case of COPD patients that when compared head to head, clinicians judgements have 
poorer discrimination than models and are less well calibrated 12 . Studies of decision 
making by UK clinicians has reinforced the variability of clinicians unaided 
judgements6 8. The quality of survival is crucial and survivors views must be collected. 
1.7 Conclusions 
Patients with COPD comprise a substantial proportion of emergency medical 
admissions and have high hospital mortality. There is evidence that LJK clinicians are 
often called upon to decide whether or not to withhold life sustaining therapy for these 
patients because a proportion will have reached a stage where aggressive therapy will be 
likely merely to prolong the process of dying. The crucial decision is to decide which 
patients will benefit from intubation. The identification of patients who will benefit 
requires clinicians to make prognostic estimates, and there is evidence that UK 
clinicians show important variability even when considering an individual patient with 
identical characteristics and identical preferences under conditions of identical resource 
availability. Simulation studies suggest that UK clinicians are pessimistic, and one 
explanation for this is it that pessimism has grown up as a defence against the cognitive 
dissonance faced by clinicians who have historically been unable to offer intubation to 
some COPD patients because of a shortage of beds8. 
The SUPPORT study in the USA also found that clinicians tended to be pessimistic. 
However it also showed that outcome prediction models for COPD patients can be 
produced and that the models show better discrimination and calibration than unaided 
clinicianS12 . The best outcome predictions occurred when clinician's judgement was 
used along with a carefully produced outcome prediction model. 
-711 
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One option in producing a model to improve UK decision making would have been to 
simply carry out an external validation study of the SUPPORT model in the UK. 
However the SUPPORT study had a grant of $25 million dollars and concentrated data 
collection in five hospitals with full time study staff dedicated to data collection. This 
allowed them to collect relatively complicated variables such as body mass index and 
ensure that difficult to collect variables such as PaO2/FI02 were collected well. 
Experience in the UK during pilot studies suggested that collecting all the data required 
for a replication of SUPPORT would be too difficult using data collectors whose 
primary responsibility was not CAOS in around 100 units rather than five. For this 
reason it was decided to simplify data collection as much as possible in order that the 
burden placed on collaborators would be reduced, for example the 19 item Charlson 
comorbidity scale was used instead of the 42 comorbidities used in SUPPORT and 
alternative strategies were used to estimate body mass index. This meant that all the 
data in SUPPORT was not collected. 
Given the frequency of COPD admissions in the M the suggestion of variability in 
decision making for identical patients, and the potential for this decision making to be 
improved by objective outcome models, this study set out to develop an outcome 
prediction model to help clinicians predict 180-day mortality for COPD patients with 
respiratory failure considered for intubation. 
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Chapter 2 Developing prognostic models 
2.1 Introduction 
In chapter I it was argued that accurate information about a patient's prognosis plays a 
central role in equitable decision making for patients with COPD considered for 
intubation, and that the most accurate prognostic estimates are likely to result when 
clinicians are supported by well developed prognostic models. In this chapter the 
methodological approach required to produce robust prediction models is reviewed. 
2.2 Methodological aspects of outcome prediction 
There is now a good understanding of the important methodological issues that underlie 
a rigorous randomised controlled trial (RCT) and most journals require that RCTs are 
reported systematically using the CONSORT guidelines 16 .A similar consensus 
statement has not yet emerged about the development of prognostic modelS17 . However 
a number of authors have highlighted the methodological pitfalls that may occur in 
prognostic studies" and summarised the crucial aspects of prognostic model 
development 19-21 . Omar 
has recently suggested a systematic approach to the reporting of 
the model development process22 . The development of the COPD and Asthma 
Outcome Study (CAOS) model will be reported using a modification of this framework 
as outlined in Figure 2.1 below. Harrell has pointed out that prognostic models can be 
inaccurate because of "violation of assumptions, omission of important predictors, high 
frequency of missing data and/or improper imputation and especially with small data 
sets, overfitting721. Systematic reporting of the processes of prognostic model 
development should allow readers to understand clearly how the various threats to 
model validity have been dealt with, so that models that are likely to be accurate can be 
distinguished from those that are not. The robustness of model development should then 
be explored by well designed and adequately powered studies in further data sets to 
allow external validation. 
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Figure 2.1 Prognostic model development frameworks. 22 
State clinical aim for model 
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Select a suitable 
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I Model validation 
2.3 The clinical aim of the model 
There are many decisions to be made in the design of a study to produce an outcome 
prediction model, and it is crucial that the clinical aim of the model is clearly 
understood since this understanding will inform the design of the study. For example 
to understand the performance of individual surgeons, highly detailed information about 
individual patients will be needed and in general this requires prospective data 
collection 23 . If the mortality rate is low (for example 2%) investigators will require 
thousands of cases. If decision making requires the identification of patients with a zero 
probability of survival with treatment in order to limit that treatment, the model will 
require rigorous external validation before it can be used. Attempts to produce models 
that predict death with certainty have been disappointing and confidence in their use is 
often undermined when their specificity in external validation has been shown to be less 
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than 100%24. The ability of outcome models to identify patients certain to die has 
intuitive appeal but in many clinical situations patients at a very high risk of death are 
rare and are usually so ill that any benefits that might come from the early move from 
aggressive to comfort care may be minimal since even with the most aggressive care the 
patients will die quickl Y25. In the SUPPORT Study, 4301 patients with a series of 
medical conditions (including 10 16 patients with COPD) thought to have a high risk of 
hospital mortality were studied, and prognostic models produced with the aim of 
allowing patients with dire prognoses to choose comfort over aggressive care26. Only 
115 patients (2.7%) out of the 4301 patients had a predicted probability of 2-month 
survival of <I%, indicating that among even the sickest of hospitalised medical patients 
the identification of patients with virtually no chance of survival is difficUlt25. 
The clinical aim of a model to support decision-making for COPD patients has been 
highlighted in sections 1.2 and 1.6. It will involve estimates of individual patient's risks 
of mortality and so will require prospective collection of data describing individual risk 
factors, but since the mortality rate after critical care admission with COPD is in the 
region of 38% the sample size needed to achieve this will be relatively moderate 27 . In 
addition the aim is to produce a bedside model, so there will be an emphasis on 
identifying variables for which it is easy to collect data reliably and which can be 
quickly used to generate a survival probability. 
2.4 Relevant potential risk factors for mortality based on clinical knowledge. 
Simon and Altman 20 suggest the classification of prognostic factor studies into phase 1, 
phase II and phase III studies. In phase I studies tentative relationships between risk 
factors and outcomes are explored and positive associations are considered to generate 
hypotheses. They include assay refinement in this stage. In phase II studies exploratory 
analyses are carried out, for example to generate the hypothesis that an age change of 10 
years is associated with an increased risk of death. In phase III studies pre-stated 
hypotheses are tested and the magnitude of effects confirmed. Though Simon and 
Altman's emphasis is on prognostic factors rather than prognostic models, their 
classification is helpful in stressing the importance of avoiding multiple data driven 
40 
comparisons and exploratory analyses other than in phase I studies. In the development 
of the CAOS model a systematic review of COPD outcome studies was carried out in 
such a way as to fulfil as far as possible the role of Simon and Altman's phase I and 
phase Il studies. Critical appraisal of the COPD outcome studies provided greater 
insight into the likely robustness of risk factors/outcome associations, with relationships 
that had been identified in numerous well conducted studies given more weight than 
associations only identified in one study of poor quality. This allowed much of the 
variable selection used to produce the final model to be carried out prior to explorations 
of the relationship between predictors and mortality. In addition knowledge about the 
likely robustness of predictors could be linked with information from the study about 
ease of data collection to make choices about variables without resorting to data driven 
choices. Furthermore a clear understanding of which variables are robust becomes 
important if stepwise selection methods are used in the ultimate stages of model 
development. For example, it might be decided to force a well-established variable into 
a model, whilst accepting that a variable shown to have an association in only one 
poorly conducted previous study should be dropped. The systematic review of the 
literature is outlined in Chapter 3 below. 
2.5 Selecting a suitable sample of patients 
Altman points out that ideally the development of prognostic models should use an 
inception cohort of patientS28, that is to say patients who are all at the same point in the 
illness. The identification of such patients may be easiest at the onset of a disease 
process. However identifying an inception cohort is not always possible and then it 
becomes important that care is taken to differentiate and classify patients according to 
the characteristics which classify their severity. In addition care must be taken to avoid 
selection bias so as to ensure that the patients used to develop the prediction model are 
representative of those in which the model will be used in the ftiture. These issues are 
discussed in more detail in the sections below. 
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25.1 Defining the diagnosis ofpatients included 
As explained in section 1.1, airways obstruction can be caused by pure asthma, pure 
COPD or by a mixture of asthma and COPD. A clear distinction can be impossible 
clinically and may even be controversial after extensive laboratory tests. For this reason 
the patients to be included were all those patients over the age of 45 with airways 
obstruction, with clinicians classifying the patients on clinical grounds as pure asthma, 
pure COPD or a mixture of COPD and asthma. The age 45 was used as a cut-off as the 
aim of the study was to support decision-making for patients in whom clinicians might 
consider that treatment should be limited because the probability of survival was so low. 
COPD is a chronic progressive disorder that is unlikely to reach a state associated with 
severe respiratory failure below the age of 45 and young patients with terminal disease 
are likely to be atypical. Thus most patients with airways obstruction requiring 
intubation below the age of 45 would be likely to have asthma and there is consensus 
that all these patients should be intubated if they require it. Rather than use the finite 
resources of the study to collect data about patients for whom decision support is not 
required an age cut-off of 45 years was used. 
2.5.2 Selecting a subset ofhospitalizedpatients with airways obstruction 
The clinical aim of the model dictates which of the hospitalised patients with airways 
should be selected for the model. The clinical aim is to help clinicians to decide whether 
aggressive care is likely to enable a patient with COPD to realise their goals for 
treatment or whether aggressive care is likely merely to prolong the process of dying. 
In order to realise this aim it is necessary to understand how patient characteristics 
available prior to the institution of aggressive care predict outcome with that aggressive 
care. It is for this reason that the patient characteristics in the 24 hours prior to ICU 
entry will be the basis of this study. It is also crucial that associations between patients' 
characteristics and outcome are understood in the context of all appropriate care being 
available, and it is for this reason that model development should include only those 
patients who would be considered eligible for intubation if conservative treatment 
including non-invasive ventilation failed. The importance of assessing the significance 
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of prognostic factors in patients treated the same way has been stressed by Altman 17 
and is particularly relevant in COPD patients given that there is evidence of variation in 
treatment limitation decisions6 8 29 and the majority of patients who require intubation 
will die if it is withheld. 
2.5.3 Estimating sample size 
Sample size calculations were informed by the recommendation that for each prognostic 
variable, the dataset should include at least 10 events in order to develop a robust 
mode130. It should be noted that a risk factor with k categories contributes k-1 levels to 
the model, e. g. with age categorised into three levels, 20 deaths are required to allow 
reliable estimates of the contribution of each age category to the risk of death. An 
estimate of the likely number of levels in the CAOS model was based on the SUPPORT 
COPI) model that was developed and tested in a sample of 1016 patients 12 and had an 
ROC area of 0.73 and good calibration. The SUPPORT model was a Cox proportional 
hazards model which contained 10 variables; age, PaO2/FiO2, Body Mass Index, no 
Body Mass Index, activities of daily living, albumin, an acute physiology score, 
congestive cardiac failure as a cause, cor pulmonale and number of comorbid illnesses. 
It was considered likely that the CAOS model would contain similar predictors, but 
because it was intended to categorise variables for ease of bedside scoring, it, was likely 
that 10 predictors might result in 20 levels in the model. On this basis it was likely that 
200 deaths would be required. The SUPPORT model was developed on the first 600 
patients recruited and then tested on the subsequent 416 patients. 71be CAOS model 
development strategy involved bootstrapping (section 2.11 below) so that the whole 
sample could be used in model development and validation without any loss of external 
validity in comparison to SUPPORT. If the 180-day mortality in CAOS was similar to 
the 33% observed in SUPPORT this would require a minimum sample size of around 
600 patients. However it was unclear at the start of the study what proportion of patients 
would have treatment limitations and also the larger the sample size the lower the risk 
of over-fitting during model development. For this reason it was decided to stop the 
study either when 1500 patients had been recruited or at the latest date that allowed 
-Iqq 
43 
adequate time for follow-up and analysis, as long as there was a minimum of 200 deaths 
in patients without treatment limitation. 
25.4 Patient selection: implicationsfor external validity 
A clear understanding of patient selection is crucial in understanding which patients the 
model might be applied to in the future. If there is any selection bias, attempts should be 
made to define this and an appropriate warning attached to the model when it is used in 
clinical practice. The observation that there is a process of selection that determines 
which patients with COPD receive aggressive care is the reason why a model needs to 
be developed in the first place. As highlighted above such selection is actively 
recommended by the COPD NICE guidelines4. However this means that there is an 
inevitable danger of selection bias in the patients who are actually recruited to the study. 
It might be thought that the way to deal with this would be to develop the outcome 
model on all patients with COPD, whether they were selected as candidates for 
aggressive care or not. Such a strategy poses major logistical problems. Patients not 
selected as candidates for aggressive care are scattered all over the hospital, whereas 
those selected are brought to the critical care area where data collection can be 
concentrated. In addition, and more importantly, the whole point of the model is not to 
provide an answer to the general question "what is the probability of survival of a 
patient with a severe exacerbation of obstructive airways disease", but to provide an 
answer to the question "what is the probability of survival of a patient with a severe 
exacerbation of obstructive airways disease who receives all treatment up to and 
possibly including intubation". This emphasises Altman's point that outcome prediction 
models cannot ignore treatment 17 . The strategy used in this study to deal with selection 
bias was to recruit patients from a large number of different units so that all patient 
types who might be appropriate for active treatment would be likely to be selected 
somewhere. The success of this approach in overcoming selection bias depends upon 
clinicians being unable to operate a consistent admitting strategy across the 95 units in 
the study. As long as such inconsistency exists, all the patient types who might be 
considered for aggressive therapy will be likely to be included in the sample. This will 
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allow the model to be applicable to all the patients who might be considered for 
aggressive therapy in the real world. There is evidence to suggest that even when 
prescriptive guidelines exist about which patients should receive which treatments, the 
guidelines are followed inconsistently and patients either receive treatment that they 
should not receive or do not receive treatment that is appropriate. For example, 
Hemmingway showed that patients with ischernic heart disease were both over and 
under treated 31 . 
2.6 Select an appropriate statistical modelling technique 
Since the outcome of interest, survival at 180 days is binary, logistic regression is an 
appropriate technique to develop a model predicting 180-day survival. 
2.7 Adopt a systematic strategy to handle missing values for risk factors 
The recruitment of sufficient patients to develop robust prognostic models is expensive 
and time consuming. Statistical techniques such as logistic regression will omit cases if 
there are data missing in even one of the risk factors that are being evaluated. For this 
reason it is crucial that every effort is made to limit the amount of missing data. Data 
are rarely missing completely at random and this means that imputation of missing 
values may introduce bias. The methods employed in this study to minimise missing 
data are outlined in section 4.10 below. Harrell has suggested that straight-forward 
imputational strategies can be used for missing data with little detriment to the model as 
long as less than 5% of live subjects are affected 32 . Under these circumstances 
imputation using the mean or median value for all the subjects with data present can be 
appropriate, and when there is a good correlation of missing variables with other non- 
missing variables imputation of correlated means or medians may offer some 
advantage. However Harrell points out that such simple strategies are inadequate once 
the proportion of missing data exceeds around 5%. 
When it comes to developing a parsimonious bedside model the frequency of missing 
data can be useful in identifying variables that are difficult to collect and might be 
inappropriate for use in a busy clinical setting. Also any information about variables 
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vulnerable to error can inform final variable selection for the model. The information 
collected during the study that highlighted problems of data collection is outlined in 
Chapter 8. 
2.8 Adopt a systematic strategy to select a final set of risk factors 
2.8.1 Methodological issues the selection of the variables in thefinal model 
The strategy used to select a final set of risk factors for model building requires great 
care because attempting to fit too many predictors in a sample with too few events will 
produce an unstable model that is likely to contain false positive associations (over 
fitting) and is unlikely to predict well in future data. This is particularly important in the 
case of the CAOS model because even with a multi-centre study the number of patients 
recruited will be limited. As outlined in section 2.5.3 around 10 deaths per risk factor 
level are required for model stability" but the greater the number of deaths the lower 
the chance of overfitting. Harrell suggests that adequate model validation requires at 
least 100 deaths in the validation sample 33 . To achieve this for COPD would require 
data collection in most of the units in England for a year. It is important that the 
rigorous requirements of external validation studies are understood otherwise a well 
developed model may appear to perform poorly simply because the external validation 
study has been inadequately powered. External validation is discussed further in section 
2.10.2 below. 
There is therefore an argument for carrying out as much risk factor selection as possible 
before beginning the model development process. One method of achieving this is to 
collect information about the ease and likely reliability of candidate variables and use 
this information to produce a short list of variables to take forward to model 
development (Section 2.8.2 below). 
The most important bias in variable selection occurs when variables are selected using 
the outcome observed in the data set that is used for modelling. Harrell suggests that 
clinical knowledge should guide the selection of candidate predictors, and that "early 
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deletion of those (factors) with little chance of being predictive or of being measured 
reliably will result in models with less overfitting and greater generalisability" 21 . 
Strategies that can be used to reduce candidate risk factors before any analysis with 
outcome are briefly listed below and summarised in Figure 2.8.1. 
28.2 Strategies used to select variablesfor modelling independent ofpatient outcome 
i. Literature review 
Critical appraisal of existing literature sources can allow risk factors to be classified into 
those with evidence of a robust relationship with outcome and those where the 
relationship appears less well established or has only been suggested in studies of poor 
methodological quality. 
ii. Practicality and simplicity ofineasurement 
If a model is intended to be used in a busy clinical environment and there are two 
possible methods of collecting information about a single domain the simplest 
acceptable method should be chosen. In the CAOS study the functional score and Katz 
activities of daily living score were both calculated from information about the patients' 
independence prior to hospitalisation. If data collectors found that both were practical 
then the shortest and simplest might be chosen if prognostic performance was similar. 
iii. Accuracy in measurement 
Efforts should be made to identify risk factors that are measured accurately and reliably. 
iv. Frequency of missing data 
Variables that are frequently missing are often difficult to collect and are rarely missing 
at random. Unless complicated strategies are used variables with more than 5% missing 
cannot be imputed without the risk of introducing major bias. 
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Figure 2.8.1 Summary of strategies used to reduce the list of candidate variables 
before any modelling occurred 
Literature review 
Identify risk factors with an association with mortality 
Critical appraisal 
Stratify risk factors into those with a robust relationship with outcome on the basis of a 
consistent relationship demonstrated in numerous studies and studies of high quality. 
Practicality of measurement and simplicity 
Ask units about how easy they found it to collect variables 
Accuracy in measurement 
During the data collection process data collectors were asked about problems encountered 
and out-of-range or unreasonable values were identified 
Magnitude of missing values 
Drop variables with more than 5% missing values 
Subjectivity 
Consider the degree of subjectivity 
Correlated variables 
Explore the correlations between all variables and if values are highly correlated 
consider will be given to dropping one of them 
Alternative method for measuring a single domain 
Use data driven methods only if good evidence exists for different measures of a single 
domain and all else was equal data driven methods were used to choose between them at the 
last moment 
Variables thought to be associated with selection bias 
Identified any absolute contraindications to ICU admission in some units and drop such 
variables prior to modelling e. g. home oxygen 
V. Subjectivity 
Variables that are subjective are a potential source of bias particularly when they are 
collected from proxies i. e. carers and friends rather than the patients themselves. Proxy 
ratings are most accurate when they describe concrete observable domains such as those 
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comprising the fimctional score or activities of daily living, and least reliable when 
describing subjective domains such as patients' global ratings of their quality of life 34 
vi. Strong correlation with another variable 
If two variables are strongly correlated, incorporation of both can introduce instability 
into the model. Also in some cases correlations occur because variables measure the 
same domain, in which case including both may add little to the model but increase its 
complexity. 
ViL Possible selection bias 
If a variable is seen as a virtual contraindication to intubation in many units the patients 
with that characteristic who are admitted to ICU may be selected because they are 
"super fit" in other respects. If there are sufficient numbers of these patients, the 
variable may be retained in a final model with a coefficient that would be wholly 
inappropriate if applied to the patients who do not reach critical care. Selection bias is 
of course a potential problem for all the variables in the data set, but for the majority 
there is likely to be inconsistency in the way that such bias operates between units. 
Selection bias should only be grounds for excluding a variable if the impression is that 
the bias has been strong and widespread. 
2.8.3 Com ite physiology scores Pos 
Risk adjustment models for hospitalised patients typically measure a number of 
biochemical and physiological variables to assess the magnitude of the homeostatic 
derangements as a marker of the severity of the acute illness. Examples include the 
acute physiology score (APS) in APACHE 11 35 and APACHE 11136. The SUPPORT 
study developed a score specifically for COPI) patients. This used the APS from 
APACHE III but gave additional weight to albumin and PaO2/FiO2, indicating that 
disease-specific acute physiology scores can be more useful than generic scores 12 . 
Developing a composite score to weight and select the 17 or so biochemical and 
physiological variables that are available during the assessment of a patient with COPI) 
would require at least 170 deaths even if all the risk factors were modelled as 
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continuous variables. Generic or COPD acute physiology scores developed in the USA 
may be poorly calibrated for the UK13 37. In order to deal with this problem it was 
decided to develop a disease specific acute physiology score for the UK using data from 
the UK Case Mix Programme. This allowed acute physiological variables to be 
weighted in a dataset containing over 8000 COPD patients admitted to ICU (Chapter 8). 
As a consequence the acute physiological variables collected in the CAOS study could 
then be used without the risk of data driven weighting that would occur if the acute 
physiological variables were weighted and selected within the much smaller CAOS data 
set. Though this is not a perfect strategy since the acute physiology from patients in the 
case mix programme would be measured following admission to ICU, it is likely to be 
the best strategy available given the limitations of the alternatives. 
2.9 Moving from a logistic regression model to a useable score 
Once a model has been produced it is often useftil to transform it into an integer scoring 
system. This allows users to easily calculate a total risk score once the patients' 
characteristics are known without the need to carry out complex mathematical 
calculations. The production of an integer score involves the multiplication of the 
model coefficients by a number that converts them to whole numbers. This will require 
that some coefficients have to be rounded up or down. It is sensible to carry out this 
process before any validation or adjustment for overfitting is carried out so that the 
reported performance of the model takes into account any drop off in performance 
produced by the transformation and rounding. 
2.10 Validating the model 
Harrell points out that "only with appropriate model validation can an apparently 
accurate model be shown to be inaccurate"21. In this section the various strategies that 
can be used for model validation are briefly reviewed followed by a description of the 
bootstrap approach used for the CAOS model. 
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Z 10.1 Internal Validation 
L Data splitting 
In this method, a portion of the data, e. g. 2/3rds, is used for model development. The 
model is then tested on the remainder of the data. The area under the receiver operating 
curve (ROC) is calculated to determine discrimination and a measure of calibration is 
estimated. 
An advantage of this is that it may be possible to make a split with respect to geography 
or time so that the validation is more stringent in demonstrating generalisability. 
However this method is wasteful of data since only a portion of the data is used to 
produce the final model. Also different ways of splitting the data will produce different 
answers. 
iL Cross-validation 
Cross-validation is repeated data splitting. Multiple models are developed and tested 
with the results averaged over multiple repetitions. In a sample of say 1000 patients the 
model might be developed 400 times leaving out a random 50 patients each time. It has 
been suggested that to produce accurate estimates more than 200 models may need to be 
developed 38 
. 
Cross-validation is similar to data splitting, but it has the advantage that a) the training 
sample can use a much greater proportion of the data since less data is discarded from 
the training set and b) cross-validation does not rely on a single data split. 
The disadvantage is that there is a tendency to get different estimates of validity when 
the process is repeated (though this is nowhere near as bad as the variation seen with 
simple split sample validation). 
iii. Bootstrapping 
Bootstrapping is an alternative fonn of internal validation that depends upon the 
generation of large numbers of 'bootstrap' samples. Patients are dropped randomly from 
the model development sample and replaced by including other patients more than once. 
51 
This results in a population of patients with a slightly different spread of severity than 
that seen in the original sample. This can be automated and carried out hundreds of 
times with the model developed and tested in each sample. Thus if the original sample 
contained 600 patients the bootstrap sample still contains 600 patients but spread of 
severity will have been altered by the random replacement and replication procesS38. 
Bootstrapping strategies are described in more detail in section 2.11. 
2.10.2 External validation 
External validation involves testing the model in a completely new population of 
patients. It has the advantage of providing an estimate of the model's performance in the 
"real world" and may for example give insight into the effect of secular trends on 
predictions made by the model. 
In order for the validation to be meaningful Harrell suggests the sample needs to 
contain around 100 eventS33. In England, this would be likely to require 95 units 
collecting data for 9 months, or 48 units collecting data for 18 months. A large well 
designed validation study would also allow researchers to investigate the possibility that 
the results of CAOS had altered admitting behaviour so that for example clinicians had 
started to admit sicker patients. If such a change in behaviour had occurred the CAOS 
model might have the potential to be recalibrated. ideally prognostic scores should be 
seen as tools that need to be continually validated and updated to take account of 
changing practice. This area holds great potential for methodological advances that 
would make prognostic scores more trusted and therefore useful. This area is discussed 
in more detail in chapter 12. 
2.11 Bootstrapping strategies to take account of overfitting 
2.11.1 Boolstrapping to modify model coefficients to adjustfor overfitting 
The intercept and coefficients from the model produced in a certain set of data will tend 
to fit that data well and be influenced by the range of the values of the variables in that 
data. If the variables measure disease severity the model fit will be influenced by the 
spread of severity in that sample. If the model is subsequently used in another sample of 
patients where the range of severity is different, the model fitting the range of severity 
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in the original sample may tend to predict less well in the new population. However 
bootstrapping can be used to adjust the intercept and coefficient in the final model to 
take account of the potential heterogeneity in future patient samples by using multiple 
bootstrap samples to drop and replace patients from the original sample. This procedure 
mimics the heterogeneity of future patient populations and alters the calibration of the 
final model so that the calibration performance will be more robust. The usefiAness of 
this procedure depends upon the original sample having recruited the types of patients 
likely to be encountered in the future. As in any application of trial data to future 
patients, external validity requires that the original study population are similar to the 
population in which one wishes to extrapolate the findings. If the original sample was 
biased and totally excluded an important subset of patients bootstrapping will be unable 
to remedy the situation. 
A typical approach would involve the generation of 500 bootstrap samples. The new 
intercepts and coefficients fitted would differ from those in the original model by a 
magnitude that reflected the original model's lack of fit in the new bootstrap samples. 
The average of the new intercept and coefficients could then be used to produce a new 
model that had a coefficient and intercept that produced less good fit in any individual 
sample, but performed better on average in samples of patients with varying 
distributions of severity. 
211.2 Bootstrapping to estimate theperformance ofthe model infuture samples 
In this use of bootstrapping the variables selected in the final model are fitted in a large 
number of bootstrap samples and then tested in the original patient sample. This allows 
an almost unbiased estimate of the expected discrimination of the final model in future 
populations. This is expressed in terms of an adjustment to the area under the receiver 
operator characteristic (ROC) curve that describes the estimate of the model's 
discrimination in future patient populations. 
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2.12 Model calibration 
2.12.1 Calibration curves 
Calibration curves are useful ways of describing the predictive performance of 
prognostic models. Patients are placed in a number of equally sized groups and the 
mean predicted probability of mortality for each group is plotted against the observed 
proportion of that group that actually do die. A clear understanding of the calibration of 
predictions is crucial to understanding how predictions can be used to guide patient 
management. For example in Chapter 1, Figure 1.4.2 shows the calibration curve for the 
COPI) SUPPORT model and the unaided American clinicians. It showed that clinicians 
tended to be pessimistic for most patients except those with the highest probability of 
survival, while the model tends to be pessimistic for patients with a moderate 
probability of survival (around 70%) and optimistic for patients with an 80% probability 
of survival, but is otherwise well calibrated. 
2.13 Conclusions 
The development of a robust model for the prognosis of COPD patients has been 
12 
achieved in the United States using a group of patients with 330 deaths at 180 days 
This nine-variable model out-performed clinicians in terms of both discrimination and 
calibration The technique of bootstrappine 8 was not used in the US model, but this 
permits more efficient use of data and holds out the prospect of producing a more robust 
model in a sample of equivalent size. Nevertheless model development must be carried 
out with great care in order to avoid data driven overfitting, and OMar22 has suggested a 
schema to guide model development. A crucial step in avoiding overfitting is to ensure 
that only variables that have a robust relationship with outcome are used in model 
development. The next chapter outlines the systematic review that was carried out in 
order understand the risk factors associated with outcome in COPD. 
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Chapter 3 Systematic review of intubation studies for patients with 
COPD 
3.1 Identifying relevant publications 
Systematic reviews aim to identify and evaluate all the relevant studies in order to avoid 
the biases inherent in merely selecting the latest or best known studies, and aim to 
provide a comprehensive summary of the available evidence. There is no consensus 
about the best search strategy for finding studies that identify prognostic factors28. The 
search strategy used was developed from the sensitive search strategy for prognostic 
studies outlined for Medline by McKibbon et a139 and used in Embase using the CASP 
filters modification (Appendix 1). The same strategy was used to search the grey 
literature using the SIGLE database. The bibliographies of the identified studies were 
searched and in addition Web of Science was used to carry out a citation search on the 
papers identified as describing the outcomes of COPD patients with acute respiratory 
failure. Papers were selected for further review if the abstract suggested that: (1) the 
study reported the outcome of COPD patients intubated for the treatment of acute 
respiratory failure and (2) data were available on the outcome of intubated patients. 
Data were extracted if the study reported the outcome of more than 10 COPD patients 
as a distinct group. Twenty nine studies were identified that reported outcomes of more 
than 10 COPD patients admitted as emergencies and intubated and these studies are 
reviewed in more detail below. 
3.2 Studies reporting outcomes for more than 10 intubated patients 
Twenty nine studies reported outcomes for more than 10 intubated COPD patients. 
Many of these studies also attempted to identify patient characteristics that have 
prognostic value in predicting survival. Altman has recently described the problems of 
systematically summarising studies of prognostic variables 17 28 . Table 3.2.1 below 
summarises the problems that Altman highlights and illustrates them with examples 
from the COPD literature with the strategies used in this study to address the problem if 
relevant. 
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As Table 3.2.1 illustrates, the pitfalls encountered in producing high quality prognostic 
studies are legion and consequently very few studies that set out to identify prognostic 
factors are sufficiently rigorous to produce evidence that is likely to be accurate and 
generalisable4o. In addition the methodological heterogeneity of study design means that 
meta-analysis of results is likely to be difficult and lack precision. A recent workshop 
on the meta-analysis of observational studies emphasised that these have much more 
potential for bias than randomised controlled trials, and as a result reporting single 
summary estimates of outcome will often be misleading4l. It is for this reason that the 
results of the studies identified in the systematic search will be presented in a narrative 
descriptive format describing the mortality attending intubated COPD patients and the 
factors that have been explored as predictors of this mortality. In view of the marked 
heterogeneity in study design, aggregate mortality figures should be interpreted with 
caution, and where possible the mortality of relevant subgroups will be presented. 
3.3 Mortality following intubation for COPD 
Table 3.3.1 displays the reported mortality in Intensive Care Unit (ICU), hospital or 
post hospital) for the intubated COPD patients in the 29 studies identified by the 
literature search. The heterogeneity in mortality is shown in Figure 3.3.1, in which the 
results of the 24 studies that report hospital mortality are plotted along with the 95% 
confidence intervals. 
The heterogeneity of survival in the different studies partly reflects the small size of 
many of the studies and also arises because of a number of the factors that Altman has 
highlighted as barriers to meaningful meta-analysis of prognostic studies 17 , such as 
differences in inclusion criteria. 
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Table 3.2.1 Problems with systematic reviews of prognostic studies 
(modified from Altmant) 
Problem identified by 
Example relevant to Intubated COPD outcomes 
Altman 
Difficulty in identifying all studies A multifaceted approach was used in which a sensitive strategy designed to identify 
in the literature prognostic studies was used along with bibliography and citation searches. 
Only one of the studies12 had published a prior analysis stratee, so it is impossible to Negative (non-significant) results 
tell whether a study has reported negative results. In addition negative studies may never 
may not be reported (publication have been published. This makes it difficult to know if associations noted in one study bias) 
were found to be negative in other studies and not reported. 
Data driven associations are prone to false positive findings and most of the studies did not Inadequate reporting of methods 
report how the analyses were planned and how many comparisons were made. 
In the SUPPORT study" the acute physiology data used to build the outcome model are 
Variation in study design collected on the third day of hospital admission. In the APACHE III stue the worst 
value recorded in the first 24 hours after critical care entry is used. 
This often means that the data used are those available in existing data bases and are often Most studies are retrospective 
generic e. g. APACHE II scores rather than COPD disease specific. 
In some studies only COPD patients with a clear chest x-ray are included. In others all Variation in inclusion criteria COPD exacerbations are included. 
Differing methods of handling In many studies continuous variables are categorised and risk ratios presented for the 
continuous variables (some grouped categories. This makes comparism between studies difficult. It is also likely that 
dependent on data) categorisation decisions will have been data driven. 
Many studies simply report univariate associations between risk factors and outcome. In Different statistical methods of 
addition some studies explore associations with critical care mortality, others hospital 
adjustment 
mortality and others 180-day or even 365-day mortality. 
Adjustment for differing sets of When multivariate associations are reported it is not always clear what the other risk 
variables factors were that were adjusted for and no two studies adjust for the same set of variables. 
Inadequate reporting of 
It is not always clear when mortality is reported how many patients have been lost to 
quantitative information on 
follow-up. 
outcome 
Variation in presentation of results In some American hospitals hospital mortality is reported when a large proportion of 
( for example survival at different patients are discharged back to chronic care facilities where they may die soon afterwards. 
time points) Reporting mortality at fixed time points e. g. 30-day is more informative. 
Different assays or measuring For example: FEVI- post bronchodilator in period of stability is most accurate, but 
techniques frequently not stated 
Some studies use logistic regression, others use Cox proportional hazards, others use chi- Variation in methods of analysis 
square tests. 
Whereas published randomised controlled trials should be published in accordance with Lack of rccognised criteria for 
the CONSORT statement". there is no such agreed convention adopted for prognostic 
quality assessment 
studies. 
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3.3.1 Variations in mortality due to case-mix 
The difficulty in establishing a clear understanding of the meaning of the differences in 
mortality can be illustrated by a comparison between the studies where some 
information was available on the case mix of the included patients using measures such 
as APACHE II score, aetiology of the exacerbation or the age of the population (Table 
3.3.1 below). It can be seen that for many studies the age and case mix measures for the 
intubated patients are not specifically reported but grouped with the non-intubated 
patients, making comparisons difficult. In addition it can be seen that for the majority of 
these studies the 95% confidence intervals around the hospital mortality figures are 
similar (Table 3.3.1.1 and 3.3.1.2). In studies with higher mortality there are typically 
differences in case mix. Either the patients are older, or the sample has included patients 
with pneumonia, or the APACHE score is higher. For example in the Seneff StUdY43 the 
170 intubated patients had a mean (SD) APACHE III score of 63 (24.9) which was 
lower than the mean (SD) APACHE III score of 67.8 (22.9) for the definitely/probably 
intubated patients in the Wildman stud Y27. However there are studies from single 
centres which appear to represent outliers. For example the Moran study from 
Australia" has low hospital mortality despite APACHE II scores and patient ages that 
were comparable with other studies. However it did not include patients with 
pneumonia. 
3.3.2 Variations in mortality due to poorly defined outcome time point 
Though almost all studies report hospital mortality, measures such as 30 or 60-day 
mortality are more robust for comparison purposes because the definition of hospital 
mortality may be influenced by local discharge practices. Nevins reported 45 the 
comparatively low hospital mortality of 27.7% (95% CI 21.1-35.2) in 166 intubated 
COPD patients from one US centre in which 38% of patients were transferred to 
chronic care facilities. When patients are transferred to chronic care facilities the 
hospital mortality is difficult to interpret. 
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Figure 3.3.1 All studies reporting hospital mortality for 10 or more intubated 
patients 
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The low mortality found by Nevins was accompanied by a relatively low case mix 
score, in this case APACHE 11, mean (SD) score 15(6) vs. mean (SD) APACHE 1119.7 
(6.4) in the Wildman stud Y27 and once again the Nevins study did not include patients 
with pneumonia and heart failure. In the Wildman study intubated patients had a 
mortality of 35.9% (95% CI 34.1 - 37.6%) in the hospital housing the CMP unit, but an 
ultimate hospital mortality of 40.6% (95% CI 38.8 - 42.4%). Ely reports a hospital 
mortality of 38.6% (95% Cl 24.4 - 54.5) for 44 intubated COPD patients from a US 
academic centre in which patients had a mean (SD) APACHE II of 19.4 (5) 46 Which is 
similar to that observed in the Case Mix Programme study. In the Esteban study 47 the 
522 patients with COPD receiving mechanical ventilation in 361 ICUs in 20 countries 
had a hospital mortality of 28% (95% CI 24 - 32) and a Median IQR SAPS 11 of 38 (31 
- 49). This compares to a median (IQR) SAPS II of 42 (35- 52) for the intubated 
patients in the CMP study. 
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Table 3.3.1.1 29 studies reporting outcomes for more than 10 intubated COPD 
patients: ICU and hospital survival 
Author publication Number Intubated Critical care Intubsted hospital Other mortality Country 
year intubated mortality mortality period 
Kettel 1971" USA 35 NA 11(28.7%) (19.5-39.4) NA 
Stutter 1972" Holland 45 NA 21(30.9%) (20.243.3) NA- 
Nunn 1979' LTK II NA 9(81.8%) (48.2-97.7) NA 
Gottlieb 197351 USA 30 NA 9 (30*/*) (14.749.4) 
2 year 20 (66.7%) 
(47.2-82.7) 
Petheram 198052 UK 25 NA 11 (441%) (24.4-65.1) 
1 year 15 (60%) 
(39.7-78.9) 
Vathesatogkit 1983" Thailand 17 NA 7(41.2%) (18.4-67.1) NA 
Dardes 1986 ' Italy 15 NA 11(73.3%) (44.9-92.2) NA 
Gillespie 198653 USA 21 NA 5(23.80/*) (8.2471) 
1 year 12 (57.1%) 
(34.0-78.2) 
Kaelin 1987' Switzerland 39 NA NA 
180 -day 15 (38.5%) 
(23.4-55.4) 
Menzies 198957 Canada 95 20 (21.1%) (13.4-30.6) NA 
I year 59 (62.1%) 
- 
(51.6-71.9) 
Limthongkul 1991w Thailand 66 NA -33(50%) (37.4-62.6) NA 
Swinburne 1993" USA 2(* 1 NA 74(37.0%) (30.3-44.1) NA 
Rieves 1993' USA 58 NA 25 (43.10/9) (30.2-56.8) 
1 year 37 (71.2% 
(56.9-82.9) 
Stauffer 1993 61 USA 67 18(26.9%) (16.8-39.1) 22(32.8%) (21.8-45.4) 
1 year 38 (56.7%) 
(44.0-68.8) 
Esteban 1994 47 Spain 59 20 (33.9%) (22.147.4) NA NA 
Fuso 19951 Italy 37 NA 21(56.8%) (39.5-72.9) NA 
Seneff 1995" USA 170 NA 54 (31.8%) (24.8- 39.3) NA 
Torres 1996" Spain 22 5(22.7%) (7.8-45.4) 5 (22.7%) (7.8-45.4) NA 
C, =,, 199612 USA 358 NA NA 
180-day 150 (43%) 
(37.848.5) 
Hill 199864 UK 41 
12/41(29.3 %) 
20(48.8%) (32.9-64,9) 
1 year 24 (59%) 
(16.145.5) (42.1-73.7) 
Moran 199841 Australia 43 NA 6(14%) (5.3-27.9) 
Anon 1999" Spain 20 7(351/9) (15.4-59.2) 10(50%) (271-72.8) 
1 year 15 (75% 
(50.9-91.3) 
Hoo, 200e USA 74 NA NA 
30 -day 7 (12.5%) 
(5.2-24.1) 
Ely 200e USA 44 1 NA 17(38.6%) (24.4-54.5) NA 
Nevins 200 1" USA 166 NA 46(27.7%) (21.1-35.2) NA 
Esteban 2002" World 459 109 (23.7%) (19.9-27.9) 128 (28%) - (23.8-32.2) NA 
Afessa 2002" USA 113** NA 24 (21.2%) (14.1-29.9) NA 
Breen 2002' Australia 63 10(15.9%) (7.9-27.3) 15(23.8%) (140-36.2) NA 
§Wildman 200327 UK 3052 
757/3052 (24.8%) 1187/2927 (40.6%) I 
L 1 1 
(23.3-26.4) 
1 
(38.842.4) 
NA 
1 
Mortality given as number (; /-. ) 95% CL These a re the patients intu ba(ed within 24 hours. we don't kno w About Patients intubated bevond 24 h ours. the denominator hm A&I 
mortality is only 2927 because of missing dat& 
"In the Afficat papersome piftientswere intubsted after fidlingNtV, the 113 reported in this table we the patients who wereirmanned ftm the oubeL 
I It should be noted dot the Wildman 2003 study is based on patients admitted to ICU prior to the period during which the CAOS study was carried out 
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Table 3.3.1.2 Studies published since 1995 reporting hospital mortality for 10 or 
more intubated COPD patients in which the case mix data are 
reported 
Hospital 
Number of mortality for Number APACHE APACHE 
Study, year & Intubated intubsted Age Pneumonia 
of M 11 
country patients/ total patients Mean (SD) Included 
centers Mean (SD) Mean (SD) in study % 
(95% CI) 
Seneff 199541 31.8% 
40 170/362 63(24.9) NA t66 No 
(USA) (24.8-39.3) 
Torres 1996 63 23% 
8 22/124 NA NA t67 (11) Yes 
Spain (7.8-45.4) 
Moran 199844 13.9% 
1 431100 NA No 
Australia (5.3-27.9) till (5) t68.5 (7) 
Hill 199864 490/6 
1 41141 NA NA NA Yes 
UK (32.9-64.9) 
Ely 200e 38.6% 
All 
44(44 NA intubated 65(12) Unclear 
USA (24.4-54.5) 
19A (5) 
Nevins 200145 27.7% 
Ali 
1 1661166 
1 
NA intubated 67(13) NO 
USA (21,1 -35.2) 15(6) 
Atessa 2002 67 20.3% 
1 153/250 NA t63.1 (8.9) Yes 
USA (14.2 - 27.51/o) t 19.0 (7.3) 
Breen 2002'3 23.8% 
1 63/74 NA t22 (7) t65.5 (9.0) No 
Australia (14 0- 36.2%) 
Wildman 200327 40.6% 
tMedian 67.8 
128 3052/3752 67.8(22.9) (IQR 60.5- Yes 
UK (38.8- 42.3) j 19.0 (6.7) 
73.6) 
T In these studies the case mix data is not milablc separately for the intubated patients and the x2lue 
presented includes both intubated and non-intubated patients. 
The authors of this international study found the 30-day mortality of the ventilated 
COPD patients to be 19.5% (95% CI 16.2 - 23.2) (Personal communication F. Frutos), 
such that only 2/3rds of deaths occurred within 30-days, a proportion which was 
considerably lower than the 35.7% (95% CI 33.9 - 37.4) 30-day mortality calculated in 
the CNT study which comprised around 90% of hospital deaths. 
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3.3.3 Overall mortalityfrom studies reporting outcomesfor intubated COPD patients 
It can be seen from the foregoing discussion that the observed variation in mortality 
between studies reflects both the heterogeneity of the studied populations and 
imprecision in definitions such as hospital mortality. As a result any summary mortality 
figure that incorporates data from all the studies must be treated with caution. In 
addition the UK CMP study is by far the biggest and of the studies and therefore has a 
dominant influence on the overall figure. Figure 3.3.3 below displays the overall 
mortality at discharge 180 days and I year for all the studies, and it can be seen that 
around 40% die in hospital (based on 4675 patients), around 43% die by 180 days 
(based on 387 patients) and around 60% die by I year (based on 327 patients). 
3.4 Risk factors associated with mortality 
Risk factors associated with the outcome of intubation for patients with COPD can be 
classified into two main groups; those which describe the patient's characteristics in the 
period of stability prior to the exacerbation, and the clinical findings and results of 
investigations that become available during the emergency admission. The evidence 
from the literature will be reviewed below. 
3.4.1 Age 
Age has an important association with mortality since people are more likely to die at 
80 years of age than at 20 years of age. In prognostic models which take account of 
some of the other factors that increase with age such as comorbidity, age may become 
less important when patients are compared over a smaller age range. However it is 
often the case that age retains an important association with mortality simply because 
studies cannot measure every risk factor and may measure some risk factors 
imperfectly. 
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Figure 3.3.3 All studies reporting outcomes for 10 or more intubated patients 
(combined outcomes for all studied patients). 
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Hospital mortality draws on 24 of the 29 studies with 1771 deaths out of 4675 patients studied (mortality 37.9%, 95% Cl 36.5-39.3). 
180-day mortality only draws on 2 studies with 165 deaths in 387 patients (mortality 42.6%, 95% Cl 37.7 - 47.7%). 
I -year mortality draws on 7 studies with 200 deaths in 327 patients studied (mortality 61.2%, 95% Cl 55.6- 66.5%). 
On occasions age will appear to have no relationship with mortality. For example age 
may not be associated with mortality in patients admitted to critical care following a 
cardiac arrest, and this will often be because rigorous selection pressures have only 
allowed the fittest of the elderly to be admitted to ICU. Table 3.4.1.1 below summarises 
the ages of the COPD patients in the studies where there was no analysis of age with 
outcome and Table 3.4.1.2 summarises the studies where some analysis of the 
relationship with age and outcome was carried out. 
Twenty one of the 29 studies identified in the systematic search reported data on age of 
the included COPD patients. The mean age in the majority of studies was in the mid- 
sixties. The largest study from the UK included just under 4000 patients of which 80% 
were intubated, and reported a median (IQR) age of 67.7 (60.4 - 73.5). 
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Table 3.4.1.1 Studies in which the age of patients was summarised but no analysis 
with outcome performed 
Study Age 
Analysis 
(Years) 
Sluiter 1972 4" Mean 61.2 Summary statistics only 
Gottlieb 1973" 
Mean 57 
Summary statistics only 
(range 27-75) 
Bronchitis survivors mean 623, non- 
survivors mean 65.3 Emphysema 
Petheram 198052 Summary statistics only 
survivors mean 54, non-survivors 
mean 59.2 
Dardes1986 54 Mean (SD) 69(8) Summary statistics only 
Torres 1996 63 Mean (SD) 67(l 1) Summary statistics only 
Ely 2000 46 
Mean (SD) 
Summary statistics only 65(12) 
Six of the 21 studies report summary statistics only. In keeping with much of the COPD 
outcome results analysis tends to be based on end-points such as hospital mortality 
rather than more robust outcomes such as 30-day survival or 60-day survival. Eight 
studies found age not to be significantly associated with mortality. In four of the 
negative studies the numbers of deaths were small with 20 or fewer deaths in each 
study'6 64 65 68 . In one of the negative studies with only 39 episodes in total, the analysis 
of outcome predictors was carried out after the sample had been stratified by FEVI, 
which is likely to reduce the impact of age in such a small sample6o. Three studies had 
5767 larger numbers of patients and reported no association between age and outcomcýs 
In one of these studies the age of 36 I-year survivors and 59 non-survivors was 
compared but formal survival analysis to 1 -year was not carried ou t57. In another of the 
negative studies the age of 120 hospital survivors was compared with 46 non-survivors 
in a sample where 45 patients were discharged to chronic care facilitieS45. In the final 
study finding age to be non-predictive of survival 250 episodes were analysed in 180 
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patients and a univariate comparison was made with hospital survival, though the 
numbers being discharged to chronic care facilities was not reported67 
Seven studies reported an association between age and outcome. In one of the positive 
studies which included patients with respiratory failure due to both COPI) and other 
causes, though the age of the COPI) patients was reported separately the survival was 
analysed for the group as a whole 61 . Two of the positive studies contained large 
numbers of hospitalised patients of whom only a small proportion were intubated5g 62 . 
Two studies that reported only on critical care patients also found increasing age to be 
significantly associated with hospital mortality. The Seneff stud Y43 included 362 
patients with COPI) identified from the APACHE III development data set, and the 
larger Wildman stud Y27 included just under 4000 patients of whom 80% were intubated. 
The Wildman study reported univariate and multivariate odds ratios for hospital 
mortality for 10 year age increments, with an OR (95% CI) univariate of 1.59 (1.46 - 
1.73), and a multivariate OR of 1.58 (1.44 - 1.73). Only two studies carried out formal 
survival analysis 1244 . One was small with only 8 hospital deathsý4, but found that age 
was associated with mortality beyond hospital. The other larger study that included 
1016 COPI) patients 12 reported a significant association between age in 10 year bands 
and mortality in both univariate and multivariate analysis, with univariate hazard ratio 
(95% CI) 1.30 (1.14 - 1.47), and multivariate 1.22 (1.05 - 1.41). 
Though the data from studies looking at the association between age and outcome 
conflict (8 studies reporting no association between age and mortality, 7 reporting 
increasing mortality with increasing age) it is likely that 4 of the negative studies were 
too small to show any effect. Of the 4 remaining negative studies none used formal 
survival analysis. In one study hospital outcome may have been a poor measure because 
around 27% of patients were discharged to chronic care facilitiesý5, and in another study 
analysis was by episode rather than by patient67. Of the positive studies two used formal 
1244 survival analysis 
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Table 3.4.1.2 Studies in which there was investigation of relationship between age 
and outcome 
Study Age 
Analysis Findings Comment 
(Years) 
Kaelin Mean (SD) 64.0 (7.5) Univanate analysis by No significant association with survival All 39 patients intubated 
987-'4 
1 80day survivors, I 80-day survival and 15 lived Less than 1 
67.6 (8.1) non-survivors. 180 days 
Menzies Mean (SD) Univariate analysis by I- No significant association with survival, 36 I-year survivors, 59 
198937 
69.6(9.3) year survival. Analysis: 36 survivors mean age of 67, non- non-survivors 
independent T tcslý 30 survivors 71 years. 
Total group mean (SD) Univanate analysis by Survivors mean (SD) 67.6 (10.1); Study includes 400 
Litnthongku 69.4(0.5) hospital an-viva] non-survivors 721 (8.5) episodes of which 66 
9139 
P<0.001 involved intubation. 
119 
Analysis is for total 
group. 
Swinbumc 18 1 COPD patients aged Hospital survival: % (950/. Cl) 64.6% 181 COPD patients aged 
1993" <80 years and 
19 patients (57.2 - 71.6) of patients aged <80, <90 years and 19 
aged ý 80 years 47.4% (24.4 - 71.1) patients aged ý 80 patients agede 80 years 
mean (SD) not presented years 
Mean age of whole group Uttivariatelmuluvariate Age not a significant pre(bctor either as 39 episodes analysed in 
Rieves not reported. analysis in groups a univariate or a multivariate 33 patients, so numbers 
199360 
defined by FEV, small and stratifying by 
FEV, likely to reduce 
impact of age. 
Mean (range) in 67 COPD Univariate estimate of OR (950/. Cl) hospital death 67 out of the total 383 
Stauffer patients 64.6 (48-93) odds of hospital and 1 1.60 (1.28-2.00), men in this study had 
1993 61 year 
death for whole 393 1 year death assuming survival from COPD but age was 
patients per 5-year hospital analysed in total group 
increase in age 1.20 (1.02 -1.43) 
Mean (SD) total group Univariate analysis by Hospital survivors 66.3 (10) vs. Note that the sample 
Fuso 199562 
67.9(10.2) hospital survival 73.1 (8.4) non-survivors contained 590 patients 
P<0.001 of whom 37 were 
intubatedL 
Mean (SD) Multiple regression Increasing age significantly associated 
All n=362, age 66 (9.6) analysis with hospital mortality. 
Seneff Intubated n-170, 
1995 43 age 66 (9.5) 
Not intubaled n-192, 
age 66 (9.7) 
Median (IQR) Univariate and Hazard ratio (950/60) per 10 year age 
Connors 70(63-77) multivariate Cox increase. 
199612 proportional hazards for Univariate 1.30 (1.14 - 1.47). 
mortality up to 180-days Multivariate 112 (1.05 - 1.4 1) 
Median (-ge) Univariato analysis by No significant difference 
21 hospital survivors 67 hospital survival 
Hill 199864 (59.5 - 72.0) 69.5 
20 non-survivors median 
69.5 (64 - 72.8) 
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Table 3.4.1.2 Studies in which there was investigation of relationship between age 
and outcome continued. 
Study Age 
Analysis Findings Comment 
(Years) 
Total group Univartate & Age was reported as significant Of the 75 patients only 43 were 
mean (SD) multivariate Cox univariate predictor of survival mechanically ventilated. 
68.5(7) proportional hazards beyond hospital discharge only, but The hospital mortality was 11% i. e. 8 
analysis of ICU & not hospital discharge and was not a patients and the 180-day mortality 
Moran 1998" 
hospital length of stay multivauriate outcome predictor was 25% i. e. 19 patients. 
hospital and beyond Hence little power to determine 
hospital, survival. The associations with hospital mortality. 
analysis was on total 
cohort not just intubated 
patients. 
Mean 64 years Univariate analysis with Mean (SD) ICU survivors 61 (8.9) 20 intubated patients with 7 deaths in 
Anon 199965 (median 64 ) ICU survival non-survivors 68 (7.1) p=0.06 ICU and 10 deaths in hospital 
(range 44-77) 
Mean (SD) Univariate comparison Hospital survivors 67.4 (11.9) 166 intubated patients with 46 
Nevins 200 145 
67(13) with hospital survival Non-survivors 66.3 (14. )0 p=0.64 hospital deaths. 
Note 45 patients were transferTed to 
a chronic care facility. 
Mean (SD) Univariate comparison Hospital survivors 62.5 (8.6) 213 survivors and 37 non-survivors. 
63.1(9.9) by hospital survival. non-survivors 63.9 (8.3) Analysis was by episode with 250 
Afessa, 200V p=0.34 episodes in 180-patients. 
Number discharged to chronic care 
facilities not reported. 
Mean (SD) Univa6ate comparison Age not associated with outcome Only 15 hospital deaths, and 30 
Breen 200V 
65.5(9.0) by hospital survival and deaths at 180-days 
median (range) 6 month survival 
65(46-85) 
Median (IQR) Univariate and OR (95% Cl) hospital mortality per 
Wildman 67.7 (60.4 - 73.5) multivariate comparison 10 year age increase 
200327 by hospital survival UMnivariatc 1.59 (1.46 - 1.73) 
multivariate 1.58 (1.44 - 1.73) 
The two largest studies that included almost 5000 patients in total showed broadly 
similar odds of death per 10 year increase in age, with the SUPPORT study that 
contained a lower proportion of intubated patients having the lower unadjusted hazard 
of death 1.30 (1.14 - 1.47) and the Wildman study an unadjusted odds of death of 1.59 
(1.46 - 1.73). Given the agreement of the largest studies and the methodological 
problems of the negative studies it would be reasonable to conclude that age is an 
important risk factor for mortality, a conclusion that would be consistent with outcome 
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in most critically ill patients since age takes account of much unmeasured confounding 
in terms of physiological reserve. 
3.4.2 Sex 
The majority of the studies did not investigate sex as a predictor of outcome and in a 
number of studies 60 61 all the patients were male. The eight studies that did investigate 
the relationship between sex and outcome are shown in Table 3.4.2. It can be seen that 
only the UK case mix programme study found sex to be associated with outcome, with 
males having a univariate increased risk of mortality that was lost when multiple factors 
were adjusted for. The message from the systematic review regarding sex is unclear. 
The negative studies are relatively small and the finding of a univariate association 
between male sex and mortality that loses significance with adjustment for other risk 
factors in the large UK study raises the possibility that male sex may be a marker for 
other risk factors and therefore might have a role in a parsimonious model where all 
possible risk factors are not measured. It is of interest to note that a recent paper from 
Spain looking at 135 consecutive COPD patients admitted to hospital found women to 
have an increased mortality compared to men, but in this study the women were 
significantly older than the men (women mean (SD) age 79.4 (8.96) men 72.2 (9.3)69. 
3.4.3 Lungfunction 
i. As an indicator ofprognosis in stable outpatients 
As highlighted in Chapter I (Section 1.1 above) COPD involves lung damage which 
reduces lung function, and the forced expiratory volume that the patient can blow out in 
70 one second (FEVI) has been used in the classification of the severity of disease . Much 
of the work investigating the relationship between FEVI and prognosis has been carried 
out in stable outpatients. The FEVI cut-offs demarcating severity vary around the world. 
The British Thoracic Society classifies patients into mild: FEVI 60 - 80% predicted, 
moderate: FEVI 40 - 59% predicted and severe: FEVI <40% predicted2. 
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Table 3.4.2 Sex and mortality for intubated COPD patients 
Study 
Number 
Analysis Findings Comment 
(%) male 
50/95 Univariate comparison between No significant difference 
Menzies 1989ý7 
(52.6%) survivors & non-survivors between men and women 
203/362 No significant difference 
Scneff 1995 43 Unclear but probably univariate 
(541/6) between men and women 
21/41 Univariatc comparison with hospital 
Hill 1998" No significant difference 
(51.2%) mortality 
103/166 Univariatc comparison with hospital 
Nevins 200143 No significant difference 
(6211/o) mortality 
147/250 Univariate comparison with hospital 
Afessa 200V No significant difference 
58.8% mortality 
44n4 Univariate comparison with hospital 
Breen 20&8 No significant difference 
59.5% mortality 
Males at 
increased risk 
Univariate male 
which becomes 
Wildman 1869/3611 Univariate & multivariatc comparison 1.19 (1.03-139) 
non-significant 
2003" 51.8% with hospital mortality multivariate 1.04 (0.89- 
when all other 1.22) 
factors taken 
into accouritt 
t In this case the multivariate analysis involved age, comorbidity, length of stay prior to ICU, CPR pre- 
ICU, acute physiology, organ failures. 
Note in SUPPORT 523 (51.5%) were male and only factors that had been previously identified as likely 
to be associated with mortality were analysed with mortality 
The European Respiratory Society use slightly different cut-offs of mild: ý: 70%, 
moderate: 50-69%, and severe:, <50%71. The American Thoracic Society classify 
COPD into 3 stages, with patients in stage I having FEVI ý: 50% predicted, stage 1135- 
49% predicted and stage III <35% predicted 72 . The cut-offs reflect the fact that studies 
have found that low FEVI identifies patients with a poor prognosis. The post- 
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bronchodilator FEV, was considered to be the best measure of FEV, since it was 
thought to measure the fixed impairment73. Though FEVI and age are correlated 
Anthonisen 74 found that post-bronchodilator FEVI was still a significant predictor of 
mortality when age was taken into account. Anthonisen also attempted to find a 
threshold at which FEV, began to be associated with poor prognosis. He found that 
patients with a FEV, <30% predicted had a significantly higher mortality than those 
with an FEV, lying between 30 to 39%, but that patients with an FEV, between 40 to 
49% did not differ from those with an FEVI >50%, who in turn did not differ from 
normal smokers. Clearly, as the proportion of deaths decreases, the sample size needed 
to find important differences in mortality will need to increase. Nevertheless, the 
message of higher mortality associated with lower FEVI was borne out in the majority 
of studies and the data from Traver 73 are useful in this regard as shown in Table 3.4.3.1. 
Table 3.4.3.1 Survival rates in COPD according to % predicted post 
bronchodilator FEVI (PBFEVI) in patients: 5 65 years of age 
(Traver 73 ) 
Cumulative survival rate (%) 
Initial Post 
bronchodilator 
FEV, 
(0/o Predicted) 
Number At 2 years At 5 years At 10 years At 15 years 
<20 9 44 11 11 0 
20-29 40 65 30 10 3 
30-39 43 83 47 21 7 
40-49 26 92 89 39 30 
50-59 21 95 95 57 32 
60+ 9 100 89 89 67 
Hodgkin75 points out that an important limitation in some of the studies that found FEVi 
to be a poor predictor of mortality was a lack of spread of FEVIs and the Postma, stud Y76 
illustrated this with the FEVI of the 129 study patients lying between 0.35L and 0.91 
litres. An understanding of the contribution that a variable makes to outcome requires 
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patients to be distributed along a continuum from mild to severe. Even the best FEV, of 
0.91 in the Postma study reflects marked impairment of airflow. 
Hodgkin also highlights the variability in prognosis that persist despite patients having 
similar lung function, drawing attention to comment by Traver 73 that "perhaps the most 
important point to be made from the overall study, and one often ignored in previous 
reports, is the very wide variability in survival of individual patients whose initial 
findings appear similar. " In a growing recognition of the limited predictive power of 
FEVI in isolation, more recent studies have tended to look at a number of patient 
characteristics to predict outcome. Celli and co-workers have recently published work 
investigating a multidimensional grading system (the BODE index) that consists of four 
factors: body mass index, dyspnoea (Modified MRC dyspnoea score) and exercise 
capacity (using the 6 minute walk) in addition to FEVI in a single indeX77. This index 
was developed in 859 outpatients with COPD and had an area under the ROC curve of 
0.74 in comparison to 0.65 if the FEVI % predicted was used alone. In this study a 
mortality of 80% at 52 months was observed for those patients in the highest quartile of 
the BODE score. 
ii. As a predictor ofhospital outcome 
The literature investigating the usefulness of FEVI in predicting mortality in intubated 
patients is less clear in its messages than that in stable patients. Fifteen of the 28 studies 
identified in the systematic review report lung function and these are summarised in 
Table 3.4.3.2.1 (studies where FEVI was analysed with outcome) and Table 3.4.3.2.2 
(studies where FEVI was reported but not analysed with outcome) below. 
In 13 of the studies the absolute FEVI was reported and in 9 of these the mean or 
median FEVI of the group was less than IL. Four studies reported FEVI percent 
predicted. The FEVI percent predicted was reported separately for survivors and non- 
survivors by Kaelin 56 and Nevins4s with survivors having mean (SD) FEVI percent 
predicted of 36.6% (14.5) and 47% (20) respectively, and non-survivors 30% (15.7) and 
54% (25) respectively (NS). Tbree studies reported the mean FEVI % predicted for the 
whole group which was 40% in a population with COPD and pneumonia ý3 , and 35%57 
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o/46 and 23 C in two studies with unselected COPD exacerbations. Of the 15 studies 8 did 
not report analysis of the relationship between lung function and outcome. In 2 of the 8 
studies without outcome analysis, though FEVI was sought, it was available in less than 
40% of the patients 1246 . In the 7 studies in which analysis was carried out to investigate 
a possible association between FEVI and survival, 4 studies found no significant 
relationship between FEVI and survival. However in 2 of these studies there were fewer 
than 15 hospital deathS44 68. Of the other 2 negative studies one included only 39 
patients 56 and the other only identified lung function in 56 patients which was 34% of 
the total sample5. 
This systematic review demonstrates that the majority of COPD patients intubated in 
critical care have fairly similar lung function with an FEVI of less than IL. It is likely 
that relatively large studies would be required to explore differential outcomes in a 
population with such narrowly distributed lung function and none of the negative 
studies would be considered large. In two of the studies reporting associations between 
lung function and outcome the association is described without a clear presentation of 
statistical significance. Menzies 57 describes survival curves for patients with differing 
FEVI % predicted and Rieves 60 reported that as the FEVI of patients rose the mortality 
ratio fell. One study reports a significant univariate association between FEVI and both 
hospital and 1-year survival with survivors having better lung function65. This is also a 
small study but it differs somewhat from the others in that the patients were selected to 
be homogeneous, all being on long term oxygen therapy prescribed by a chest 
physician. 
It should be remembered that lung function is just one determinant of outcome in 
COPD, and that whilst patients with very poor lung function may require only mild 
intercurrent illness to precipitate ICU admission, patients with better lung function may 
frequently require a more major insult such as pneumonia to require intubation. It is 
noteworthy in this respect that whereas Ely' S46 patients with heterogeneous causes of 
respiratory failure had a mean FEVI of 23% predicted, the patients reported by Torres 63 
with COPD and community acquired pneumonia had a mean FEVI of 40% predicted. In 
the Nevins4s study patients with respiratory failure and a clear x-ray had a mean (SD) 
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FEVI of 0.99 (0.40) and those with other causes of respiratory failure had a mean (SD) 
FEVI of 1.39 (0.62) p=0.006. It seems likely that on average patients with better 
preserved lung function require a greater insult to end up requiring intubation than those 
with greater lung function impairment. The SUPPORT study 12 demonstrated the 
importance of acute physiological derangement as an independent outcome predictor 
and the CMP data 27 demonstrated the independent prognostic significance of organ 
failures. Patients with fairly good lung function and pneumonia are more likely to have 
other organ failures than patients with extremely poor lung function whose deterioration 
has been precipitated by a mild exacerbation. This possibility along with the association 
of age with declining lung function makes it clear that an understanding of the 
contribution of lung function to survival requires large studies in which potential 
confounders are explored in an adequately powered multivariate analysis. It would seem 
fair to conclude that though the majority of the studies do not confirm a relationship 
between FEVI and outcome in intubated COPD patients, the literature might be 
considered inadequate to inform an assessment of the predictive significance of FEVI. 
That is to say there is an absence of evidence of a relationship rather than evidence of 
lack of a relationship. 
3.4.4 Functional capacity 
i. Mortality in stable outpatients with COPD 
Advanced COPD is associated with a progressive decline in patients' functional 
capacity and increasing shortness of breath on exertion. It might be expected that 
functional impairment and increasing dyspnoea would be associated with an increased 
risk of mortality and this has been shown in a number of studies of stable outpatients. 
In a study of 227 COPD patients enrolled in a 5-year prospective study Nishimura et 
a178 found a five point dyspnoea scale 79 (similar to the ATS dyspnoea scale) to be better 
able to identify patients at different risk of dying over 5 years than a classification of 
patients into categories of severity using FEVI. (Using a Cox proportional hazards 
analysis, grade 11 dyspnoea was taken as the reference group, and the relative risk for 
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death (95% CI ) for worsening dyspnoea was grade 1112.21 (0.93 - 5.27), grade IV 8.31 
(3.41 - 20.27), and grade V 61.3 (13.2 - 285.4)). 
Table 3.4.3.2.1 Lung function in studies investigating intubated patients: 
analysis with outcome 
FEV, 
Study (absolute and or % Analysis Findings Comment 
predicted) 
Mmn (SD) % Prdicted 
36 6% prc&cted (14.5) 180 day Cmparison of mean FEV, 
Kaefin 198756 vimvor% % pr"cted betwom ISO- No mignificam diffemnov Only 39 paficam 
30 0% pmdicted (15.7) 190 day day unvivorshmm-navivors 
no*-murvivom 
Univari ato analysis Data were available on FEV, mean (SD) 0 90 (0.38) . 
FEV, % predicted significantly 
FEV, (*A predicted) mean (SD) 
competing survivors, to son- 
higher in survivors than son- 
79/95 patients. 
survivors. 71m risk rafics associated 
Menzies 35%(15) Model constructed 
survivors 40% vs. 3 1% 
with specific levels ofFEV, 
198917 
75%ofpafients had FEV, <45% 
containing FEV, (% 
Survival curves constructed for 
were not preser. ad and the 
predicted, FEV, (% predicted) >4M 25- 
' predictedl functional SOOM model produced was not SOIA of patients had FEVj< 301/. 40V% <200/ý no significance 
albumin, am pulmonale. validated in a" ad ofnew 
predicted testsofourvespresented, 
LVF p- 
Analysis looked for FEVI % predicted was not a 
FEV, % predicted was 
prodicsonsofmortalityin 1"graficant mortality predictor in 
39 episodes in patients with FEVj<lI analysed in the patients 
Rieves 199360 mean 0.75. 
patients with FEV, >1 or <11 the 
, 
patients analysed in FEV, > 
tdready classified by FEVI. 
Another analysis found that or< IL Infiltrates predicted 
19 episodes FEVI>11 mean 1.56 There were 26 comparisons 
as FEV, in the whole group mortality in patients with FEV, 
in total only 59 subjects. 
fell the mortality ratio row. < 11 but am >11 
Moran 199V 0.7 (0.34) mean (SD) 
Univariste comparison for FEV, not a significant predictor 
Lou than 10 hospital deaths 
hospital mortality ofhospital mortality 
Mean (SD) FEV, 
ICU non survivors 0 68 (0.3) vs. 
ICU survivors 1.0 (0.34) Only 20 pancras in the 
P-0 089 somple. 
Anon 19991's 
FEV, total group median (range) Univariate comparison 
FEV, was reported as significant All on Long term oxygen 
0 83 (0.49-1.07) survivors vs. am-Anvivorl 
for hospital death mid death therapy, 
within I yew as a univariste 
association p-0.03 Hosphal, 
P-0 05 1 year 
Survivors mean (SID) 1.23 (0.54) 
Nevins 
Entire group 1.24 (0.58ý Univariate comparison 
,% predicted 
47% (20) vs. FEV, data only available for 
200 145 
COPD clear chest x-ray 0 99 (0.40ý hospital survivors Vs. non. 
Noti-survivors; 1.26 (0.7) 54% 56 pts La 34%. 
others 1.39 (0 62) survivors 
(25) p-os 
Whole group mean (SD) median (range) 
Multivariate logistic Reported as no a significant Breen 2002 " 0.74(0.34) 
regremi- produlor ofbospital monality 
Only 15 hospital deathL 
0.69 (0.2-1.9) 
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Table 3.4.3.2.2 Lung function in studies investigating intubated patients: 
descriptive studies 
Study 
FEVj 
Analysis Findings Comment 
(absolute and or % predicted) 
0.75L non-intubated 
Sluiter 1972 49 0.67L delayed intubated Descriptive only No outcome analysis 
0.85L immediate intubated 
Gottlieb 1973 51 
Mean 1.151, 
Descriptive only No outcome analysis 
(range 0.5-1.9) 
Mean 1.13L survivors vs. 0.781, 
Note the dying 
died bronchitis, 
emphysema patients 
Petherain 1980-'2 
Mean 0.8 survived vs. 0.48 
Descriptive only had a mean age of No outcomc analysis 
emphysema 
59.2 compared to 54 
in survivors. 
Limthongkul 
FEVI 0.58 (0.39) mean (SD) Descriptive only No outcome analysis 199118 
Torres 199663 Mean FEV, % predicted 40*/o Descriptive only No outcome analysis 
FEV, sought on all 
Connors 1996 12 0.80 (0.58-1.20) median (IQR) Descriptive only 
patients, but only 
available in 27% so no 
analysis carried out. 
74 out of 138 patients 
intubated, but total 
Hoo 2000" FEV, total group 0.79(0.4) Descriptive only 
group lung function 
presented 
FEVIO. 67(0.27) %predicted FEV, available for 16 
Ely 200e Descriptive only 
23.13% (7.8*/o) mean (SD) pts (361/9) 
In a study of 158 COPD patients recruited in pulmonary rehabilitation who were 
followed up for 40 months patients with a low 12 minute walking distance were at 
significantly increased risk of mortality in a multivariate logistic model that included 
age, FEVI and BM180. 
ii. As a predictor of outcome in patients with COPD hospitalised with 
exacerbations 
Ten of the 29 studies identified in the systematic search collected data on functional 
capacity and/or dyspnoea. In three of the studies there was no clear investigation of the 
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relationship between functional capacity and outcome (Table 3.4.4.2.1 below) and in 
seven studies some analysis with outcome was carried out (Fable 3.4.4.2.2 below). 
Table 3.4.4.2.1 Studies of hospitalised COPD patients reporting functional 
capacity but not analysing with outcome 
Study Measure of exercise capacity Analysis Findings Comment 
26168 Patients graded as capable 
No analysis with 
Sluiter" of light work. 32 graded as 
outcome 
having severe capacity 
20/30 Patients were breathless 
Ilese 30 patients with 
after walking about 100 yards or No analysis with their first episode of 
Gottlicbs' a few minutes on the level . outcome respiratory failure due 
10/30 were bedridden or 
to COPD 
confmed to the house 
It was not clear from the 
Pre-qnorbid exercise capacity, 
study report whether 23% able to walk long distance, No analysis with 
Moran" exercise capacity was 33% able to walk 100m own outcome. 
tested as an outcome 
pace, 44% housebound. 
predictor. 
Ten studies reported functional capacity or dyspnoea, and all reported a high proportion 
of patients to be unable to carry out at least one activity of daily living. Two studies 
presented descriptive data onl Y49 51 and in one study it was unclear whether functional 
capacity had been explored as an outcome predictor". 
Two of the seven studies investigating the association between functional capacity or 
dyspnoea and outcome did not find a significant association; both were small (25 
patients 52 and 58 patients6) and in the study with 58 patients analysis was stratified by 
FEV, making the strata more homogeneous. Five studies showed a significant 
association between functional capacity or dyspnoea and outcome. Two studies 5768 used 
the fimctional score (lifestyle score) and found more severe impairment to be associated 
with post discharge mortality. One of the studies did not report any analysis with 
hospital mortalityý 7 and the other reported that an analysis had taken place but that no 
association with hospital mortality had been found, 68. 
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Table 3.4.4.2.2 Studies of hospitalised COPD patients reporting functional 
cap acity in which there is some analysis with outcome 
Measure of exercise Study Analysis Findings Comment 
capacity 
-Exercin tolerance unhelpfid in 
Exercise tolerance wu graded 
predicting outoome in 7 patients 
ar. "normar. able to walk long 
ptthmm" distanoess at own pace, 
Univariate analysis with hospital with aMbyscire *Survivom Small numbers. 
. mortedity. unded to have better 
"intennedister- able to walk 100 
tolisance in Is patients with chronic 
yards on flat and "housebound": bronchitis" 
Univairiate analysis with I 80-day LInivanate comparison mean 
mortality. Sanctional score survivors 1.9 va. 
Men6s, 17 
Functional scoret Also Kaplan.. Meir type survival curve 
2.8 min-survivors p<O 001 
ATS DyspnDea woreu$ showed that patients grouped by Dyspnoes score survivon; 3.1 vs. function were differest p<D. I group 32 non-survivors p<D. 01 
(0+ 1) vs. (2) va. (3+4) 
Activity wore O=performs Activity score did not predict 
vigorous activity, I- hospital mortality-mean (SD) 
Independent, limited exercise Separate univariate analysis by hospital The we groups stratified by FEVI<IL* survivors 2.86 (0 39) vs. Rkvee capacity, 2- Independent, mortality with patients stratified by FEV, vicre, smell and relatively 3.12(0 96) nose-survivors, FEV, > 
severely limited exercise ability. FEVI>lLor<IL b-WB- IL survivors 1.92 (0.75) vs. 1.75 
3-puforms self-care cannot five (1.04) nosi-survivors 
almie, 4- bad or disk bound 
Activity score V Functional limits only significantly Note they only bad post 
Patients dichotomised for Univariate ad nuiltivaiiate analysis of associated with 1-year mortality. discharge outcome data on 
S. e analysis into those with patients with finctional limits vs. so Mortality 69% in patients with patients 65 years or okkr and of 
finictional limits vs. no functional limits to all time points functional limits, 50% without these 216 they had I year 
functional limits. filuctional limits P-0 01 outcome data on 167 
Katz ADL' and Duke Activity Hazard ratio (95% CI) ADL I point 
Score Index (DASIP in period change Univariate 124 (1.14 - A I-point change in ADL Univariate and multivariste Cox 
ofstability 2 weeks prior to 1.34). multivariste 1.14 (1.03 - indicates increasing disability. A Connor, 12 proportional hazards analysis to ISO- 
exacerbation. 1.26) DASI 3 point fall. univariate fall in DASI indicates poorar days 
Total population median (IQR) 104 (1.01-1.07) multivariste 1.07 exercise tolerance 
ADL 1 (0-2) DASI 17 (15-20) (0.90-1.29) 
Functional woret used with 
Functional score was not associated 
grade 0 and I anialgarristed. Univariste analysis by hospital Only 15 hospital deaths and 47 
Breen with hospital mortality or Itinger- 
40.5% of patients housebound mortality and survival to three years deaths at 3-years 
term survival. 
(Functional score grade 3 or 4) 
34.9% ofadmissions had severe Odds ratio (95%Cl) for hospital 
respiratory disease as measured mortality patients with severe 
Wildman" by APACHE U "severe 
Univariate and multivariate analysis by 
respiratory disease verms those hospital survival. 
respiratory disease definition without Univariate 1.15 (0 gg - 
when "lei 1.34) multivariats 1.20 (101- 1.42) 
Not= tmcxdmpwKdorw wmGjfw*w=ý': 0-warkmi& I-Welmdent- idly WrbU&AWYWdfivftWdhDlsq SaMmom 2- Rednm&*k to li"wdteirýmd go ad ofdwbýoD do 
býmomwikbufwvwdyfimftdm, ,ý lsbdq. 3loNounbowkd-cleModagaftbebmammm*Warldoda(debýonly; "" I aff-cm W mbb to do homy cbý mch u 
hýkmlor. CMM live ADW WAY be WAMUOMAINOL 4- Bad a chair boundL 
$AT$dyspý@DOW'. (])An 3Nm Woubkd by dwromafbresib wbm kOfYi*gm The bmd at %*&". Pa lh8M bdi? (2) Do ym bm 10 waft dý dm poopkafywý np= dw Wd bý of 
bmathk-MO (3) Do yo. am OW fw I "Olm Yom om pme as 69 L-4d? (4) Do ym ý ba" ID OV fm bleMb Wkg -alms Abod 100 Y" (w aft a kw =-. 6m) m fle kvd? (5) An 
you Wo bmtblm to hal lbe bý w bmddm m &a" at wdamW 
VSwefi*. (I)Smv b=ft'SboltQ(be&tb&tmdw&dmw I OWScblitaefddybýing(ADL! ')Wbotb. (Z)MldmftliftSbgtof lWiibfigWwdilywd 11 iDwwkmdl I wo or 
mom ADEA (3) No bwAtc No dyqmm wd wý dm I rwtmm in ADLL 
I APACHE 11 defimtm of wm mepm" diý. " Pai- bu PWMMOM dwmm of bmath with ligM AcWty due I* pidmonmy dwaW firAwoWly " pMxd Is un" to work wid be& shamim of 
bmth pofonning mod mormW saiwtks d4uly lWft emb u wa0dog 2D met= m Ir4W Sra" wa8mg dowJy im die hmom dunbog ý M& of omm, dmums a dmdwg 
Both studies were relatively small. Two studies used data routinely collected for 
APACHE scoring to dichotornise patients into those with functional limits versus those 
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without functional JiMits27 43. The APACHE III dataset study found that functional 
limits were only associated with 1 -year mortality, but not with hospital mortalitY43 . The 
UK study using APACHE Il found that though the functional impairment group had a 
non-significantly increased univariate risk of hospital mortality (OR (95%CI) for death 
1.15 (0.98 - 1.34)), the risk was marginally significant in the multivariate analysis (OR 
(95% CI for death) 1.20 (1.01 - 1.42))27. The SUPPORT study 
12 using Katz's 
Activities of daily living score (ADLS)82 and the Duke Activity Score index (DASI)83, 
found that ADLs had a significant association with hospital mortality in both univariate 
and multivariate analysis, but found an association with mortality only in the univariate 
analysis using the DASI. It should be noted however that the multivariate model also 
contained Katz's ADLS and there was likely to be some co-linearity between ADLs and 
DASI. 
iii. "y isfunctional capacity not a better predictor ofoutcome in acutely ill COPD 
patients? 
The above studies suggest that functional capacity does have a relationship with 
mortality in acutely ill patients but the relationship appears less robust than in out- 
patients followed up over longer periods, with performance in a 12 minute walk 
0 showing a particularly strong association with outcome in the outpatient setting, . 
There may be a number of explanations for this finding. It is known that when a risk 
factor is measured with non-differential error any risk ratios will tend towards the null 84. 
COPD patients requiring intensive care will often be too ill to give a clear account of 
their functional capacity and this information will often need to be collected via a proxy 
such as the next of kin. This method of data collection has important limitations. 
Various authors have reviewed the reliability of proxy data in describing quality of life 
domainS34 85 86. Exploration of the reliability of proxy report classically involves 
comparison with the patients self report which is taken as the gold standard. Sprangers" 
points out that though reviews of the literature generally show a relatively low 
concordance between proxies and patients some of the low concordance may arise 
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because of methodological difficulties in measuring concordance rather than being a 
real measure of disagreement. 
There are three main methodological issues. Firstly the dimension that is being explored 
and the way it is categorised will impact upon concordance. The more visible and 
concrete a construct, the higher the concordance. Concordance in determining affective 
states is likely to be lower than in determining visible functional attributes. For example 
asking proxies whether a patient is happy or sad will be less reliable than asking if the 
patient can feed themselves or not. In addition questions that dichotomise an attribute as 
present or absent are likely to show greater concordance than when questions require 
responders to judge the degree or frequency of participation in an activity. Secondly the 
statistical tests used to measure agreement are influenced by the range and variability of 
responses. If there is little variability in scores, correlations will be low simply because 
of lack of score variability. Sneeuw demonstrated this phenomenon in a study exploring 
proxy reports of quality of life in patients with brain cancer 87 . Thirdly neither the patient 
nor the observer will be entirely reliable in reporting the underlying construct described. 
In this regard Magaziner has shown that patients can differ in their description of their 
functional capacity when that description is compared with observation of patients 
actual performance in the tasks reported 86 . Spranger? 
5 draws upon Nunnally88 and 
Bland 89 to point out that this potential for unreliability is important since the correlation 
between two scores can never exceed the square root of the product of the scores' 
reliability. A recent study highlighted the issue that patients and proxies may not agree 
because patients may report their function in a biased way. In this study a number of 
patients who were only able to carry out light physical activities reported that they had a 
high level of physical fitness9o. 
Certain aspects of the research on proxy ratings have particular relevance for 
understanding the results of studies that have used functional capacity in predicting 
outcome. The literature suggests that there is a tendency for proxies to report greater 
disability than subjects self-reporel 92, though this bias can be lessened if questions 
about function are modified to refer to "explicitly defined and observable behaviors"86 . 
Since proxy ratings are most reliable when they relate to concrete and observable 
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domains and least reliable when they relate to subjective experiences such as anxiety or 
pain, measures such as Katz's ADLs 82 are likely to be relatively robust since they ask 
whether the patient is or is not independent in an ADL. It might be expected that proxy 
ratings of breathlessness would be intermediate between dichotomised descriptions of 
observed function and proxy ratings of subjective mental states such as anxiety. The 
definition of severe respiratory disease used in the UK CMP study" is open to some 
interpretation in that it asks whether the patient has "permanent shortness of breath with 
light activitieS"35. If a disability rating tended to encourage proxies to over report 
disability one would expect more patients to be categorised in the lowest functional 
group than occupy that group in reality, thus diluting the prognostic significance of 
maximally impaired function. In routinely collected data such as that used in the CMP 
study and the APACHE III study there is also the possibility of failing to collect data 
and if these data were missed at random it would again dilute the predictive ability of 
function. 
iv. Summary: Functional capacity and outcome in COPD 
In conclusion, the evidence reviewed suggests that in COPD outpatients measures of 
function do predict outcomeso. In the acute setting, errors in collecting true descriptions 
of patients function may limit the predictive ability of functional information, but 
complete collection of dichotomised attributes are likely to be the most reliable. This 
speculation is borne out by the observation that the best predictor of outcome in the 
studies described is Katz's ADLS, a dichotomised description of function that is likely 
to have been completely collected since the SUPPORT study was a very well funded 
study with high standards of data monitoring and general data completeness 12 . 
80 
3.4.5 Self-rated quality of life 
Some studies have used patients' self-rated quality of life as a way of capturing 
patients' overall views of the impact of disease on their life. Lynn found that in 
hospitalized patients with COPD those patients with self-rated quality of life that was 
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excellent or very good had better survival rates than those with poor quality of life . 
The difficulty with self-rated quality of life is that it is a subjective non-observable 
patient attribute that is likely to be unreliable if collected via proxies 96 . 
3.4.6 Co-morbidity 
COPD is mainly caused by smoking and in the recent summary of the results of 50 
years of follow up of British doctors Doll listed 10 broad categories of disease 
associated with cigarette smoking in addition to COPD94. With cigarette smoking 
associated with disease in so many body systems it might be expected that comorbidity 
would be an important problem in patients with COPD. 
3.4.61 Methodological issues in comorbidity measurement 
Elixhauser95 provides a useful categorisation of the entire burden of disease of a patient 
admitted to hospital in the following 5 categories 1) The primary reason for 
hospitalisation, as reflected in the principal diagnosis, 2) The severity of the principal 
diagnosis, 3) Complications that result from the process of care, 4) Unimportant 
comorbidities or other conditions present on admission that have a trivial impact on 
resource use and outcomes and, 5) Important comorbidities or conditions present on 
admission that are not related directly to the main reason for hospitalisation, but that 
increase the intensity of resources used or increase the likelihood of a poor outcome. 
Elixhauser considered a secondary diagnosis to be a comorbidity only when it did not 
relate directly to the primary diagnosis, on the basis that comorbidity related to the 
primary diagnosis might in reality be a marker of the severity of the original disease 
rather than a distinct comorbidity. 
The evidence outlining the contribution of comorbidity to outcome prediction in COPD 
is limited and what evidence there is might be taken to suggest a relatively minor role in 
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hospital mortality. In the SUPPORT study 12 comorbidity data were collected by nurses 
using the 42 comorbidity classes defined in the APACHE III prognostic systeM36. 
Seventy five percent of COPI) patients in SUPPORT had 2 to 3 comorbidities93. The 
contribution of comorbidity to mortality was explored by using the total number of 
comorbidities as an explanatory variable in the regression model and this did not have a 
significant hazard ratio for death (univariate hazard ratio (95%CI) for each additional 
co-morbidity 1.09 (0.98-1.21), multivariate hazard ratio 1.13 (0.99-1.28). Elixhauser 
makes the point that counting the number of comorbidities can produce spurious results. 
This is illustrated by Elixhauser's finding that studies have shown that minor 
comorbidities such as hypertension may seem "protective" because they are coded in 
patients who have no other comorbidities but missed in patients with many 
comorbidities. Hence hypertension only appears in the otherwise healthy patients since 
though it may well be present it is not coded in the sickest patients. In Elixhauser's 
study95 this finding was confirmed in that hypertension decreased the odds of in- 
hospital death by 40% Elixhauser points out that "a seriously ill patient may have so 
many medical problems that hypertension though detected was not abstracted for the 
discharge record. "ý- hence hypertension only gets abstracted in the non-sick patients. It 
is unclear whether this process of "under abstraction" might contribute to the poor 
predictive performance of the total number of comorbidities in SUPPORT. 
Elixhauser's study also provides compelling evidence for disease specific weighting of 
comorbidittles by demonstrating significantly different disease specific weightings in 
data derived from 1779167 medical admissions in California. Unfortunately disease 
specific weightings are not presented for COPD and personal communication with the 
author confirms that these were not calculated. Nevertheless the fact that different 
comorbidities do bear different weights depending upon the primary diagnosis suggests 
that a more sophisticated approach to comorbidities other than simple counting them is 
likely to discriminate better. In keeping with this work Incalzi 96 collected comorbidities 
in COPD patients using the Charlson indeX97 and showed that though the weighted 
Charlson index did not add useful explanatory power to models predicting mortality, 
individual comorbidities, (specifically chronic renal failure and previous myocardial 
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infarction) were predictive. The Incalzi study was relatively small (270 patients 
recruited at hospital discharge) but showed that collecting comorbidities in a more 
detailed way did increase their predictive power. (A history of myocardial infarction in 
Charlson was not predictive, whereas specific ECG changes were). This suggests that 
increasingly sophisticated ways of collecting comorbidity data might yield greater 
discrimination. It should be noted however that some studies that have used very 
sophisticated and time consuming measures of comorbidity have shown only modest 
increases in the capability of comorbidity measures to predict increased ris0s. 
3.4.62 Comorbidity in studies identified in the systematic literature search 
Ten of the 29 studies identified in the systematic search reported comorbidities for the 
included COPD patients 12 27 43-45 57 62 63 65 and these are summarised in Table 3.4.6.2.1 
and Table 3.4.6.2.2. Most of these studies used different non-validated measures of 
comorbidity making comparisons difficult. However the APACHE II comorbidity 
classification was used by both the Nevins studY45 that included 166 intubated patients 
from a critical care unit in the USA and the CMP stud Y27 that included 3752 patients 
from 128 UK critical care units. Patients admitted to the USA study had a 10-fold 
increased prevalence of comorbidity compared to the UK study (42% USA versus 3.8% 
UK). Though it is impossible to exclude coding differences, as a cause for these 
differences it is noteworthy that the USA has many more critical care beds than the UK 
and the differences may reflect UK gatekeeping policies which tend to exclude COPD 
patients with comorbidity. 
Of the nine studies seven explored the relationship between comorbidity and survival. 
Four found no significant associationý' 44 11 ". In two of the negative studies there were 
less than 20 deathS44 65. In the Menzies stud Y57 there were only 95 patients and there was 
a non-significant trend towards both cor pulmonale and a history of left ventricular 
failure being commoner in non-survivors. In the other non-significant stud Y43 it is 
unclear how comorbidities were analysed and the author states that "comorbidity was a 
non-significant determinant of hospital mortality once severity of illness was taken into 
accounf'. Of the three studies identifying comorbidities as being associated with 
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outcome, each used different classification systems. Fuso62 looked at individual 
comorbidities as defined for his study and found atrial fibrillation, previous myocardial 
infarction and ventricular arrhythmias to have a univariate relationship with survival, 
and atrial fibrillation and ventricular affhythmias to have a multivariate relationship 
with survival. Nevinsý5 used the APACHE II comorbidity classification system and 
found that patients with any comorbidity had significantly lower survival than those 
without. Analysis of individual comorbidities found only active malignancy to have a 
significantly poorer survival, but numbers were small. Connors 12 used the APACHE III 
comorbidity classification system and found that though single additional comorbidities 
did not quite convey significantly poorer prognosis, differences of greater than one 
comorbidity did. 
Table 3.4.6.2.1 Studies describing comorbidity but not exploring association 
with outcome 
Study Measure of comorbidity Analysis 
gjimes 60 Stable angina 36 4** congestive cardiac failure 30.36/6, hypertension 
Assocuition between chrome health problems and outcome not reported 33 
patients described, but total % oweads 100% since some patients had more than 30.3-* diabetes 21.2% 
I comorbidity 
Torree 
No comorbidities in 3 10/6, c4rdiovascular comorbidity in 290/s, diabetes in Association with outcome not explomd. 60/% neurological in 40/9, surgery in 86/aý others in 23%. 
Comorbidity was presence of APACHE 11 defined illness with <40/. of 
Wildman3 cohort having comorbidity Numbers too small to allow individual exploration ofoomorbidity with hospital 
7 0.2% cinhosis. 08% immunosuppression. 0.34/o chronic renal faidure. mortality 
0.20/a active malignancy and 2.3% cardiovascular disease 
3.4.63 Comorbidity measurement in COPD: Conclusions 
The foregoing suggests that measuring comorbidities is difficult. There is a tension 
between finding a validated measure that is easy to use and the fact that simplistic 
descriptions of comorbidity may fail to identify those patients at greatest risk. For 
example the fact that a patient has had a myocardial infarction is nowhere near as 
useful as knowing the patient's cardiac ejection fraction". 
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Table 3.4.6.2.2 Studies exploring association between comorbidity and 
outcome in hospitalized patients with COPD 
Study Measure of comorbidity Analysis Findings Comment 
thstory of left ventricular failure us 19% Cor pulmonale present in 3 1% survivoin; vs. 
' 
Univariste ansly as 
MenAes 
Cor pulmonale on ECGt in 41% of sample 
with I 80-day 
%O/s non-survivors . 05<p<O 
I Notary LVF 
History of myocardial infarction - distribution not al i 
present in 11% survivors vs. 24% non- 
reported 
surv v 
survivors, W not associated with outcome, 
OfthO 590 Patients, 23.7% bypestension, 11.0% 
diabetes, 7.66/* chronic renal failure, 53% ischaernic Significant univariate association with hospital 
heart discasi% 3.7% chronic liver disease, 3.2% Univariate and death OR (95% Cl) atrial fibrillation 3.95 (1.99 
previous myocardial infarction, 0.7% valvular ban multivariate analysis -7 901 previous myocardial infarctios 3.69 
Fuso disease, 18 Vla ventricular arrhythmias, 14 9% ST ofindividual (1.26 - 10.51 ventricular arrhythmias 2.49 
segmenit &T wave changes, 14.4% right bundle comorbidities with (1.43 - 4.28) and multivariate atrial fibrillation 
branch block, 8.5% atria[ fibrillation, 6.10/oprevious hospital mortality 2.27 (1.14 - 4.51) and venuicular arrhythmias 
myocardial necrosis, 4 1% previous myocardial 191 (1.10-3.31) 
necrosis. 
Not explicitly stated, 
though textual 
Text mports that comorbidity was a noo. 
scineff, 111 Distribution ofconxwbidity not described 
description suggest 
.a 
significant detemunart ofbospital mortality 
mukivarime analysis 
inchiding acute 
owe severity of illneso taken into account, 
physiology 
Proportion ofpop"on with number of Univariate and 
Hazard ratio (95% Cl) per I ctimorbidity, 
increase: Univariste 1.09 (0 98 - 1211 cornorbiditics: multivariate Comorbidities 
Co,.., MI3 0-2.7% 1-19^ 2-34.5*/% 3-23.25A 4-12. M association with 
Multivariate 1.13 (0 99 - 1.28ý 
classified using Though the Presence of& single additional >4-7.6% mortality to 1804"S the 42 categories 
comorbidity did not identifý patients at Congestive cardiac Whire as cow ofexaoubgtion explored with Cox used in APACHE 
and cor pulmonale both associated with lower propor6ionall hazards 
significantly increased hospital! mortality 
Inx 
additional comorbiditics did and comorbidity 
mortality in univariate arid nwhivariate analysis analysis 
wu included in the outcome modeL 
proportion ofpc"dation with comorbiditier. Car 
expbration of 
Only It hospital 
Morw, 44 pulmonale 32%, congestive cardiac fikilure 356/o. 
comorbidities in 
No association ofcomorbidity and outcome. deaths and 19 
association with ischaernic heart disease 291/% hypertension 17% 
hospital and post 
190-daydeaths 
discharge mortality 
Univanate 
Conmxbidity present in 40% ofpatients: Wle 
An., 43 
hypertension, 10% diabdm 10% strial fibrillation. 
20% i9chentic head disesso, 60*/* had ECG signs of 
right ventricular hypertrophy. 
Comorbidity was presence of APACHE H defined 
Nevins 
illness with 42% ofcohM having cmnorbidity. 
3 6% cirrhosis, 17.7% immunouippression, 4.2% 
chronic renal fkilwvý 21.7% active nudignancy 
association between 7 tat of 12 patients with right vennWar 
right vadriculw hypernophy died bLd this was no statistically 
hype"hy and ICEJ significam 
mofwity investigaw 
comparigoo with 
Any veran no comoFbidity anvivom w non. hospha nlortwty, 
uffvivom 376A vL 54% V-0.04. Acfm 
any aDmorbidity and 
maligmncypiese. labmtmnvivomvs. son- 
canoer signiflout. 
Kwvivors 14% vL 41% p<D. 001 Othen non- 
significant. 
Note only 20 
paticas in this 
suldy. 
tP pulmonale defined as any one of , (1) p puhnonale, (2) right ventricular failure, (3) right axis 
deviation, according to Marriot criteria. 100 
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The results from the case mix programme database in which comorbidity was present in 
only 4% of over 3000 COPD patients admitted to critical care raises the possibility that 
in the UK patients with COPD and comorbidity tend not to be admitted to critical 
care 27 . Of the validated comorbidity measures the Charlson'01 is one of the simplest and 
the possibility of individual weightings of comorbidities holds promise for greater 
discrimination. In addition certain comorbidities such as atrial fibrillation 62 are easy to 
collect and have been shown in some studies to have value. 
3.4.7 Body mass index 
The nonnal range of BMI is 20 - 25k g/M2 
102 
. BMI does not distinguish between 
depletion of fat and protein stores, but in general terms patients with a BMI less than 
20kg/m2 may be at risk of nutritional depletion. 
Table 3.4.7 BMI in UK adults 103 
BMI (kghný) Interpretation 
>40 Grade III obesity 
3040 Grade 11 obesity 
25-30 Grade I obesity 
17-20 Underweight 
<17 Severely underweight 
3.4.7.1 Body mass index in stable outpatients with COPD 
The association between low body mass index and poor prognosis has been studied by 
Landbo et al in COPD patients identified from the Copenhagen City Heart Study 104. in 
this study of over 2000 patients with obstructive spirometry (FEVI to FVC ratio <0.7) 
multivariate Cox regression was used to identify risk factors for mortality occurring 
over 17 years. In mild to moderate COPD there was a nonsignificant U-shaped 
relationship between BMI and mortality, with the lowest risk in normal-weight to 
overweight subjects, whereas in severe COPD the relative risk for low versus high BMI 
was 7.11 (95% CI 2.97 to 17.05). The risk ratios were adjusted for age, ventilatory 
function and smoking habits. Schols studied the relationship between BMI and outcome 
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using a Cox proportional hazards model including age, sex, spirometry, blood gases and 
smoking in a population of 400 COPI) patients enrolled in a pulmonary rehabilitation 
scheme and suggested a threshold value of 25kg/m2 below which mortality was clearly 
05 increased' . Schols also carried out a post hoc survival analysis of a randomised 
controlled trial of nutritional support and though the intervention group did not differ 
from the non-intervention group response in terms of overall survival, those patients 
who demonstrated a weight gain of >2kg in eight weeks did show significantly 
increased survival. More recently Celli has demonstrated BMI to be an important 
contributor to a multidimensional BODE index (see section 3.4.3) in predicting 
mortality in COPD patients77. 
3.4.7 2 Body mass index and outcome in acutely ill patients with COPD 
Only two of the studies identified in the systematic search investigated the role of body 
weight and mortality, a weakness possibly related to the retrospective nature of the 
majority of the studies which often depended on routinely collected data. The two 
studies are summarised in the table 3.4.7.2 below. 
Table 3.4.7.2 Body mass index and outcome in acutely ill patients with COPD 
Study 
BMI in study 
population 
Analysis Findings Comment 
Mean (SD) ideal body No significant difference between 180-days 
weight was reported for Kaelin* Univariate comparison 
survivors vs. Don-survivors. Mew (SD) Very small 
180-day survivors vs. non- 180-day survivors 87 (15) vs. non-survivors sample n-39 
survivors 88(17) 
Summary statistics not 
Cox proportional Hazards Hazard ratio (95%Cl) BMI 5 Kgtn? fidl, 
Connors 12 for 180-day survival, Univariate 133 (1.20 -1.49ý presented. 
univariate and multivariate Multivariate 1.33 (1.17 - 1.49) 
The only study to investigate body mass index in COPD patients with acute respiratory 
failure found it to be significantly associated with outcome in a well designed 
12 
prospective study using Cox proportional hazards . The only other study that 
investigated body weight did not report body mass index and studied only 39 patients in 
56 
total 
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3.4.7 3 Problems with measuring body mass index in acutely ill patients 
The SUPPORT study demonstrated a robust relationship between BMI and outcome in 
acutely ill COPD patients, which is consistent with the observations in stable 
outpatients 12 . However, though the number of patients with missing BMI is not reported 
there was clearly a problem with missing data since the final outcome model contained 
a dummy variable for those patients where the BMI was missing. This was despite the 
study only recruiting in five centres and having full time data collectors in each centre. 
3.4.7.4 Mid-upper arm circumference 
Collins demonstrated that the mid-upper arm circumference (MAC) had a good 
correlation with BMI in 98 severely malnourished adults in a feeding centre in Sudan, 
the correlation between the two being 0.88 (95% CI 0.82-0.92 P<0.001)106 .A French 
study identified MAC to be significantly associated with 180-day mortality in a 
population of 116 consecutive patients aged 70 years or older admitted for various 
reasons to a single French critical care unit and intubated for at least 24 hours 107 . In this 
study a MAC under the IOh percentile for the older French population in good health 
was used as a threshold value and reported to have an odds ratio of 3.43 for mortality 
compared to patients with a MAC greater than this level. They report that this threshold 
had a sensitivity and specificity for 180-day mortality of 35% and 89% and a positive 
predictive value of 78% and a negative predictive value of 56%. The analysis involved a 
data driven exploration of several variables with outcome. The patients who survived 
180-days had a mean (SD) MAC cm 30.2 (4.6) cm and the patients who died within 
180-days had a mean (SD) MAC of 27.5 (3.5). 
MAC is easy to measure and does not require expensive equipment like the more 
sophisticated mid-upper arm muscle circumference which requires a skin fold calliper, 
and as such it provides a potential way of estimating BMI in patients who are acutely ill 
with COPD although up to now, this has not been explored in this context. 
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3.4.8 . 4cute physiology as a predictor ofoutcome 
The APACHE score'08 has found widespread acceptance as a method of measuring the 
risk of death for patients admitted to critical care and is now in its third version 36 . It has 
components that take account of the chronic health of the patient, the primary diagnosis 
and the acute physiological impact of the illness (acute physiology score (APS). The 
APS gives weights to the various biochemical and physiological derangements 
associated with acute illness. The APACHE score is a generic acute physiology score 
and when the SUPPORT study 12 produced an outcome prediction model for patients 
with COPD, albumin and the Pa02/FiO2 ratio added explanatory power to a model that 
already contained the generic APS from APACHE III (which already takes account of 
albumin and oxygenation). This suggests that a disease specific APS might be useful. A 
number of the studies identified in the systematic search investigated individual acute 
physiological factors and these are highlighted below. Section 2.5.3 above discussed the 
need for at least 10 deaths per level of a risk factor. This makes it clear that many of the 
studies were too small to systematically investigate the significance of acute 
physiological factors. 
3.4.9 Albumin 
Albumin has been noted to be an important predictor of outcome in a wide range of 
hospitalised patients. In 509 male patients identified because they were inpatients in a 
Veterans Affairs Hospital with any diagnosis and selected for the study because of the 
finding of an albumin less than 34g/L, there was a linear relationship between 30 day 
mortality and serum albumin. For the 50 patients with an albumin less than 20g/L the 
30-day mortality was 62% (95% CI 47.2 - 75.3)109. Albumin is included in the generic 
severity scores APACHE 1135 and APACHE 11136. In the SUppORT12 COPD model, 
albumin was retained in the mortality prediction model that already contained albumin 
as a component of the acute physiology score from APACHE III. A lOg/L fall in 
albumin was associated with an independent relative hazard of death of 1.37 (95% Cl 
1.02- 1.82). Hypoalbuminaemia may reflect poor hepatic synthetic function, acute 
inflammatory response or malnutrition. It seems likely that the prognostic importance of 
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albumin in COPD patients will reflect both the impact of malnutrition and the impact of 
the acute inflammatory response. The acute inflammatory response reduces albumin by 
four mechanisms; (1) haernodilution, (2) leakage into the extra vascular space due to 
increased vascular permeability, (3) increased albumin consumption by cells and (4) 
decreased albumin synthesis by direct inhibition by cytokines. Though albumin has a 
half-life of approximately 20 days with around 4% being degraded daily, the falls 
associated with the acute inflammatory response may be relatively rapid. Nevertheless 
the long half-life of albumin may partly explain its marked importance in the 
SUPPORT model that used day 3 acute physiology allowing more time for the effects 
of the acute illness to impact upon the albumin. 
Table 3.4.9.1 below shows the relationship between albumin and outcome reported by 
the studies identified in the systematic search. Nine of the 28 studies reported albumin 
levels in the studied COPI) patients, five studies carried out univariate analysis and 
three studies carried out multivariate analysis. Many of the studies were small and had 
limited numbers of deaths. Only the Kaelin study 56 found that albumin levels were the 
same in patients who lived or died but this was a small study (n--39). In the studies 
using univariate analysis, one study reported lower albumin in ICU non-survivors 
compared to survivorS65 and two studies reported lower albumin levels in patients 
dying in hospital compared to survivorsý 5 60 , though in the Rieves study where the 
analysis was stratified by FEVI, there were few events and the difference between 
survivors and non-survivors did not reach statistical significance. One study using 
univariate analysis found the albumin on hospital admission to be significantly lower in 
patients who died before one year than one year survivors". Of the three studies 
reporting multivariate analysis 122744 two studies used an explicit a priori analysis plan 12 
27 and both these studies showed albumin to be significantly associated with mortality. 
In the SUPPORT study 12 1016 COPI) patients were studied of whom 348 were 
intubated and albumin was found to have an independent relative hazard of death of 
1.36 (1.02- 1.8) in a multivariate analysis that also contained body mass index and age. 
In the CMP stud Y27 in a multivariate analysis of 3752 patients of whom 3052 were 
intubated comparing hospital survivors and non-survivors in which patients with an 
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albumin greater than 25g/L were used as the reference group, patients with an albumin 
<20g/L had an OR (95%CI) for hospital mortality of 1.94 (1.46 - 2.58) and patients 
with an albumin 20 - 24g/L had an OR (95% CI) of 1.28 (1.01 - 1.61) for hospital 
mortality. This multivariate analysis did not contain body mass index but did contain 
age. Though once again many of the studies are small there is a consistent message that 
albumin is an important predictor of outcome. This is confirmed in the bigger studies 
where albumin is shown to be an independent predictor of outcome, even in the 
SUPPORT study that also included body mass index. 
3.4.10 Acidosis. 
Acid-base balance is an important aspect of homeostasis and blood pH, (the negative 
logarithm of the hydrogen ion concentration), is closely controlled in the range 7.35 to 
7.45. In COPD patients, acute type II respiratory failure (PaOXe 8kPa, PaCO2 >6.50a), 
will cause a respiratory acidosis. Metabolic acidosis will reflect developing failure of 
other organs, for example acute renal failure will cause metabolic acidosis, as would 
cardiac failure that might result in circulatory shock. 
Acidosis is an important marker for the severity of the acute illness and contributes to 
the acute physiology score of both APACHE II and APACHE 111. PH has been 
identified as a risk factor for mortality in hospitalised COPD patients with respiratory 
failure"O 111 and this is partly because it identifies those patients who will require 
intubation. Sluiter49 reported intubation rates of 85% in patients with a pH <7.20 and 
63% in patients with a pH between 7.21 and 7.40 and Hoo 66 described an intubation rate 
of 70% in patients with a pH <7.20 and 50% in those with a pH >7.25. However there 
are no hard and fast rules about intubation though the decision will often be driven by 
the pH. Table 3.4.10.1 below shows those studies identified in the systematic review 
that have reported pH and Table 3.4.10.2 those that analysed pH with outcome. 
Twelve studies report the pH of the included COPD patients. However only 8 analyse 
the association between pH and mortality. In two of the studies 12 62 that report no 
association between pH and mortality the reported pH is close to the normal range. In 
SUPPORT 12 the day three pH is analysed (median (IQR) 7.36 (7.30 - 7.40) and in the 
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Fuso study62 the mean (SD) pH in both survivors and non-survivors is in the normal 
range at 7.35 (0.07) and 7.35 (0.09) respectively. The three other studies reporting no 
association between pH and mortality include data from acidotic patients but carry out 
the analysis using the pH at the time of intubation45 64 68 . PH values at the time of 
intubation measure the pH before aggressive treatment has started and reflect process of 
care factors such as oxygen management, whereas pH measured once aggressive care 
has been established may reflect poor response to therapy which may be more 
associated with outcome. 
In a study of 983 patients with COPD presenting in casualty, Plant showed that 20% of 
patients with acidosis improved with initial simple treatments and that the pH was 
inversely correlated with arterial oxygen tension 112 . This highlights the impact of 
oxygen management on pH in spontaneously breathing COPD patients. Of the studies 
finding no relationship between pH and survival two were small, with the Hill study", 
including only 20 hospital deaths and the Breen stud Y68 only 15 deaths. A finther 
negative study included 166 patients with 46 hospital deaths with the mean (SD) pH in 
survivors 7.27 (0.12) compared to the mean (SD) in non-survivors 7.25 (0.12) p=0.6. 
Of the three studies showing a significant association between pH and hospital mortality 
one included a large proportion of non-intubated patients and used the pH at hospital 
admissiorý8. The other two positive studies, which include over 4000 patients in total, 
used the pH from ICU 27 67 and in the CMP study which was the largest of these studies 
the pH used was selected as the lowest in the first 24 hours in ICU. The CMP study 
included just less than 3000 intubated patients and found significant increased odds of 
hospital mortality with increasing acidosis in both univariate and multivariate analysis. 
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Table 3.4.9.1 Albumin and outcome in hospitalised COPD patients 
Study Albumin level Analysis Findings Comment 
Kaelift" Mean (SD) 34 (9) SIL us 
Univanate. IS patients dying Early mortality group me" (SD) Them are small numbers 
Wore 190 days were compared albumin was 34(&)SIL and in (albumin closest to 180-day deaths, 34 (6)g/L in ofpstients with a small 
to 24 patients surviving more survivors beyond 190-ilays was 
intubation) I&G-day survivors. number ofevents. 
than 180-days 34(6)&/L 
Menzies, 
Mesa in survivors 32SA in Univiviate analysis for I yew Main in survivors 3Zg/I in non- 95 patients with 59 
(albumin on 
no" 29sA survival survivors 29&4 P<0.05 deaths at I year. 
hospital admission) 
Mean(SD)FEVI<IL 
There were half as many 
hospital survivors albumin deaths in those patients, 
34. I(S 1) g/l., nori-survivors A lower albumin (borderline 
with FEVi> 11ý Oack of 
Rieved" (Albumin 
albumin signifkant) was observed in the 39 
power explisining the 
30.2(0.71)g/L p-0056 Univariate analysis by hospital episodes in the pts with FEV, <II 
within 24 hours of lackofstatisticall 
FEVI>IL hospital survivers survival and in those with FEVI> 14 
intubation) significance) but overall 
albumin 36.5(8.2) &T, ison.. patients who died had a lower 
the study supports 
survivorsalburnin albumin but numbers were small 
albumin as a univariate 32.2(9 9)WL 
outcome predictor. 
p-0.26 
Given that these patients; 
Torres" (Albumin all 
W pneumonia the 
Mean (SD) albumin fir effect ofacute phase 
measured on No analysis 
population 31(7) g/L might be expected to 
admission) 
produce a low time 
albumin. 
Multivariate analysis 
included both intubisted 
Hazard ratio (95% CI) 1.78 (1.35- 
and non, -intubsted Connors" Cox proportional hazards model. 2.39) - increased risk ofdesth for Distribution in cohort not patients and both body 
(Reported albumin Multivariate and univariate every 10g/I fill in albumin 
reported mass index aid acute 
measured at day 3) andysis oftime to death univariate and 1.36 (102- 1.9) 
physiology scom that 
multivasiste, 
already includes 
albumin. 
Multivariste analysis 
Moran ' (Albumin 39 (SD 6) investigating 2 year mortality 
Arournin taken at ICU admission Albumin did not predict 
predicted long term 2-year sumvid hospital mortality but 
at ICU admission) (range 1&49) with model containing age, ICU in a inultivariate p<0.01. only hospital deaths. 
adviission and plainna alliumin 
AnorP Mean (SD) ICU sumvors 30 6 
Median range total group Univariate companson between 
(Albumin at ICU (0.34) non survivors 27.8 (0 191 
29.5 (23-39) ICU survivors and non-survivors 
admission) p-0.05 
Nevin0' Univariate comparison between Hospital survivors mean (SD) 30g/I Distribution in satal group 
(Lowest albumin in hospital survivors and non. (6) son- 
1' 24 boom in ICU) 
not reported 
survivors survivors 26 (6) P-001 
Albumin <20 g/L univariate OR 
Univariate and multivariate (951% CI) 2 73 (2.11 - 3.54ý 
Wildman CMP compan between hospital multivariate OR (95% CQ 194 Median QQR) in total group (Lowest albumin in survivors and nori-survivors, (1.46-2.59) 
1" 24 hours in ICU) 
28(23-33) 
relative to patients with albumin Albumin 20 - 24 g1l, univariate OR 
>- 25 or not recorded (95% CI) 1.49 (1.20 - 11.84ý 
multivariate 1.28 (101 - 161) 
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Table 3.4.10.1 Studies reporting but not analysing pH with outcome 
Study pli of Included patients Analysis Findings Comment 
GottlieV 
Mean PH 7.3 range 
None done 
Includes urtubated and non- 
(6.95- 7.47), on air intubated patients. 
Moran44 
Mean (SD) 7.24 (0.11) for 
100 patients in total group, Study includes intubated and 
(Pre-ICU admission None done 7.21 (0.12) in 43 intubated none intubated. 
PH) 
patients 
Anon' No analysis ofpH Median (range) whole group 
(In first 24 hours in done instead All patients were intubated. 7.2 (7.0-7.34) 
ICU) APACHE H analysed 
Intubated PH mean (range) Intubation rate 70% in No analysis ofpH in 
Hoe (PH on 7.26 (0.07), range (6.96-7.35); patients with PH< 7.20, 
association with hospital admission) not intubated PH 501/e in those with PH 
survival 7.28 (0.06), range (7.04-7.35) >7.25 
Table 3.4.10.2 Studies that have investigated the association of pH and 
outcome 
pli of included Study Analysis Findings Comment 
patients 
Limthongkul 1991 " 
Group mean not 
Univariate comparison of Mean (SD) pH survivors 7.37 (0.9) Includes intubated and Don-intubeted (pH at hospital d 
hospital survivors versus vs7.29 (0 015) non-survivors i 
admission) 
reporte non-survivors P<0.001 Pat ents. 
Fuso 1995 
Group mean not 
Univariate comparison of Mean (SD) pH survivors 7.35 (0.07) 
Includes intubined and non-intubated 
(pH at hospital hospital survivors vemis patients with 85 deaths fiom 590 reported 7.35 (0.09) non-survivors p-ns 
admission) wo-survivors patients 
12 Connors 1996 
Group median Univariate and multivariate pH was wither a significant 
(IQR) Cox proportional hazards univariate nor a multivariate, 
Includes 1016 COPD patients of whom 
(lowest pH day 3) analysis for 190-day 349 were intubsted. 7.36 (7.30-7.40) 
mortality predictor of 
I 80-day mortality 
Hill 1998" Univariate comparison of Median (range) hydrogen ion 
All patients intubsted. 20 deaths and 21 
(W immediately 
Group median not hospital survivors versus concentration 69.2 (57.1 - 91.2) 
survivors and paradoxically the 
reported survivors were more scidotic, though 
prior to intubation) Don-11turvivon died 62 8 (49.4 - 91) not significant not significantly so. 
Nevins 2001 Univariate comparison of Mean (SD) 7.27 (0.12) hospital 
(pH at time of pli 7.26 (0.12) hospital survivors versus non survivors 7.25 All patients intubated. 
intubation) survivors (0.13) non-survivors p-0 6 
Afessa 200267 Group mean not 
Univariate, comparison Mean (SD) Hospital survivors 7.25 
250 admissions in 180 patients ofwhom 
between hospital survivors (0. lk aim-survivors 7.21 (0.12) (pH in IM reported 153 episodes involved intubation 
and wo-survivors p-0.0408 
Breen 2002 
Mean (SD) for 34 Multivariate analysis Analysis included itittibated mid non. (pH directly before 
intubated patients 
hickiding intubated and non. 
pH reported as no"gnificut. intubated patients with IS hospital intubation or on intubated for hospital 
ICU admission) 
7.13(0.13) 
mortality 
deaths. 
Wildman 2003 27 
Median (IQR) Univariate and multivariate OR (95%Cl) per 0.1 decrease in pH 
Analysis included intubated and non 
i b d i h (lowest pH in first analysis fbr hospital Univariate 1.31 (1.23 - 140) 
ntu ate pat ents. t ough 90% of 
24 hours in ICU) 
7.26 (7.18 - 7.33) 
mortality Multivariate 1.25 (1.15 - 1.23) 
samples were definitely or probably 
intub&W in first 24 hours in ICU. , 
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3.4.10.1 Acidosis: conclusions 
In summary, of the eight studies investigating the relationship between pH and 
mortality five found no significant relationship and three found that patients who were 
more acidotic had a higher mortality. It is likely that the relationship between pH and 
mortality is complicated by the fact that a respiratory acidosis soon after hospital 
admission occurring due to uncontrolled oxygen therapy is likely to have a very 
different significance to a metabolic acidosis that may indicate additional organ failures. 
3.4.11 Oxygenation 
As COPD progresses patients become increasingly hypoxic so that hypoxia, is a marker 
of how advanced the COPD is. In addition acute illnesses such as pneumonia will 
worsen hypoxia with greater hypoxia reflecting greater severity. For these reasons it 
might be expected that worsening hypoxia would be associated with worsening 
outcome. Typically hypoxia is measured by analysis of the oxygen in the blood and 
because the oxygen in the blood can be corrected by supplemental inspired oxygen it is 
important to correct for supplemental oxygen if the arterial oxygen concentration is to 
be used as a marker of severity. 
3.4.11.1 Alveolar-arterial oxygen gradient 
The Alveolar-arterial oxygen gradient is a relatively complicated way of taking into 
account the influence of both the inspired oxygen concentration and the level of the 
alveolar carbon dioxide concentration and the equation is given below. 
A-a gradient = Fi02 X (pAtm - pH20) - (paCO2/R) + [paCO2 x Fi02 X (I -R)/R] - Pa02 
Where pAtm = 760mmHg x exp - (altitude in Metres/7000) 
And pl-120 = 47mmHg x exp ((Temp in centigrade - 37)/18.4) 
R= respimtory quotient 
Non-nal A-a gradients have not been established but they tend to increase with age. One 
study produced a predictive equation based on 80 patients breathing room air and 
suggested that a normal 60 year old breathing room air might be expected to have an A- 
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a gradient of 2kPa, 113 . Pathological processes that impair gas exchange will lead to 
increases in the A-a gradient. 
3.4.11.2 PaO21RO2 ratio 
The PaO2/FiO2 ratio is often used clinically in place of the A-a gradient because though 
it takes account of the inspired oxygen concentration it is much easier to calculate. Here 
the Pa02 is the arterial oxygen concentration and the FiO2 is the inspired oxygen 
concentration which will be 0.21 for individuals breathing air. The equation is: 
PaO2 (kPa) ý Fi02 
So for a patient breathing air the Fi02 would be 0.2 1, whilst for a patient breathing 40% 
oxygen it would be 0.40. Covelli 114 has suggested that the normal range of PaO2/FiO2 
is 4lkPa to 68kPa with a value <34kPa indicating clinically significant impairment of 
gas exchange. Esteban 47 showed that in 5183 patients ventilated for respiratory failure 
of various aetiologies in 361 ICUs from around the world ICU mortality had a 
significant univariate and multivariate relationship with PaO2/FiO2 ratio such that 
compared to patients with a PaO2/FiO2 ratio of >40KPa, the univariate odds ratio (95% 
CI) for ICU mortality were, (a) PaO2/FiO2 26.7 - 40.0 kPa OR 1.10 (0.92 - 1.33), (b) 
PaO2/FiO2 20-26.69 kPa OR 1.36 (1.16 -1.61), (c) PaO2/FiO2 13.3 - 19.99 kPa OR 2.29 
(2.26 -3.54), (d) PaO2/FiO2 <1 3.3kPa OR 15.73 (10.45 - 23.69). 
Sixteen of the 28 studies identified by the systematic search strategy report at least some 
data about oxygenation and these data are summarised in Tables 3.4.11.1 and 3.4.11.2. 
In three studies 515466 there was no investigation of the association with mortality. In one 
study oxygenation was grouped with other respiratory aspects of the acute physiology 
score and reported to predict 180-day survival better than hospital survival though the 
reporting lacks detail43. Six studies report the Pa02 Without taking into account the Fi02 
and all these show no significant relationship with morWity45 52 56 64 65 68. One study 
reported the Pa02 on air in a period of stability, but the results are dichotomised as 
above or below 7.3kPa and the cut-point of 7.3kPa is unrelated to 12 month survival 57. 
One study reported the Alveolar-arterial (A-a gradient) oxygen gradient two hours after 
starting therapy in a sample of 590 hospitalised COPD patients of whom 37 were 
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intubated, and found that though univariate analysis did not show the A-a gradient to be 
associated with mortality, the multivariate analysis found an A-a gradient >6kPa to be 
associated with increased odds of hospital death 62 . It is possible that this was a data 
driven cut-off. 
Four studies reported PaO2/FiO2 ratios 12274467 . In one study 
it is not clear what analyses 
were carried out". Of the three remaining studies two 1227 showed both a univariate and 
a multivariate relationship with hospital mortality and one did not. The study that did 
not show a significant association between PaO2/FiO2 and mortality analysed 250 
episodes in 180 patients and included 153 intubated episodes. Although the PaO2/FiO2 
67 ratio was higher in non-survivors it did not reach statistical significance . it was 
unclear which gases were selected for analysis. Of the two studies that showed a 
multivariate relationship with mortality, one study used logistic regression to investigate 
hospital mortality and found an odds ratio (95% CI) for hospital death of 1.13 (1.04 - 
1.23) per lOkPa decease in Pa02/FiO227 and the other study used Cox proportional 
hazards and included deaths to 180 days and found a hazard ratio (95% CI) of 1.28 
12 (1.05 - 1.54) per 13.2 kPa fall in Pa02/Fi02 
Table 3.4.11.1 Studies reporting oxygenation but not analysing with 
outcome 
Study 
(Time oxygenation Oxygenation patients Analysis Findings Comment 
measured) 
Gottlieb 1973" 
Mean (range) No analysis with (PaO2: breathing air on 
PaO2 6.4kPa (3.9-10.9) outcome 
hospital admission) 
- - --6a r&-s -198 6T Sample included 152 
Mean (SD) of total group No analysis with 
(PaOt on hospital patients only 15 were Pa% 5.2kPa (1.1) outcome 
admission) intubated 
Moran 1998 44 
Mean (SD) kPa PaO2/Fi% for 43 intubated It is not explicitly stated 
patients Unclear whether what fikctors were (PaO2/FiO2 at time Pre-ICU 24.7 (10.3) PaCh/FiQ,, was analysed investigated in 
points quoted for 43 On ICU admission 29.2 (10.5) with outcome association with hospital intubated patients) 
- - - 
24hrs post ICU admission 31.5 (13.6) mortality. 
Ruu2 055W Mean (SD) kPa PaOVFiOl Intubated 
No analysis ofoutcome (PaOz/FiOj on hospital patients 
admission) 30.0 (13.9) kPa 
predictors 
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Table 3.4.11.2 Studies investigating the association between oxygenation and 
outcome 
Study 
(rime Oxygenation 
Analysis Findings Comment 
oxygenation patients 
measured) 
Petherans IM " Mc&nP&% 5.15kPain Univaiiate analysis hospital 
The P*02 in noo-survivors was Inspired oxygen not specified. but the non. 
lower but statistically sinvivors with the higher PaO2 also had higher 
(PaDs: immediately hospital survivors vs, survivors versus non- insignificant though only 18 PaCO2 i a. 35 kPa in survivors. 10.23 kPa in 
prior to insulation) 7.53kPa in non-survivon survivors 
patients in the ample. non-awvivom 
The PaO2 in non-survivon was 
Kielin 1987m 
Mean (SD) in I 80-day 
UniVAfi&ft comparison Of lower but statistically 
Inspired oxygen am specified, but the non. 
survivors PaO2 14 (1.9) * 
survivors with the higher PaQ, also had higher 
(P10i --. in period of 190-&y survivors with non. insignificant- Only 39 patients in 
Pa(h 91 (2.5) in ISO PaC% in. 6.02 (1.3) kPa in survivors 6.5 (L 1) 
stability) survivors the sample and only 15 deaths 
day nori-survivors kPa non-survivom before 190-days. 
The PaO2 in a period of 
Menzies 1989 
stability was dichotomised A P&% in period of stability 
The dichotomising ofthe PaO2 kinan 
49% ofthe 95 study into hypoxic and non- <7.3 was piesen in 491% of 
(P&%: in perriod of information about the mom PaO2 in living and 
patients had Pa%<7.3 hypoxic and used the binary patients who died befiwe 12 
clinical mability) 
' 
dying populations 
variable in univariatis survivors, months mid 501A of 
analysis. 
Univariatis comparison showed 
Mean (SD) Alveolar 
that non-survivom was more The multivariate model used factors found to 
Fuso 1995 
arterial (A-a) oxygen 
hypoxic though this did not be significiust in the umvanate analysis and 
(A-a gradient: 2 
gradient in surviving vs. 
Univariate mid multivariate reach statistical significance. In contained age, A-a gradient, strial fibrillation 
hours after starting 
dying 6.1 (2.9) kP& 
analyses for hospital survival Multivariate logistic regression a and ventricular arrhythmias, Note this the 
vL7 6 (3 8) kPa PaO2 in 
oxygen therapy) A-a gradient or> 6 kPa was sample contained 390 patients ofwhom 37 
stirvivom 7.5 (1.7) vs. 
associated with OR (95% Cl) or were intubated. 
7A (2.2) kPa 
death 2.33 (1.39 - 3.90) 
Arterial oxygenation was not reported 
seneff 1995 separately, but along with the other respiratory 
(Worst value in first Not reported Not analysed alime components ofthe APACHE III score was 
24 hours in ICU) reported to predict I 80-day mortality better 
than hospital mortality. 
13.2kPa decrease in ratio 
Connors 1996" Multivariste and univariate associated with a univariate The Hazard ratio assunies a constard 
(PaO3/FiOi): third 
Median (IQR) 
Cox proportional hazards for Hazard ratio (950/oM for deoh relationship to deaths occurring throughout the 
29 13 (22 8-35.59) kP& 
day ofadmission) mortality to 190-days of 1.28 (1.06 - 1.54) and 180-dayperiod 
multivariale 1.29 (1.05.1.54) 
Hill 1998 Median (range) 9.3kPa 
(1,903: (6 1- 114) in survivor% 
Univariate analysis No significant difference. No adjustment for FKh 
immediately prior 6.7kP& (5.5 - 11.5) in 
tointubation) non-survivors 
Anon 1999 " 
Median (range) kPa Univariate comparison of 
(Pa0i in first 24 
P&02 5.73 (3 47 - Pa% in ICU survivors and No significarst difference 
hours in ICU for 20 
S. 13)kPa no*-onvivoll 
intubated patients) 
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Table 3.4.11.2 Studies investigating the association between oxygenation 
and outcome continued 
Study 
(rime Oxygenation 
Analysis Findings Comment 
oxygenation patients 
measured) 
Mean (SD) pm 
Nevins2001'" 12.3(9.1) kPa hospital 
Univariste comparison of No significant difference 
Ola% prior to survivors hospital survival (p-0-3) 
intubation) 10 4(5 3) kPa non- 
survivors 
Mean (SD) Pa, 03/1`102 Includes both 153 intubated patients and 97 not 
Afessa 2002ý7 Hospital survivors 28 0 No significant difference intubsted. Ilia study analysed 250 episodes in 
(pa%X1% in ICU) (14 1) kPa non-survivors (p-0.72) 190 patients, though the PaO2 is measured in 
27.2(14.8)kPa ICU it is not dear how the value was selected 
Breen 200V 
Whole group MearKSD) 
(PaOr : on Pa()ý did not predict hospital 
12 9 (9 7) kPa Multivariate logistic 74 patients in sample and 63 were intubsted. 
admission to ICU mortality on multivariate logistic 
Median (range) regression Small numbers ofdeuh& 
or immediately 
9 6(4.5-62.4) kPa 
regression 
prior to intubation) 
Wildman 2003 ' 
OR (95% CI) per 10 kPa 
(P&WFI02 from Whole group Median Univariate and Multivariate decrease in P&Oj/FI02 Analysis carried out on all 3439 patients with 
ABO with lowest (IQR) logistic regression in relation Univariate 1.17 (1.09-1.26) data ofwhich Wle were mtubated 
PaO2 in first 24 23 0 (17.2 - 29 7) kPa to hospital mortality Multivariate 1.13 (104 - 123) hours in ICU) 
3.4.11.3 Conclusion oxygenation and outcome 
The larger studies support the suggestion that gas exchange is a risk factor for mortality 
but confinn that the association is best shown when the arterial oxygen concentration 
takes account of the inspired oxygen concentration. 
3.4.12 Carbon Dioxide 
As COPD progresses hypercapnia may occur with exacerbations and in more advanced 
disease hypercapnia may become present between exacerbations. Hypercapnia is 
usually defined as a PaCO2 > 6kPa. In a 5-year prospective study of 85 patients 
admitted with COPD exacerbations, patients who became hypercapnic during the 
exacerbation and those who remained eucapnic had a similar prognosis with 28% and 
33% 5-years survival respectively. However patients who remained hypercapnic had a 
5-year survival of only 11% 115. In COPD patients who are intubated the PaCO2 may be 
influenced by ventilatory strategies such as low tidal volume ventilation which is 
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employed to minimise ventilator-associated lung damage. For these reasons it might be 
expected that the PaC02 level measured once patients were intubated would not be an 
important predictor of mortality in COPD patients intubated with respiratory failure. 
Table 3.4.12.1,3.4.12.2 and 3.4.12.3 below shows the studies identified in the 
systematic review that described carbon dioxide levels. 
Fifteen of the 29 studies identified in the systematic search reported data on carbon 
dioxide levels. Four studies presented summary statistics without analysis by outcomeý4 
516566 
. Two studies 
investigated the association between outcome and the PaC02 in the 
period of stability56 57 . Both 
found the steady state PaC02 to be higher in patients dying 
within 180 days or I year after admission compared to survivors, and though neither of 
these small studies reached statistical significance they raise the possibility that 
adequately powered studies might be consistent with the findings of Costello who 
15 showed that patients with hypercarbia in periods of stability had lower survival' . 
Nine studies reported the results of analysis of the association between PaC02 measured 
during hospital admission and outcome, and eight of the nine failed to find an 
association'2 27 45 52 62 64 67 68 . In the largest of the studies analysis included over 3000 
patients of whom 80% were intubated and used the most acidic blood gas in the first 24 
hours in ICU27 . The one study that 
found an association between PaCO2 and outcome 
showed similar survival at hospital discharge but significantly increased mortality at I 
year in patients 65 years and older with a PaCO2 ý: 6.7kPa compared to patients with a 
PaC02 lower than this valUe43 . The other 
large study with outcomes to 180 days was the 
Connors study 12 and in this study patients with a PaCO2 less than 6.7kPa were explicitly 
excluded. 
The studies identified in the systematic review suggest that the level of the PaCO2 in the 
acute setting does not predict hospital outcome, though it should be remembered that 
some studies will have required a raised PaCO2 as part of the inclusion criteria. The 
Seneff study3 suggests that when patients with only mildly raised PaC02 are included 
and outcomes over a prolonged period are compared, significant differences emerge at I 
year. It may well be that the group with a PaC02 < 6.7 kPa will include a greater 
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proportion of patients who have a normal C02 when stable than patients with a PaC02 2: 
6.7kPa. An understanding of the natural history of respiratory failure in patients with 
COPD leads to the expectation that patients with hypercarbia in the stable state 
represent a prognostically distinct group, though the numbers of patients in the 
systematically identified studies that had had PaC02 measured in the period of stability 
were small. 
Table 3.4.12.1 Studies in which PaC02 was measured in period of stability 
pre-exacerbation 
Study 
Crime measured) 
P&C% included patients Analysis Findings Comment 
Kaclin 198756 Mean (SD) 6.0 (13) kPa. No All 39 patients intubated Univariate comparison by 
(In period of 180day survivors 6.5 (1.1) significant and IS lived less than 180-day mortality 
stability) kPaNon-survivors difference 180 days 
Summary statistic not 95 intubatcd patients 
presented, P&CO2 > 6kPa Comparison of proportion of Menzies 1989 57 No with 59 deaths at I -year. 
was present in 39*/* of patients with PaM > 6kPa (In period of significant The analysis loses 
those who survived 12 between I year survivors and 
clinical stability) difference power by dichotomising 
months and 56'! /* of those non-survivors PaC02 into >< 6. OkPa 
who died by 12 months 
3.4. IZ I PaCO2 and outcome conclusions 
None of the studies demonstrated a convincing relationship between the PaC02 
measured during the exacerbation and survival. Though there are studies which do not 
concentrate on intubated patients that suggest that the PaC02 measured in the period of 
stability might predict outcome, only two studies from the systematic search used the 
PaC02 from the period of stability and both were small and neither found a significant 
association. It seems likely that the most promising way to use PaC02 to predict 
outcome would be using PaC02 from the period of stability but this is likely to be 
unavailable in the acute setting. 
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Table 3.4.12.2 Studies in which PaC02 was measured in critical care and/or 
the relationship of PaC02 to intubation status is unclear 
Study 
(Time measured) 
P&C% included 
patients 
Analysis Findings Comment 
Sample contained 
Whole group 1016 patients 
Connors 1996 12 Univariate and multivariate Cox No significant 
median (IQR) selected if they had 
(PaCO2 measured proportional hazards for association with 7.46 (6.67-8.66) PaC02 ý: 6.67kPa of 
on day 3) mortality up to 180-days survival. kPa whom 348 were 
intubated , 
Hoo, 2000 66 74 Intubated 
(PaCOý measured patients mean 
Summary statistics only 
on hospital (SD) PaCO2,9.73 
No analysis of PaC02 with 
admission) (1.9) kPa 
mortality 
Includes both 153 
intubated patients 
and 97 not intubated. 
Mean (SD) 8.1 
Afessa 2002 61 The study analysed 
(2.7) kPa Hospital No significant 
Univariate comparison by (PaCO2 measured 250 episodes in 180 
survivors 7.54 association with hospital outcome. in ICU) patients, though the 
(2.3) kPa non- survival PaM is measured in 
survivors ICU it is not clear 
how the value was 
selected. 
Wildman 2003 27 
Univariate and multivariate No association with Analysis carried out 
(PaC02 from Whole group 
companson of PaM levels in hospital mortality on all 3439 patients blood gas with median (IQR) 1 OkPa increments by hospital either in univariatc or with data of which lowest p1l in first 8.7 (6.9 - 10.7) outcome multivariatc analysis 80% were intubated 24 hours in ICU) 
3.4.13 Composite acute physiology scores 
Three studies 12 43 45 reported the association between the weighted acute physiology 
scores from APACHE II and APACHE III and outcome. In all three studies there was a 
significant association between the higher scores and outcome. No studies reported a 
lack of association between a composite acute physiology score and outcome. The three 
studies are outlined in table 3.4.13. 
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Table 3.4.12.3 Studies in which PaCO2 was measured prior to critical care 
admission or documented as prior to intubation 
Study 
(Time PaC% included patients Analysis Findings Comment 
mcasurcd) 
Gottlieb" 
Mean(range) 
(On hospital Summary statistics only 
PaC(h 9.6 ( 6.4-13.3 )kPa, 
admission on air) 
Petheram' Mean 8.5 kPa hospital In 18 intubated patients Univariate comparison by No significant 
(Immediately prior survivors vs. 10.2 kPa non- with chronic bronchitis 12 hospital mortality difference 
to intubation) survivors survived to I yew, 
FUS062 
No significant 
Mean (SD) 7.5 (2.2) kPa difference. (Mean in Note that the sample (2 hours after Univariate comparison of hospital survivors; survivors non- contained 590 patients of 
starting oxygen hospital survival 
7.45(2.6) kPa non-survivors. significantly higher whom 37 were intubated. 
therapy) 
than non-survivors) 
HiIIIA 
Median (range) 20 patients 
dying in hospital No significant 
(PaC% measured Univariate comparison by 
9.7 (6.6 - 11.7) kPa, association with immediately prior to hospital sin-viva] 21 survivors 11.2 (9.7 - 13.1) survival. intubation) 
kPa 
Morad" Univariate and multivariate No significant 
PaCO2 was not a significant 
Mean (SD) for 43 intubated predictor, but it looks like it (PaC02 measured analysis were those with association with 
patients 12 (4) kPa was investigated & 
pm-ICU admission) univariate p value <0.01 survival 
mjected. 
Hoo 66 
Summary statistics only No 
(PaC% measured 74 Intubated patients Mean 
analysis of PaCO2 with 
on hospital (SD) Pa(703ý 9.73 (1.9) kPa 
mortality 
admission) 
w Median range for all 20 Summary statistics only. 
(PaC02 measured intubated patients. No analysis of PaCO2 with 
on ICU admission) 11.3 (5.9-17.7) kPa mortality 
Mean(SD) No significant (PaC(h measured Univariate, comparison by 
Hospital survivors 9.1(3.9) kPa association with All patients intubated immediately prior to hospital outcome. 
Non-survivors 9.3(3.7) kPa survival. p=0.7 intubation) 
Breen" 
Pa% did not predict (PaCO2: on Whole group mean (SD) Multivariate comparison hospital mortality on 74 patients in sample and 
admission to ICU or 12.0(3.1)kPa median(range) by hospital outcome multivariate, logistic 63 were intubated immediately prior to 11.9 (5.5-20.3*N 
intubation) regression 
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Table 3.4.13 Acute physiology score and outcome 
Study 
Acute Pbysiology Score 
(APS) /Time measured 
Analysis Findings Comment 
Respiratory components more 
strongly predictive of 180-day 
Seneff APS III Multivariate 
199543 1' 24 hours in ICU analysis 
outcome, non-respiratory organ 
dysfunction more strongly 
predictive of hospital mortality 
10 point change in APS associated 
Connors APS III Multivariate 
with Hazard ratio for death over 
1996 12 Day 3 of hospital admission analysis 180-days of 1.32 (1.20-1.45) 
Nevins APS Il 6 hours after onset of Multivariate 
2001 's mechanical ventilation analysis 
APSIII acute physiology score from APACHE III 
APS II acute physiology score from APACHE 11 
3.4.14 Aetiology ofexacerbation 
Mean (SD) APS in survivors 7(5) 
vs. non-survivors 11(6) p<0.001 
In studies which have included patients for whom the disease process leading to 
intubation has included causes other than COPD e. g. Adult Respiratory Distress 
Syndrome (ARDS) following sepsis, the aetiology of respiratory failure identifies 
patients with distinct outcomes. In a prospective international study of 361 intensive 
care units 5183 intubated, patients were studied with an overall ICU mortality of 
30.70/647. Patients intubated because of ARDS had an ICU mortality of 52% (95% CI 
45%-59%), patients with pneumonia an ICU mortality of 38% (95% CI 35 - 42), and 
patients intubated because of COPD exacerbation had an ICU mortality of 22% (95% 
CI 19-26). In this study only patients intubated because of asthma (with an ICU 
mortality of 11% (95% CI 6- 21)) and neuromuscular disease (with an ICU mortality 
of 15% (95% CI 9- 24)) had lower ICU mortality than the COPD patients. Studies 
reporting the aetiology of the exacerbation are summarised in Table 3.4.14. 
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Table 3.4.14 Table outlining the aetiology of the exacerbation in 
hospitalised COPD patients. 
Study Aetiology of exacerbation Analysis Findings Comment 
Pneumonia in 59% oftotal sample of 39 Chii-alusm Pneumonia less common 
KjwJin 1997"' patients: 54 2% of I 80-day survivors comparison 190. day in 180-day survivors 
Pneumonia described as 'clear-cut" diagnostic 
criteria not PMVidCdL 
66.7% non-survivors Revival p<D. 05 
OWN Of respiratory 
Exacerbation ofCOPD 49"A Comparison of Pneumonia- new airspace shadowing on CXR 
Menzies 1989" pneumonia Wls, LW 70A surgery &etiology by 1-year 
failure am significamly 
plus >- raised white cell counk firverý positive 
associated with 190 
1154. other 13% outcome 
outcome 
blood culture, mid CXR response to antibiotics. 
(1) Pneumonia: CXR infiltrates phis any 3 of FEVi< IL (n-39) 
fever, positive blood cultures, raised white 
Rieves 1993" 
Pulmonary infiltrates 9% 
counk pathogenic sputum cultum (2) Comparison of survivors vs, 94% non- 
(survival defined as Congestive cardiac failure: king infiltrates phis 
Exacerbation ofCOPD47*A COPD presence ofinfiftrates survivon; P< 0.001 
spontaneous I elevated wedge pressure, (3) Exacerbation wit It CXR infiltrates 531A by 72 hour survival FEVI> IL (n-19) 
ventilation fiir >72 COPD no odw cause fbr deterioration. Note 
strafified by FEV, Pulmonary infiltrates 
hours) Analysis by episode 39 episodes in 33 patients 54% survivon; vs, 99% 
with FEV, < 11 and 19 episodes in patients 
Don-survivors p=0.127 
withFEV, >IL 
Fuso 199542 LW in 26% CXR inflammatory 
CXR findings of 
Univariate analysis pneumottia or LW no (590 in simple only x intubated) 
exudates 9% 
associated with mortality 
No analysis of 
actiology by 
outcome, but the 
The study inclusion criteria wigged that 
study probably Hospital mortality in included patients will have COPD end a clear 
s. ftff 19954, 
This sample only included COPD identifies the intubsted patients 3 1.8% CXR in that patients with COPD mid 
patients without poinuncinia or LVF outcomeol7paticats (248-39.3) pneumonia or LW would be coded as 
without pneumonia 
prieummus or LVF and not included 
or left vermicular 
failure i. e. a dear 
CXR 
124 patients in total. Sample only 22 patients intubated 
Tonve 1996 
included COPD patients with proven 
with hospital mortality of Patients had relatively good king functioa. 
pneumonia. Note that mean (SD) FEVI 23% (95% Cl 8- 45) 
40%(Il) 
Infection as cause, of 
&cute deterioration not 
associated with survival 
CCF as cause protective 
"Infection as a cause Hazard ratio (95% CI) 
Univariate and Respiratory infection =a come was reported in 
Connorsl996 
Congestive cardiac fitihmi (CCF) as 
multivariate Cox 
univariste 0 67 (0 47 - 47.4% ofthe 1016 patients however the 
cause 0.94) multivariate 0.66 
survival analysis definition is not reported. Cor pulmonale (0.45- 0.97). Car 
pulmonalle protective 
univariate 0 64 (0.44- 
0.93ý multivariate 0.67 
(0.45-099) 
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Table 3.4.14 Table outlining the aetiology of the exacerbation in 
hospitalised COPD patients continued. 
Aetiology of 
Study Analysis Findings Comment 
exacerbation 
Consolidation on CXR in 33% of 
Hill 199s" 
Consolidation on CXR in Univariate analysis by hospital 
survivors and 55% of non-survivon; 
44% survival 
no"gitifiCRIlt 
No analysis ofactiology, by 
outoonw, but the, study probably 
Monm Excluded all patients with identifies the outcome of Hospital mortality in intubated 
1998*` pneumonia or heart failure patients without pneumonia or patients 14% (5.3 - 27.9) 
left ventricular failure i. e. a clear 
CXR 
A greater proportion of patients Proportion ofpstients with CXR 
Univariste comparison of admitted to hospital with infiltrates in patients intubated % 
Hoo 200e 
139pafients in group 201A presence ofCXR infiltrates by (95% CT) 27% (17- 39) in patients 
hypercapnic fitilure who 
had CXR infiltrates success orconservative intubatima had CXR infiltrates, but 
successfully managed 
management the diffuence failed to reach 
conservatively 13% (6- 23) p-0.06 
statistical significance. 
% Survivors with actiological factor 
n r i 
COPD acacerbation 2r* 
vs, so -su v vom 
COPD vascerbation survivors 29*/* 
Nevins 
20014' 
pneumonia 430A ARDS 99A 
Univariate comparison ofcause, 
va, non-survivors IM p- 0049 
unstable angins/kH 121A Congestive head failure All 166 ofthese patients were 
oftietericirstion in COPID patient 
Congestive bewt failure SurAvors 26% vs. non-survivors intubated. 
by survival 
241/6, iepsis 111/6. 201A p-0.40 Pneumonia survivors 
encephak)Why, 7% 39% vs. 50% non-survivors p-0.40 
Other varvivors 13% vs, non.. 
survivors 241% p- 0.10 
Acute COPD exacerbation 
M., pneumonia 231%, Afessa 2002 Nowmalysisofoutcomeby 
67 cardiac Ift sedatives 31A 6 k 
pneurnothorim M sepsis or 
- 0 w 
ARDS IIA other 4% 
tPncumoms 20 r* right Adjusted OR (950A Cl) Pneumonia 
ventricular failure 4%, left Multivariate analysis of 
Wildman 1.04 (0 85 - 1.26) Right ventricular 
2003 
vennicular fifflure 3.81A diagnostic group versus patients failure 1.60 (1.07 - 2.39) Left COPD alone or phis other with COPD alone 
venaticular failure 0.79 (0.52 - 1.20) 
secondary diagnosis 71% 
tPatients were assigned to one of the three subgroups of COPD (pneumonia in a patient with COPD, 
right ventricular failure in a patient with COPD or left ventricular failure in a patient with COPD) if the 
first or second cause of admission was pneumonia, right ventricular failure or left ventricular failure in a 
patient in whom the other cause of admission was COPD, exacerbation of COPD or emphysema. 
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Of the 29 studies identified in the systematic search, 13 provide information on the 
aetiology of the respiratory failure. However the criteria used to classify the aetiology 
varied between studies and were not always explicit. In four studies the cause of the 
43446367 respiratory failure was described but there was no analysis of outcome . In two 
of these studies patients with pneumonia or heart failure were excluded! 3 44 and one 
study confined itself entirely to patients with COPD patients presenting with 
pneumonia 63 . 
3.4.14.1 Pneumonia 
Eight studies identified patients with pneumonia or pulmonary infiltrates and explored 
the association with outcome 27 45 56 57 60 62 64 66 . Seven of these studies carried out 
univariate comparisons of the frequency of patients with pneumonia/pulmonary 
infiltrates in survivors and non-survivors. Of the studies employing univariate 
comparisons two studies reported that there was no association between pneumonia and 
survival but do not report figures 5762 . Two studiesý5 
64 report greater numbers of patients 
with pneumonia amongst non-survivors than survivors (Nevins non-survivors 50% 
pneumonia vs. survivors 39% pneumonia, Hill non-survivors pneumonia 55% vs. 33% 
survivors) but both studies failed to reach statistical significance. In the Hoo 66 Study 
27% of patients with pulmonary infiltrates required intubation compared to 13% of 
patients without infiltrates though again the difference did not reach statistical 
significance (p=0.06). Two studies report that pneumonia/pulmonary infiltrates were 
significantly commoner in non-survivors than survivors 56 60 . The 
Kaelin study does not 
report the proportions. In the Rieves study where the analysis was stratified by lung 
function, of 39 patients with an FEVI <IL, 94% of non-survivors had pulmonary 
infiltrates compared to 9% of survivors (p<0.001). In the 19 patients with an FEV1>lL 
pulmonary infiltrates were present in 88% of non-survivors compared to 54% of 
survivors p=0.127. In the CMP study" pneumonia was not associated with hospital 
mortality in an analysis adjusted for case-mix that included careftil adjustment for the 
severity of disease within the first 24 hours in critical care. The Connors study 12 ýpwried 
out both a univariate and multivariate analysis to identify factors associated with 
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survival and investigated the role of "infection as a cause" of the respiratory failure. 
The diagnostic group "infection as a cause" was not associated with increased mortality 
but it is unclear what proportion of patients in this group would have had pulmonary 
infiltrates and what proportion would have had an infective exacerbation of COPD with 
a clear chest x-ray. 
It is likely that the relationship between pulmonary infiltrates and outcome is 
complicated because of confounding related to lung function and severity of illness. On 
the whole patients with well-preserved lung function will require a substantial 
additional burden of illness in order to develop respiratory failure that requires 
intubation and ventilation. Many of these patients are likely to have pneumonia 
accompanied by additional organ failures. The SUPPORT study showed that mortality 
in COPI) patients has an independent association with increased physiological 
derangement 12 and the CMP study showed an independent association between organ 
failures and mortality" . Patients with advanced COPI) and very poor lung function will 
develop respiratory failure of sufficient severity to require critical care with relatively 
little additional illness burden. There is some support for this hypothesis from the 
Nevins study in which COPI) patients intubated in ICU with a clear CXR had a 
mean(SD) FEVI of 0.99 (0.40) compared to the whole group FEV, 1.24 (0.58ý5. In the 
Ely study46 that included COPI) patients intubated for exacerbations the FEVI % 
predicted was mean 23%, whereas in the Torres study63 that included only COPI) 
patients with pneumonia the FEV, % predicted was mean 40%. 
When studies simply compare COPD patients in critical care with and without 
pneumonia, it is likely that the group of patients with pneumonia will contain relatively 
more patients with well preserved lung function and a severe acute illness, and on 
average the patients without pneumonia will have a relatively minor acute illness and 
markedly impaired lung function. Thus in order to understand the role of pneumonia, 
studies need to adjust for the patients functional capacity, carefully define pneumonia 
clearly and measure the severity of illness in terms of an acute physiology score or 
organ failure score. One reasonable interpretation of the available evidence is that at any 
given level of lung function patients will have a worse outcome with more severe 
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physiological derangement, and since pneumonia often has widespread adverse 
physiological consequences patients with pneumonia will have a worse outcome. 
However in comparisons of outcome if the acute physiology is adequately controlled for 
chest x-ray shadowing alone may be relatively unimportant. 
3.4.14.2 Cor pulmonale and congestive cardiacfailure 
Cor pulmonale is effectively right heart failure where the aetiology is attributed to lung 
pathology, whereas congestive cardiac failure may be due to a primary cardiac problem. 
The Connors study 12 and the CMP stud Y27 investigated the association of heart failure 
with outcome. In the Connors study cor pulmonale was found to have an association 
with improved outcome (adjusted hazard ratio for survival over 180 days 0.67 (0.45 - 
0.99)) and in the CMP study right ventricular failure had an association with increased 
hospital mortality (adjusted OR (95% CI) 1.60 (1.07 - 2.38)). In the Connors study 
congestive cardiac failure was also associated with improved survival (adjusted hazard 
ratio 0.67 (0.47 - 0.94)). It is interesting that the Connors study reports almost identical 
hazard ratios for both congestive cardiac failure and cor pulmonale, and in fact the study 
definitions for the two conditions are quite similar so that clinicians may have found it 
difficult to differentiate the groups. 
3.4.15 Length ofstay in hospitalprior to critical care 
Lead time can have important implications for prognostic models. Seneff reported an 
association between length of stay before ICU admission and death in COPI) patients 
admitted to US critical care units but did not report the magnitude of risO 3. The 
SUPPORT prognostic model for functional capacity after critical care estimated that the 
independent odds ratio (95% CI) for severe dysfunction following critical care was 1.04 
(1.02 - 1.06) per day in hospital pre-critical care 116 . Analysis of 3400 patients admitted 
to UK critical care units with COPI) estimated an independent odds ratio (95% CI) for 
hospital mortality of 1.02 (1.01 - 1.03) per one day increase in hospital length of stay 
prior to critical care 27 . 
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3.4.16 Longterm oxygen therapy 
There is some evidence that some clinicians consider long term oxygen therapy (LTOT) 
to be a contraindication to intubation6. However since patients with hypoxia on long 
term oxygen survive longer than those not on oxygen it might be supposed that all else 
being equal in terms of baseline hypoxia. those patients on LTOT might be expected to 
have a better prognosis if intubated 117 118. No studies provide a comparison of intubated 
patients with and without LTOT. Only the Anon study considers patients with LTOT 
and in a group of 20 such patients 35% died in ICU, 50% in hospital and 75% in one 
year65. ln a study from Spain that looked at 135 consecutive hospitalised COPD patients 
(but did not specifically report outcomes for intubated patients) patients on long term 
oxygen therapy had higher death rates after 2 years' follow-up69. It is possible that a 
study including all hospitalised patients may include patients with a wider spread of 
severity than a critical care study, and LTOT use may identify a frailer subgroup. LTOT 
was not included in a multivariate analysis. 
3.4.17 Non-invasive ventilation use prior to intubation 
Systematic reviews have suggested that non-invasive ventilation (NIV) is the optimal 
first line treatment for patients with exacerbations of COPD and patients treated with 
NIV had a decreased need for intubation and a lower hospital mortality than those 
treated with conventional therapy 3 119 120 . However there are some limitations to the 
generalisability of these results because in all of these studies patients who required 
immediate intubation were excluded prior to randomisation. 
It is likely that the survival benefit of using NIV first line documented in the RCTs 
partly results from NIV patients avoiding the additional risks of intubation. Chastre 
suggested that ventilator associated pneumonia occurred in 8 to 28% of intubated 
patients 121 . Some information about outcomes of patients intubated following NIV is 
available from an observational study in a single ICU in which 212 COPD patients were 
treated with either intubation first line (n--1 13) or NIV first line (n--99), followed by 
intubation in patients in whom NIV failed. Eighty nine of the 113 patients intubated 
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first line survived (79%, 95% Cl 70-86%), 47 of the patients treated with NIV first line 
Olf 67. failed and 40 were intubated of whom 30 survived (75%, 95% CI 59% - 87 () 
3.4.18 Previous intubation 
A single study found that patients who had survived a previous intubation were at lower 
risk than patients who were intubated for the first time45. 
3.4.19 Repeated hospitalisations 
In the SUPPORT study patients with repeated admissions in the period following the 
index admission in which study recruitment occurred had an increased mortality, but 
there were no studies which explored the association with information available at the 
time of index admission and outcome 12 .A study from Spain that included 135 
hospitalised COPD patients did not explicitly report the outcome for intubated patients 
but found that patients who had been admitted to hospital in the previous year had 
increased univariate odds of mortality of 2.28 (95% CI 1.36-3.82) compared to patients 
who had not had multiple admissions69. 
3.5 Quality of life after intensive care admission 
The duration of time that has elapsed after ICU is likely to be important in determining 
patients' health status. Patients will want to know how long it will take before the 
effects of ICU have worn off and their functional capacity has reached a plateau. 
However the data on the trajectory of patient's health status following ICU are limited. 
In a patient who was previously well and suffers an injury, the trajectory of recovery 
simply takes account of the recovery from a single insult against a background of full 
function. In patients with chronic disease, there is the need to consider the recovery 
from the acute exacerbation that resulted in ICU admission, but there is also the impact 
that the exacerbation and critical care admission will have on the trajectory of a chronic 
disease that may well have a progressive component. There have been no studies that 
have explicitly addressed this question in COPD patients admitted to ICU. 
III 
Probably the most useful data relating to COPD patients comes from the SUPPORT 
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study. In 10 16 patients with COPD , 11% died in hospital, 20% by 60 days, 33% by 
180 days, 43% by I year and 49% by 2 years. The SUPPORT study also provides data 
on perceived quality of life at 6 months 12 and 12 months93. Only group comparisons are 
available and some patients who report quality of life at 6 months will not have survived 
to 12 months. At 6 months 518 patients provided data on self-rated quality of life and 
600 at 12 months. 
Table 3.5 Quality of life after hospital admission in COPD patients from the 
SUPPORT study 
Quality of life rating 
6-months 
n--518 
12 months 
n=600 
Very good or excellent 21.1% 10% 
Good 30.1% 21% 
Fair 28.4% 53% 
Poor 20.1% 16% 
Interpretation of these data is complicated by there being only 518 respondents at 6 
months but 600 respondents at 12 months, and it is unclear how far differential response 
of patients with better quality of life at 6 months accounts for the better quality of life at 
that time point. Nevertheless there were 109 patients describing their quality of life as 
excellent or very good at 6 months when there was incomplete response and only 61 at 
12 months with complete response, so that whatever group the 6 month non-responders 
belonged to, there had been some decrease in the number of patients rating their quality 
of life as good or very good by 12 months. If poor quality of life at follow-up was 
largely due to the reversible effects of an index acute illness it might be expected that 
these effects would lessen over time so that patients' quality of life would be worse at 6 
months than it was at 12 months. That there are less patients with excellent or very good 
quality of life at 12 months than 6 months is consistent with the possibility that there are 
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aspects of progression of the chronic disease that are causing patients' health to 
deteriorate. 
In 101 patients with COPD studied primarily in the outpatient setting, 75% had peak 
expiratory flow values that had recovered to baseline by 35 days, and only 7% of 
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patients had not recovered their baseline peak expiratory flow rate by 91 days . These 
data suggest that the time course of recovery of COPD exacerbations is relatively short 
and might be expected to be complete by 180 days, though how applicable this is to a 
patient with a critical care admission is unclear. It is known that as COPD becomes 
more severe, exacerbations become more frequent and that exacerbations are associated 
with deterioration in quality of life. In an earlier paper involving 70 COPD patients 
Seemungal reported that over I year some patients had three or more exacerbations, and 
that quality of life measured using the St Georges Respiratory Questionnaire was 
significantly worse in the frequently exacerbated'23. These data suggest that measuring 
quality of life at 180 days in CAOS provides a reasonable estimate of the recovery that 
might be expected after ICU, but that in patients having frequent exacerbations these 
might be expected to result in ongoing decline in quality of life. 
3.6 Summary and conclusions 
The systematic review has shown that there are number of risk factors associated with 
outcome in COPD patients. The quality and number of the studies that have identified 
associations varies from risk factor to risk factor. The risk factors have been organised 
into tables (Tables 3.6.1,3.6.2 and 3.6.3 below) that surnmarise the findings of the 
systematic review with a brief comment about the strength of evidence supporting the 
association of each risk factor with outcome. The risk factors are organised into those 
that describe the patients' characteristics in the period of stability pre-exacerbation, and 
those that describe the patients' characteristics after hospital admission and before 
critical care admission. These tables were used to guide the choice of data to collect. 
The weight of evidence supporting the various risk factors helped to inform the 
selection of variables used in the final model as outlined in chapter 10 below. 
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Table 3.6.1 Patient characteristics available in the period of stability pre- 
exacerbation that have been shown to be associated with outcome 
Variable Association with outcome Strength of evidence/comment 
Most studies show age to be Evidence mainly consistent 
associated with increased mortality However occasional studies showed no increased mortality with age, Age 
but this was usual in small studies or where there was a suggestion of 
selection bias so that only the fittest of the old were selected. 
Only a few studies examine the The association between sex and mortality that disappears after 
relationship with sex. The case mix adjustment for other risk factors in a large data set raises the possibility 
programme study with over 3000 that being male is a marker for other risk factors. As such in a Sex 
patients found a univariate parsimonious model male sex may be a useful predictor if the model 
increased risk of death in males" does not adequately take into account all the other risk factors that are 
associated with male sex 
Studies in the outpatient setting Likely to have an association with outcome as long as them is a great 
find FEVI to be associated with enough range of values in the patients ending up requiring intubation. 
FEVI mortality. Many studies have found that FEVI is unavailable in the acute setting. 
Inadequate data in the acute 
setting. 
Many studies have found some Strength of relationship is perhaps weaker than expected which may 
Exercise relationship between functional reflect under and over-estimation by both patients and proxies. 
tolerance in capacity and outcome. Useful 
the period of scores included Katz ADL score 
stability and the functional score and the 
Duke activity score index. 
Self-rated Single study found an association A single study found an association, but self-Tated quality of life is 
prior quality with mortality 
93 likely to be difficult from proxies. 
of life 
Some studies found an association Co-morbidity is difficult to measure adequately and counting 
comorbidities may be biased by mild comorbidities being recorded in fit 
Comorbidity patients and ignored in patients with multiple problems. Probably the 
most effective way of taking account of comorbidities is to weight them 
individually depending on the patient's primary disease. 
No evidence about relationship A univariate association with 2 year mortality found in 135 hospitalised Long term 
with outcome for intubated patients patients. It is unclear whether LTOT was a marker of the sickest oxygen 
subgroup since multivariate analysis not carried out!. 
One study suggested prior Previous 
intubation associated with intubation 
survival" 
One study identified patients who A study from Spain that didn't explicitly report intubation outcomes Previous 
survived index admission and were identified that admissions in the past year had a univariate and admissions 
I readmitted had worse survival 12. 1 multivariate association with 2 year mortal ity". 
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Table 3.6.2 Patient characteristics available in the 24 hours after hospital 
admission and prior to critical care admission and outcome 
Variable Association with outcome Strength of evidencelcomment 
Body mass index (BMI) had a Body mass index was also identified in studies in outpatients and the 
Body mass multivariate association with relationship appears robust However the SUPPORT study found it 
index outcome in the SUPPORT study 12. difficult to measure BMI in all its patients and had to use a dummy 
variable in the final model for patients with a missing BMI. 
A French ICU study found mid- Mid-arm circumference may be easier to measure than BMI in 
arm circumference to be associated acutely ill patients. Mid-arm 
with survival in older patients with 
circumference 
heterogeneous reasons for 
intubation'07. 
No studies reported this. suggested that recent weight loss might be an important Recent weight 
predictor of mortality after observing that BMI was so important in loss 
SUPPORT. 
Quantified small but significant Likely to have a small but important effect Length of stay 
multivariate association in two 
pre-critical 
studies" "" and reported but not 
care 
quantified in a third 43 
Atrial An easy to measure comorbidity identified in I study. 
fibrillation 
Part of the UK folklore in which acute changes are thought to 
identify a group of patients with a reversible component who will 
Chest x-ray benefit from ICU. Only I study small study provides any data and 
suggests that acute chest x-ray changes identify a group at higher risk 
of mortality. 
The SUPPORT study suggested 
Congestive that congestive cardiac failure was 
cardiac failure associated with improved 
outcomes. 
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Table 3.6.3 Acute physiology and outcome 
Association with Variable Strength of evidence/comment 
outcome 
Acute physiology Acute physiology scores show a The finding in SUPPORT that albumin and PaO21Mý added 
consistent association with explanatory power to the acute physiology score from 
outcome. APACHE IH suggested that a COPD specific acute physiology 
score might well perform better than a generic score. 
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Chapter 4 Methods 
4.1 Introduction 
In Chapter I it was argued that there was a need to produce a prognostic model to 
estimate the probability of survival of COPD patients admitted to Intensive Care Units 
(ICU), with the prognostic information most useful in informing intubation decisions. 
The introduction also argued that it was important to understand whether patients rated 
their quality of life after ICU as worth living. Chapter 2 set out the methodological 
challenges that must be overcome to make the development of a successful model a 
possibility and emphasised the need for careful collection of data on risk factors on a 
large number of patients with minimal missing data. Chapter 3 indicated what those 
variables should be. In this methods section the practical steps that were taken to make 
the development of a COPD risk model a reality are outlined. 
4.2 Study setting and overview 
The CAOS study was carried out in collaboration with the Intensive Care National 
Audit and Research Centre (ICNARC) and the ICUs contributing to the ICNARC Case 
Mix Programme (CMP). The CMP is a national audit that collects case mix and 
outcome data on consecutive admissions to ICUs in England, Wales and Northern 
Ireland. The units that contribute to the CMP have experience of ongoing case mix data 
collection, and most units have individuals trained in data collection, with time set aside 
for this task. The CMP data are generic case mix data that are collected once a patient 
has been admitted to ICU. However clinicians making the decisions to admit patients to 
ICU will necessarily use the data available prior to ICU and will typically seek out 
information specific to the patient's presenting condition in addition to more generic 
data about severity of illness. CAOS captured both the disease specific and generic 
severity data that would be available to the gatekeeping clinician prior to ICU 
admission. Nesting CAOS within the CMP infrastructure allowed the pre-ICU data to 
be collected by experienced data collectors with an ongoing commitment to data 
collection for these patients. 
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4.3 Unit recruitment 
In November 2001 a letter was sent from Dr Kathy Rowan, the Director of ICNARC, to 
all the 178 units in the Case Mix Programme (Appendix 2). The letter briefly outlined 
the purpose of the study and invited units to express an interest in participating. Units 
expressing an interest were then invited to a launch meeting on 26th April 2002 in 
Birmingham. At the launch meeting, the background to the study and data collection 
methods were outlined, and units who wished to take part were provided with a CAOS 
box that contained all the relevant data collection booklets and patient information 
sheets. 
4.4 Unit visits and training 
Dr Wildman visited units that were unable to attend the launch meeting but wanted to 
take part in the study. During the unit visit the background to the study was explained 
and the nominated data collectors were instructed in the data collection process. 
4.5 Respiratory High Dependency Units 
In some hospitals much of the care for COPD patients with respiratory failure is carried 
out on Respiratory High Dependency Units (RHDUs). These units do not take part in 
the CMP. In order to gain some understanding of how the case mix data collected in the 
CMP units could be applied to patients treated in the RHDU environment three such 
units were recruited, two from Leeds and one from the West Midlands. These units 
were able to collect the CAOS data but did not collect the CMP data from the first 24 
hours in ICU. 180 day follow-up was carried out in the same way as for the CMP units. 
RHDUs have been set up in an ad hoc fashion around the country and there are no 
centralized data that allow comparison with the units recruited. 
4.6 Patients inclusion criteria 
The objective was to recruit consecutive patients, aged 45 years or older, admitted to 
ICU with breathlessness, respiratory failure or changes in mental status, due to an 
exacerbation of COPD or asthma as the major reason for admission. 
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4.7 Patient exclusion criteria 
Patients were excluded if they had had surgery in the past ten days or had been 
transferred from another hospital. Surgical patients were excluded because patients who 
have had surgery, particularly if the surgery involved abdominal wounds, were likely to 
have a different prognosis to patients with respiratory failure unrelated to surgery. 
Patients from other hospitals were excluded because the pilot study suggested that 
patients were likely to have missing data if treatment had been started in another 
institution. 
4.8 Patient classification 
It can be difficult to distinguish between patients with COPD and patients with asthma, 
and clinicians were asked to use clinical judgment to categorise the patient as having 
COPD, asthma or a mixture of COPD and asthma. 
4.9 Data collection 
4.9.1 The CAOS data collection booklet 
The CAOS data collection booklet collected information on the risk factors identified in 
the systematic review as being associated with outcome (Chapter 3 above). These data 
related to the patients' characteristics in the period of stability prior to hospital 
admission, to the severity of illness after hospital admission but prior to ICU admission, 
and descriptive of the respiratory support strategies employed in ICU (Appendix 3). 
4.9.2 Development ofCAOS data collection booklet 
The data collection booklet was prepared in dmft form in November 2001 and piloted in 
two units in the West Midlands in November and December 200 1. 'Me final version 
was produced in January 2002. 
4.9.3 Layout of CAOS data collection booklet 
The inpatient data collection booklet (Appendix 3) combined data collection sheets with 
instructions. This ensured that the instructions for data collection would always be 
119 
available when and where they were needed. Also an overall summary of the study was 
provided on the inside of the booklet cover. The sixth sheet illustrates particularly well 
how facing pages contain guidance notes to support data collection. In this case 
guidance notes give additional detail about steroid inhalers to assist completion of 
question 17, and clarify exactly what is meant by home oxygen to clarify question 18. A 
diagram and instructions were provided to standardise the measurement of the mid-arm 
circumference, and every data collection booklet was provided with an attached paper 
tape measure. 
Each data collection booklet had a unique identification number that was used to 
identify the patients concerned, allowing all other identifiers to be removed from 
electronically stored data. The booklet contained seven blue sheets and one yellow 
sheet. The blue sheets were for data that would be available within the first 24 hours in 
ICU and the yellow sheets for data on the treatment received whilst the patient was in 
ICU. 
4.9.4 The instruments in the data collection booklet 
A copy of the data collection sheet is included in the pocket inside the cover of the 
thesis. The first blue sheet (page 1) incorporated inclusion and exclusion criteria, date 
and time of admission, demographics, and patient and General Practitioner contact 
details. 
The second blue sheet (page 3) was the only one that had to be completed by medical 
staff, and was for data about: 
" the presence or absence of atrial fibrillation and congestive cardiac failure; 
" the appearance of the pre-ICU chest x-ray; and 
" the admitting clinician's estimates of the probabilities of the patient's surviving until 
leaving the ICU, leaving the hospital, and until 180 days after admission to the ICU. 
Clinicians were also asked to predict the patient's self-rated quality of life at 180 days if 
they were to survive, using a thermometer scale bounded between best imaginable 
health state corresponding to a score of 100 and worst imaginable health state 
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corresponding to a score of zero. The then-nometer scale was the same as that used in 
the EuroQol questionnaire that surviving patients received at 180 days 125 . The date and 
time of the prediction were noted along with the grade and specialty of the clinician 
making the prediction. 
The third blue sheet (page 5) covered function and the patient's self-rated quality of life 
in the period of stability two weeks prior to admission to hospital. The functional score 
had originally been used with five levels that included whether the patient was working. 
This category was omitted in this study as the majority of patients would be beyond 
retirement age 57 and the scale simply started with what had been level 2 in the original 
version i. e. "Fully mobile and living without assistance". The data collector was asked 
to indicate the information source for the data, ticking all categories that applied. 
Possible sources included the clinical record, the patient or another witness. 
The fourth blue sheet (page 7) was again for information on the patient in the period of 
stability two weeks prior to admission to hospital. It involved the Katz classification of 
activities of daily living 82 which was found to have a significant association with 
survival in the SUPPORT study 12 
The fifth blue sheet (page 9) was for on the patient's co-morbidity, using the Charlson 
index. This has been used extensively to investigate the relationship between co- 
morbidity and length of stay'01 
The sixth blue sheet (page 11) was for other aspects of medical history that have been 
shown to be associated with mortality, including treatment with inhaled steroids 126 , 
home oxygen treatment via a prescribed oxygen concentrator65, prior intubation 45 , and 
number of hospital admissions in the past 6 months 12 . This sheet also covered smoking 
history in terms of pack years, with the aim of identifying never smokers as patients 
who were likely to have simple asthma. Data were also collected on the patient's weight 
and height. Pilot studies for CAOS indicated that nursing staff found it difficult to 
weigh and measure acutely ill patients and three methods were used to assess BMI. Data 
collectors were asked to: 
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* rate patients' weight on a five point scale running from very underweight to very 
overweight; 
provide the patient's weight and height and to state whether this was estimated or 
measured; and 
measure the mid-arrn circumference. 
The seventh blue sheet (page 13) was for acute physiology recorded in the 24 hours 
prior to ICU admission. This was to help characterise the severity of illness at that time. 
These data included: the most acidic gases in the 24 hours prior to critical care 
admission, the paired systolic and diastolic blood pressure measurements from the 
blood pressure with the lowest diastolic, the highest and lowest central temperature, 
non-central temperature, heart rate, respiratory rate, haernatocrit, haemoglobin, white 
cell count, serum sodium, serum potassium, serum creatinine, serum urea, serum 
albumin, senun bilirubin, serum glucose and the Glasgow Coma Scale. 
Page 15 was the only yellow sheet in the booklet and contained questions that 
determined the type of respiratory support that the patient received in ICU. Question 
32.1 determined the date and time of intubation and its duration, defined as ending once 
the patient had ceased to receive pressure support via a tracheostomy or endotracheal 
tube. The date and time of a tracheostomy was recorded. Data were also collected that 
identified those patients who only received non-invasive therapy, with question 31.2.1 
determining whether patients only receiving non-invasive ventilation would have been 
intubated if the non-invasive ventilation had failed. 
4.9.5 Hospital outcome 
For patients surviving to leave critical care, the duration of the hospital stay following 
ICU and the patients' vital status were sought at weekly intervals following receipt of 
the yellow sheet. The cause of death was sought for all hospital deaths, and units were 
asked whether there had been a decision to withdraw treatment. 
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4.10 Strategies for minimising missing data 
Every effort was made to ensure that missing data were identified and chased on a day 
by day basis. The blue sheets (for data that described the patient prior to ICU 
admission) were faxed to the CAOS co-coordinating centre within 24 hours of ICU 
admission. This allowed inconsistencies to be resolved before the patient left ICU, after 
which it was unlikely that the data would be readily available. 
4.11 A qualitative understanding of feasibility of data collection on risk factors 
Ongoing dialogue with units about the verification of out-of-range values and chasing 
of missing data provided an opportunity to identify the variables that were difficult to 
collect. This information was to be used in the final selection of variables during 
prognostic model development. 
4.12 180-day follow-up 
Data describing patient's quality of life after ICU discharge were collected by postal 
questionnaire at 180 days (Appendix 4). The 180 day questionnaire consisted of a single 
sheet of paper folded to produce a booklet (Appendix 4). This format was chosen so that 
all the questions to be completed were easily seen. A covering letter was included with 
the questionnaire. The questionnaire contained two well-validated health status 
instruments: the EuroQoI and the AQ-20. 
4JZl TheEuroQol 
The EuroQol is a generic quality of life measure for collecting information about a 
patient's level of function in 5 domains: mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression 125 . For each domain the patient is asked to 
indicate their level of function, e. g. for mobility patients are asked to choose from three 
options: 'I have no problems walking about", "I have some problems walking about" or 
"I am confined to bed". With 5 domains and 3 levels in each domain there are 243 
possible health states or combinations. The developers of the EuroQoI used a 
representative sample of the general population to value these health states using time 
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trade-offs, so that for any possible health state there was a valuation between 1.0 
(perfect health) and -0.59 (a state worse than death). The population derived value for 
the health state is called the EQ-51). In addition the EuroQol questionnaire contains a 
visual analogue scale which asks the patient to record their health state on the day of the 
data collection, on a scale from 100, corresponding to the best imaginable health state to 
0, corresponding to the worst possible health state. (This visual analogue scale was also 
incorporated into the data collection booklet used at ICU admission to collect clinicians' 
predictions of the patients' quality of life at follow-up. ) 
4.122 TheAQ-20 
The AQ20 questionnaire 127 is a disease-specific health status measure for patients with 
airways disease developed from the St Georges Respiratory Questionnaire (SGRQ) 128 . 
The AQ20 was used in preference to the SGRQ because it contains only 20 questions in 
contrast to the 50 in the SGRQ. The booklet also contained the modified functional 
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score that was part of the inpatient dataset . In addition patients were asked: 
9 whether they would choose intensive care treatment again under similar 
circumstances; and 
how their current health status compared to how they were when well prior to 
hospitalisation 6 months ago, on a five point scale running from much worse to 
much better. 
4.13 Strategy to identify patients who died after leaving hospital 
In order to avoid causing distress by sending questionnaires to bereaved relatives, steps 
were taken to identify patients who died prior to the time of follow-up. Hospital 
outcome was obtained as part of the in-patient data collection protocol. Two weeks 
prior to sending the follow-up questionnaire a letter (Appendix 5) was sent to the 
patient's GP and this was followed up with a phone call to the GP's receptionist to 
confirm that the patient was still alive. 
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4.14 Outcomes for non-responders and patients lost to follow-up 
Patients who were lost to follow-up were traced through the Office of National Statistics 
(ONS), who provided a date and cause of death for those patients who had died. In the 
case of patients who were lost to follow-up because they had moved GP, the ONS 
identified the Health Authority of the patient's new GP. The GP's identity was obtained 
from the Health Authority, and the practice was contacted to obtain the patient's new 
address and to confirin that they were alive. 
4.15 Strategies for improving the 180 day response rate 
Strategies to improve the response rate to postal questionnaires have been studied and 
reported in a recent Cochrane review 129 . Where practical, these strategies were 
incorporated into the questionnaire design and mailing strategy. Table 4.15 shows the 
strategies used to improve response and the odds ratio (95% CI) associated with these 
strategies that were calculated in the Cochrane systematic review. Great care was taken 
to make the questionnaire short and user-friendly. The questionnaire was printed on 
high quality paper with coloured ink. An unconditional incentive was provided in the 
form of a biro and the questionnaire was personalised with a hand-written post-it note 
asking the patient to answer questions that involved unfolding the questionnaire. In 
addition, the questionnaire was sent out by recorded delivery. A return, stamped 
envelope was enclosed. Patients received three mailings, the first two by recorded 
delivery and the third by normal post. The final mailing by normal post was in case 
patients were unable to answer the door to sign for a recorded delivery. In patients in 
whom the response was very delayed the GPs were contacted again to confirm that the 
patient was still alive, and to ensure that the GP did not know of a reason why the 
patients should not be contacted. If the study team had a phone number available these 
patients were contacted by phone. 
4.16 Causes of death 
Death certificates were sought for all patients from the ONS at the end of the study in 
spring 2004. This meant that causes of death were obtained for all patients who had died 
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Table 4.15 Strategies to improve postal questionnaire response rate 
Strategy Application in CA OS Odds ratio (95% CI) for 
response rate with 
strategy vs. without 
Non-monetary incentive All questionnaires contained a 1.19 (1.11-1.28) 
with questionnaire biro 
Shorter vs. longer Questionnaire kept as short as 1.86 (1.55 - 2.24) 
questionnaire possible 
Coloured ink vs. Coloured inks used 1.39 (1.16-1.67) 
standard 
Folder or booklet vs. Fold out booklet formatused, 1.17 (0.94-1.45) 
stapled pages 
More personalised vs. Hand written post-it notes 
less personalised naming the recipient 1.16 (1.06 - 1.28) highlighted the need to answer 
all parts of questionnaire 
Recorded delivery vs. Recorded delivery used 2.21 (1.51 - 3.25) 
standard 
Stamped return envelope Hand written stamped return 1.26 (1.13-1.41) 
vs. business reply envelopes included 
within 180 days of admission to ICU. In addition, in those patients who had entered the 
study early, deaths beyond 180 days were identified. 
4.17 Identification of missing patients via the Case Mix Programme database 
In order to identify patients who were eligible for admission to CAOS, but had been 
missed by individual units, the CMP database that covered the period when the unit was 
taking part in CAOS was searched to identify eligible COPD patients. The CMP coding 
system was used to identify patients who had not had recent surgery and who had a 
primary reason for admission of COPD, exacerbation of COPD, emphysema or asthma, 
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or any of these four reasons for admission as the second cause when pneumonia, right 
ventricular failure or left ventricular failure were the primary cause. 
4.18 Maintenance of study momentum 
As soon as a unit recruited their first patient they were sent a CAOS mug with a thank- 
you note to celebrate. Each time a patient's details were faxed to the CAOS 
coordinating centre the unit was contacted by phone the same day and thanked, and any 
details that were missing or ambiguous were checked. Follow-up of the hospital 
outcomes maintained regular contact between the CAOS coordinating centre and 
individual units. In addition, newsletters were produced updating units on study 
recruitment (Appendix 6). The newsletters had an ongoing therned section called 
"Voices from the Trenches" where unit data collectors gave tips describing successful 
methods for avoiding missing patients. The units who provided the "Voices from the 
Trenches" received a box of CAOS biscuits decorated with the CAOS logo, as did units 
recruiting the 100th, 20e etc. patient. It was hoped that the brightly coloured biscuit 
boxes decorated to resemble the unit CAOS boxes also maintained the study profile in 
individual units. CAOS post-its were provided to units and carried the study logo and 
inclusion criteria, and were designed to be attached to unit admission packs, so that each 
time a patient was admitted to ICU, they would be considered for inclusion in the study. 
Posters were also provided (Appendix 7). The CAOS study was also presented at 
Annual Case Mix Programme meetings in January 2002 and 2003, and was on the 
ICNARC stand at National Intensive Care Society meetings. A description of the study 
was also carried in the British Thoracic Society Newsletter. 
4.19 Data management and analysis 
All data were entered using Epi-Info 2000, with data entry fields set up to mirror the 
data collection questionnaires. Epi-Info stores data in Access. The data entry 
programme contained range checks so that out of range values were not accepted. In 
addition the data entry programme calculated derived variables such as age, the number 
of days after hospital admission that ICU entry occurred, and the length of stay in 
hospital. This served to highlight illogical data entry such as patients having a negative 
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length of stay. The study database was registered through the hospital data protection 
officer. 
Data were converted from the Epi-info Access format to Stata, by Stat-transfer and all 
analysis was carried out in Stata, 7.0. 
4.20 Data protection 
Though the CAOS inpatient data booklet contained the patient's name and address only, 
the patient's CAOS number was entered into the CAOS database. Once the data were 
entered, the first page of the data booklet, the only sheet containing patient identifiers, 
was removed and locked away. At this point, the follow-up dates for the patient were 
noted and the remainder of the data booklet was filed. 
4.21 Multi-centre Research Ethics and Research and Development approval 
The study received Multi-Centre Research Ethics Committee (MREC) approval 
(Appendix 8). Since the study was observational and did not involve altering patient 
treatment the Local Research Ethical Committees were not required to give additional 
approval but were all informed of the study and provided with patient information 
sheets and protocol. In addition approval was obtained from the Research and 
Development (R & D) departments in each participating hospital. 
4.22 Patient information and consent 
Patients were provided with an information sheet on leaving ICU that explained the 
study and informed them that they would be contacted after 180 days to determine their 
health status. The patient information sheet contained a sentence approved by the ONS, 
explaining that ONS data sources would be used to determine their survival up till that 
point. Patients were asked to sign a form confirming that they had received the 
information sheet. In discussion with the MREC it was felt that patients who had just 
left intensive care might find taking in this kind of information difficult and should be 
provided with written information, with contact details, which enabled them to opt out 
of the study at any point in the future. At 180 days the patients received a second 
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information sheet and completed a consent form. The MREC felt that it would be 
impossible to obtain the consent of patients who entered ICU unconscious and then died 
on the unit, and considered that including these patients without formal consent was 
acceptable. All the patient information sheets were approved by the MREC. Information 
sheets were produced in Welsh, Gujarati, Punjabi, Urdu and Bengali. Information sheets 
are included in the appendix (Appendix 9). As recruitment proceeded it was found that 
patients entering the study were able to speak English or had a carer who could speak 
English and as a consequence the 180 day follow-up questionnaire was not translated. 
4.23 Study steering group 
A steering group was formed to oversee the study and to provide guidance and support 
in the development of the PhD. The members of the group were Dr Colin Sanderson 
(Reader in Health Services Research), Dr Barney Reeves (Senior Lecturer in 
Epidemiology) and Dr Martin Wildman (MRC Training Fellow in Health Services 
Research and study coordinator) all from the London School of Hygiene and Tropical 
Medicine, Professor Jon Ayres (Professor of Respiratory Medicine, Birmingham 
Heartlands Hospital), Dr Kathy Rowan (Scientific Director of ICNARC), Dr Duncan 
Young (Senior Lecturer, Nuffield Department of Anesthetics, Oxford) and Mrs. Jayne 
Groves (Research Nurse, Birmingham Heartlands Hospital). 
4.24 Dissemination 
The recruitment rate and study progress were given a high priority during the conduct of 
the study, with an emphasis on regular contact with individual units, and the production 
and dissemination of CAOS newsletters. 
The results for individual units will be fed back to the collaborating units along with the 
anonymised data from the whole study. In addition the results of the study will be 
published in articles submitted to peer review medical j oumals. 
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Chapter 5 Units and patients 
5.1 Unit recruitment 
5. LI Intensive Care Unit Recruitment 
In January 2002 the 178 ICUs in the case mix programme were invited to take part in 
CAOS. Four units were ineligible; three were specialist units that did not admit COPD 
patients and one unit was located outside the UK. Seventy-three units indicated that 
they did not want to take part. A hundred and one units agreed to take part, and of 
these, three never received Caldicott approval and six never started to collect data. This 
left 92 ICUs that collected data, 53 % of those eligible to take part (Figure 5.1.1 below). 
Figure 5.1.1 Units taking part in the CAOS study 
178 Case mix programme units 
approached 
4 excluded 
I cardiothoracic 
I neurosurgical 
I paediatric 
I outside UK 
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1 
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92 Critical Care units took part 
53% of eligible units 
3 Respiratory 
Critical Care 
Units added 
95 units in total 
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5.1.2 Comparisons between participating and non-participating units 
For 170 of the 174 eligible units there were data that allowed comparison of the 
characteristics of units that participated and units that did not participate (Table 5.1.2). 
The table draws upon the data in the CMP database for the end of CAOS study period 
in August 2004. It can be seen that CAOS units were broadly similar to the non- 
participating units. In particular the percentage of admission diagnoses likely to fulfil 
the CAOS inclusion criteria was 3.6% for both groups of units, and the mean COPD 
acute physiology scores were almost identical (CAOS ICUs 30.6, non-CAOS ICUs 
30.7). Slightly fewer University hospitals took part in CAOS, but taken together, 
University and University-affiliated hospitals made up 32.2 % of CAOS units and 
32.5% of non-participating units. 
5.1.3 Respiratory High Dependency Unit recruitment 
Three RHDUs participated. There is no directory of hospitals with RHDUs, and those 
that took part were known to the author and had the infi-astructure and commitment to 
collect data. The units recruited 35,45 and 28 patients respectively. In addition 6 were 
admitted to RHDU but were transferred to Critical Care. The RHDUs had relatively 
large proportions of patients with treatment limitation decisions, with 18/35 (51%), 
12/45 (27%) and 21/28 (75%) designated not for intubation respectively. 
5.2 Patient recruitment 
The number of patients recruited was 832. Of these, 108 were recruited to RHDU. Of 
the 724 patients admitted to ICUs, case mix programme data were available for the 
period corresponding to the admission for 684 (94.5%). 
5.3 Identifying missed patients via the Case Mix Programme 
CAOS relied on staff in participating units to identify and then recruit patients who met 
the inclusion criteria. Typically units had one or two staff who were the study 
champions and did most of the data collection. 
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Table 5.1.2 CAOS and non-participating CMP units compared 
In CA OS Not in CA OS 
Number of Units (%) 90(52.9) 80(47.1) 
Total number of admissions in CMPD, number 158,226 (57.2) 118,505 (42.8) 
Admissions potentially eligible for CAOS, number 
N 
5,726(3.6) 4,281(3.6) 
COPD acute physiology score, mean (SD) 30.6(14.4) 30.7(14.6) 
Hospital Type, University 12(13.3) 18(22.5) 
number of units 
(0/0) University Affiliated 17(18.9) 8(10.0) 
Non-university 61(67.8) 54(67.5) 
ICU Type, ICU 39(43.3) 32(42.1) 
number if units 
(0/0) ICU\CCU 3(3.3) 4(5.3) 
ICU\HDU 43(47.8) 38(50.0) 
ICU\HDU\CCU 5(5.6) 1(1.3) 
HDU 0(0.0) 1(1.3) 
Number of 2-4 21(23.3) 21(26.6) 
beds, number of 
units 5-6 39(43.3) 26(32.9) 
7-9 20(22.2) 18(22.8) 
10-13 7(7.8) 12(15.2) 
14-22 3(3.4) , 2(2.5) 
Since a data collector would usually only be in the unit for 40 hours per week this left 
128 hours each week when they would not be available. It seemed likely that patients 
would be missed. 
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The CMP dataset allowed the patients admitted to ICU that were recruited to CAOS to 
be compared to those who satisfied the inclusion criteria for CAOS but were not 
recruited (Section 4.17). 1873 CAOS eligible patients were identified through the CMP 
data set and of these 684 were recruited to CAOS and 1189 were missed. The total of 
recruited patients is less than the total of patients recruited to CAOS because CMP data 
were not collected in the RHDU, so RHDU patients are not included in the comparisons 
of included and missed patients. 
5.3.1 Missedpatients and ICU mortality 
Patients who died quickly might be expected to have a greater risk of being missed, in 
which case missed patients would have higher ICU mortality. Table 5.3.1 shows the 
ICU mortality in the 1189 missed and 684 recruited patients. There was no significant 
increase in the risk of ICU mortality in the missed patients. 
Table 5.3.1 ICU mortality for missed and recruited patients 
Recruited to CAOS Died in ICU (916) Survived ICU (116) Total 
No 246(20.7%) 943 (79.3%) 1189 
Yes 130 (19.01/o) 554 (81.0%) 684 
Relative risk ofdymg in ICU in patients not recruited to CAOS compared to CAOS patients was 1.09 (95*/. Cl 0.9-1.32) chi-square 0.77 p-0.38 
5.3.2 Missedpatients and severity 
As is explained in Chapters 10 and II below, the study led to the development of a 
CAOS score that allowed individual patients' risk of death at 180-days to be calculated. 
This score used patients' characteristics prior to ICU admission, with aspects of their 
physiological status used to produce a severity measure, the COPD acute physiology 
score (CAPS) (Chapter 8 below). Some components of the CAOS score were missing 
for patients admitted to critical care but not recruited to CAOS. However the CMP data 
contained all the variables required to calculate the CAOS acute physiology score 
(CAPS). Table 5.3.2 shows the CAPS for missed and admitted patients. There was no 
difference in acute severity between recruited and missed patients. 
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Table 5.3.2 COPD Acute Physiology Score for missed and recruited patients 
Recruited Mean APS (SD) 95% Confidence interval 
No 
Yes 
28.9(13.8) 
28.9(10.9) 
(28.1-29.7) 
(28.1-29.7) 
inuepenuent sampies mest p-u. vo 
5.3.3 Missedpatients and age 
There was no difference in mean age between the missed and recruited patients (Table 
5.3.3). 
Table 533 Age for missed and recruited patients 
Recruited Mean age in years (SD) 95% Confidence interval 
No 
Yes 
66.3(9.8) 
66.4(9.6) 
(65.9-66.8) 
(65.7-67.1) 
Inaepenaent sarnpies t-test P-U. 4V 
5.3.4 Missedpatients and sex 
Of the 832 patients recruited, 47.7% (44.3-51.2%) were male. This was slightly lower 
than in other published series in which males typically comprised just over 50%, though 
the 95% confidence intervals suggest that the difference could have been due to chance. 
Table 5.3.4 shows that though there was a very slightly higher proportion of males 
amongst the missed patients, but the difference does not reach statistical significance. 
Table 5.3.4 Sex amongst missed and recruited patients 
Recruited Male ('16) Female ('1q) 
No 
Yes 
583(49.0%) 
333(48.3%) 
606(51.0%) 
356 (51.7%) 
Pearson Chi-square 0.09 p-0.77 
5.3.5 Missedpatlents and day ofcritical care admission 
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It might be the case that patients would be more likely to be missed if admitted at the 
weekend. Table 5.3.5 shows that there was no evidence for a difference between 
recruited and missed patients in the percentages of patients admitted at weekends. 
Figure 5.3.5 below shows the day of week on which included and missed patients were 
admitted. 
Table 5.3.5 Weekend vs. non-weekend admissions in missed & recruited patients 
Recruiled Weekend (/o) Weekday (016) 
No 
Yes 
320(26.9%) 
196 (28.7) 
869(73.1%) 
488 (71.3) 
Pearson Chi-square 0 81 p 0,32 
Figure 5.3.5 Day of week admitted to critical care in CAOS patients and missed 
patients 
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5.3.6 Missed patients and the working day 
Thursday Friday Saturday 
135 
Patients admitted out of hours might be more likely to be missed. Table 5.3.6 shows 
patients grouped by whether they were admitted between 0800hrs, and 1759hrs or 
between 1800hr and 0759 hrs. There was no significant difference between the 
proportions of missed patients between the time periods. 
Table 5.3.6 Patients recruited and missed during working day and out of hours 
Recruited Working day r1o) Out of hours ('16) Total 
No 
Yes 
545 (45.9%) 
341 (49.4%) 
642(54.1%) 
349 (50.6%) 
1189 
684 
Pearson Chi-square -2.15 p-0.14 
5.3.7 Conclusion: missingpatients in CAOS 
Although the objective of consecutive series was not achieved, there was no evidence of 
any systematic differences in the characteristics of patients recruited to CAOS 
compared with those who were not. Of particular relevance was the fact that there were 
no differences in ICU mortality, or in the sex, age and acute physiology scores. There is 
no evidence to suggest selection bias sufficient to undermine the external validity of the 
CAOS model. 
5.4 Diagnostic groups 
As explained in Section 1.1, there can be difficulty in distinguishing elderly patients 
with asthma from those with chronic obstructive pulmonary disease (COPD). It seemed 
possible that patients with chronic asthma, who had not smoked, might have a different 
prognosis from those patients with COPD and a major smoking burden. In order to 
attempt to understand more about the clinical classification of patients into those 
thought to have asthma, COPD, or a mixture of asthma and COPD, information was 
collected about inhaled steroid use and smoking history. It was expected that patients 
with asthma would take more inhaled steroids and would have smoked less than 
patients with COPD. Patients with a clinical diagnosis of a mixture of asthma and 
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COPD might be intermediate. It should be remembered that any association may have 
occurred because clinicians use the smoking and inhaled steroid history in their 
classification decisions. 
5.4.1 Inhaled steroid use 
Five hundred and forty three patients (65.3%) were taking inhaled steroids. Of patients 
with a diagnosis of asthma, 79.4% were reported to be taking steroids, while the figure 
for the patients considered to have a mixture of asthma and COPD was 72.2%. These 
were in contrast to the rate of 63.5% for patients considered to have COPD alone. 'Me 
distribution of inhaled steroid use supports the diagnostic classification. 
5.4.2 Smoking status 
A patient with asthma is more likely never to have smoked than a patient with COPD. 
Figure 5.4.2 shows the proportion of patients in each of the three diagnostic groups, 
together with the accumulated smoking burden in pack years, grouped by smoking 
status. It can be seen that the "pure" asthmatics comprise the largest diagnostic group in 
the never smokers (48%) but the smallest group among current and ex-smokers (5% and 
10% respectively). 
5.5 Classification of patients by treatment limitation 
Altman has stressed that treatment cannot be ignored in the development of prognostic 
models 17 (section 2.5.4). For this reason units were asked to identify those patients who 
would not be considered for intubation if less aggressive treatment was unsuccessful. 
The prognostic model was developed only in those patients without recorded treatment 
limitation. 
5.6 Recruited patients summary 
In total 832 patients were recruited to CAOS, and in 181 the decision was made not to 
intubate the patient if less aggressive treatment failed. The remaining 651 patients had 
no treatment limitations. The available data comparing patients recruited with patients 
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missed suggested that the patients recruited to CAOS were representative of eligible 
patients admitted to UK ICUs. 
Figure 5.4.2 Smoking in the CAOS diagnostic groups 
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Chapter 6 Mortality 
6.1 Overall mortality rate 
Table 6.1 shows the mortality in ICU, in hospital and at 180 days after ICU admission 
for all the patients recruited to CAOS and for the patients classified by treatment 
limitation. In addition the mortality of the 450 intubated patients is shown. Kaplan- 
Meier survival curves are presented for the patient groups in Figures 6.1.1 to 6.1.3. 
Table 6.1 Mortality to 180 days in CAOS 
Patient group 
Critical care mortalily 
% (95%CI) 
Hospital mortalityt 
% (95%CI) 
180 day mortality* 
% (95%CI) 
Patients without 16.4% (13.7-19.5%) 26.6% (23.2-30.1%) 34.0% (303-37.7'Yo) 
treatment limitation 
n= 651 
Patients not for 27.6% (21.3-34.7'Yo) 40.3% (33.1-47.9%) 51.9% (44.4-59.4%) 
intubation 
n-- 181 
Intubated patients 23.3% (19.5-27.5'Yo) 35.8% (313-40.4%) 41.6% (37.0-46.2-Yo) 
n=450 
All patients 18.9% (16.3-21.71/o) 29.6% (26.5-32.81/6) 37.9% (34.6-41.3'Yo) 
n=832 
The hospital mortality includes those patients dying in critical care. 
* 180 day mortality includes critical care, hospital and 180 day deaths. 
6.2 Causes of death in CAOS 
There were 315 deaths during 180 days from ICU admission, and a finther 80 deaths in 
those patients with longer follow-up. Figure 6.2 shows the causes of death found in the 
study. 
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Figure 6.1. Kaplan-Meier survival plot for all 832 CAOS patients 
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Figure 6.1.2 Kaplan-Meier survival plot for the 450 intubated CAOS 
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Figure 6.1.3 
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6Z1 Deaths with COPD on the death certificate 
Of the 395 deaths during the total period of follow-up, 256 (64.8%) had COPD 
somewhere on the death certificate. Table 6.2.1 shows the causes of death in these 
patients. It can be seen that in most cases the certificates included other causes of death 
as well as COPD, and the more frequently occurring causes are listed individually in the 
table. 
Kaplan-Meier survival plot comparing CAOS patients with 
and without treatment limitation 
-------------- 
141 
Figure 6.2 Schema used to summarize causes of death in CAOS 
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The common causes of death were those that occurred frequently with COPD or with 
other diagnoses and comprised the following: (i) respiratory failure, (ii) 
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failure, (vi) asthma, (vii) carcinoma of the lung and (viii) cor pulmonale. 
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Table 6.2.1 Certified causes of death 
Cause ICUdeath 
n- 157 
In hospital 
afierICU 
discharge 
n=89 
After discharge 
up to 180 days 
n-69 
> 180 days 
afier ICU 
onset 
n=80 
Total number of 
deaths with 
COPD on 
certificate 
Total number of 
deaths in 180 
days 
n=315 
COPD anywhere on 84 60 52 60 256 196 
certificate (53.51/6) (67.40/6) (75.41/6) (751/6) (62.0%) 
COPD alone 31 19 21 11 82 71 
(19.7%) (21.3%) (30.4%) (13.81%) (32.2%) (26.0%) 
COPD & respiratory 13 11 17 0 41 41 
failure 
(8.31/o) (12.4%) (24.66/o) (16.11/6) (13.0%) 
COPD & pneumonia 18 6 1 0 25 25 
(11.5%) (6.7%) (1.40%) (9.8%) (7.9%) 
COPD & 9 7 10 15 41 41 
bronchopneurnoma 
(22.0%) (17.1%) (14.5%) (12.5%) (16.1 */o) (13.00%) 
COPD & 13 16 8 18 55 37 
cardiovascular dis. (8.31/e) (18.0%) (110/6) (22.5%) (21.50%) (11.7%) 
COPD & organ 4 1 0 1 6 5 
failure/sepsis 
(2.5%) (1.1%) (1.25%) (2.7*/o) (10/6) 
COPD & 3 1 0 1 5 4 
renal failure (1.9%) (I. Io/. ) (1.256/o) (2.0%) (1.3%) 
COPD & Asthma 0 0 0 1 1 0 
(1.250/. ) (0.41/o) 
COPD & carcinoma I 1 0 3 5 2 
of lung (0.6 1/6) 1.1-/. ) (3.75%) (2.0%) (10/6) 
COPD & 2 0 2 3 7 4 
cor pulmonale (1.3%) (2.9%) (3.8*/*) (2.7%) (2.28/o) 
§COPD & other 6 16 8 14 44 30 
(3.80/. ) (18.0%) (1 1.6*/o) (17.5%) (17.2%) (9.5%) 
Note column totals will exceed 100% because some patients have more that 2 diagnoses e. g. COPD and 
ischaemic heart disease and bronchopneumonia, and other etc. § Diagnoses in "othee, category listed in 
section 6.2.2 below 
143 
6 2.2 Other cause ofdeath given with COPD 
There were 44 causes of death that made up the 'COPD and others' category in Table 
6.2.1 above: i) hyperkaleamia, ii) schizophrenia, iii) cigarette smoking (0), iv) urinary 
tract infection, v) obstructive sleep apnoea, vi) osteoporosis, vii) fractured femur (0), 
viii) acute myeloid leukaemia (x2), ix) autonomic neuropathy, x) pulmonary 
hypertension, xi) diverticular abscess, xii) paraproteinaemia (x2), xiii) hypercaleaemia 
(1), xiv) gastrointestinal bleed, xv) pulmonary fibrosis, xvi) hypertension, xvii) coal 
workers pneumoconiosis, xviii) non insulin dependent diabetes mellitus (NIDDM), 
xviv) acute large bowel obstruction, xx) korsakoff syndrome & depression, xxi) liver 
metastasis, xxii) cerebrovascular accident (0), xxiii) atrial fibrillation, xxiv) old age, 
xxv) obesity induced hypoventilation, xxvi) PE (x2), xxvii) alcoholic, xxviii) 
bronchiectasis, xxviv) cardiac arrest (A), xxx) allergic broncho-pulmonary 
aspergillosis, xxxi) alpha-I antitrypsin deficiency, xxxii) peritonitis, xxxiii) 
ostcoarthritis, xxxiv) lung metastasis with unknown primary. 
6Z3 CAOS deaths with cardiovascular, respiratory or renal causes without COPD 
Table 6.2.2 shows the cause of death for patients where COPD did not appear on the 
certificate but where the cause given was one commonly found to accompany COPD in 
certificates where COPD does appear (i. e. the categories specified in table 6.2.1 
excluding "other"). 'Miscellaneous' was far the largest group. 
624 Miscellaneous causes ofdeath given without COPD orfrom Table 62.2 
Other causes of death that appeared on certificates without COPD or any of the 
common causes in table 6.2.2 included a range of conditions that are listed below. Some 
of these occurred more than once. This group corresponds to the "Other causes of death 
not including COPD or the causes above" category in table 6.2.2 were: a) terminal lung 
disease, b) metastatic breast cancer, c) gall stone pancreatitis, d) peritoneal bleed, e) 
massive pulmonary embolus & gastrointestinal bleed, f) metastatic cancer with 
unknown primary, g) end stage lung disease, h) old age, i) abdominal compartment 
syndrome following perforated viscus, j) pulmonary hypertension & leukaernia, k) 
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alcoholic cirrhosis, 1) bowel perforation, m) cardiac or respiratory arrest, n) 
cerebrovascular accident, o) peritonitis, p) gastrointestinal bleed, q) pulmonary fibrosis. 
Table 6.2.2 Cardiovascular, respiratory or renal deaths without COPD 
Cause Number (o/,, ) 
oftotal ICU 
deaths 
n= 157 
Number r1q) of 
total hospital 
deaths (post 
ICU 
discharge) 
n =89 
Number ("16) of 
total deaths 
after hospital 
discharge up 
to 180 days 
n=69 
Number (0/6) Of 
total deaths 
>180days 
after ICU 
onset 
n=80 
Number (016) 
oflotal 180 
day deaths 
n =315 
Respiratory failure alone 12(7.6%) 9(10.1%) 2 (2.9%) 0 23(7.3%) 
Pneumonia alone 6(3.8%) 0 1(1.4%) 2 (2.5%) 7 (2.2%) 
Bronchopneumonia I (0.61/o) 4(4.5%) 1(1.4%) 1 (1.3%) 6 (2.2%) 
alone 
Cardiovascular disease 4(2.5%) 1 (1.10%) 3(4.3%) 3(3.8%) 8 (2.5%) 
alone 
Organ failure & sepsis 5(3.2%) 0 0 5(l. 6%) 
alone 
Renal failure alone 0 0 0 0 0 
Asthma alone 1(0.6%) 0 0 1(1.3%) 1(0.3%) 
Carcinoma of lung alone 0 1 (1.1%) 1(1.4%) 0 2(0.6%) 
Cor pulmonale alone l(0.6%) 0 0 0 l(0.3%) 
tMiscellaneous causes 
of death not including 43 (27%) 14 (161/6) 9(13%) 13 (16%) 66(21%) COPD or the causes 
above 
Column total 
(0/o of all deaths 73(471/o) 29(33%) 17 (251/o) 20(25%) 119 (38%) 
in time period) 
t These are the patients who had causes of death that did not include COPD and did not include one of 
the commoner causes explicitly named in the other rows of this table. The causes of death making up this 
group are listed in section 6.2.5 below. 
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625 Common causes ofdeath in Table 6 2.2 appearing with diseases other than 
COPD 
This section provides the list of other diagnoses that appear with the common causes of 
death in which the common cause does not appear with COPD and does not occur 
alone. The accompanying diagnoses are as follows: 
i) renal failure: (1) clostridium. difficile. ii) bronchopneumonia: ischaernic colon, 
gastric cancer, rheumatoid lung & cigarette smoker. W) Respiratory failure: (2) 
pneurnothorax, hypertension, NIDDM, obesity, iv) Pneumonia: bronchiectasis, 
(pneumothorax & pneumonia & surgical emphysema), respiratory failure, 
kyphoscoliosis, atrial fibrillation, v) Cardiovascular disease: liver failure; vi) Multi- 
organ failure and morbid obesity. 
6.3 Discussion 
63.1 Mortality 
Hospital mortality is difficult to compare between studies because of differences in case 
mix (section 3.3.1). Restricting the comparison to intubated patients is one way of 
ensuring relatively homogeneous groups of patients, although differences in inclusion 
criteria and also in the definitions of outcome (e. g. hospital mortality rather than 30-day 
mortality) may remain problems. Nonetheless comparing hospital mortality for the 
intubated patients it can be seen that the rate in the CAOS patients, 35.8% (95% Cl 
31.3-40.4%) is close to that observed in systematic review 37.9% (1771/4675) (95% CI 
36.5-39.3%), chi-square 0.77 p=0.38. Mortality at 180 days was available for fewer 
intubated patients in the systematic review, but the 165 deaths in 387 patients again 
gave a similar rate, 42.6% (95% CI 37.747.7%) compared to 41.6% for CAOS (95% CI 
37.046.2%), chi-square 0.10 p--0.75. The similarity of these rates supports the 
contention that the patients included in CAOS are representative of intubated COPD 
patients in general. 
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63.2 Causes ofdeath 
It has been suggested that the accuracy of death certificates is greatest in young people 
and deteriorates with increasing age and increasing numbers of coexistent diseases 130 . 
Studies of causes of death in airways disease have tended to concentrate on the 
misclassification of asthma as COPD, particularly in the elderly 130-132 .A study from 
Finland 133 followed 2,237 patients identified from hospital episode data as having 
COPD as the primary reason for admission, and determined the causes of death in 1,070 
patients who died over the subsequent 10 years. They found that coronary heart disease 
was the most frequent, comprising 37% of deaths, and the second most common was 
COPD in 30.2% of deaths. Lung cancer accounted for 12.1%. A study from the UK 
that used the records of the ONS to identify all death certificates that mentioned COPD 
or asthma found that a disease of the circulatory system was listed as a frequent 
underlying cause of death, as was a neoplasm 134 . In CAOS, the proportion of all deaths 
in study patients attributed to COPD was 53.3% for within ICU mortality, and 75% for 
180 day mortality. This increase in the percentage of patients with COPD with length of 
follow-up may be because many patients who die in ICU develop complications such as 
gastrointestinal bleeding and peritonitis, and the doctors providing the death certificate 
may give these as the immediate cause of death, having lost sight of the fact that the 
patient was admitted to critical care with an exacerbation of COPD. It is interesting that 
these percentages certified as COPD are higher than in the Finnish study. It might be 
that COPD patients recruited to CAOS and dying soon after hospital discharge had 
severe COPD. 
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Chapter 7 Quality of life after intensive care 
7.1 Introduction 
A major concern for clinicians admitting COPD patients to critical care is that the 
treatment provided will merely prolong the process of dying, and that survivors will be 
left with such poor quality of life that they will regret having been treated aggressively. 
The 180-day follow-up questionnaire was designed to collect data that would enable 
clinicians to understand the likely health status and views about aggressive treatment of 
survivors. 
7.2 Response rate 
Four hundred and twenty of the 518 (81.1%) 180-day survivors provided answers to the 
follow-up questionnaire. Figure 7.2 below shows the number of days after ICU 
admission at which responders returned the 180-day questionnaire. The mean (SD) and 
median (IQR) number of days elapsed between hospital admission and questionnaire 
return was 268 (104), 231 (200-299). 
Figure 7.2 Time elapsed after ICU admission until questionnaire completed 
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73 The implications of non-response 
Non-response is an important threat to the conclusions that can be drawn from quality 
of life questionnaires, because non-responders may differ systematically from 
responders. Three strategies were used to gain insight into the effects that non-response 
might have had on the follow-up in this study. First, responders were compared with 
non-responders in terms of data collected while both groups were in hospital. Second, 
very late responders would have been non-responders had the study closed earlier and 
may give some insight into the characteristics of non-responders. For this reason, in 
analyses of hospital and follow-up data, responders have been classified as prompt (up 
to and including patients who responded within 220 days after ICU admission), delayed 
(221 days to 364 days) and very delayed (>365 days). Quality of life measures were 
presented for each response group. Third, sensitivity analyses were carried out to 
investigate the outcomes if all non-responders had had the most favourable response 
and if they all had had the most unfavourable response. 
7.4 Responders vs. non-responders: hospital data 
The non-responders were older, more of them were male, and more had been intubated 
(Table 7.4.1). These differences were small and did not reach statistical significance. 
With only 98 non-responders the power of statistical tests to identify significant 
differences is limited and such analyses are subject to the risk of spurious findings 
inherent in post-hoc subgroup analyses. Nevertheless these data suggest that the 
responders and non-responders were not markedly different in terms of the 
characteristics examined. 
Table 7.4.2 shows that the differences between the different response groups in terms of 
functional score and self-rated Quality of Life before admission to the ICU were also 
small. 
7.5 Patient characteristics at follow-up: summary 
Table 7.5 summarises the characteristics of the patients at follow-up. 
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Table 7.4.1 Characteristics of responders and non-responders 
Admission data 
Total cohort 
n=832 
Survtvingnon- 
responders 
n=98 
Allresponders 
n- 420 
Prompt 
n=184 
Delaved 
n= 179 
Very deZ2)vd 
n=57 
Age 
n mean (SD) 67.0(9.7) 65.4(9.6) 65.2(9.5) 65.7(9.6) 65.4(9.1) 63.0(9.9) 
n median (7QR) 68.0 (60-75) 66.0 (58-73) 65.0 (59-72) 66(58-73) 66(59-72) 61.5 (57.5-71.5) 
Male n% 397 (47.7%) 46 (47.40/9) 187 (44.4%) 81 (43.8%) 87 (48.3%) 19 (33.90/9) 
Intubated n (8/. ) 450 (54.1%) 52 (53.6*/*) 212 (50.41/6) 86 (46.5%) 95 (52.8%) 31 (55.40/6) 
Table 7.4.2 Pre-ICU functional score and QoL by response delay 
Total cohort Survivingnon- Allresponders Prompt Delayed Very delajvd 
n=832 responders n= 420 n=184 n= 179 n=57 
n=98 
Functional Score 
Fully mobile n (%) 207 (24.9%) 25 (24.7%) 130(30.9*/o) 56 (303%) 53 (29.41/6) 21 (3 7.5 
Independent n (0/. ) 308 (370/6) 34 (35.1%) 160 (38.2%) 71 (38.9%) 71 (40.0%) 17 (30.40/6) 
Housebound n (%) 280 (33.7%) 35 (36.11/o) 121 (28.7%) 52 (28.1%) 53 (29.4/o) 16 (28.61/o) 
Bed/chair bound n (5/6) 37(4.5%) 4 (4.11/6) 9 (2.1%) 5 (2.71/9) 2 (1.1%) 2 (3.6%) 
Selkated QoL 
Exccllent 21 (2.5*/o) 2 (2.1 */o) 14 (3.3*/o) 6(3.2%) 6 (3.3*/o) 2(3.6%) Very good 142 (17.1 */o) 17 (17.55/6) 88 (20.9*/*) 37 (20.0%) 40 (22.8%) 10 (17.9*/o) Fair 361 (43.4*/o) 47 (48.51/9) 169 (40.21/6) 77 (42.2*/*) 70 (38.9*/o) 22 (39.30/9) Poor 
Voy poor 
248 (29. r/o) 
* 
30 (29.9*/o) 
1 
I 18 (2 8.11/6) 51 (27.61/6) 47 (26.1 */o) 20 (35.70/6) 
60 (7.2 /o) 2 (2.1 /o) 31 (7.4%) 13 (7.0*/o) 16 (8.91/6) 2 (3.6*/o) 
7.6 Self-rated health at follow-up compared to the period of stability pre-ICU 
In the follow-up questionnaire patients were asked to choose the statement that best 
described their current health compared to their health in the period before the acute 
illness that resulted in ICU admission. Options ran from "much worse" to "much 
better. Of the 420 patients who completed the follow-up questionnaire 415 answered 
this question. Seventy-two percent (302/415), (95% CI 68.2-77.0) considered their 
health at follow-up to be the same or better and 27.2% (113/415), ( 95% CI 23.0-31.80/0) 
considered their health to be worse. If all the non-responders are considered to have 
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quality of life that is worse than prior to ICU 59% (306/518), (95% CI 55-63) would 
have a quality of life 180-days after ICU that was the same or better than prior to ICU. 
The proportions are almost identical if just the intubated patients are considered. Of the 
450 intubated patients 263 (58.4%) survived to 180-days and 166 (78%), (95%Cl 72- 
84%) of responders considered their quality of life at 180-days to be the same or better 
than prior to ICU. If all non-responders are considered to have worse quality of life than 
pre-ICU 166/263 intubated patients would have quality of life that was the same or 
better than prior to ICU (63%, 95% Cl 57-69%). 
Figure 7.6.1 and Table 7.6.1 show the responses of patients grouped by promptness of 
response, and it can be seen that there was no significant difference in quality of life 
between prompt and delayed respondents. Again this is a post-hoc analysis and the 
numbers are relatively small but there is adequate power to detect a major difference. 
For example, if 30% of delayed responders had a worse quality of life compared to 15% 
of prompt responders, a study with a sample size of 280 (140 early responders and 140 
late) would detect such a difference as significant at the 5% level with a probability of 
85%. 
If the very delayed responders are taken as giving some insight into non-responders 
there is no evidence to suggest that non-response has mainly occurred in patients with 
the worst quality of survival. 
Figure 7.6.1 Current compared to pre-admission quality of life, by response 
delay. 
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tMissing responses to the health state transition question. 
Prompt group 4 missing responses, delayed 2 missing responses, very delayed no missing responses. 
M.. h worse A httle worse Thesame A LitUe better Much befter 
M Prompt (<220 days) 
13 Delayed (221-365 days) 
13 Very delayed (-365 days) 
Prompt n=1 81, Delayed n=1 78, Very delayed n=56 
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Table 7.5 Patient characteristics at follow-up 
Mean(SD) Alfresponders Pro-pt Delayed Very delayed 
Median (IQR) n- 420 n=184 n=179 n=57 
I lealth status measure 
Prior health 
Much worse 41 (9.81/o) 19(103-1. ) 16 (9.01/9) 6(10.50/9) 
Little worse 72 (17.21/6) 33 (17.9%) 28 (15.71/o) 11 (19.3%) 
Same 80 (19.10%) 30 (16.31%) 34 (19.1%) 16 (28.1%) 
Little better 102 (24.31/6) 45 (24.5%) 47(26.41/6) 10 (17.5 1/6) 
Much better 124 (29.65/6) 57 (30.91/6) 53 (29.8%) 14 (24.6%) 
lWagain 
Yes 400 (96.41/6) 174 (94.5%) 169 (96.0%) 57 (1 0(r/*) 
No 15(3.60/*) 7 (3.90/*) 8 (4.5%) 0 (00%) 
Functionalicore 
Fully mobile 91 (21.7%) 40 (21.7%) 38 (21.2%) 13 (22.81/9) 
Independent 141 (33.61/6) 62 (33.71/9) 59 (33. (r/*) 20 (35.10%) 
flousebound 171 (40.7%) 70 (38.01/o) 79 (44.1%) 22 (38.61/6) 
Bed/chair bound 17 (4.1%) 12 (6.5*/*) 3(1.7%) 2(3.56/*) 
AQ20 score 11.2(4.7) 11.1(4.7) 11.2(4.8) 11.7(4.2) 
12(8-15) 12(8-15) 12(8-15) 13(9-14) 
E&JD 54.6(31.0) 53.3(32.3) 56.2(29.8) 53.8(31.0) 
62(35-74) 62(29-74) 62(52-74) 62(38-74) 
Thermometer score 54.9(19.5) 54.1(20.8) 55.5(17.7) 55.1(20.6) 
50(40-70) 50.5 (40-70) 50(45-70) 55(50-70) 
Mobility 
No problems 72 (17.21/9) 37 (20.11/9) 26 (14.71/6) 9(15.8'/o) 
Some problems 341 (81.61/6) 145 (78.81/9) 150 (84.81/6) 46 (80.71/6) 
Bed bound 5 (1.21/6) 2 (1.11/0) 1 (0.61/o) 2 (3.50/*) 
Setkare 
No Problems 211 (50.55/6) 92(500/*) 94 (53.11/6) 25 (43.9*/*) 
Some problems 183 (43.81/6) 83 (45.1%) 73 (41.21/o) 27 (47AO/9) 
Unable wash/dress 24 (5.71/6) 9(4.90/*) 10(5.6%) 5 (8. r/0) 
Usual activities 
No problems 78 (18.71/6) 35 (19.0%) 36 (20.31/6) 7(12.3%) 
Some problems 250 (59.81/6) 104 (56.51/6) 105 (59.3%) 41 (71.9%) 
Unable 90 (21.5*/oO 45 (24.50/*) 36 (20.31/6) 9 (15.8%) 
Pain1discomfort 
None 160 (38.31/6) 61 (33.21/6) 70 (39.61/6) 29 (50.9%) 
Moderate 231 (55.31/6) 109 (59.21/6) 97 (54.81/6) 25 (43.49%) 
Extreme 27 (6.51/6) 14 (7.61/6) 10 (5.71/6) 3 (53%) 
Anxiety1depression 
None 180 (43. r/o) 81 (44.31/6) 75 (42.41/9) 24 (42.11%) 
Moderate 205 (49.2%) 91 (49.7%) 88 (49.71/6) 26 (45.61/6) 
Extreme 31 (0.21/6) 10(5.5%) 14 (7.91/6) 7 (123%) 
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If all the 98 non-responders had worse quality of life at follow-up than in the period 
prior to ICU the proportion of 180-day survivors with the same or better quality of life 
would be 58.3% (302/518). If all non-responders had better quality of life than in the 
period of stability prior to ICU the proportion of 180-day survivors with the sarne or 
better quality of life would be 77.2% (400/518). 
Table 7.6.1 Current compared to pre-admission quality of life, by response delay 
Worse quality Same or better Total Prompt vs. Prompt vs. 
of life than in quality of life than patients in delayed very delayed 
periodstability in period of response Chi-square Chi- square pre-ICU stabilitypre-ICU group P value P value 
Prompt 52 129 181 
Responders 29% 71% 
Delayed 44 134 178 ChiSq=0.74 
responders 25% 75% P=0.39 
Very delayed 17 39 56 ChiSq=0.05 
responders 30% 70% P=0.81 
tOverall: all 113/415 302/415 415 
responders 27.2% 72.8% 
t The denominator of 415 is used in this table since this makes no assumptions about the views of non- 
responders and the sensitivity analysis below explores the impact of non-responders 
7.7 Preference for admission to ICU again 
Overall 96.4% of the responders (400/415) would be willing to undergo ICU again 
under circumstances similar to the original admission. If all non-responders are assumed 
to not want ICU again the overall preference for entering ICU again under similar 
circumstances would fall to 77.2% (400/518). Of the 450 intubated patients 263 (58%) 
survived to 180-days and 212 (81%) responded to the question about ICU, Of these 
204/212 would want ICU again under similar circumstances (96.2%). If all of the 
intubated non-responders are assumed to not want ICU again the proportion of all 
survivors who would want ICU again would be 204/263 (78%). 
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7.8 Functional score at follow-up compared to the period of stability pre-ICU 
The functional score that described patients exercise tolerance was collected at ICU 
admission (to describe the patients' functional capacity in the period of stability prior to 
critical care admission) and also at follow-up (to describe the functional capacity on the 
day that they completed the follow-up questionnaire). In Figure 7.8.1 the functional 
score at follow-up is shown for patients grouped by their pre-ICU functional score. 
Table 7.8.1 shows the numbers that correspond to the percentages shown in the figure. 
Of the 420 patients with functional score data both before ICU and at follow-up 198 
(47.1%) had the same level of function at follow-up, 129 (31%) had dropped by one 
level and 26 (6.2%) had dropped by 2 levels and 41 (9.8%) had improved by one or 
more levels. 
Table 7.8.1 Functional capacity before and 180-days after ICU admission 
Functional capacity I Functional capacity in period of stability prior to ICU admission 
180-days 
After ICU onset 
Fully mobile Independent Housebound Bed/Chair bound 
n--131 n=160 
I 
n=120 n--9 
Fully mobile 44.3% 16.3% 5.8% 0% 
Independent 37.4% 41.0% 21.7% 11.1% 
Housebound 18% 41.9% 61.7% 77.8% 
Bed/Chair bound 0.8% 1.3% 10.8% 11.1% 
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Figure 7.8.1 Functional score at follow-up for patients classified by functional 
score in the period of stability prior to ICU. 
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7.9 AQ-20 Questionnaire 
In the AQ-20 questionnaire patients we asked about symptoms associated with airways 
disease. Table 7.9 summarises the data from the 420 respondents. 
The AQ20 has a maximum score of 20 and a minimum score of zero. The mean (SD), 
and median (IQR) scores were 11.2 (4.7), 12 (8-15). Figure 7.9 displays the distribution 
of scores in the CAOS respondents. 42.7% of CAOS respondents report feeling 
breathless when trying to get to sleep and 82.3% considering that the fullness of their 
lives is limited by their chest trouble. 
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Table 7.9 AQ-20 responses 
Question Yes No Not applicable Missing 
n% n% n% n% 
Do you cough during the day? 230 (54.8%) 18 5 (44.1 %) 3(0.70/9) 2 (0.9*/o) 
Does your chest often make you feel restless? 274 (65.2%) 139 (33.1%) 2(0.5%) 5 (I. -M) 
Does gardening make you breathless? 218 (51.9%) 41(9.8%) 157 (37AO/. ) 4 (1.41/6) 
Do you worry when going to a friend's house that 148 (35.20/. ) 215 (51.2%) 55 (13.60%) 2 (0.5%) 
there might be something there that will upset 
your chest? 
Do you get chest problems when you come into 323 (76.91/6) 84 (20.00%) 10(2.4%) 3(1.2%) 
contact with strong smells, exhaust fumes, 
perfumes etc? 
Does your partner find your chest trouble 171 (40.71/6) 78 (18.61/6) 169 (40.7%) 2(0.5%) 
upsetting? 
Do you feel breathless when trying to sleep? 179 (42.7%) 230 (54.9%) 4(1.2%) 6(1.70/6) 
Do you worry about the long term effects of the 179 (42.7*/o) 233 (55.5%) 4(1.2%) 1(0.9-/. ) 
drugs you take for chest trouble? 
Does emotional upset make your chest trouble 286 (68. B/6) I 18 (28.11%) 11 (2.6*/o) S(I. 7%) 
worse? 
Are there times when you have difficulty getting 303 (72.1%) 109 (26.0%) 5(l. 40/0 3(0.9%) 
around the house because of your chest trouble? 
Does your chest problem make you breathless 33(7.90/*) 26 (6.21/o) 358 (85.5%) 3(0.9%) 
when you do things at work? (paid employment) 
Does walking upstairs make you breathless? 313 (74.5%) 58 (13.8%) 47 (11.71/6) 2(0.5%) 
Do you get breathless doing housework? 265 (63.31/6) 55 (13.1%) 96 (23.4%) 3 (0.751/6) 
Does your chest trouble make you go home 158 (37.6%) 92 (21.91/6) 164 (39.5%) 6(1.4%) 
sooner than others after a night out? 
Do you suffer from breathlessness when you 186 (44.30/9) 223 (53.1%) 6(l. 7%) 5 (1.4*/o) 
laugh? 
Does your chest trouble make you feel impatient? 292 (69.5%) 123 (29.30/*) 2 (0.71/6) 3(0.90/9) 
Do you think the fullness of your life is limited 345 (82.3%) 69 (16.5%) 2(0.70/. ) 3 (0.9*/o) 
by your chest trouble? 
Do you feet drained after a cold because of your 334 (79.5%) 55 (13.1%) 28(6.91/o) 3 (0.90/c) 
chest trouble? 
Do you have a feeling of chest heaviness? 257 (61.2%) 156 (37.1%) 3(0.70/*) 4 (1 A01e) 
Do you worry a lot about your chest trouble? 250 (59.50/(o) 163 (38.8%) 3(0.7%) 6(l. 9%) 
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Figure 7.9 The distribution of AQ-20 scores in questionnaire responders 
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7.10 EuroQol 
7.10.1 EQ-51) values in the CA OS responders 
Responders had a mean (SD) EQ-513 of 54.6 (31.0) and median (IQR) of 62.0 (35-74). 
The distribution of the EQ-513 in the responders is shown in Figure 7.10.1. The 
distribution of patients between the individual domains is shown in Table 7.5 above. 
Figure 7.10.1 EQ-51) values for the CAOS population. 
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Z 10.2 EuroQol visual analogue score (VAS) 
Responders had a mean (SD) VAS of 54.9 (19.5), median (IQR) of 50 (40-70). 
Clinicians provided VAS estimates for 414 of the 420 respondents. Figure 7.10.2 
displays the clinician's prediction of the patients VAS rated quality of life at 180-days 
after ICU. The spearman's rho was 0.22 p<0.001. 
Figure 7.10.2 Scatter plot of clinicians' prediction of the patients VAS rated 
quality of life 180-days after ICU 
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7.11 Discussion 
The striking aspect of these data drawn from the follow-up questionnaire is the high 
proportion of patients who state that they would want ICU again under similar 
circumstances. The 96.2% of all responders only falls to 77% if all non-responders are 
assumed to not want ICU again. These proportions are virtually the same if just 
intubated patients are considered: 96.2% for responders and 78% if non-responders are 
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all assumed not to want ICU again. This figure is similar to that observed in a group of 
84 US medical ICU patients interviewed at I year after ICU135 The majority of 
survivors also consider that their quality of life is similar to the quality of life they 
experienced in the period of stability prior to ICU admission. This finding reproduces 
the observation from the SUPPORT study that the functional capacity in the 2 weeks 
prior to ICU best predicted quality of life at 180-days after ICU. This is despite the 
actual level of disability and symptom burden being considerable. The AQ-20 scores 
show just how many symptoms the patients had and the severity of symptoms in the 
CAOS population is illustrated by comparison with a population of 165 stable COPI) 
outpatients with a mean (SD) age of 69.0 (6.8) years and a mean (SD) FEVI % 
predicted of 39.8% (16.5%) studied in Japan using Japanese translations of the AQ20 
where the mean (SD) AQ20 score was 5.9 (4.6) 136 in comparison to the mean CAOS 
score of 11.2 (4.7). It is interesting however that when the patients make a global 
assessment of their quality of life using the EuroQoI VAS responders had a mean (SD) 
VAS of 54.9 (19.5), median (IQR) of 50 (40-70). This was similar to the VAS in stable 
UK COPI) outpatients, who had a mean (SD) VAS of 50.9 (16.4) and a median of 
50.0 137. The EQ-51) values in the CAOS responders [mean (SD) EQ-51) of 54.6 (3 1.0) 
and median (IQR) of 62.0 (35-74)] were also similar to 125 outpatients with COPI) 
recruited in a UK chest clinic for whom the mean (SD) EQ-51) was 52.4 (15.7) and the 
median was 53.1 137 . 
The scatter plot comparing clinicians predictions of the patient's quality of life 
compared to the patients self-rated quality of life serves to emphasise that clinicians are 
not good at predicting patients' self-rated quality of life after ICU, an observation that 
has been documented elswhere 138 . 
A weakness of the questionnaire data is that patients may have tended to give positive 
responses because of concerns that responses that seemed negative might undermine 
future care. In the CAOS study though the patient information sheet that accompanied 
the questionnaire explained that the data would be anonymous, patients may have still 
been worried that negative opinions might influence their future care. 
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7.12 Conclusion 
The questionnaire data are useful for decision making and for informing conversations 
with patients when used alongside survival predictions. Patients are likely to find it 
helpful to know that if they do survive that by 180-days or so after ICU admission they 
will have between at least a 77% chance and probably nearer to 96% chance of being 
willing to undergo ICU again under similar circumstances, information that suggests 
that they will not regret the decision to go ahead with ICU if they survive. It is also 
helpftil to know that between 60 to 73% of survivors will consider the quality of life if 
they survive to be the same or better than in the period of stability prior to ICU 
admission. Given the poor correlation between clinicians' estimates of patients self- 
rated quality of life and patients actual rating, clinicians will perhaps be best to simply 
explain to patients that if patients do survive the best predictor of their quality of life at 
180-days or so after ICU will be their quality of life in the period of stability prior to 
ICU. 
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Chapter 8 An acute physiology score for UK COPD patients 
8.1 Introduction 
As explained in section 2.5.3, investigation of the independent effects of a 20 potential 
acute physiological variables would require at least 200 deaths in the study, even if the 
effect of each variable was simply assumed to be linear. The drawbacks of generic acute 
physiology scores are highlighted in section 2.8.3, and it was felt that the best approach 
would be to develop a UK COPD-specific acute physiology score (CAPS). 
In this chapter the CAOS data on each of the physiological variables are first examined 
for suitability for inclusion in a prognostic index. This is mainly based on the amounts 
of missing data. The distributions of each variable are also reported to permit 
comparison with other studies and populations. 
The intercorrelations between the different physiological variables in the CAOS dataset 
are presented. Then the development of a new acute physiology score for UK COPD 
patients, using data from all the participants in the CMP over the period from December 
1995 to January 2004 (with admissions to units participating in CAOS during the time 
period of the study excluded) is described. The analysis of the CMP data was carried 
out by Dr David Harrison, the chief statistician at the Intensive Care National Audit and 
Research Centre, using data on 8527 patients aged 45 years and older admitted to 
critical care with obstructive lung disease. 
The relationships between the new CAPS score and each of its component parts, and 
with 180-day mortality is described. 
The chapter concludes with a discussion of the findings. 
8.2 Blood gases 
Table 8.2 shows the distribution of blood gas measurements in the CAOS population. 
The aim of the study was to identify patients with respiratory failure due to obstructive 
lung disease, and such patients would be expected to have Type II respiratory failure 
characterised by a PaC02 > 6. OkPa and respiratory acidosis with a pH < 7.35. The 
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results show that the majority of patients were indeed hypercarbic with a median (IQR) 
PaCO2 of 10.4 kPa (8.1-13.3) and acidotic with a median (IQR) pH of 7.2 (7.1-7.3). 
Table 8.2 Blood gases 
Allpatients Patientsfor all Treatment Patients notfor intubation 
Variable 
n=832 n=651 N=181 
Number Mean SD Number Mean SD Number Mean SD 
Median (IQR) NO. ) Median (IQR) MY Median (IQR) 
7.2(0.1) 7.2(0.1) 71(0.1) 
PH 
7.2 (7.1-7.3) 7.2(7.1-7.3) 7.3 (71-7.3) 
Missing 0 0 0 
48.1(26.2) 50.7(26.9) 38.7(21.1) 
R02 r1o) 
35.0(28.0-60.0) 40.0 (28.0-77.5) 28.0 (25.0-40.0) 
Missing 3 (0.4*/o) 3 (0.5*/o) 0 
12.7(10.1) 13.3(10.9) 10.7(6.2) 
PaO2 (kPa) 
9.6 (7.2-13.9) 9.7 (73-14.8) 8.9 (6.7-12.0) 
Missing 0 0 
11.0(4.2) 11.0(4.3) 10.9(3.9) 
PaCO., (kPa) 
10.4 (8.1-13.3) 10.5 (8.0-13.3) 10.1(8.5-13.1) 
Missing 0 0 
29.3(16.9) 28.7(16.6) 31.4(17.8) 
PaO21FiO, j 26.3 (17.4-37.1) 25.8 (16.9-36.8) 27.4 (19.7-38.6) 
Missing 3 (0.41/6) 0 3(0.50/o) 0 
821 P4021ROjratio 
Most of the units found it difficult to determine the Fi02 measurements that took place 
outside critical care. Though blood gases were well recorded in the notes the FiO2 was 
poorly recorded and certain units expressed the concern that the Fi02 recorded was 
often incorrect. Collecting Fi02 data often required repeated contact with the units to 
check values that did not correspond to possible values according to the accepted 
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perfonnance of the various delivery devices. For this reason the Pa02/FiO2 ratio was 
considered likely to be unreliable in clinical practice. 
8.3 Other acute physiology 
Table 8.3 displays the distribution of the other acute physiological variables measured 
in CAOS. If we consider the median values we can see that though patients were 
tachycardic (median (IQR) heart rate 120 (101 - 132)) and tachypnoeic (median (IQR) 
respiratory rate 30 (25-37)) with a raised PaC02 (Median (IQR) 10.4 kPa (8.1-13.3)) 
indicating respiratory failure, the other measures of acute physiology were not markedly 
deranged suggesting that the majority of patients had single organ respiratory failure. 
8.3.1 Non-ventilated respiratory rate 
Non-ventilated respiratory rate had 47 missing values, which at 5.6% is one of the 
highest for missing data. Respiratory rate is notoriously poorly collected in the medical 
notes. However 41 of the 47 patients with a missing respiratory rate were intubated and 
this may in part explain the high number of data unavailable. 
8.4 Correlations among physiological variables 
The significant correlations are indicated in bold face in Table 8.4.1. Those which arose 
because the same (or closely related) variables were involved in calculating both 
indicators (matrix 1 Pa02 and PaO2/FiO2, matrix I systolic and diastolic blood pressure 
and mean arterial pressure) are not discussed ftirther. Correlations arising because of 
known associations for example between a high PaC02 and a low pH or between 
creatinine and urea, and potassium are also not discussed ftirther. 
8.4.1 Correlations with the Glasgow Coma Scale 
There is a correlation between falling GCS and rising FiOZ, Pa02 and PaC02 (Table 
8.4.1). This is likely to reflect the fact that as the PaC02 rises the patients develop C02 
narcosis and the GCS falls. 
163 
Table 8.3 Other acute physiology 
Variable Allpatients n=832 Patientsfor all Treatment Patients notfor intubation 
n=651 n=181 
n (W M=fSD 7QR) 
Man SD 
Ue&a" (1(? R) (9Q 
MeMSD 
Afe&m 00R) 
Systolic blood 
pressure 
1308(33.7) 
3 
1309(346) 130.5(301) 
(MM11g) 
130(106-1 2) 130. (105-154) 130(110-M) 
Missing 2 (0. r/. ) I (O. r/. ) 1(06%) 
Diastolic blood 
pressure 
690(207) 
9 5" 
68.8(21.2) 696(190) 
(MM11g) 
6 ( 0) 68.0 (5"0) 69(57-92) 
Missing 3 (0.4*1. ) 2 (0 41/6) ](06%) 
Mean arterial 
pressure 
89.6(23.2) 
8 
995(23.9) 899(206) 
$ . 3(73.3-104.3) 99 3 (73 3-103.7) 99 5(75.5-104.8) (MM11g) 
Missing 3(041/. ) 2 (0.4%) 1 (0 &/. ) 
Central 37.0(1.3) 37.0(1.3) 370(1.2) 
temperature OC 37.1(36 1-37.9) 37.1 (36 1-37 8) 36 9 (36.2-38.0) 
Missing 5(06-/. ) 5 (0 9*/. ) 0 
Heart rate 1190(23.7) 1191(26.1) 1142(23.7) 
(bpm) 120(101-132) 120 (104-135) 115 (99-129) 
Missing 1(0.1%) 1 (0. rl. ) 0 
Non-ventilated 
respiratopy rate 
30.2(10.2) 30.1(106) 30.5(87) 
30(25-37) 30(24-38) 30(25-36) 
(bpm) 
Missing 47(5.6-/. ) 46(7.1%) 1(0 6*/. ) 
Hoemoglobin 13.8(14) 139(2.4) 138(13) 
(gldl) 14 0 (113-15.4) 14 0 (112-15 4) 14 0 (114-13.4) 
Missing 0 0 0 
White Cell 15.6(149) 15.7(15.1) 15.2(13.8) 
Count (xl 09/L) 13.3 (10.0-19.4) 13.5 (10 4-19 6) 111 (9.0-17.6) 
Missing 0 0 0 
Sodium 137.0(5.4) 137.1(5.5) 1368(5.2) 
(mmoVL) 139 (134-140) 138 (135-140) 139(134-140) 
Missing 0 0 0 
Potassium 4.5(08) 4.3(0.8) 4.5(0.7) 
(MMOM) 4.4(404.9) 44 (3.9-4.9) 44(4149) 
Missing 2 (0 r/. ) 0 0 
Creatinine 109.4 (69.3) 111.1(71.0) 1058(57.5) 
(mmoVL) 93(74-122) 94(75-121) 92(72-124) 
Missing 0 0 0 
Urea 9.3(6.5) 92(6.5) 9.6(66) 
(mmoVL) 7.5 (5.1-11.2) 7.5 (5.0-108) 7.8 (5.7,17 5) 
Missing 0 0 0 
Albumin 345(73) 342(7.6) 354(5.7) 
91L 35(30-40) 35(29-40) 35(3240) 
Missing 3(0.41/. ) 2(0 4*/. ) 1 (0 61/6) 
Bilirubin 11.5(100) 11.3(8-1) 173(15.0) 
pmoIAL 9. (6-14) 9(6-14) 10(7-13) 
Missing 15(1.8-/. ) 9 (1.4%) 6(3.3%) 
Glucose 9.2(4.0) 95(42) 80(2,7) 
(Mmon) 81(64-106) 83 (6.5 -11.1) 7.6 (6 1-9.1) 
Missing 1 14 (1.7%) 8 (1. r/. ) 6(33%) 
Glasgow coma 1 12.1(4.2) 11.8(4.3) 12.9(3 , 7) 
scale 15(9-15) 14.0(9-15) 15(13-15) 
Missing 3 (0.4%) 3(0.5%) 0 
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The fact that the Fi02 and Pa02 rise in parallel with this may be because uncontrolled 
oxygen is causing the rise in PaCO2, or that once the PaC02 rises and the GCS falls 
patients are given uncontrolled oxygen in preparation for intubation. In addition patients 
with a low GCS have a low respiratory rate. As the Glasgow Coma Scale (GCS) 
improved, the pH and respiratory rate also rose. 
There is a correlation between diastolic and mean arterial pressure and albumin. The 
reason for this is unclear. One possibility is that patients with low blood pressure 
received more additional fluids that cause the measured serum albumin to fall. 
There is a correlation between glucose and PaC02. The reason for this correlation is 
unclear and it may have arisen by chance. 
8.5 Use of acute physiology to calculate the COPD acute physiology score 
In view of the problems with measurement of Fi02 outlined in section 8.3.3, Pa02 and 
PaO2/FiO2 ratio were not investigated in the CMP data set. Also since many of the 
patients in the CMP data set were intubated the respiratory rate was not used. GCS was 
dropped because it correlated with many of the factors associated with intubation such 
as pH and in any case is often used as a prompt to intubate. This left 13 variables from 
the case mix programme data set (Table 8.5). Mean arterial pressure was found to 
discriminate better than either diastolic or systolic blood pressure and was therefore 
used in preference to either component alone. 
Each variable was inspected on a univariate basis and divided into a number of 
categories developed in part from normal ranges. Adjacent categories were combined if 
the difference in mortality was not significant at 10%. All the variables were then put 
into a multiple logistic regression model in a development sample of 2/3 of admissions 
(5513 patients from 2/3rds of units) and removed one by one in a stepwise manner, with 
measures of model fit, calibration and discrimination observed at each step in the 
validation sample of 1/3 of admissions (3014 patients in 1/3"' of the units). 
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The "best" model was then selected based on a combination of performance and 
parsimony. Five variables were dropped because they had a minimal impact on 
discrimination or calibration. These were potassium, temperature, PaC02. glucose and 
bilirubin (Table 8.5.1). This gave an acute physiology score containing the following 
eight variables: heart rate, white count, sodium, pH, creatinine, albumin, mean arterial 
pressure and urea. An integer score on the log-odds scale was then constructed by re- 
estimating coefficients for the final model on all available data, and multiplying all 
coefficients in the model by a constant that allowed the acute physiology score to range 
from 0 to 100. The score is shown in Table 8.5.2. 
The Hosmer-Lemeshow chi-squared goodness of fit statistic gives an estimate of the 
impact of removing variables on the goodness of fit i. e. on the model's calibration 
(whereas the area under the curve gives a measure of discrimination). The higher the 
HL chi-square the poorer the calibration, though the absolute magnitude will depend 
upon the degrees of freedom. (Tbat is why the model with just urea, mean arterial blood 
pressure (MAP) and albumin has a lower HL chi-square than a model with more 
variables. ) 
8.6 COPD acute physiology components and 180 day mortality 
Table 8.6.1 shows odds ratios for 180 day mortality for each of the acute physiological 
variables used to develop the COPD-specific APS. The variables have been grouped 
according to the intervals used in the score. In general the individual variables show the 
expected relationships with mortality. The relationships of heart rate and mortality are 
inconsistent though, and this may reflect error of measurement outside ICU. 
Table 8.6.2 shows the odds ratios for the variables not used in the COPD physiology 
score. None of them show a significant association with mortality. 
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Table 8.5.1 COPD acute physiology model: variable selection 
Variables dropped Variables Parameters AUC HL X! 
None 13 47 0.7341 11.46 
Potassium 12 45 0.7350 11.50 
Temperature 11 42 0.7345 16.50 
PaCO2 10 40 0.7339 12.79 
Glucose 9 38 0.7334 14.39 
Bilirubin 8 35 0.7314 15.30 
------------------------------- 
Heart rate 
------------------- 
7 
---------------------- 
30 
----------------- 
0.7271 
------------------ 
15.27 
Sodium 6 27 0.7260 13.51 
PH 5 23 0.7230 19.63 
WBC 4 19 0.7205 16.70 
Creatinine 3 16 0.7092 13.78 
Albumin 2 11 0.6962 15.49 
MAP 1 5 0.6557 --- 
Urea 0 1 0.5000 
I'lie variables in bold were retained in the final APS score. This table shows their impact when dropped 
during model development. 
AUC: Area Under the (ROC) Curve; HL: Hosmer-Lemcshow goodness-of-fit statistic on 10 degrees of 
freedom. Values over 18.30 indicate a significant lack of fit at the 5% significance level; WBC: VAdte 
Blood Count; MAP: Mean Arterial Pressure 
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Table 8.5.2 The CAOS Acute Physiology Score 
bpm < 80 80-109 110-129 130-149 150-169 2: 170 
Heart rate 
score 3 
1 
0 
1 
2 3 5 7 
mmHg < 40 40-49 50-59 60-69 70-89 
- 
90-99 2t 100 
MAP 
score 19 12 9 6 3 0 4 
pH < 7.00 7.00-7.09 7.10-7.19 7.20-7.24 2: 7.25 
pH 
score 9 6 3 1 0 
mmol/l < 130 130-134 135-144 2: 145 
Sodium 
score 6 2 0 2 
mmol/l < 2.5 2.5-6.7 6.8-11.9 12.0-17.9 2: 18.0 
Urea 
score 0 8 16 22 24 
pmol/I < 150 150-199 Z: 200 
Creatinine 
score 0 5 8 
g/l < 15 15 - 19.9 20 - 24.9 25 - 29.9 30-34.9 2: 35 Albumin 
score 20 14 8 6 4 0 
x 10911 <4 4-14.9 15-19.9 20-24.9 2: 25 
WBC 
score 7 0 1 4 7 
MAP: Mean Arterial Pressure; WBC: White Blood Count 
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8.7 Discussion 
The blood gas results indicate that the CAOS population had more severe respiratory 
failure than the patients recruited to the SUPPORT study where the median (IQR) 
12 PaC02 was 7.47 kPa (6.67-8.67) and the median (IQR) pH was 7.36 (7.30-7.40) . The 
CAOS population was probably more severely ill because they were all admitted to 
ICU, whereas in SUPPORT only 53% of patients entered ICU. 
8.7.1 Pa02IFi02ratio 
There is good evidence that the PaO2/FiO2 ratio is associated with mortality in patients 
with COPD, including data from the American SUPPORT study 12 and from the UK 
Case Mix programme 27 . However the reliability of the PaO2/FiO2 ratio is crucially 
dependent on accurate measurement of the inspired oxygen concentration (FiO2). It is 
well known that in the UK there are difficulties in prescribing defined oxygen 
concentrations, and for this reason the CAOS data collection booklets contained a table 
that described the Fi02 delivered by the various oxygen delivery devices. Nonetheless, 
during data collection it became clear that units were finding it difficult to determine 
accurately the FiO2 corresponding to the most acidic blood gases measured in the 24 
hours prior to ICU. Once the patients were admitted to ICU, accurate Fi02 measurement 
was straightforward. However the blood gases after ICU admission would not be the 
ones used to make the decision to admit. Discussions with the units led us to conclude 
that inaccurate calculation of the Fi02 was sufficiently widespread outside ICU that 
incorporating the PaO2/FiO2 ratio into the model would be accompanied by frequent 
errors. For this reason it was dropped as a candidate variable.. Interestingly the 
Pa02/FiO2 ratio in CAOS was, with median (IQR) 26.3 (17.4-37.1), similar to that in 
the SUpPORT12 (28.1 (22.8 - 35.6). It should be remembered however that the data 
eventually recorded in CAOS often involved quite a lot of checking and double 
checking of results that had initially been received at the CAOS co-ordinating centre 
and considered unlikely. In addition it should be remembered that the critical care staff 
recording the Fi02 data had the data collection booklet charts and day to day experience 
of calculating Fi02- 
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8. Z2 Conclusion 
The UK COPD Acute Physiology Score (CAPS) allows the acute physiology collected 
in the CAOS study to be weighted for use in the outcome model. In an ideal study 
sufficient data would have been collected to have enabled the development of the acute 
physiology score using the acute physiology available prior to ICU collected in the 
CAOS study. However assuming the need for a minimum of 10 deaths for each level in 
the model at least 410 deaths would have been required to develop the acute physiology 
score. Thus, the study would not have had adequate power to weight the acute 
physiology and take into account other aspects of the patients. Clearly though the APS 
score has been developed using data from ICUs, at least these are patients over the age 
of 45 years admitted to UK ICUs with chronic obstructive airways disease. This is 
likely to be a better measure of the severity of disease than to have used, for example, 
the acute physiology score from APACHE III that was developed on all types of ICU 
patients in the US healthcare system, and included a measure of oxygenation which had 
to be excluded from the UK model because of problems with the data (feedback from 
the units indicated that estimates of the F102 outside ICU was unreliable). 
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Chapter 9 Predictors of outcome 
9.1 Introduction 
This chapter is concerned with the non-physiological variables found in the systematic 
review to be associated with survival following critical care admission with an 
exacerbation of COPD. These include: age and sex; data relating to the period of 
stability before the exacerbation, (including function and quality of life, comorbidity 
and previous use of health care); and data relating to the 24 hours before admission to 
ICU (including diagnosis, length of stay and prior intubation). Data are presented for all 
832 patients recruited to CAOS, for the 651 patients without treatment limitation, and 
for the 181 with treatment limitation, i. e. those who would not have been intubated if 
more conservative treatment had been unsuccessful. 
Information gained through contact with units during the data collection process is 
presented where it informs an understanding of the reliability of a variable or ease of 
collection. 
Then the distribution of each variable is described, to allow comparison of the CAOS 
patients with those in other studies and populations. 
In section 9.5 the intercorrelations of these variables are considered, and in section 9.6 
the relationship of each of variable with 180 day mortality is described. 
9.2 Age and sex 
9. ZI Age 
As Table 9.2 shows, the mean (SD) age was 67.0 (9.7) years and the median (IQR) was 
68.0 (60-75). Overall the patients considered suitable for intubation were slightly 
younger that those who were not. 
9.2.2 Sex. 
There were about 48% men and 52% women in both the 'all treatment' and 'no 
intubation' groups. 
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Table 9.2 Data about patients in the period of stability pre-exacerbation 
Variable Patientsfor 'All 
treatment' 
n=651 
Patientsfor 'No 
intubation' 
n=181 
Allpatients 
n=832 
Number 
NO 
Mean SD 
Med (IQR) 
I 
Number 
NO 
Mean SD 
Med (IQR) 
Number 
6) 
1 
r1yo 
Mean SD 
Med (IQR) 
Age 66.1(9.5) 67.0 (59-73) 
70.3(9.4) 
72.0 (63-77) 
67.0(9.7) 
68(60-75) 
Missing 
0 0 0 
Sex 
Female 340(52.2%) 95(52.5%) 435(52.3%) 
Male 311(47.8%) 86(47.5%) 397(47.7%) 
Missing 0 0 0 
FEV, 
1.1(0.7) 
0.9 (0.6-1.4) 
0.7(0.3) 
0.6 (0.5 -0.9) 
1.0 (0.6) 
0.8 (0.6-1.3) 
Missing 437(67.1%) I(M (57.5%) 514(61.8%) 
Functional score 
Fully mobile 189(29.0%) 18(9.90/0) 207 (24.9%) 
Out of house 267 (4 1.0%) 41(22.7%) 308 (37.0%) 
Ilousebound 176(27.0%) 104 (57.5%) 280(33.7%) 
Bed/chair bound 19(2.9%) 18(9.9%) 37(4.5%) 
Missing 0 0 0 
Prior quality of 
life 
Excellent 17(2.6%) 4(2.2%) 22 Y( I (' 5 
Very good 122 (18.8%) 16 (8.9%) 138(16.6%) 13 
b 
8 1 
Fair 286(44.0%) 71(39.4%) 35 7 (4 . 0%) 
Poor 178(27.4%) 69(38.3%) 247(, 247 (29.80%) 
Very Poor 41(6.3%) 19 (10.6%) 60(7.2%) 
Missing 7(l. 1%) 2(1.1%) 9(1.1%) 
Activities ofdaily 
living 
0.6(l. 2) 
0(0-1.0) 
1.5(l. 7) 
1.0 (0.0-3.0) 
0.8(1.4) 
0(0.0-1.0) 
Missing 0 4(2.2%) 4(0.5%) 
Comorbidity 0.8(1.0) 
1.0 (0.0-1.0) 
1.0(1.1) 
1.0 (0.0-1.0) 
0.8(1.0) 1 
1.0 (0.0-1.0) 
Missing 0 0 0 1 
Long term 
Oxygen 
I I 
No 582(89.4%) 112 (61.9%) T 694(83.4%) 
Yes 69(10.6%) 69( 8.1%) 138(16.6%) 
Missing 0 0 0 
Previous 
Intubation 
No 575(88.3%) 160(88.4%) 735(88.3%) 
Yes 76(11.7%) 21(11.6%) 97(11.7%) 
Missing 0 0 0 
Admissions in 
past 6 months 
0.7(1.4) 
0.0 (0.0-1.0) 
- 
1.0(1.4) 
0.0 (0.0-1.0) 
0.8(1.4) 
0.0 (0.0-1.0) 
Missing 1(02%) T o- 1(0.1%) 
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93 Data about the period of stability pre-exacerbation 
9.3.1 FEVI 
Lung function was only available in 38.2% of patients and of these around half had to 
be obtained from old notes. This could often take a number of days. At hospital 
admission patients were often too unwell to perform the FEVI manoeuvre. In the 318 
patients in whom FEVI was available the mean (SD) FEVI was IL (0.63), median 
(IQR) 0.8 (0.6-1.3). 
9.3.2 Functional score 
In 321 patients (38.6%), the patients described their own ftmction in the period of 
stability. Otherwise the information came from other sources. Overall only 37 patients 
(4.5%) were bed- or chair-bound, and this fell to 19 (2.9%) of the 651 in the 'all 
treatment' in contrast to 18 (9.9%) in the 'no intubation' group. 
The proportion of patients who were 'housebound or worse' in the patients in the 'all 
treatment' group was 29.9% compared to 67.4%, in those who were not, suggesting that 
the functional capacity may be used to select patients for the level of treatment offered. 
9.3.3 Prior quality oflifie 
In 358 patients (43%) the information regarding self-rated quality of life came directly 
from the patient themselves in the other 57% it came from others. Table 9.3.3 shows 
the proportions of patients with each quality of life rating according to whether the state 
was self-rated or reported by a proxy. 
Investigation of how proxy assessments of quality of life might differ from self-report is 
only possible where data exist for both types of source. In this study only one rating of 
prior quality of life was available for any given patient. Some data collectors mentioned 
that this was a fairly subjective item to collect. However the spreads of the ratings of 
quality of life provided by proxies and patients were similar. This seems likely to be 
because patients who were unable to give quality of life ratings were similar in this 
respect in the period of stability prior to ICU to those in whom the rating came from a 
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proxy. An alternative explanation is that they were worse, but that proxies tended to 
give unduly favourable assessments, and so this conclusion should be treated with 
caution. 
Table 933 Prior quality of life: patient and proxy ratings compared. 
Prior quality of life 
Patient rated (n = 358) 
n% (95%CI) 
Proxy rated (n = 464) 
n% (95%CI) 
Excellent 15 4.2% (2.4-6.8) 6 1.3% (0.5-2.8) 
Very good 57 15.9% (12.3-20.1) 81 17.4% (14.1-21.8) 
Fair 162 45.3% (40.0-50.6) 195 41.9% (37.4-46.6) 
Poor 100 27.9% (23.3-32.9) 147 31.6% (27.4-36.1) 
Very poor 24 6.7% (4.3- 9.8) 36 7.7% (5.5-10.6) 
Chi-square = 8.66 on 4 degrees of freedom and the p=0.0701 
9.3.4 Activities ofdaily living 
In 354 patients (42.5%) the data about activities of daily living (ADLs) came from 
patients and in 476 (57.2%) it came from proxies. Figure 9.3.4 shows the number of 
patients with each type of impairment and it can be seen that bathing caused the most 
problems and feeding the least. 
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Figure 9.3.4 Activities of daily living in CAOS population. 
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9.3.5 Comorbidity 
One patient had 6 comorbidities, 5 had 5 comorbidities, 10 had 4 and 39 patients had 3. 
Patients with three or more comorbidities were amalgamated into one group for 
analysis. The commonest comorbidity was congestive cardiac failure (23% of those in 
the study). This was followed by previous myocardial infarction (11%) and 
uncomplicated diabetes (9.5%). The percentages of patients with specific comorbidities 
are shown in Figure 9.3.5. 
9.3.6 Long term oxygen therapy (LTOT) 
There were 136 patients in the total sample on LTOT. The observation that 38.1 % of the 
'no intubation' group were on long term oxygen, compared to only 10.6% of the 'all 
treatment' group suggests that LTOT may have been a clinical indication for treatment 
limitation. 
9.4 Patient characteristics in 24 hours before critical care and intubation 
Table 9.4 summarises patient characteristics in the 24 hours prior to critical care 
admission and intubation status. Each variable will be discussed in turn. 
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Figure 93.5 Comorbidities in the CAOS population 
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MI: Myocardial infarction 
PVD: peripheral vascular disease 
HEMI: hemiplegia 
PEPTIC: peptic ulcer disease 
Cancer: non-metastatic 
AIDS: aids. 
Sevliver: moderate or severe liver disease 
Diabetes: diabetes without complications 
9.4.1 Diagnostic groups 
CCF: congestive cardiac failure 
CVA: cerebrovascular disease 
CTD: connective tissue disease 
Metastatic: metastatic cancer 
Mliver mild liver disease 
Renal: moderate or severe rcnal disease 
Diabcomp: with end organ damage 
The vast majority of patients recruited (76.31/o) were considered to have COPD alone; 
14.1% were considered to have a mixture of COPD and asthma, and 9.6% to have 
asthma alone. 
9.4.2 Length ofstay before admission to critical care 
As figure 9.4.2 shows, most patients (452,54%) were admitted to critical care on the 
day of admission to hospital. However there were some patients with a very long length 
of stay prior to critical care entry. 
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A Lowess Smoothing Plot (Figure 9.4.3) was produced to explore whether outliers were 
distorting the relationship between the number of days in hospital prior to critical care 
entry and outcome. The plot suggested that the relationship between outcome and 
hospital stay prior to critical care was not distorted by the outliers and was relatively 
linear 139 
. 
Table 9.4 Data about patient in the 24 hours before critical carefintubation 
Patientsfor all treatment Patients notfor intubation Allpatients Variable 
n=651 n=181 n=832 
Number Mean Number r1q) Mean SD Number Mean SD (0/. ) Med OQR) Med (IQR) (0/0) Aled (IOR) 
Diagnosis 
Asthma 78 (12.0%) 2(1.11%) 80 (9 6*/. ) 
COPD/Asthma mix 104 
(160/6) 13(7.21/. ) 117(14.1%) 
COPD 469 (n. 01/6) 166 (91.7%) 635 76.3% 
Missing 0 
Length ofstaypre- 651 2 1(93) 181 16(3.5) 832 20(94) 
Critical care 
00(00-10) 00(0()-10) 00(00-10) 
Missing 0 
Atrialfibrillation 
No 587 (9D 2/. ) 142 (78 5%) 729 (97. &Y. ) 
Yes 64 (9-M) 39(21.6%) 103(124%) 
Missing 0 
ChestX-ray 
No acute changes 278(417%) 69(39.1%) 347(42%) 
Acute Changes 367 (56 41/. ) 109 (60.2%) 476 (57 2-/. ) 
Missing 6(0.9%) 3(1.7%) 9(1.1%) 
Congestive cardiac 
failure as cause 
No 520(800%) 125(69.1%) 643 (77. &Y. ) 
Yes 130 (20.01/6) 55 (30.41/6) 185(22.3%) 
Missiniz ](0.1%) ](0.1%) 2(0.2%) 
Ankle oedema 
No 492(758%) 121(66.9%) 613(73.9%) 
Yes 156 (24.01%) 60 (33.2%) 216 (26.0%) 
Missing 2(0.3%) 0 2(0.2%) 
Intubated 
No 201(3091/. ) 181(100%) 392(45.9%) 
Yes 450(691%) 0 450(54.1%) 
Missing 0 
9.4.3 Atrialfibrillation 
Atrial fibrillation occurred in only 12.4% of the group as a whole but was more 
common (21.6%) in those patients designated 'no intubation'. 
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Figure 9.4.2 Length of stay pre-critical care 
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9.4.4 Chest x-ray changes 
On admission to critical care, clinicians rated the chest x-ray as having abnormal 
shadowing or not. Abnormal shadowing was found in 507 (61%). In 9 patients (1.1%) 
there were missing data. Of patients with abnormal shadowing 43 were classified as 
'other' and a free text description was recorded. The free text was examined and 31 of 
the entries described chronic changes such as old TB calcification or pleural plaques or 
old scarring. These patients were then classified as 'chronic changes'. Of the remaining 
II patients three had pneumothoraces, 4 had probable cancer, and one each had 
pulmonary infarction, pleural effusion, collapsed lung, and unknown. One patient had 
infection and was recoded as such. 
The classification of x-rays for analysis was guided by the a priori questions that the 
study set out to answer. There is a common belief amongst clinicians that the prognosis 
is worse in patients without an acute abnormality on the x-ray because there is nothing 
reversible. In addition there is a suggestion that of the reversible processes, pure heart 
failure is particularly readily reversed and has a fairly good prognosis. For this reason 
patients were classified into two groups: (1) 'No acute changes' which included patients 
with a clear chest x-ray or old chronic changes, or (2) 'Acute changes' which included 
isolated heart failure and other miscellaneous acute changes including patients with 
infection or heart failure plus infection and also the patients with prieurnothoraces or 
lung collapse. 
Table 9.4.4 surnmarises the chest x-ray appearances in the two groups. Missing data 
were imputed as most common category i. e. acute changes present as infection. 
9.4.5 Congestive cardiacfailure as a cause and ankle oedema 
Congestive cardiac failure as a cause was difficult to distinguish from cor pulmonale on 
clinical grounds. It was also noted that patients with ankle oedema included both 
patients with congestive cardiac failure and those with cor pulmonale 
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Table 9.4.4 Chest x-ray appearances 
Acute changes (n = 485) 
n (Olooftotalpopulation) 
No acute changes (n = 347) 
n rlooftotalpopulation) 
Heart failure alone 34 (4.1 %) Chest x-ray clear 316 (38%) 
Infection 326 (39%) Chronic changes 31 (3.7%) 
Combined failure/infection 105 (12.6%) 
Pneumothorax 3 (0.6%) 
Miscellaneous 8 (1.6%) 
Missing 9 (1.10/0) 
9.4.6 Measurement of body mass 
Table 9.4.6 summarises the measures used to estimate patients' body mass index (BMI). 
i) Body weight Lickert scale 
All patients had their body weights estimated using the Licked scale and though the 
data collectors found the scale subjective they said it was easy to use. 
ii) Body mass index estimation 
Even though each data collection booklet had a tape measure attached to it, only 284 
(34.6%) of patients had their heights measured. 'Me rest were estimated, the majority 
(586 70.4%) in feet and inches. It was mentioned by a few units that using the tape 
measure to determine a patient's height gave the impression that the patient was being 
measured up for a coffin. Only 195 (23.4%) patients were actually weighed; weights 
were estimated in metric units in 60.7% of cases. 
The information from units suggested that deriving a body mass index would be 
difficult. It would often involve estimates of weight and height, conversion from 
imperial to metric units, and finally the calculation itself. 
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iii) Mid-arm circumference 
Mid-arm circumference (MAC) had one of the highest frequencies of missing data (22, 
2.6%). It seems likely that these values were not missing at random in that of the 22 
patients with missing values 18 (81.8% of those missing) died within 180 days. 
Discussion with the units with missing MACs revealed that often where the MAC was 
not recorded the patient had died before the nurses on the critical care unit had had 
chance to measure it. This problem arose in CAOS because data collection was 
centralised in ICU. 
MAC has a close relationship with the Lickert scoring of body weight with a correlation 
coefficient of 0.7563 P<0.0001. (Figure 9.4.6 shows a scatter plot of MAC and the body 
weight Lickert scale for those patients with both measurements). All the patients with 
missing MACs had full data for the Licked score of body weight. For this reason it was 
decided to impute values for MAC based on the mean MAC corresponding to the 
Lickert scores. Of the 18 patients with missing MAC who died before 180 days 3 were 
described as very underweight, 2 described as mildly underweight, 6 as normal, 6 as 
overweight and I as very overweight. For the 4 patients who survived 180 days with 
missing MAC 2 were rated as mildly underweight, I as normal weight and I as mildly 
overweight (Table 9.4.6 below). Imputing the MAC from the Lickert rating of weight 
would be an alternative strategy since it is independent of outcome as long as there are 
differences in measured MAC for each of the classifications of body weight using the 
Lickert. 
9.5 Correlation between predictors 
Correlations between predictors were explored (Table 9.5). The key to the abbreviations 
used are summarised, at the foot of the matrix. 
Correlation coefficients greater than 0.2 at a significance level p<0.00001 are discussed. 
A conservative significance level has been chosen since the correlation matrix contains 
several hundred correlations so there is a high risk of correlations appearing simply by 
the play of chance. 
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Table 9.4.6 Measurements of body mass index 
Variable Patientsfor all treatment No intubation Allpatients 
n=651 n =181 n=832 
Number Mean SD Number Mean SD Number Mean SD 
NO Med (IQR) NO Med (IQR) NO Med (IQR) 
Body wt Lickert 
Very under 39(6.0%) 25 (13.80%) 64(7.7%) 
Mildly under 131 (2 0.1 %) 41 (22.7%) 172 (20.7%) 
Normal wt 218 (33.5%) 61 (33.7%) 279 (33.50/c. ) 
Mildly over 185 (28.4%) 30 (16.60/. ) 215 (25.80/9) 
Very over 78(12.0%) 24 (13.31Y. ) 102 (12.3%) 
Missing 0 
Weight loss in 6m 
No 471 (72.7%) 114 (63.0%) 585 (70.6%) 
Yes 168 (25.90/6) 66 (36.50/*) 234 (28.20/6) 
Missing 12(1.8%) 1(0.6%) 13(l. 60/*) 
Mid-arm 28.8 (5.3) 27.4 (5.9) 28.5 (5.4) 
circumference 29 (25-32) 27 (23-31) 28 (25-32) 
<30cm 271 (42.7%) 58 (33.1%) 329 (40.60/6) 
25-29.9cm 228 (35.9%) 51 (29.1%) 279 (34.4%) 
20-24.9cm 115 (18.1%) 57 (32.6%) 172 (21.2%) 
<20cm 21 (3.31/6) 9(5.1%) 30(3.7%) 
Missing 16(2.5%) 6 (3.31/o) 22(2.6%) 
25.0(8.9) 
Body Mass Index 
25.8(7.9) 
23(19.4- 
25.6(8.1) 
24.9 (21.4-29) 24.8 (20.8-28.9) 
28.6) 
Missing 7(l. 1%) 2(1.1%) 9(1.1-/. ) 
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Figure 9.4.6 Scatter plot of MAC and the Licked scale 
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Table 9.4.6i Lickert Body weight rating and mean MAC measurement 
Lickert rating AIAC measurement mean (SD) cm 
Very underweight 21.2(2.6) 
Mildly underweight 24.3(3.4) 
Normal weight 27.7(3.3) 
Mildly overweight 31.5(3.7) 
Very overweight 35.8(4.7) 
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9.5.1 Correlations between variables measuring similar domains 
The various measures of body weight were correlated. For body weight Lickert and 
MAC the correlation coefficient was 0.756, for bodyweight Lickert and BMI it was 
0.7368, and for BMI and MAC it was 0.7302. BMI, MAC and bodyweight Lickert were 
all correlated with weight loss in the previous 6 months, with correlation coefficients of 
0.2298,0.2873, and 0.3320 respectively. 
The various measures of functional capacity were correlated. For ADLs and functional 
score the correlation coefficient was 0.5658. Functional capacity and ADLs were 
correlated with the patient's self rated quality of life (correlation coefficients 0.4911 and 
0.3771 respectively). 
9.5.2 Correlations with age 
Age was correlated with acute physiology score (correlation coefficient 0.2856). This 
may be mediated in part by creatinine, and urea and also by declining physiological 
reserve with increasing age. Atrial fibrillation was correlated with age (correlation 
coefficient -0.2219). 
9.5.3 Correlations with intubation 
Patients with increasing numbers of impaired activities of daily living and patients with 
lower functional capacity were less likely to be intubated. This had been noted in the 
distribution of risk factors between the groups for all treatment versus those not for 
intubation. Patients using long term oxygen therapy were also less likely to be intubated 
(correlation 0.1987). Patients with higher acute physiology score were more likely to be 
intubated. This is not surprising since it is the most severely ill patients who will be 
intubated. 
9.5.4 Correlations with long term oxygen therapy 
Patients with lower FEVI were more likely to be using long term oxygen therapy 
(LTOI). LTOT was also correlated with worsening functional capacity. 
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9.5.5 Miscellaneous correlations 
Acute chest x-ray changes are associated with increased acute physiology scores. This 
is likely to be because causes of acute chest x-ray changes such as pneumonia also 
cause increased acute physiology scores. 
Diagnosis is associated with FEVI and this will be because COPD is coded as I and 
COPD/asthma mix is coded as 3. As patient's FEVI increases clinicians' certainty that a 
patient has pure COPD is likely to decrease. 
There is a correlation between being on long term oxygen therapy and repeated 
admissions. This may identify a group who are fi-ailer in whom a minor exacerbation 
leads to admission. 
There is also a correlation between the presence of oedema and congestive cardiac 
failure, and higher levels of the body weight Lickert, BMI and mid-arm circumference. 
9.6 Predictors of 180 day outcome 
9.61 Characteristics in period ofstabilitypre-exacerbation and 180 day outcome 
Table 9.6.1 tabulates the characteristics that describe the patients in the period of 
stability pre-exacerbation and shows their relationships with 180 day outcome. 
Considering the odds ratios in the 651 patients without treatment limitation, age and 
functional capacity show a significant consistent relationship with mortality, with the 
95% CI not including 1, and the effect of sex comes close. Better prior quality of life is 
also related to better outcomes. 
There is a suggestion of a relationship between increasing activities of daily living 
(ADL) and mortality, and between comorbidity and mortality, but the numbers with 
more than I impairment of ADL or comorbidity are small. The low numbers of patients 
with ADL impairment and comorbidity are likely to reflect selection. In the total group 
the median (IQR) number of ADLs was 0 (0.0-1.0) whereas in SUPPORT which 
recruited all COPI) patients admitted to 5 US hospitals the median (IQR) number of 
ADLs was 1.0 (0.0-2.0)12. This is an important observation and is consistent with the 
findings of the Heart of England Critical Care Network study that suggested that UK 
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clinicians might be nihilistic about the survival prospects of COPD patients8. The weak 
univariate relationship between increasing ADLs and comorbidities will partly be 
explained by low numbers but also may well be explained by selection in that only the 
otherwise fitter patients with increased ADL and comorbidity are likely to be recruited 
to CAOS. 
9.62 Characteristics in the 24 hours before critical care and outcome 
Table 9.6.2 tabulates the characteristics in the 24 hours before ICU admission and 
outcome. The factors with significant relationships with outcome in the patients for all 
treatment were diagnosis, length of stay prior to critical care, presence or absence of 
atrial fibrillation and whether or not the patient was actually intubated. 
9.63 Body weight variables and 180 day mortality 
Table 9.6.3 shows the relationship between body weight variables and 180 day 
mortality. There is a consistent trend between decreasing weight and mortality. This 
relationship is also apparent when mid-arm circumference is used as a surrogate for 
body mass index. 
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9.7 Summary and implications for outcome model development 
9.7.1 Selection bias 
A number of centres commented that the unit had a tacit policy of not admitting patients 
on home oxygen. Patients designated for 'no intubation' were more likely to be on 
home oxygen [no intubation 38.1% vs. 10.6% for intubation, chi-square 77.5 p<0.001]. 
It was decided that home oxygen should not be used as an outcome predictor since any 
patients getting into ICU on home oxygen were likely to have been highly selected as 
having an unusually good prognosis in other respects and so not representative of the 
population as a whole. 
In addition considering Table 9.2 and using post hoc subgroup analysis to compare the 
characteristics of patients by intubation designation illustrates that patients designated 
for 'no intubation' tended to be older [(70.3 vs. 66.1 T-test p<0.001)], to have a lower 
FEVI [(0.7 vs. 1.1 T-test p<0.001)], to have a lower functional score, [out of house or 
better (no intubation 32.0%, for intubation 70.0%) vs. housebound or worse (no 
intubation 68.0 % vs. for intubation 30.0%) chi-square 84.2 p<0.001)], to have a poorer 
prior quality of life, [fair or better (no intubation 50.8% vs. for intubation 66.0%) poor 
or very poor (no intubation 49.2% vs. for intubation 44.0%) chi-square 13.76 p<0.001], 
to have more impairments of activities of daily living, [no intubation median (IQR) 
ADL impairments 1.0 (0.0-3.0) for intubation ADL impairments 0.0 (0.0- 1.0) p<0.001 
Mann-Whitney)], and to have had more admissions in the last 6-months, [no intubation 
median QQR) 0.0 (0.0-1.0) for intubation 0.0 (0.0-1.0) p=0.0013 Mann-Whitney], 
though the difference in cornorbidities and previous intubation did not reach statistical 
significance. Though these analyses are post-hoc, subgroup analyses suggest that there 
is a consistent pattern that indicates that patients designated as not for intubation have 
been selected using characteristics that suggest that they are older and frailer. In section 
9.7.6. iv below the proportion of patients in the worst fimctional groups is compared 
with a historical cohort assembled in one centre where all COPD patients admitted to 
hospital were included irrespective of whether they had been selected for ICU or not. 
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The historical 'total cohort' study contained a greater proportion of patients who were 
housebound or worse than the CAOS study. 
9.7.2 Proxy responses 
Responses describing prior quality of life, activities of daily living and functional score 
only came directly from the patient in 43%, 42.5% and 38.6% of subjects respectively. 
Though activities of daily living and function are readily observed and therefore likely 
to be relatively accurately reported by proxies, patient rated quality of life is subjective 
and proxy reports may be unreliable. 
9.7.3 Complicated variables 
The estimation of BMI was difficult, both because of difficulties in weighing and 
measuring patients, and because many clinicians thought in imperial measures. Thus 
calculating the BMI involved estimates, conversion to metric measures and then a final 
calculation. 
9.74 Missing data 
Data was missing in more than 5% of patients for only FEVI (missing in 61.8%) and 
non-ventilated respiratory rate (missing in 5.6%). Though lung function is an important 
measure of the severity of COPD other studies have also found that it tends not to be 
available in the acute setting. Even in the SUPPORT study 12 that had full time dedicated 
data collectors, FEVI data was only obtained in 22% of the model development set. 
9. Z5 Variables measured with error 
Despite measures of oxygenation having a robust association with outcome in patients 
with respiratory failure (section 3.4.11.2), liaison with the units made it clear that there 
was uncertainty about the inspired oxygen concentration (FiO2) delivered to patients 
when the Pa02 was measured. Since the Pa02 can only be interpreted in the light of an 
accurate Fi02, oxygenation was not used in the modeling process. 
1% 
9.76 Selected comparisons with other COPD outcome studies 
i Age 
In the studies identified in the systematic review the mean age ranged from 57 to 69 
years and the median from 64 to 70 years. In the UK CMP study the median (IQR) age 
was 67.5 (60.4-73.5)27. In CAOS the age was similar. 
ii Sex 
Most data sources suggest that men slightly out number women in ICU admissions with 
COPD. Men made up 51.8% (1869 of 3611) (95% CI 50.1- 53.4%) and women 48.2% 
(95% CI 46.649.9%) of patients with COPD admitted to critical care units in the CMP 
study that analysed admissions between 1995 and 200 127. Though the 95% confidence 
intervals include the possibility of the predominance of women being accounted for by 
the play of chance it is interesting to note that whilst age-adjusted mortality rates for 
men with COPD have fallen over the last 20 years (from 1070 to 634 per million) 
mortality rates have increased in women from 230 to 323 per million 
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predominance of women with COPD admitted to ICU was also observed amongst the 
eligible patients not recruited to CAOS identified via the CMP patients of which 51% of 
were women (section 5.3.4). It may be that the predominance of women observed in 
CAOS reflects demographic changes in the numbers of women with COPD being 
admitted to ICU. 
iii FEVI 
The CAOS result is very similar to the results seen in SUPPORT median (IQR) 0.8 
(0.58- 1.20). The similarity to SUPPORT is reassuring in that the SUPPORT study was 
a total cohort study including both critical care and ward patients. 
iv Functional score 
Since it is intended that the CAOS model should be used in patients who have not yet 
reached critical care it would be useful to understand the distribution of functional score 
in all hospitalised admissions with COPD. An early pilot study in preparation for the 
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CAOS study applied the functional score to 242 consecutive admissions to hospital with 
COPD irrespective of the area of care 141 . In this study carried out 
in one centre, less 
than 10% of COPD admissions were admitted to a critical care area. Table 9.7.6. iv 
shows the distribution of functional score between unselected. and selected groups of 
patients and it can be seen that that whereas in the early pilot amongst unselected. 
patients 49% (95% CI 43-56) were housebound or worse, amongst all the CAOS 
patients only 38% (95% Cl 35-42) were housebound or worse. 
Table 9.7.6. iv Functional score in patients with COPD. 
Functional score 
Hospitalised 
patientsfrom 
earlypilot 
n=242 
AIICAOS 
patients 
n=832 
CAOSpatients 
without treatment 
limitation 
n=651 
CAOSpatients 
whowouldnotbe 
intubated 
n=181 
% (95%CI) % (95-/. Cl) % (95%CI) % (95%Cl) 
Fully mobile 12%(8.2-16.8) 24.90/o(22.0-28.0) 29.0%(25.6-32.7) 9.9%(6.0-15.3) 
Out of house 38.8%(32.745.3) 37.0%(33.740.0) 41.00/o(37.244.9) 22.7% (16.8-29.4) 
Housebound 42.3%(35.948.6) 33.7%(30.4-37.0) 27.0% (23.7-30.6) 57.5% (49.9-64.8) 
Bed/chair bound 6.6%(3.8-10.5) 4.5%(3.2-6.1) 2.9% (1.84.5) 9.90/o(6.0-15.3) 
v Activities ofdaily living 
A comparison of the distributions of activities of daily living (ADLs) in this study and 
in SUPPORT 12 also suggests that important selection is occurring in CAOS. In 
SUPPORT all patients admitted to 5 US hospitals with COPD and Type II respiratory 
failure were recruited and the median (IQR) number of ADLs was 1.0 (0-2). In contrast 
in the 651 patients in CAOS without treatment limitation the median (IQR) number of 
ADLs was 0.0 (0-1). 
9.8 Conclusions 
Overall data completeness was good and the variables collected were broadly similar to 
those collected in other studies that examined COPD outcomes. Comparison of patients 
for all treatment with those who were not for intubation suggests that the patients 
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selected for all treatment were on the whole fitter and comparison with a single 
historical cohort suggests that those patients selected for ICU are likely to be fitter than 
the total group of hospitalised patients from which they have been drawn. This selection 
has important implications for the how the model should be used in clinical practice and 
is discussed in more detail in chapter 12. 
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Chapter 10 Development of the CAOS survival prediction model 
10.1 Introduction 
The various stages involved in developing a prognostic model were summarised in 
Figure 2.1: 
1. State clinical aim for model 
2. Prepare a list of potential risk factors for mortality based on clinical knowledge 
in relation to stated aim 
3. Select a suitable sample of patients 
4. Select an appropriate statistical modelling technique 
5. Adopt a systematic strategy to handle missing values for risk factors 
6. Adopt a systematic strategy to select a final set of risk factors 
7. Fit the model and estimate coefficients 
8. Convert regression coefficients to risk scores for mortality 
9. Model validation 
To allow the model-building process to be presented as a cohesive whole, each of the 
first 4 stages will be reviewed briefly in the first substantive section of this chapter. 
This is followed by sections devoted to stages 5 and 6. Stages 7,8 and 9 are addressed 
in Chapter 11. 
10.2 Stages 1 to 4. 
10.2.1 Clinical aim ofthe model and choice ofoutcome variable 
The aim of the model is to provide clinicians, who are assessing a patient with an 
exacerbation of obstructive airways disease, with an estimate of the patient's survival to 
180-days if they are treated with all appropriate therapy (section 1.2). An important 
issue in decisions of this kind is whether survival is associated with such poor quality of 
life that the patient would rather have died. One way of addressing this would have 
been to develop a model that predicted survival with acceptable quality of life124. 
However the CAOS study had missing quality of life data in 20% of the surviving 
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subjects. Developing the model on only the 80% of the subjects would have reduced 
power and could have introduced bias. 
Fortunately 96% of 180-day survivors who did return the questionnaire stated that under 
circumstances similar to their original ICU admission they would want such treatment 
again. There was no evidence that this percentage was any different in prompt, delayed 
and very delayed respondents (section 7.5, Table7.5). Carrying out a sensitivity analysis 
in which it was assumed that all the non-respondents would not choose critical care 
again, it was nevertheless found that 77.2% of all patients would want ICU again 
(section 7.7). It was therefore decided to focus on survival, with the implicit assumption 
that almost all surviving patients found their quality of life worthwhile. 
10. Z2 Potential riskfactors 
The risk factors associated with outcome identified in the systematic review are given in 
Tables 3.5.1,3.5.2 and 3.5.3. The distributions of these risk factors in the study 
population are given in the Tables in chapters 8 and 9. In order for a risk factor to be 
used in model building, the data had to be available before critical care admission 
occurred. The only exception to this was the use of the patients' intubation status. 
10.2.3 A suitable sample ofpatients 
The 651 patients selected for model development were 
" aged 45 years or older; and 
" in hospital with an exacerbation of obstructive lung disease; and 
" classified clinically as COPD, asthma or a mixture of COPD and asthma; and 
" admitted to a critical care area; and 
" considered suitable for any treatment including intubation by the clinicians 
supervising the patients' care. 
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IO. Z4 An appropriate statistical modelling technique 
The outcome was the binary outcome of survival/non-survival at 180 days and therefore 
logistic regression was used to develop the model. 
10.3 Handling missing values for risk factors according to a systematic strategy 
10.3.1 The imputation strategy 
The rationale behind the approach to missing values is outlined in section 2.6. Variables 
with more than 5% of the data missing were dropped from the modelling process 
because imputational strategies become speculative beyond this level and because 
variables that are frequently missing are likely to be unavailable at the bed side. Data 
that were missing in less than 5% of patients were imputed using either the total 
population mean or median, or using the mean or median for the closest category in a 
correlated variable for which data were not missing 
10.3.2 Variables dropped because oftoo much missing data 
Two variables, FEVI (61.8% missing) and non-intubated respiratory rate (5.6% 
missing), were eliminated. Respiratory rate is often not measured outside ICU because 
there is no machine to measure it. In addition it had been decided that a composite acute 
physiology score would be developed using data from the Case Mix Programme 
database, and in this database non-intubated respiratory rate is often unavailable 
because many patients in ICU are intubated. 
10.3.3 Imputationfor characteristics in the period ofstabilitypre-critical care. 
i Prior quality oflifie 
Nine patients (1.1%) had missing data. Functional score and prior quality of life were 
strongly correlated (r = 0.49 p<0.0001), and 9 patients with data missing on prior 
quality of life had data on functional score. Table 10.3.3 shows the most common prior 
quality of life category for each functional score category, and this mapping was used 
for imputation in the numbers of cases also shown in the table. 
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Table 10.3.3 Prior quality of life imputation strategy 
Functional score Number ofpatients Commonestprior 
category with missing data on quality of life 
prior quality of life category 
Fully mobile 4 Very good 
Gets out of house to do 4 Fair basic necessities 
Out of house rarely I Poor 
Bed or chair bound 0 Poor 
ii Activities ofdaily living 
There were four patients (0.5%) with missing data, in one patient for all domains, in one 
patient for four domains, and in two patients for one domain. The commonest state, "no 
impairment", was imputed for all missing data. 
iii Previous admissions in the past 6 months 
One patient had missing data and the commonest state, "no admissions"was imputed. 
10.3.4 Imputationfor characteristics in the 24 hoursprior to critical care 
i Chest X-ray appearance 
Eleven patients (1.3%) had missing data. The most common chest X-ray appearance, 
"acute changee', was imputed. 
ii Congestive cardiacfailure as a cause 
Two patients (0.2%) had missing data. 'Me commonest state, "congestive cardiac 
failure absenf' was imputed. 
iii Ankle oedema 
Two patients (0.2%) had missing data. The commonest state, "ankle oedema absenf', 
was imputed. 
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10.3.5 Imputationfor data relating to body weight 
i Weight loss in the previous six months 
Weight loss data were missing in 13 patients (1.6%). The commonest state, "no weight 
loss", was imputed. 
ii Mid-arm circumference (AMQ 
MAC had one of the highest frequencies of missing data: 22 (2.6%). It seems likely that 
these values were not missing at random; 18 of the 22 people with missing MAC 
(81.2%) died within 180 days. To use the mean MAC for patients who died would be to 
introduce bias given that the main outcome of interest is 180-day survival. However 
MAC is closely correlated with the Lickert score for body weight (r = 0.756, p<0.0001) 
and all the patients with missing MACs had data on Lickert score. MAC values were 
imputed using the mean MAC for the subject's Lickert score. 
Table 103.5ii Lickert rating and corresponding MAC measurement 
Lickert rating N dying before 180 
days with missing 
data 
Nsurviving 180 days 
with missing data 
MACmeasurement mean 
(ND) cm 
Very underweight 3 21.2(2.6) 
Mildly underweight 2 2 24.3(3.4) 
Normal weight 6 1 27.7(3.3) 
Mildly overweight 6 1 31.5(3.7) 
Very overweight 1 35.8(4.7) 
iii Body mass-index 
Nine patients in total (1%) had height and/or weight data missing (5 weight, 3 height 
and one both), making calculation of BMI impossible. However all had Lickert 
estimates of weight. Figure 10.3.5 below shows that there was a relationship between 
BMI and Lickert weight estimates, and missing BMIs were imputed using the median 
BMI of their Lickert weight group. 
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Figure 103.5 Body mass index according to estimated weight using 
Lickert scale 
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Table 10.3.5. iii Licked score for weight and estimated BMI 
Lickert weight 
BMI KgIM2 
Mean (SD) Median (IQR) 
Very underweight 16.8(3.9) 17.0(15.1-18.6) 
Mildly underweight 20.5(4.0) 20.2 (18.1-22.6) 
Normal weight 24.2(3.7) 24.2 (21.9-25.9) 
Mildly overweight 28.4(5.8) 28.4 (25.8-30.9) 
Very overweight 38.2(10.9) 36.8 (32.3-41.8) 
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10.3.6 Imputationfor acute physiological variables 
The ten physiological variables with less than 5% missing data are surnmarised in the 
table below, which also shows the mean values for all patients with data, which were 
used for imputation. 
Table 10.3.6 Imputation for acute physiological variables 
Acute physiology variable Number (116) missing Imputed value 
Fi02 3(0.4%) 48.1% 
Systolic Blood pressure 2(0.21/o) 13 1 mnfflg 
Diastolic Blood pressure 3(0.4%) 69mmHg 
Central Temperature 5(0.61/o) 37.0 OC 
Heart rate 1(0.1%) 118 bprn 
Potassium 2(0.2%) 4.5mmol/L 
Albumin 3(0.4%) 34.5g/L 
Bilirubin 15(l. 8%) 11.5 mmol/L 
Glucose 14(l. 7%) 9.2mmol/L 
Glasgow coma scale 3(0.4%) 12.0 
10.4 A systematic strategy to select a final set of risk factors 
10.4.1 Introduction 
Five physiological variables were dropped during the development of the COPD 
specific acute physiology score (CAPS), i. e. potassium, temperature, PaC02. glucose, 
and bilirubin (table 8.5.1). The CAPS was developed using a data driven strategy in a 
model building set of 5513 patients, and then tested in the other 3014 patients. The nine 
physiological variables retained in the CAPS were: heart rate, white blood count, 
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sodium, pH, creatinine, albumin, systolic blood pressure, diastolic blood pressure and 
urea. 
A number of strategies were used to reduce the remaining potential risk factors to a 
smaller number for use in the final model. This was necessary since with 220 deaths in 
the model development data, a maximum of around 20 variable levels could be 
modelled. Also the model was intended for use by busy clinicians at the bedside so that 
model parsimony was an important consideration. Data driven variable selection 
processes were to be avoided, and the criteria for dropping or retaining variables were 
as set out in chapter 2. 
" Practicality and simplicity 
" Accuracy of measurement 
" Lack of subjectivity 
" Low correlation with other variables 
" Unlikely to introduce selection bias 
" Less than 5% missing data 
10.4.2 Practicality and simplicity 
Information provided by units about the practical aspects of data collection was outlined 
in Chapter 9. 
There were practical problems with body mass index because weight and height often 
had to be estimated rather than measured, and the estimates tended to be in imperial 
units, which would require conversion for use in the model. 
There were some practical problems with the data on Activities of Daily Living 
(ADLS). Clinicians found the scale unfamiliar and if it were to be used as part of the 
CAOS score a description of the ADL scale would need to be provided leading to 
difficulties in producing a score that fitted on a single side of paper. The Charlson Co- 
morbidity score was also unfamiliar to clinicians and posed similar problems. 
However it was decided not to drop these two variables at this stage but to continue 
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model development so as to understand the implications for discrimination and 
calibration of dropping them or retaining them at a later stage. 
10.4.3 Variables dropped because ofconcerns over accuracy in measurement 
Any data collected inaccurately would tend to reduce the apparent effects of the variable 
concerned if the errors are random, and might lead to biased results if the errors are 
systematic. 
The variables in Table 10.4.3 below were dropped because of concerns about accuracy 
of measurement. 
Table 10.4.3 Variables dropped because of concerns over accuracy in 
measurement 
Variable Reasonsfor dropping 
PaO2/FiO2 ratio Units commented that it was often difficult to be sure of the delivered FiO2 
outside critical care. 
Congestive It was found difficult to differentiate between patients with congestive cardiac 
cardiac failure failure and Cor pulmonale, and the two conditions have very different prognoses. 
as a cause 
10.4.4 Variables dropped because ofsubjectivity 
The CAOS model was developed because clinicians' subjective estimates of outcome 
were highly variable, and every effort was made to ensure that the CAOS model was as 
objective as possible. The widespread use of estimates of weight and/or height as a basis 
for BMI has already been referred to. Because of the combination of subjectivity in 
these estimates and practical problems in conversion of imperial to metric units, it was 
decided to drop BMI. 
The assessment of prior quality of life was subjective, not least because 57% of the data 
were provided by proxies. It was decided to drop this variable. 
Body weight Lickert is subjective and dropping it was considered as it was felt that an 
objective measure of body weight would be superior. However it was retained for 
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modelling because it correlated well with mid-arm circumference (MAC) and could 
provide a substitute for missing MAC data. 
10.4.5 Variables dropped because ofcorrelation 
The various measures of body weight were not surprisingly highly correlated. BMI was 
dropped on subjectivity and practicality grounds, but the correlation coefficient for 
MAC and Lickert bodyweight assessments was 0.756. There were a priori grounds for 
choosing MAC in the model because though body weight Lickert is easier to obtain, it 
is subjective and the MAC is better at identifying the thin patients at highest risk 
(MAC<20cm); all these patients are lumped together in the lowest category of the body 
weight Lickert scale. It was decided to check this once the remainder of the variable 
selection process was complete, by examining the ROC and Hosmer-Lemeshow 
statistics for logistic regression models with 180-day survival as the dependent variable 
and MAC or body-weight Lickert among the independent variables. 
The Glasgow Coma Scale was correlated with intubation and many other factors that 
are associated with intubation such as pH. (Impaired conscious level is often used as a 
reason to intubate. ). Also the GCS is a scale that involves collecting data on several 
variables and therefore adds complexity. For these reasons it was decided to drop it. 
10.4.6 Variables dropped because ofpossible selection bias. 
The problem of selection bias is discussed in section 2.5.4 and section 9.7.1. Long term 
oxygen therapy (LTOT) was a risk factor that seemed to be mentioned frequently as a 
reason not to intubate and selection on the basis of LTOT use seemed to be sufficiently 
widespread that the patients on LTOT admitted to CAOS might be highly selected. For 
this reason LTOT was dropped from model development. It might be argued that 
functional capacity also showed selection, but there was not the same explicit consensus 
about the level below which patients should or should not be admitted as for LTOT. 
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10.4.7 Summary ofvariable selection prior to modelling with outcome 
Table 10.4.7 below shows the variables that were dropped before any modelling with 
outcome was undertaken. This left 16 variables that were taken forward to the next 
stage. 
Table 10.4.7 Summary of variable selection prior to modelling with outcome 
Variable Reason 
Body mass index Complicated and unreliable 
PaO2/FiO2 Unreliable 
Congestive cardiac failure Concerns over accuracy 
FEV, Missing data 
Respiratory rate Missing data and often unavailable in CMP 
Prior quality of life Subjective 
Glasgow coma scale Correlated with intubation 
Long term oxygen therapy Selection bias 
PaC02 Dropped by physiology score process 
Glucose Dropped by physiology score process 
10.4.8 Variables droppedfollowing backward stepwise selection usingp < 0.2 
Using backward stepwise selection can introduce bias because relatively subtle 
differences in the distribution of risk factors in a population may cause them to be 
selected for inclusion in the model in one data set and rejected in another2l. Also 
important risk factors that are relatively rare (atrial fibrillation might be such a factor in 
the CAOS dataset) may be dropped because of a borderline significance value that 
reflects its rarity in the population rather than its importance as a predictor. For this 
reason Harrell advocates defining risk factors in advance and then producing a full 
model that contains all those risk factors. If risk factor selection is to be based on a data 
driven strategy Harrell suggests that the significance level should be very conservative 
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and advocates only deleting predictors if their total chi-square is <2xd. f. (degrees of 
I freedorný . 
Because this study involved collecting data on a number of risk factors for which there 
was only weak prior evidence of association with outcome, it was decided to use a very 
conservative data driven strategy to test whether these variables should be retained in 
the model. These were variables where an association with outcome might have been 
noted in one study (ankle oedema 142 , previous intubation 
43) or associations that were 
part of the folklore but without much evidence, such as recent weight loss and recent 
hospital admissions. The model subjected to backward stepwise reduction also 
contained variables that had a good base in the evidence and were likely to be 
correlated, such as functional score and activities of daily living, and it was decided a 
priori that these would be retained at this stage of model development even if dropped 
by the stepwise selection process. 
Backward stepwise selection was carried out using the 651 patients without treatment 
limitation. The variables in the model subjected to backward stepwise selection were: 
" Length of stay pre critical care 
" Ankle oedema, 
" Age groups 
" Sex 
" COPD acute physiology score 
" Activities of daily living 
" Functional score 
" Mid-ann circumference 
" Atrial fibrillation 
" Intubation 
" CXR appearance 
" Admissions in past 6 months 
" Weight loss in previous 6 months 
Diagnosis 
Comorbidities 
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* Previous intubation 
Backward elimination identified a further five variables that might be dropped (Table 
10.4.8). Four of these were accepted as suitable for dropping at this point since the 
evidence that they might be important in the systematic review was relatively weak. 
However chest X-ray appearance was kept in the model at this stage because the 
majority of clinicians put great emphasis on this in their decision-making. 
Table 10.4.8 Variables dropped after backwards selection. 
Candidate Variables Values Rationalefor exclusion 
variable with >0.2 
Chest X-ray appearances are established in the folklore as important and Chest X-ray X clinicians frequently mention them in decision making processee so they 
aetiology were kept in the model until die next round. 
It is likely that ankle oedema patients include both patients with a good 
prognosis i. e. those with congestive cardiac failure as the cause and those Ankle X X with cor pulmonale. In addition ankle oedema had only been identified as 
oedema associated with outcome in a single study that included all COPD hospital 
admissions and not just those admitted to critical care". 
Previous Dropped on grounds of parsimony since 
there is no few effect on outcome 
X X and only identified in one study as important. Likely to be a marker of intubation survivor bias. 
Previous Dropped on grounds of parsimony since no real effect on outcome and 
X included in the study to 
investigate a part of the folklore rather than because 
adniissions X of previous high quality study evidence. Also possibly affected by levels of in past 6m health care provision. 
Dropped on grounds of parsimony since no real effect on outcome and Weight loss X X included in the study to investigate a part of the folklore rather than because in past 6m of previous high quality study evidence. 
10.4.9 Mid-arm circumference (AIA Q or bodyweight Lickert? 
Comparisons of ROC area and likelihood ratio statistic were made for models with mid- 
arm circumference (MAC) and with bodyweight Lickert. The models had very similar 
discriminative ability in terms of ROC area (MAC: 0.7809; Lickert: 0.7801). In terms 
of the likelihood ratio Chi- square, both variables were significant contributors to the 
model (MAC: p=0.021, Lickert: p=0.013). However the advantage of the MAC is 
that it separates out the thinnest patients who are at highest risk into two categories 
whereas the Lickert scale amalgamates these patients into a single category. It was for 
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this reason that it was decided to use the MAC in the final model. In addition given two 
scales that measure a similar domain the least subjective should be chosen as long as 
this does not have too great a price in terms of ease of use. The MAC is easy and quick 
to use and for this reason this was chosen for the final model. 
10.4.10 Further simplification: reducing the number ofnew scores required 
After the backward stepwise selection there were 12 risk factors left in the model. In 
section 10.4.2 the possibility of dropping the Charlson comorbidity index and activities 
of daily living was raised on grounds that they involved additional scales that are not in 
common clinical practice. At that stage it was decided to keep them in so that the 
impact of dropping them from a simpler model could be assessed in terms of the trade 
off between parsimony and model performance. In addition comorbidity is very difficult 
to measure using simple scales and the Charlson comorbidity scale was likely to be 
considered inadequate by clinicians. For example simply scoring the presence of prior 
myocardial infarction misses important factors such as the ECHO findings that 
document residual left ventricular function in - myocardial infarction survivors. 
Elixhauser has argued that counting comorbidities is an inadequate way to take them 
into account and that each comorbidity should be weighted depending on the primary 
condition95. Currently studies have not reported a weighting scheme for comorbidities 
that coexist with COPD patients, and of course the more specific weighting that would 
be required would be for patients with COPD who are intubated. 
The effect on the model of dropping these variables was assessed using the area under 
the receiver operating characteristic curve (ROC) to estimate effects on discrimination 
and the Hosmer-Lemeshow Chi-square statistic to estimate the effects on calibration. 
This process is summarised in Table 10.4.10 and outlines the impact of dropping the 
complex ADL and Charlson scores and also the effect of dropping the chest X-ray 
classification that had been forced into the model up till this point. Dropping the ADL 
score reduced the ROC from 0.781 to 0.776. The Hosmer-Lemeshow Chi-square 
statistic, was 3.76 (p = 0.333) and the Log-ratio chi-square, a measure of whether the 
variable makes a significant difference to the fit of the model, was 3.4 (p = 0.333). 
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Dropping the Charlson index reduced the ROC from 0.781 to 0.771. The Hosmer- 
Lemeshow Chi-square statistic, was 2.4 (p = 0.966) and the Log-ratio chi-square was 
3.37 (p = 0.338). 
Table 10.4.10 ROC and HL statistics as variables are removed from the 
reduced model 
Independent variables in Variable ROC HL LR test Decision 
model (n = 65 1) area 
los agegip sex APS ADL funsc HL Chi-sq 5.9 
MAC AF intubation CXR 0.7809 P--0.655 
diagnosis comoborbidity--- 
Length of HL Chi-sq 5.9 
LR Chi-sq - Length of stay is significantly 
stay 
0.7660 P=0.656 4.74 associated with 
180-day outcome 
P-0 0295 so retain in final model 
HL Chi-sq 9.5 LR Chi-sq= Age is significantly associated 
Age group 0.774 P=0 38 
9.08 with I 80-day outcome so retain in 
. P-0.028 final model 
HL Chi-q 6.8 LR 
Clu-sq Sex has a borderline significant 
Sex 0.7765 P=0 55 -335 * association with I 80-day outcome . P-O . 
067 once other factors adjusted for 
Acute HL Cbi-sq 3.2 LR Chi-q APS is significantly associated 
physiology 0.765 92 Pý0 -12.5 with 180-day outcome so retain 
in 
score . P-0.0004 final model 
HL Chi-sq LR Chi-sq ADL is not significantly 
ADLs 0.776Y 3.76 -4 associated with I 80-day outcome. 
P=0.878 P-0.333 
HL Chi-sq LR Chi-sq Functional score is significantly Functional 0.772 7.04 -8.47 associated with I 80-day outcome 
score P-0 532 P-0.0372 so retain in final model 
HL Chi-sq LR Chi-sq MAC is significantly associated Md-arm 0.7685t 9.29 -10.45 with 180-4ay outcome so retain in 
P-0.318 P-0 0151 final model 
AF not significantly associated 
LR Chi --sq 1 
with 180-day outcome when other 
Af 778 0 
BL Chi-M 7.9 2 49 
factors taken into account, but 
. P=0.443 . 1149 P-0 retained in 
backward stepwise 
. regression and easy to measure so 
Le! ain 
HL Chi-sq LR Clu -sq Intubation significantly associated Intubation 0.7491 10.9 34.9 with 180-day outcome 
status P4 21 P4 0000 
HL Chi-M 5.7 LR Chi-sq Chest X-ray appearances are not 
X-ray 0.7803 67 " 0.05 associated with 180-day outcome . P-0.83 
Diagnostic HL Chi-sq 4.7 
LR Chi-sq Diagnosis significantly associated 
0.773 78 P-0 -9.68 with I 80-day outcome group . P-0.0079 
. Comorb- 0,7706 HL Chi-sq 2.4 LR Chi-sq Co-morbidity not signi icantly 
idity -3.37 associated with outcome- though P-0.966 ROC falls 
P=0.338 
Vrhe ROC hardly changes i. e. 0.78 to 0.776 a market that ADI-s are not improving discrimination. 
t The ROC falls from 0.78 to 0.76 when MAC is removed showing the importance of MAC 
Note using the Hosmer-Lemeshow chi-squared goodness of fit statistic on 10 degrees offireedom, values over 19.30 indicate a significant lack of fit at 
the 5% significance level. Hence removing ADI, CXR appearance and AF makes little difference to the ROC AUC or the LH statistic, but taking out 
age groups though making little difference to the ROC makes a big difference to the LH statistic. 
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Despite the limitations of this method (i. e. that the result may not be stable in samples 
of patients with different distributions of risk factors) it does provide some reassurance 
that dropping these factors is not likely to affect the performance of the model. 
10.4.11 Testing ofchest X-ray appearance in afinalparsimonious model 
Given the importance attached to chest X-ray appearance in the folklore, backward 
stepwise variable selection with ap value of 0.2 was repeated in the final parsimonious 
model i. e. the model from which activities of daily living and the Charlson co-morbidity 
score had been dropped. Once again chest X-ray appearance was dropped and no ffirther 
attempt was made to force this variable into the model. 
10.5 Final model 
Dropping activities of daily living, comorbidities and chest X-ray leaves a final model 
which is a good compromise between parsimony and predictive performance and 
includes 10 variables with 15 levels (where a variable with k categories contributes k- I 
levels). This allows fitting in a data set with almost 15 events per variable level. The 
variables (with numbers of categories) included are age group (3), diagnosis (3), sex (2), 
functional score (4), atrial fibrillation (2), grouped mid-arm circumference (4) and 
intubation status (2). The continuous variables are COPD acute physiology score and 
length of stay prior to critical care. It is assumed that the effects of the continuous 
variables are linear. The Lowess Smoother Plot Figure 9.2.3 suggested that a linear 
relationship between length of stay and outcome was reasonable. The linear relationship 
between acute physiology score and outcome was assumed since the acute physiology 
score was constructed from the predicted log odds of mortality (i. e. a linear predictor) in 
the CMP data. 
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Chapter 11 Model testing and development 
11.1 Introduction 
In this chapter the variables selected in chapter 10 are used to construct a parsimonious 
prognostic model using the 651 patients without treatment limitations. This model, with 
10 variables and 15 parameters, is described. A prognostic scoring system is then 
derived by approximation to the exact model coefficients, and the performance of this is 
tested. 
11.2 The final parsimonious model 
Table 11.2.1 shows the univariate and multivariate risk ratios for the variables in the 
final model. 
113 Final parsimonious model in patients with and without treatment limitation 
It was decided to produce the model for patients without treatment limitation (section 
2.5.4). Using a model based on the final variables (but prior to bootstrapping) the model 
performed better in the patients without treatment limitation (n--651) than in the total 
group that included patients in whom treatment limitation decisions were made (n--832). 
In the total cohort of 832 patients the ROC for the parsimonious model was 0.7565 
(Figure 11.3.1), compared to the value of 0.7750 in the 651 patients without treatment 
limitation (Figure 11.3.2). This is what would be expected given that prognostic models 
should take account of important treatments. 
216 
Table 11.2.1 Odds ratios for 180-day mortality for risk factors in final model 
Variablellevel Number Number died Univariate odds Multivariate odds 
(116 of 65 1) (116 of gro up) ratio ratiot 
Length of stay 1.03 (1.00-1.06) 1.03 (1.00-1.05) 
Age 45-64 285 (43.80/*) 69 (24.2%) 1 1 
Age 65-74 227 (34.9%) 82 (3 6.10/6) 1.80 (1.23-2,64) 1.30 (0.84-2.00) 
Age ý35 139 (21.4%) 70 (50.4%) 2.24 (2.10-4.98) 2.07 (1.25 -3.44) 
Female 340 (52.2%) 104(30.6%) 1 1 
Male 311 (47.8%) 117 (37.6%) 1.35 (0.97-1.87) 1.43 (0.98-2.08) 
Acute physiology score 1.03 (1.00-1.06) 1.03 (1.01-1.05) 
MAC* >- 30 cm 277 (42.50/9) 82 (29.6%) 1 1 
MAC>25cm <30 cm 234 (35.9%) 77 (32.9%) 1.2 (0.8-1.7) 1.23 (0.80-1.88) 
MAC >20 <25cm 119 (18.3%) 48 (40.3%) 1.6 (1.0-2.5) 1.73 (1.04-2.90) 
MAC < 20 cm 21(3.2%) 13 (61.9%) 3.9 (1.5-9.7) 4.52 (1.55-13.14) 
Not intubated 201(30.9%) 34 (16.90/9) 1 1 
Intubated 450(69.1%) 186 (41.30%) 3.5 (2.3-5.2) 3.88 (2.43-6.21) 
"Pure" Asthma 78(12.0%) 8(10.3%) 
COPD & Asthma 104 (160%) 33 (33.8%) 4.07 (1.76-9.42) 2.73 (1.10-6.78) 
"Pure" COPD 469 (72.0%) 179 (38.2%) 5.40 (2.54-11.49) 3.52 (1.54-8.04) 
Fully mobile 189 (29. (r/9) 47 (24.9%) 1 1 
Restricted 267 (4 1. (M) 92 (34.50/6) 1.6 (1.04-2.4) 1.63 (1.02-2.60) 
flousebound 176 (27.0%) 70 (39.8%) 2.0 (1.3-3.1) 1.90 (1.13-3.18) 
Bed/Chair bound 19 (2.9%) 11 (57.9%) 4.2 (1.6-10.9) 3.80 (1.31-11.01) 
Atrial fibrillation absent 587 (90.2%) 186 (31.70/9) 1 1 
AF present 64(9.80/. ) 34 (53.10%) 2.4 (1.5-4.1) 1.63 (0.89-2.97) 
t Using thefinal CA OS model i. e. containing the variables in this table. 
* AMC = mid-arm circumference 
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Figure 11.3.1 
Figure 11.3.2 
ROC curve for final model in the total cohort of 832 
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11.4 Construction of risk scores 
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11.4.1 Converting individual riskjactor coefficients to integers 
To facilitate the use of the prognostic model in clinical practice the coefficients for the 
risk factors in the model were converted to integers. The resulting total score can then 
be easily calculated and used with a "look-up graph" displaying the risk of 180-day 
mortality for each score. 
218 
The coefficients in the original model are given in the second column of Table 11.4.1. 
The COPD specific acute physiology score took a value that ran from 0 to 100 and it 
was convenient to leave this unchanged. To achieve this, conversion to integers 
involved dividing all the coefficients by the acute physiology score coefficient and then 
rounding to produce a whole number. In the third column of the table the value of the 
coefficients is displayed after division by the acute physiology score coefficient 
(0.03278). In the fourth column the values are displayed after rounding. Once the model 
has been converted to a score the ROC becomes 0.7733 as compared to 0.7750 before 
the conversion to a score. 
11.5 Missing data on mid-arm circumference 
The mid-arm circumference (MAC) was missing in 22 (2.6%) of the 832 patients in the 
CAOS study and in 16 patients (2.5%) in the model building population. According to 
the strategy for imputation, missing MACs were estimated from bodyweight Likerts, 
and the same procedure could be invoked when using the score in clinical practice. 
Patients for whom the MAC was not available but who were very underweight would 
be allocated 46 points, mildly underweight patients 17 points, normal weight patients 6 
points, and mildly pd very overweight patients no points, as indicated in Table 11.4.1. 
11.6 Bootstrapping to adjust model coefficients for over-fitting 
The rationale behind the use of bootstrapping to take account of overfitting is outlined 
in section 2.11. 
For the purposes of this analysis, the CAOS model was formulated as: 
predicted log odds = alpha + beta x CAOS score 
The initial process of fitting the model in the sample of 651 produced the following 
equation 
predicted log odds = 4.873 + 0.03218 x score 
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Table 11.4.1 Converting individual risk factor coefficients to integers 
Predictor Coefficient in 
original model 
Raw value Oer 
division by 0.032 78 
Final score after 
rounding 
Length of stay 0.02773 0.846 1 
Age 45-64 0 0 0 
Age 65-74 0.2490 7.59 8 
Age 255 0.7167 21.866 22 
Female 0 0 0 
Male 0.3747 11.43 11 
Acute physiology score 0.032778 1 1 
Mid-ann circumference 2: 30 
cm 
0 0 0 
Mid-ann circumference >25cm 
<30 cm or normal weight 
0.1898 5.790 6 
Mid-arm circumference >20 
<5cm or mildly underweight 
0.5422 16.542 17 
Mid-arm circumference: 5 20 
cm or very underweight 
1.4901 45A6 45 
Not intubated 0 0 0 
Intubated 1.35715 41AO 41 
"Pure" Asthma 0 0 0 
Mixture COPD & Asthma 0.8601 26.24 26 
"Pure"COPD 1.1159 34.046 34 
Fully mobile 0 0 0 
Restricted 0.4600 14.035 14 
Housebound. 0.6209 18.94 19 
Bed/Chair bound 1.3149 40.11 40 
Atrial fibrillation 0.4899 14.94 15 
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The 651 subjects in the CAOS study can be considered as a sample from a larger 
population of people with COPD and/or asthma admitted to high dependency care and 
without treatment limitations. This equation provides the best predictions of mortality 
for this sample, but would in general perform less well on other samples from the same 
population. To adjust the CAOS equation to perform better on other samples, similar 
equations were derived for each of 500 bootstrap samples from the CAOS data, each 
bootstrap sample generating a slightly different intercept and coefficient. The process 
that modifies the original equation takes the form below. 
Fit the original model (logodds = alpha + beta score) in the original dataset 
We are now looking for "shrunk" estimates for alpha and beta to account for any 
overfitting. We take N bootstrap samples 
For i=I to N 
Fit the original model in bootstrap sample i, and calculate the predicted log odds from 
this model (logodds_i) 
Fit the model (logodds = gammaO i+ gammal i logodds-i) in the original data 
Store the estimates gammaO -i and-gammal-i For the N bootstrap samples 
Calculate gammaO and gammal as the mean of gammaO-i and gammal-i over the N 
samples 
The shrunk estimates for alpha and beta are: 
alpha 
- new gammaO 
+ gammal alpha 
beta_new gammal beta 
11.7 The discriminatory performance of the CAOS model in new populations 
The second bootstrapping procedure is a forni of internal validation of the model that 
provides an estimate of the discriminatory performance of the CAOS model in future 
patient populations. The assuniption of this estimate is that though future populations 
may differ in their mix of patients, all the types of patients included in future 
populations would have been included in the original population. In other words the 
estimate of future performance assumes that the original population resembles future 
populations, and that temporal change will not produce important new combinations 
and characteristics in changes in the future patient populations but will merely affect the 
proportions of patients of different types. As a simplification if we are assuming that the 
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original population contained three types of patients ABC each comprising 33.3% of the 
original population, subsequent populations will still contain patients of the type ABC 
but in different proportions rather than patients of type ABD for example, where patient 
D is a patient type that was not represented in the original population at all. 
The procedure involves fitting a model using the final parsimonious set of variables (i. e. 
length of stay, sex, acute physiology score, mid-arm circumference, diagnosis 
functional score, atrial fibrillation and intubation status) for each of a series of 500 
bootstrap samples (which differ from the original 651 patients of the original model 
development set by random deletion and replacement of varying numbers of the original 
sample). 
Model-fitting for each bootstrap sample produces a set of coefficients. The model using 
these coefficients is tested on its bootstrap sample and the area under the ROC curve is 
measured (ROC boot). The model is then tested on the original 651 patients and the area 
under the ROC curve is measured again (ROC original). This procedure is repeated for 
each of the 500 bootstrap samples and the average values of mean (ROC boot) and 
mean (ROC original) are calculated. There is no ideal number of samples for a 
bootstrap, but bootstrapping is a time (and computer) consuming process. Five hundred 
samples were chosen because once so many samples have been used little additional 
precision is obtained by using further samples and this is enough for it to be reasonable 
to expect that any optimism in the ROC estimate was 'small'. The difference between 
ROC boot and ROC original is a measure of the 'optimism' of the original model. The 
discriminatory performance of the original model in future populations is calculated by 
subtracting this measure of optimism from the ROC of the original model run in the 
original population. 
In this case the estimate of optimism in the area under the ROC curve was 0.0 190 (95% 
CI -0.0217 to 0.05685). 
The original area under the ROC curve for the model developed as a score was 0.7733. 
Though moving from the original model with unrounded coefficients changed the ROC 
of the model from 0.7750 to 0.7733 the process of revising the coefficients by 
bootstrapping did not alter the discrimination of the model but merely altered the 
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calibration so the area under the ROC curve after the coefficients were revised by 
bootstrapping was also 0.7733. The estimate of the discrimination of the model in future 
samples is given by subtracting the measure of over optimism from the area under the 
ROC curve calculated using the final model in the original population: 
Area under the ROC curve for the final model in the original population 
= 0.7733 
Estimate of over optimism in area under ROC curve 
= 0.0190 (95% Cl 0.0217 to 0.0569) 
Estimate of discrimination in future samples 
= 0.7543 (95% CI 0.7950 - 0.7164) 
11.8 Development of look-up graph 
The CAOS score can now be directly calculated as an integer score and this runs from 0 
to around 300, though there is no absolute maximum since each additional day in 
hospital prior to critical care entry adds a ftirther unit to the score. The CAOS total score 
corresponds to a probability of 180-day mortality. The two can be plotted against each 
other and the 95% confidence intervals can be estimated from the standard error of the 
linear predictor from the logistic regression model. The predicted mortality is plotted 
against the CAOS score in a look-up graph in Figure 11.8. 
11.9 95% confidence intervals for group predictions 
The 95% confidence intervals are for the group of patients with a given predicted 
mortality. If we wanted to represent the 95% confidence intervals around the CAOS 
prediction for an individual patient they would be much wider". However the approach 
to decision making based on group probabilities is the usual one because it has a 
straightforward interpretation, i. e. "if I had 100 patients like you I would expect 70 to 
survive and 30 to die. What would you like to do? " Tbey look relatively narrow on the 
graph but that is partly because of the log odds scale. As expected, in the areas where 
there are fewest patients i. e. at the highest and lowest scores, the 95% confidence 
intervals are wider. Figure 11.9 
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Figure 11.8 Graph showing probability of 180-day survival according to 
CAOS score 
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11.10 Calibration curves 
Calibration curves are a useful ways of describing the predictive perfon-nance of 
prognostic models. Patients are grouped in a number of equally sized groups and the 
mean predicted probability of 180-day survival for each group is plotted against the 
observed of 180-day survival. Calibration curves can also be plotted to show the 
proportion predicted to die versus the proportion actually dying. In Figure 11.10.1 a 
calibration curve is plotted for 10 equal sized groups comparing observed and expected 
survival rates. It can be seen that there is some variability in the predictions simply due 
to the relatively small size of the groups, and in Figure 11.10.2 the plot is repeated with 
four larger groups. 
Figure 11.10.1 Calibration curve for 10 equal sized groups. 
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Figure 11.10.2 
0 0 
0 (3)00 
22 
:3 
0)0 
c 
(0 
0 
0 
CL 
0 C: ) 
CL 
3 
Calibration curve for 4 equal sized groups 
7/ 
- 
0 
0 20 40 60 80 100 
Predicted probability of 180-day survival 
Perfect calibration -- --- Model performa 
11.11 Model calibration and clinician calibration compared 
Prognostic models are usually more effort to use than clinical intuition, and if they are 
to be used in practice they have to be shown to add something to clinicians' unaided 
decision making. The CAOS study collected the outcome predictions of unaided 
clinicians at the time that patients were admitted to ICU and this allowed comparison 
with the CAOS model predictions. The final CAOS model in score forrn had an area 
under the ROC curve of 0.75 after bootstrapping compared to an ROC area of 0.71 for 
the unaided clinicians, suggesting that the model had important advantages over clinical 
intuition in terms of discrimination. In the figures below, calibration curves comparing 
clinicians and model predictions are shown both for predictions of survival in 10 groups 
and 4 groups. The graphs show that the CAOS model is better calibrated than the 
clinicians, and that clinicians tend to be pessimistic in the more severe patients. These 
findings are consistent with the findings of the Heart of England Critical Care Network 
study which suggested that clinicians were pessimistic compared to the SUPPORT 
modeI8. It is interesting to note the similarity between the calibration curve produced in 
the CAOS study and the calibration curve produced in the SUPPORT study. 
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Figure 11.11.1 Calibration curves for clinicians' and CAOS model 
predictions. Survival predictions in 10 groups 
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Figure 11.11.2 Calibration curves for clinicians' and CAOS model 
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Figure 11.11.3 
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11.12 Calculating the CAOS score 
Using scores in clinical practice needs to be as simple as possible if they are to be 
adopted. Many clinicians carry handbooks of clinical medicine where topics are 
typically summarised on a single sheet of paper. The following Figure 11.12 
demonstrates how a single side of A4 can contain all the information required to 
calculate the CAOS score. 
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Figure 11.12 Calculating the CAOS score 
A Assess the patient and determine: 1) Length of stay- 2) Age. 3) Sex. 4) Acute physiology score. 5) Mid-arm circumference 
6) Predominant cause of airway obstruction. 7) Functional capacity in period of stability prior to this exacerbation. 8) Heart rhythm 
B Calculate the points the patient cams in each of the eight categories using the table below. 
C Calculate the total points the patient has scored. 
D Look up the predicted 180-day mortality corresponding to the total score using the predicted mortality graph below. 
Predictor score 
Length of stay Score 1 point per day in hospital 
45-64 years 0 
65-74 years 8 
2ý 75 years 22 
S 
Female 0 
ex 
_ - 
Male 11 
-4cu te physiology 
score 
Use total from algorithm below 
2: 30cm 0 
Mid-arm 
i f 
ý25 ý30crn 6 
c rcum erence 
MAC (cm) >20 ý25crn 17 
< 20 cm 45 
'pure"COPD 34 
Predominant 
cause of airways 
Mixed COPD & Asthma 26 
disease "Pure' asthma 0 
Fully mobile and living without assistance 0 
e to live alone and get out of house to 
do basic necessities but severely limited 
exercise tolerance 
14 
Functional 
capacity 
Cannot get out of house or gets out of the 
house rarely, able to perform self-care but 
unable to do heavy chores such as house 
cleaning, cannot live alone, may be 
institutionalised 
19 
- 
Bed or chair bound 40 
FA 
trial fibrillation AF present 
- 15 
Intubated 41 
Predicted mortality graph 
CO 
mj 
t. 
Heart rate 
bpm ý 80 
1 
80-109 
1 
110 -129 
1 
130-149 1 150-169 2! 17 0 
score I 0 2 3 5 7 
MAP mmHg < 40 
1 
40-49 
1 
50-59 60-69 70-89 
1 
90-99 2: 100 
score 19 12 9 6 3 0 4 
pH pH < 
7.00 7.00-7.09 
1 
7.10-7.19 7.20-7.24 2: 7.25 
scom 9 6 3 1 0 
Sodium mmol/I < 130 130-134 135-144 
1 
2: 145 
score 6 2 0 2 
Urea mmol/I < 2,5 2.5-6.7 &8 - 11.9 120 17.9 2-. 1&0 
score 0 8 16 22 24 
Creatinine i"Moll, -150 150-199 ýt 200 
score 0 5 8 
Albumin g/l < 15 15 - M9 20-24.9 25-29,9 30-349 a 
score 20 14 8 6 
-- 
4 0 
WBC . 109/1 <4 4- 14. ý 15 - 19 
; - 720 
- 24.9 k 25 7 0 1 4 7 
Measuring mid-arm circumference (MAC) 
Use the non-dominant arm. For most people who are right handed this will be the left arm 
hinthi? K /he niid-17oint of the upper arin 
Bend the arm to 90" with the palm facing downwards in order to locate the landmarks. 
Locate the tip of the shoulder. 
Locate the bony tip of the elbow. 
Mark the nud-point between the tip ofthe shoulder and the bony tip ofthe elbow. 
A lea. vuring the tind-tirtit euviin! Prence. 
Having marked the mid-point, straighten the arm again. 
Measure the circumference ofthe arm at the mid-point you have just marked. 
Look up the score that corresponds to the MAC in cm 
Acute Physiology Score 
I) Use the most extreme value front 
the last 24 hours. 
2) Read off the score for each of the 
eight variables in the acute 
physiology score to produce a score 
between 0 and I GO, 
3) Add the points from the acute 
physiology score to the other 
components of the total score. 
MAP: Mean Arterial Pressure, WBC: 
White Blood Count 
Mean arterial blood pressure = (diastolic 
+ diastolic + systolic)/3 e. g. 120/80 = 80 + 
80+120/3 = 280/3= 93 
Identifying the mid-point of the upper arm 
4, 
mid-point 
.... . .......... 
[w l4v lw lou [w - 44v jw CAOS sockre 
Precficted suvival 95%Cl 
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Chapter 12 Conclusions and implications 
12.1 Statement of principal findings 
Of 832 patients admitted to this study, 518 (62.3%) survived to 180 days and 420 (81%) 
provided answers to the follow-up health status questionnaire. Four hundred responders 
(95.2%) would want admission to the ICU again under similar circumstances, as would 
204 out of 212 patients (96.2%) who had been intubated. Even given the worse case, in 
which none of the non-responding survivors would have wanted ICU admission again, 
over 75% of ICU survivors would have wanted it. This suggests that, for COPD 
patients, survival to 180 days after ICU is a worthwhile objective. 
A model to predict 180 day survival for patients with obstructive lung disease admitted 
to ICU has been successfully developed using data available prior to ICU admission. 
The model has fair discrimination, with an area under the ROC curve of 0.75 after 
bootstrapping to adjust for 'optimism' and good calibration. The model outperforms 
clinicians in terms of discrimination (ROC area 0.71) and also in terms of calibration, 
the clinicians having a tendency to pessimism. 
12.2 Using the score in clinical practice 
The question is how to manage a patient with obstructive lung disease and respiratory 
failure who has not yet been admitted to ICU, and has deteriorated to the point at which 
intubation is at least a possibility. Intubation requires admission to intensive care. The 
issue then is, if their condition does turn out to be severe enough for intubation, whether 
their prognosis with intubation is good enough to make the intubation worthwhile. 
The question of prognosis after intubation also arises when patients are started on non- 
invasive ventilation. The British Thoracic Society Guidelines recommend that at this 
point a decision should be made about whether to intubate if NIV were unsuccessful. 
Some patients with obstructive lung disease and respiratory failure have a very low 
probability of survival, whether intubated or not. Escalation of treatment is likely to 
merely prolong the process of dying. Using the CAOS prognostic score will help 
identify these patients. The score includes a weighting for intubation, so it is possible to 
230 
get some estimate of the probability of survival either with NIV alone or with 
intubation. It should be noted that the "intubation variable" adds enormously to the 
score and identifies a group with a much worse prognosis. This is likely to be because 
intubation is an indicator for a group of prognostic factors not actually measured 
elsewhere in the score. 
12.3 Strengths of the study 
IZ3.1 Representativeness 
The study has collected prospective data from 95 units in England, Wales and Northern 
reland. Of these, 92 units were ICUs in the Case Mix Programme (CMP) and made up 
5 1.74 of the 172 units in the CMP at the time the study was carried out (section 5.1.1 
above). Using data from the CMP it was possible to compare the characteristics of 90 of 
these units with those of 80 units not involved in the study. It was found (Table 5.1.2) 
that in terms of hospital type, ICU type, numbers of ICU beds, % of admissions eligible 
for this study and mean COPD acute physiology score, there were no material 
differences between the units that participated and those that did not. 
Data from the CMP also allowed comparison of the characteristics of 684 eligible 
patients in the participating units during the recruitment period who were included in 
the study (36.5%) and the 1189 that were not. (This number is less than 852 because it 
does not include those patients admitted to RHDUs [ 108] and because for some periods 
of CAOS data collection the CMP database was not yet cleaned and available for 
analysis. ) They were similar in terms of ICU mortality, acute physiology score (APS), 
age, sex and day of admission. It seems reasonable to conclude that the patients 
recruited are representative of the type of patients admitted to UK ICUs with 
exacerbations of obstructive lung disease. 
12 3.2 Rigorous model building 
Study size is particularly important in this context because of the need to have sufficient 
power to develop a model with the number of predictors indicated by the literature 
review. With complete 180 day follow-up and data available prior to ICU admission on 
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651 patients without treatment limitation, this is the largest UK cohort and prognostic 
modelling study for COPD. The only other study to look at factors associated with 
survival after intubation in UK COPD patients was a retrospective study of only 42 
patients64. Use of the CMP data set to develop a COPD specific acute physiology score 
avoided the problems of inadequate power that would nonetheless have occurred in 
weighting physiological variables. 
Chapters 3 and 9 outline the approach to model building, which sought to avoid data- 
driven variable selection as far as possible. Bootstrapping enabled the model 
coefficients to be adjusted for overfitting, which should improve the performance of the 
prognostic model in other data. 
IZ3.3 An understanding ofthe quality ofsurvival 
A good response rate to the follow-up questionnaire interpreted in the light of 
sensitivity analysis provides the assurance that though patients who survive to 180 days 
will have many symptoms of obstructive lung disease, at least 75% of them, and 
probably nearer 95%, would want to be admitted to intensive care again under similar 
circumstances. 
IZ3.4 Feasibility of use 
Informal feedback during the data collection helped to identify risk factors that it was 
practical to collect reliably. As a result the CAOS score is simple and quick to use in 
clinical practice. All the data required 
, 
for the model should be readily available. The 
scoring sheet, that includes both the weights attached to patient characteristics and the 
look-up graph, easily fits on a single sheet of A4 that could be incorporated into a junior 
doctor's hand book or a hospital guideline (Figure 11.12). Calculating a CAOS score 
and reading off the survival probability can be accomplished in less than 5 minutes. 
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12.4 Weaknesses of the study 
124.1 Selection bias 
To make the study feasible, all the patients recruited to CAOS had to have been selected 
for admission to ICU. However the prognostic score is intended for use with patients 
who are being considered for escalation of treatment prior to the process of selection 
either for admission to ICU or admission to an area where NIV can be used. As such the 
score is intended for use amongst patients not yet selected for ICU yet the data collected 
in CAOS suggests that only a proportion of these patients will be selected for unlimited 
treatment (section 9.7.1). A careful exploration of the likely extent of selection bias and 
its potential implications is crucial in understanding the limitations of the CAOS model 
in these patients who have not yet entered ICU in order to understand its limitations in 
clinical practice. - 
IZ4.2 The implications ofselection 
A crude representation of the population of hospitalised COPD patients with respiratory 
failure might involve a continuum running from those with an excellent prognosis if 
admitted to ICU and intubated as required, to those who have entered a phase of 
terminal respiratory failure in whom intubation might be considered most likely merely 
to prolong the process of dying (Figure 12.4.2). If clinicians taking part in the study 
consistently admitted only patients with an excellent chance of survival with ICU, only 
patients in the left hand portion of the continuum in Figure 12.4.2 will have been 
recruited to the study. A model developed only in the left hand portion of the population 
used to make predictions about those patients in the right hand portion (the sickest 
patients) would be likely to be over-optimistic. 
However the degree of consistency in selection will have an impact on the 
consequences for risk factors identified in the model development process. Suppose 
there were data on only 2 risk factors, age and sex, with women on average having 
poorer outcomes. Doctors might consistently only admit women who had the same 
prognosis at given a age as men, i. e. they might be more selective of women than men. 
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Then sex would not emerge as a factor in the model. Applying the model in the wider 
population would lead to optimistic estimates for women. 
Another scenario helps to illustrate the complexity of selection. Suppose that half the 
doctors take sex into account and half do not. On average the women in the study will 
be healthier than the wider population, although not as healthy as the men in the study. 
Sex will appear in the model as a factor, but the weighting will be underestimated. 
Suppose anyone over 85 has a survival rate below the threshold at which clinicians 
switch from admitting to not admitting Most doctors will not admit them, but as long as 
those that do admit them pick over 85s who are not unusually healthy, the model will 
give advanced age the correct weighting. 
Figure 12.4.1 COPD patients considered for ICU admission 
Unlimited 
Functional 
Capacity 
Very limited 
functional 
Capacity 
124.3 Evidencefor selection in the CAOS sample 
Some light can be thrown on the types of patient likely to have been 'selected out' of 
the CAOS study by considering the factors associated with treatment limitation for 
Good Moderate Poor 
chance of Chance of chance of 
survival survival survival 
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patients who were included. Also there are some data from other studies about the 
characteristics of the broader population of patients with exacerbated COPD, and these 
can be compared with data on the CAOS subjects (section 9.7.1,9.7.6. iv and 9.7.6. v 
above). These comparisons suggest that selection did occur with a tendency for older, 
frailer patients to be less likely to be admitted to ICU and thus to enter CAOS. This 
finding is consistent with the suggestion in the Heart of England Critical Care Network 
Study that in the UK a historic lack of ICU beds has lead clinicians to form a nihilistic 
view of the prognosis of COPD patients to minimise the cognitive dissonance that 
would otherwise arise if patients were felt to have a good chance of survival with ICU, 
yet no ICU beds were available. However with hundreds of judges making decisions in 
95 centres selection is unlikely to be consistent. 
12.4.4 Baseline risk in 1he model 
The baseline risk for the CAOS ICU patients will be lower than for the wider 
population of COPI) patients if there are important prognostic factors that are not 
included in the model, and which are under-represented in the ICU population. The 
initial selection of variables in the model was based on the scientific literature and 
SUPPORT, the best of these studies, was a total cohort study that developed a risk 
adjustment model on all patients admitted to hospital irrespective of whether they were 
admitted to ICU. It is noteworthy that the distribution of ADLs in the SUPPORT study 
was higher than in CAOS suggesting that patients with greater numbers of ADL 
impairments tended to be selected out of the CAOS study. 
However there is good reason to believe that there is a good deal of variation in ICU 
selection processes. In the wider medical literature it is reported that even when there 
are reasonably clear criteria about the appropriateness of treatments, some patients who 
according to accepted criteria should not receive a treatment do receive it and some who 
should receive the treatment do not. In Hemmingway's study of coronary artery bypass 
graft surgery (CABG) in patients investigated by angiography, 23% of 992 patients who 
underwent CABG had indications for CABG rated as inappropriate or uncertain3l. In 
the case of decisions about which patients with COPD should be intubated, the available 
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recommendations are vague ('The decision on which patients with exacerbations of 
COPD who will benefit from intubation is difficult and involves balancing health status 
with an estimate of expectation of survival 94) , and the majority of studies that might 
inform predictions of outcome are of poor quality with highly variable estimates of 
survival (Figure 3.3.1). In the Heart of England Critical Care Network study of 
clinicians who had made a median of ten (IQR 6.0-20.0) intubation decisions in the 
previous 12 montliss, different decisions were made for COPD patients with identical 
characteristics and identical preferences, in the face of identical availability of 
resources. The Heart of England clinicians also varied widely in their opinions about the 
hospital survival rate at which they would move from admitting to not admitting a 
patient with COPD to ICU; some clinicians suggested that they would intubate patients 
even if they thought they had a 90% probability of hospital mortality. 
One of the strategies in CAOS for limiting the effects of selection bias was to recruit 
from a large number of ICUs so that it was likely that any single unit would recruit only 
a small proportion of the total patients and any individual clinician even smaller. 
Variation in overall unit clinical thresholds, in individual decision-maker thresholds, 
and in the consistency in the operation of these thresholds would be expected to result in 
all the patient types that some clinicians somewhere would consider admitting having 
been recruited to CAOS. With 95 units contributing patients it seemed likely that this 
inconsistency in gatekeeping strategies would mean that the recruited patients would be 
spread along most of the continuum of severity (Figure 12.2.1), even if their distribution 
along this continuum was not representative of the wider population of people with 
exacerbation of COPD. On this basis it can be argued that the model is unlikely to have 
omitted important prognostic factors entirely. 
Thus with at least 95 judges all making independent decisions, it seems likely that 
selection will have been inconsistently applied; high risk groups will be under- 
represented but not totally unrepresented, and the main prognostic factors should have 
been captured by the model. One outstanding question is whether any of the factors that 
were rejected because they were difficult to measure might otherwise have had material 
prognostic value. 
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IZ4.5 Risk sveightingsfor predictors in CA OS and SUPPORT compared 
Though it might be hoped that comparison of the weightings given to risk factors that 
arc common to the CAOS model and to the best total cohort study in the literature 
(SUPPORT), might give a rough indication of whether CAOS is correctly weighting 
risk factors, such comparisons arc bedevilled by problems of selection. In SUPPORT 
the patient population were less sick with only 51% requiring ICU admission compared 
to 100% in CAOS. Table 12.4.5 below illustrates that the point estimate of risk in 
CAOS pcr 10 year increase in age is higher than in SUPPORT though the 95% 
conridcncc intcrvals overlap. This is consistent with the patients in CAOS being sicker. 
It is interesting that the point estimate of the risk with increasing age is actually lower in 
the patients not for intubation presumably because younger patients selected not for 
intubation arc biologically older than their chronological age. 
I'his comparison highlights that the modd will only bc accuratc in a population with 
idcntical inclusion critcria. 
Table 12.4.5 Age related mortality risk in CAOS and SUPPORT 
SUPPORT* CAOS CAOS CAOS 
1016 832 'for intubation' 'no intubation' 
651 patients 181 patients 
Age 1.30 1.68 1.67 1.43 
(Per 10 years) 
1 (1.14-1.47) 1 (1.44-1.97) (1.39-2.01) (1.03-1.98) 
* SUPPORT presented risk as aI lazard ratio, in CAOS the risk is odds of death at I 80-days 
12.4.6 Ixad linic bias 
Lcad time bias can be important in risk scoring, and the CAOS score does not allow 
weighting for acute physiology measured aftcr a period of NIV during which the patient 
continues to deteriorate. This means that the score may be over optimistic in patients 
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who deteriorate despite many hours of NIV. Consequently though the use of the 
intubation variable gives some idea of what the patients' prognosis would be if they 
were to b, -- intubatcd. The limitations of the observational design of the study mean that 
unmcasurcd selection processes may have influenced the use of intubation for patients 
trcatcd %%ith NIV who deteriorate after ICU admission. 11c acute physiology measured 
prior to ICU %vill be likely to be different to the patients' acute physiology aftcr a period 
of unsuccessful NIV. For this reason survival probabilities after intubation are likely to 
be relatively robust for those patients intubatcd at the time of ICU admission. 
Probabilities orsurvival that estimate the likely survival of a patient admitted to ICU for 
NIV %ho subsequently requires intubation should be considered extrapolations that go 
beyond the data collection methodology of CAOS and should be treated as highly 
speTulativc. It is most likely that estimates of survival if intubatcd, for patients who are 
not intubatcd immediately (i. e. if patients deteriorate despite treatment in ICU) will be 
optimistic since the model does not take account of deterioration despite treatment 
%%hich as mentioned above is a form of lead time bias that typically has an important 
influence on risk adjustment models. 
IZ4.7 The role ofnon-invasive ventilation 
As discussed in section 3.4.17 systematic reviews have suggested that non-invasive 
ventilation (NIV) is the optimal first line treatment for patients with Type Il respiratory 
failure due to exacerbations of COPD 3 119120 . though there are some limitations to the 
gencralisability of thcsc rcsults bccausc paticnts who rcquircd immcdiatc intubation 
wcrc cxcludcd prior to randomisation. 
At the time CAOS uus carried out, some units did not have NIV available or had NIV 
availablc intcrinittcntly, and so somc paticnts would havc becn intubatcd who might 
havc been succcssfully managcd with NIV. 
As discussed in section 12.2 the application of the CAOS model to patients who have 
dctcriorated dcspitc hours or days of NIV might be prone to error because the 
prognostic significancc of the acute physiology score is likely to be different for patients 
who have had hours of treatment with NIV compared to those who are largely 
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untreated. The CAOS dataset did not provide for a distinction between acute physiology 
measured before, during or after NIV, and users of the CAOS model should bear in 
mind that if the acute physiology used to compute the CAOS model probability follows 
many hours of failed NIV the predictions may well be overoptimistic. 
12.5 CAOS in practice 
125.1 Implications ofselection biasfor the use ofthe CAOS model 
Perfect prediction of outcomes is not possible, and a judgement about the appropriate 
role of the CAOS model in decision making cannot be made without a careftil 
consideration of the alternatives. A decision-maker attempting to decide whether a 
patient with COPD will benefit from intubation has only four alternatives, to use 
clinical intuition alone, to use CAOS alone, to use CAOS alongside clinical intuition or 
to conclude that since all predictions are uncertain the appropriate response in the face 
of uncertainty is to institute life supporting therapy in all cases and then reassess. It 
should be remembered that clinicians' predictions arise from an intuitive model 
developed from their experience, and their interpretation of the evidence base. The 
evidence from studies of human decision-making makes it clear that human decisions 
are not free from bias (section 1.5) and in Table 12.5.1 below the biases affecting both 
the CAOS prognostic model andan individual clinicians' intuitive prognostic model are 
compared. 
This suggests that though predictions derived from the CAOS model will have 
limitations, the major competing probabilities that come from a single clinician's 
intuition are likely to be even more influenced by selection and other biases. The 
results of both CAOS and SUPPORT 12 demonstrate that when clinicians and the model 
make predictions for the same patients the prediction models show better discrimination 
and calibration. It is likely therefore that, for the type of patients used to develop the 
CAOS model, the best prognostic estimates are likely to be obtained when the CAOS 
model is used alongside clinical judgement. This assertion is consistent with the 
findings of the SUPPORT study, where the most accurate predictions occurred when 
clinical judgement and the SUPPORT model were used together 12 . 
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However there is strong evidence that selection has played an important role in the patients 
included in CAOS, and this must be borne in mind when applying the model. For example, 
comparison with SUPPORT suggests that patients with ADL impairments were unlikely to 
reach ICU in the UK (section 8.5.1) and this highlights the fact that the CAOS has model has 
been developed on patients selected to be less frail than the total population of COPI) patients 
admitted to hospital. Users of the CAOS model should be aware of the limitation that selection 
has imposed on the model, and recognise that patients who would tend to be rejected by many 
ICUs will not have contributed to the CAOS model and that the model is likely to be 
overoptimistic if applied to such patients. These will tend to be the patients with multiple 
comorbidities, impaired ADLs and/or on LTOT. 
12.6 Future research 
It will be clear that though the study had the advantages of recruitment across many units only 
53% of all units took part and only 40% of eligible patients were recruited. This has the 
potential to introduce bias. Only around 40% of the patients eligible for CAOS were recruited 
and section 5.3.1 to 5.3.6 shows that there were no systematic differences in the ICU mortality, 
acute physiology score, age, sex, day or hour of admission between patients eligible for CAOS 
and those actually recruited and it seems most likely that patients were missed at random. There 
were a limited number of data collectors in each unit who would typically work shifts and it was 
found that when these unit "champions" were away patients tended to be missed. Nevertheless 
since the model has only been developed in a subset of all the units in the UK and in a subset of 
the patients admitted to those units, selection bias in the patients recruited to CAOS cannot be 
excluded. In addition as section 12.4.1 above makes clear it is inevitable that selection has 
occurred in that patients admitted to CAOS had to be selected to enter ICU. The fact that CAOS 
model was produced on a subset of all UK COPD ICU admissions and that selection was 
involved in making the decision about which patients actually entered ICU means that external 
validation of the model is particularly important. External validation will need an adequate 
sample size (In order for the validation to be meaningful Harrell suggests the sample needs to 
contain around 100 eventS33, in England, this would be likely to require 95 units collecting data 
for 9 months, or 48 units collecting data for 18 months) and until advances such as the 
electronic patient record allow automatic data collection such a study will be a major 
undertaking. This makes it clear that the next step is for a validation study to be carried out in 
which the raw data collected in CAOS is collected in a new sample. This will allow validation 
of the original score to be carried out and also offers the potential to allow the score to be 
recalibrated if behaviour is changing. 
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Table 12.5.1 Implications of bias: clinical intuition and CAOS compared 
Bias CAOS Impact Clinical intuition Impact 
Selection 651 "decisions"by Patients from Typical ICU Any individual 
bias > 95 individual much of the admits 400 will have "learrit" 
decision makers continuum of patients per year of from a narrower 
with evidence of severity might be which 2.5% are range of patients 
only moderate expected to be COPI) patients; so than the model and 
discrimination selected so that that in an average will have been 
(ROC 0.7 1) with final model will year a hospital operating only 
studies suggesting have been might intubate their own selection 
that clinicians influenced by around 10 COPI) criteria and so 
stated admission characteristics patients & an their intuition will 
thresholds can across the individual many be likely to be 
vary from spectrum. less. Even if a informed by a 
admitting patients Adjusting clinician admitted more selected 
with predicted calibration by and remembered sample than 
hospital mortality bootstrap estimates all 10 of these CAOS. 
of 90% to of alpha & beta patients in 5 years 
predicted mortality will increase only 50 patients 
of 45%8. contribution of would be sampled 
relatively rarer using one 
characteristics in clinician's 
final model. selection process. 
Availability Predictors in Model can take The cues selected A limited number 
bias in CAOS identified fair account of will be the ones of cues are likely 
identifying by systematic independent remembered to be used with 
predictors review of literature contribution of possibly from a weights that have 
and independently multiple cues non-systematic not been 
weighted in model recollection of the systematically 
literature and the developed. 
weight given to 
individual cues 
may be biased by 
patients who are 
memorable 
because they did 
particularly well or 
badly. 
Incomplete 180 day follow-up Outcome 180 day follow-up Feedback on 
follow-up was complete predictions use all for all patients association 
information. unlikely to be between 
complete predictions and 
outcome unlikely 
to be complete 
leading to poor 
calibration. 
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The outcomes in the group could then be assessed without the problems of selection and 
if outcomes were deemed satisfactory the exercise might be repeated extending the 
inclusion criteria to a sicker group. 
12.62 Strategies to deal with the effect oftreatment 
Many patients will be considered for intubation after a period of unsuccessful NIV 
(section 12.4.2). The CAOS study did not collect data on the duration of NIV prior to 
intubation, nor was it possible to determine whether the acute physiology was measured 
before or after a period of NIV. Not collecting this data was a pragmatic decision in 
order to keep data collection simple and quick; the data collectors were all volunteers 
who collected the CAOS data in addition to their normal duties. If sufficient resources 
could be obtained, future studies might also be designed to take greater account of the 
effects of NIV on the acute physiology used in the model by carefully documenting the 
duration of any NIV delivered before or during the measurement of the CAOS acute 
physiology score. 
IZ63 Evaluation ofthe CAOSscore in clinical practice 
Evaluation of the CAOS score in clinical practice is not straightforward. Harrell 
suggests that a data set with at least 100 events would be required (section 2.8.1 above). 
Given that 95 units recruiting patients for around 18 months yielded 221 deaths, an 
adequately powered evaluation study will be a major undertaking. This is an important 
problem in the use of prognostic scores, and improvements in the quality of routine 
data, perhaps via evolution of the electronic patient record, might eventually make 
ongoing evaluation of scores a more feasible proposition. In addition changes in 
practice are likely to affect the performance of scores, especially in terms of calibration, 
which is another reason why readily available data to carry out evaluation of prognostic 
scores are so important. 
12.6 4 More sophisticated modelling strategies 
Given a certain data set there will often be several models that fit the data equally well. 
In the development of the CAOS model as far as possible it was attempted to use data- 
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independent methods in variable selection. However more sophisticated approaches to 
variable selection are now being developed that may make models more generalisable. 
For example bootstrap methods can be used in variable selection and such an approach 
might go some way to minimise the impact of the case mix of the model development 
data set on the variables selected 143 144 . Such sophisticated modelling approaches were 
not possible within CAOS, but would certainly be worth exploring in the future. 
12.7 Conclusions 
CAOS has shown that data readily available prior to ICU admission have the potential 
to give fairly accurate predictions about the 180 day survival of patients with COPD. 
Follow-up of patients suggests that despite many symptoms of airways disease the 
majority of survivors would want to go through ICU again. Clinicians were less well 
calibrated than the model with a tendency to pessimism. The major drawback of the 
CAOS model is that it has only been developed on patients selected for ICU. This 
means that caution should be exercised when using it. Clinicians should be aware that 
the model has mainly been developed on patients without impairments of daily living 
and that it will tend to give falsely optimistic predictions of outcome for frailer patients 
with multiple comorbidities. A sensible strategy would be to suggest that it would be 
appropriate to use the model alongside clinical judgement to predict outcome for COPD 
patients assessed outside ICU, with the caveat that selection bias should be borne in 
mind, and that the model should only be used for patients whom at least a significant 
proportion of clinicians would consider appropriate for ICU. 
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Appendix 1 
Sensitive search strategies, studies describing the outcome for COPD 
patients 
Appendix I 
Sensitive search strategies to identify studies describing the outcome for 
COPD patients 
Ovid Medline sensitive prognosis filter 
1) exp Incidence 
2) exp Mortality 
3) exp Follow-Up Studies 
4) mo. fs 
5) prognos$. tw 
6) course. tw 
7) predict. tw 
8) or/1-7 
9) exp lung diseases, obstructive 
10) 8 and 9 
Ovid Embase sensitive prognosis filter 
Taken from the CASP website 
http: //www. phru. nhs. uk/casp/filters. htm#ftndinp, filters and accessed 2.3.04 
1) incidence/ 
2) exp mortality/ 
3) cause of death/ 
4) fatality/ 
5) survival rate/ 
6) follow up/ 
7) prognos$. tw. 
8) predict$. tw. 
9) course. tw. 
10) or/ 1 -9 
11) exp chronic-obstructive-lung-disease 
12) 10 and II 
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Appendix 2 
Letter to CMP units from Dr Kathy Rowan 
ICNARC 
Intensive Care National Audit & Research Centre 
12 November 2001 
<(DIR_TITLE)> <(DIR_INIT>> <OIR_SURN)> 
((DIR PRF)) 
<(UNIT)) 
((HOSPITAL>> 
((ADDRESSI)) 
((ADDRESS2>) 
((TOV; N)> 
vCOUNTY)) ((POSTCODE)) 
Dear ((DIR_TITLE>> ((DIR_SURN>) 
Research and the Case Mix Programme 
Through a broad programme of research, ICNARC is seeldng to help critical care 
practitioners by encouraging and supporting collaboration between individuals/units 
with similar interests. In relation to this, I am pleased to announce a new research 
project to run in parallel with the Case Mix Programme. The project is a 
collaboration between units participating in the Case Mix Programme, ICNARC and 
the Health Services Research Unit, London School of Hygiene & Tropical Medicine. 
The initial details of this project are outlined below. 
COPD andAsthma Outcome Siudý, (CAOS) 
The aim of this Study is to investigate the factors that affect the short- and medium- 
term outcomes of admissions to critical care units with COPD and asthma. These 
conditions are likely to represent less than five percent of admissions to most units. 
By collecting a minimal amount of additional data, over and above those collected for 
the Case Mix Programme, we hope to provide important prognostic information to 
guide patients, relatives and clinicians. The Study will be co-ordinated by Dr Martin 
Wildman, Medical Research Council (MRC) Training Fellow in Health Services 
Research and Specialist Registrar in Respiratory Medicine. 
We hope you will want to participate in this new and exciting project. Please register 
your interest, or not, by completing and faxing the enclosed form to ICNARC. The 
Study Co-ordinator will then send you more detailed information. 
Yours sincerely 
lz 
Dr Kathy Rowan 
Director 
Enc 
Intensive Care National Audit & Research Centre 
Facsimile 
To: Dr Kathy Rowan 
Company: ICNARC 
Fax No: 020 7388 3759 
From: ((UNIT>>, ((HOSPITAL>> 
Date: 21 January 2004 
Re: Research and the Case Mix 
Programme register of interest 
Number of pages (including this one): I 
Please indicate below whether, or not, your unit is interested in collaborating in the 
new research project to be run in parallel with the Case Mix Programme: 
Yes No 
COPD and Asthma Outcome Study (CAOS) F-I F] 
Please supply your contact details to enable the Study Co-ordinator to send further 
information: 
Contact name ............................................................................ 
Contact address ............................................................................ 
fax 
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Appendix 5 
GP correspondence 
ICNARC 
Supported by the 
Intensive Care National Audit & Research Centre MRC 
Medical Research Council 
CAOS' 
Dr Martin Wildman. 
CAOS study Co-ordinator, 
CAOS Co-ordinating Centre, 
Heartlands Research Institute, 
Birmingham Heartlands Hospital, 
Birmingham, 
B9 5SS 
martin. wildman(&lshtm. ac. uk 
Tel. 0121424 2644 
Dear Dr 
I am writing to you on behalf of the COPD and Asthma Outcome Study (CAOS) steering group to ask for 
information about Date of Birth: admitted to Hospital 
on We wish to determine whether is alive / dead. 
We would hope to telephone your surgery and confirm these details with your receptionist in around 14 days time 
if that meets with your approval. 
The aim of the study is to develop an outcome model to predict intensive care, hospital and 180-day survival for 
patients admitted to intensive care with acute respiratory failure due to chronic obstructive pulmonary disease. We 
are also including patients over the age of 45 admitted to ICU with asthma. Diagnostic difficulty sometimes means 
that older patients labelled as asthmatic actually have COPD. There is some evidence that older asthmatics 
admitted to ICU have similar outcomes to COPI) patients and subgroup analysis of the asthmatics will allow us to 
investigate this. 
We are collecting information on patients with acute respiratory failure admitted to Intensive Care units throughout 
England and Wales with the aim of recruiting around 750 patients during the one-year recruitment period. Patients 
are then followed-up 180 days after intensive care to establish their vital status and the health related quality of 
using the well validated EuroQo1 and AQ20 questionnaires. 
The CAOS data has been collected with patient identification data in order to allow the CAOS centre to carry out 
180-day follow-up. The non-anonymised data has only been handled by Dr Martin Wildman the Research co- 
ordinator and the research nurse who are both governed by their respective professional bodies confidentiality 
procedures. The questionnaire sent out to the patient will only carry the patients study number. Patient 
identification data is kept separate from patient study data at the study co-ordinating centre and all analyses and 
publications will only handle fully anonymised data. 
We will enclose a consent form for patients receiving questionnaires and obviously patients will be free to not 
return questionnaires if they do not wish to do so. Patients were also given an information sheet explaining that we 
would contact them before they were discharged from intensive care. 
The study has been considered by the MREC and they are satisfied that patient confidentiality and consent has 
been dealt with appropriately given the difficulties of obtaining consent fi-om severely ill patients on Intensive 
Care. A copy of her consent form is enclosed with this letter for your information. 
, OS 
Co-ordinating Centre , Heartlands Research Institute Lincoln House - Birmingham Heartlands Hospital - Bordesley Green East - Birmingham B9 5SS 
I:: ' - ýA, . T- A V) I AIA I Al 111614 , P- A V) I AIA I Ald 
ICNARC 
Supported by the 
Intensive Care National Audit & Research Centre MRC 
Medical Research Council 
CAOS' 
I hope you will feel able to provide the information we require. If you have any questions about the details of the 
study I can be contacted at the MICCOS co-ordinating centre. 
Please note we will follow-up this letter with a phone call in 2 weeks time and if y2u- agree to help all you need d 
fients notes for 3Rur repoýonist to release the rMuired information. is aM6 the enclosed slip to the 2at 
Many thanks 
Yours sincerely 
Dr Martin Wildman 
CAOS Study Co-ordinator. 
,, 
OS Co-ordinating Centre * Heartlands Research Institute - Lincoln House - Binningham Heartlands Hospi I- Bordesley Green Ea - Bi nm B9 5SS r ta st rtru gha 
--L- . T- 0 1) 1 AIA 14111141A P- n V) I AIA 1 AAA 
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Appendix 6 
CAOS Newsletter 
4 
CALOS 
Issue 3 COPD and Asthma Outcome Study February 2003 
Well done - 500 patients 
Inside this issue: 
recruited! 
Well done! 
0 Crýme de la 
Despite relatively mild weather over Christmas, you have 
creme 
CAOS-progress 
kept the data coming. CAOS biscuits go to Royal Preston so far 
Hospital who faxed us data on a patient on Christmas Day ti Any ques ons? 
and to Bedford Hospital who faxed us data on a patient on Recruitment 
New Years Day... by unit-Dec 2002 
to mid-Jan 2003 
Crýme de la crýme - 100% total CA OS Voices &om the trenches 
Congratulations to those units who have not missed any Notices 
patients. COPD patients are admitted intermittendy but 
most units are succeeding in keeping up with every single 
patient admitted. Well done! Contacting us 
CA OS - progress so far For more 
information, please 
contact Dr Martin Wildman 
CAOS Co-ordinator- at 
Total to date 
martin. vAidman@lshtm. ac. uk 
7 0770 2 123 64 or on 
or 
Ms Jayne Groves 
500 patients 
CAOS Research Nurse - at 
Jayne. Groves@heartsol. 
recruited so far wmids. nhs. uk or on 0 121424 2644 
Any questions .... 7 
Does it matter if we can't fax the data within 24 hours? 
The earlier you send us the data, the quicker we can check it. This 
means that ambiguities can be sorted out while the patient is still 
in your unit. However, don't wony if you can't get it to us within 
24 hours, send it as soon as you can. 
Missing patient competition... 
Thanks to I hose Ol'you who 
have told us how you manage 
1c) cocruit. all eligible patictits. 
Keep Your suggestions comilig 
and we will post the witinirig 0 
"n'111111erits irl the "Vnin's Fr(ým 
Ihe it-eiiches" 
Recruitment by unit-Dec 2002 to midjan 2003 
... 
We never miss any 
patients. The CAOS box is 
in the middle of the unit 
and everybody is aware 
and keen... " 
Diane Murchison and team 
Cumbeiland Royal Infirmary 
I Carlisle 
to whether or not to include a patient, please contact us on: 
0121424 1631 oroutof-hours on: 07702 123764. 
CA OS prizes... 
till not too 'late to join ýoi 4001h patient - details of how to create CAOS. The team at Trafford I lospital. 
ýontact D1 Mardn 'ALdirian at the 500'h patient - CAOS Co-ordiriaiing Centre. The tearn at Prince Phillip I lospital, Llanelli 
Christmas Day fax - The team at the Royal Preston Hospital. 
No need for dreary walls. If you 
New Years Dav fax - flie team at Bedfiord I lospital. 
want more CAOS posters, Missing patient competition - please e-mail us and we will Cameron Ingrain at St james' Hospital, Leeds. 
send you a pdf poster file Diane ', vturclilson and leamat Cumberlancl Roval Infiniiarv 
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Appendix 7 
CAOS Poster 
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Appendix 8 
Letter of MREC approval 
Our Ref JR/MT/NIREC/0117/53/approval 
Dr Martin Wildman 
MICCOS Co-ordinating centre 
Heartlands Research Institute 
Lincoln House 
Heartlands hospital 
Bordesley Green East 
Birmingham, B9 SSS 
Dear Dr Wildman 
3 September 2001 
Research Protocol: Outcome prediction and gatekeeping strategies for chronic 
obstructive pulmonary disease Patients in intensive care 
StudyPýWocol, amended 31'August 2001 
Protocol Amendment Na 1 dated 31" August 2001 
Letter to GP with enclosure to append GP PatientNotes, version 3 dated 31'August 2001 
Patient Information Booklet to be given to Patient at Discharge, version 2 dated I Oh August 
2001 
Patient Information Booklet to accewnpany Questionnaires at six-monthfollmi-, up, version 2 
dated 10h August 2001 
Application Form, dated 4 July 2001 
Letter of Indemnity, dated 3 July 2001 
C V, dated July 2001 
Patient Consent Form, dated 26 June 2001 
Patient Invitation Letter, undated 
Data collection joi7n, undated 
Questionnaire, undated 
The West Midlands MREC reviewed your application on 25ýh July 2001 and agreed that there is 
no objection on ethical grounds to the proposed study. I arn, therefore, happy to give you our 
approval on the understanding that you will follow the conditions of approval set down below. 
A record of the review undertaken by the MUC is contained in the attached MREC Response 
Fonn. The project must be started within three years of the date on which MREC approval is 
given. 
While undertalcing the review of your application the NIREC noted the research involves the 
use of an existing database collected for previous research or other purposes with subsequent 
patient contact patient. For this reason you are asked to read carefully the sections 
concerning LREC involvement and local NHS management set out below as there are 
specific requirements involved when undertaking such research. 
MREC Conditions of Approval 
No research procedures are undertaken until the appropriate local research ethics 
committees is informed of the research including the name of the local clinician involved. 
The local clinician must inform his/her NHS organisation of their co-operation in the 
research project. 
The protocol approved by the MREC is followed and any changes to the protocol are 
undertaken only after NIREC approval. 
If projects are approved before funding is received, the N4REC must see, and approve, any 
major changes made by the funding body. The N4REC would expect to see a copy of the 
final questionnaire before it is used. 
You must promptly inform the IVIREC of 
(i) any changes that increase the risk to subjects and/or affect significantly the conduct 
of the research; 
(ii) any new information that may affect adversely the safety or welfare of the subjects 
or the conduct of the trial. 
You must complete and return to the NIREC the annual review form that will be sent to you 
once a year, and the final report form when your research is completed. 
LREC involvement 
When undertaking the review of your project the NIREC observed that there is/ limited patient 
contact by a local clinician who is performing technical procedures or additional data 
collection as described in the MIREC approved protocol/ initial contact by a local clinician for 
purposes of recruitment. It is felt that these tasks appear well within his/her routine 
professional competence and adequate facilities for such procedure are available as part of 
his/her normal professional practice. 
For this reason you are asked to only inform the appropriate LREC of the project by sending a 
copy of this letter and also giving the name and contact details of the local clinician 
involved. If (unusually) the LREC has any reason to doubt that the local clinician is 
competent to carry out the tasks required, it will inform the clinician and the NREC that gave 
ethical approval giving full reasons. 
You are not required to wait for confirmation from the LREC before starting your research. 
Local NHS Management 
The local clinician must inform his/her NFIS organisation of their co-operation in the research 
project and the nature of their involvement. Care should be taken to ensure with the NHS 
organisation that local indemnity arrangements are adequate. 
Legal and Regulatory Requirements 
It remains your responsibility to ensure in the subsequent collection, storage or use of data or 
research sample you are not contravening the legal or regulatory requirements of any part of the 
UK in which the research material is collectedý stored or used. If data is transferred outside the 
UK you should be aware of the requirements of the Data Protection Act 1998. 
ICH GCP Compliance 
The NIRECs are My compliant with the International Conference on Harmonisation/Good 
Clinical Practice (ICH GCP) Guidelines for the Conduct of Trials Involving the Participation 
of Human Subjects as they relate to the responsibilities, composition, function, operations and 
records of an Independent Ethics Committee/Independent Review Board. To this end it 
undertakes to adhere as far as is consistent with its Constitution, to the relevant clauses of the 
ICH Harmonised Tripartite Guideline for Good Clinical Practice, adopted by the Commission 
of the European Union on 17 January 1997. The Standing Orders and a Statement of 
Compliance were included on the computer disk containing the guidelines and application 
form and are available on request or on the Internet at www. corec. ortz. uk 
Yours sincerely 
Maureen Thrupp 
Administrator, MREC West Midlands 
Enclosures M? EC Response Fonn 
Annual Review Fonn 
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CAOS information sheets 
" 
-' 
."": " "" 
": ©* ": 
I 'Z ,,., ý"ý; ý' , 
Q 
-0 r 
cz 
112, 
-E 
El 
4ý 
C) C) 
cl (u La C) 
C) 0 
9 Z: 0 , ci 
-0 j-. ' 
2- U= (A (§ fl (4) 
IU 
.o 
E -2 ýý E 
. !Z u- = 
-0 
= CN - 
r- 
r- 
. - Z 
"2 m 
ý: 0 CD 
ce 
CD 
U v) 
191 
m0ýt -2 
eý ri -a 
"c2 
u ýe = 0. CD -tm9e- ýo 
r14 ý6i A=gu c) - 
Z ý, =08 rm 
-a 4) 4. ) r- cu -8=Ee: ü 
", -2 
T Li r£ ' 2 -, 3 L) r- ,0ýý: *ý u8 L) ýg-- :2Z _cz 
cý 
u -ac 
e=e 
r- -a U r- b, F, -= 
J-- 2e Co m EO 
Mu 
-=M 
CL) t- 
cm 
t= r- --, -, Fww940 
c: j.. -U *- r, 
> ý>ý 2ý 
(t. o« ý :2, X. e- 0= 41.0 -m 44 
.2 - 35gß. -- > cc to 50 .- 
(L) = -a z2 1u2 ui CD cc 
cu Z ý- uukZ0e: ,-Ue0 (A -0 = r- 9 ig CD C. ) mu lE >, E -ý F- , -, ý ZQua 
u-E Im - 0; cz ui 
E. 
ci 
92 Z .->= -a -ý r- u 'b' 2Z .- :E r- ü *Z ýg > IM e-2 (D ce ZM>, e- r_ - 0) = r= cc (U >, cu -- E> C-e >ý u "0 ;. ý: ýS r- eu- ic ,E ýp -- »7 r= 8 .! Z Z >ý -: s 9Qb1. ýM -- . >- .3 "iý-9 
= c:. > P- g) >, m 21 4ý 0 ,u-g 
> 
22 x. 
c2. WA 
M cu 
=S. Wo ý -U cuE r=I -': L 
r. 01) rm CU :2= 
ý- _x a. (U '5. * CU c2,. 2 =i r=0mý99c: E tu 0 . - CL. riz M> ci 0 
9E -0 >, >d, im -c - 01., 4 -. -mA 
Gn 
>, =, . 
- 
Le 
10 r- ý, ýg. 12: 2 ic ý r_ m r_ im m. ca im 0-c Jm uý >, 0 4) 2 Co .2 ; ý, 0- Uu (U - 
-ci 4) 0 e- =Z 
8 03 'EL 0 cý CL c_ . rE 1et-g --- e E cý -e x. Itt 8ým3>, eT*ý u> ü8 ýa 
ii ., 
Wr- a 
e iz r- u2! 5 >O, §4 c8 -0 -, - eu (U 
-r (= m 
ri 
. 
*E c; u .ý 
m 
u tE tz 
, - -5 0 
r_ 
cm 
S 
>, 05ýE5>>0 
cu 0uZ 
ce - 
rz 2 0* 
44 2m e2-5: Am-. -dm IL) cz r. -2 .-u IE - c:, - Im m Z: *c 00 r- e88. on ý: -- -2 .51.2 9,2 >, 0. ) b. U0 FI 0 t;. - 6 
1C3 ,983E5Ec 
*e .; 3 8-u 0 c2. -S>, 
S -0 E- 
u2 l., ' t2 e- .- 
:ý 
it, 
ib-. 
>, -- - -9 =a 10 
., Lý- 
ýc >. u0m :3 : ýj -22 ,-ge-*- cýZ, lE 
m. -s ýr- -92, -2 e ci, 
:9=c-u ýn 0c t- 8, e- 0 -ý 
3 r- c. c2. 
"t3 tu ci 0 
,uu. -2 
>ý 
S. - 13 c!. 2. -2 ME-N mZý; Ei 113 ZS ,0->, =>e-2-ý-- .- ri 8 r- u m. m, cz. 
E -0 
CD. -U jz *e 0M c6) 2ý:: g 18 - 
.2qg2-00=,,,,, u r- äi ac -ý 'u -0 
j9 :22U. Z0 eý r 
0 05 
.-g. -5 1-- =' 
'ý> 
- -m in 
082 c2. A0E -2 
ýq 0Z0u 
r- &m ý3 'ý -a .-g .-eC. U 2 -5 
8 --s EI, :E -&--) >ý -0 - 9-2- ;,. - ý= mm 2 119, ýu2--- r- 2 J-- ýd ý2 Cu J-- Q ce 9 -a Z. -5 ,ý2 2 '> 
22 
im 0 CD :9 zo: -2 cu E5 Jr-, ; -r- -. eeg -gcu ý: >I, 
10Z *= 
- lwl> = ý= 
: "* 
gz. CZ. 4 
. J, 
ICNARC 
Intensive Carc National Audit 4: Reicarch Centn: 
CAOS 
Sup; x, mcd b. % th.., 
MRC 
Medi, ml Rescirch 
Patient Information about the COPD and Asthma studý 
Patient name .................................................... Date of birth .................................................... Address 
.......................................... ...... ... ......... ......... 
(or allik p. aitit lalwl) 
The above named patient NN. -ho has been looked after in our critical care 
unit was given a COPD and astlinia outcome study information booklet 
bel'ore leaving critical care. 
Sig, I led ................................................. (for critical care unit) Please print name ....................................... Dt A&TE ..................................................... 
I linve received an information booklet that explains that I will be 
contacted about 6 niontlis aRer I IN-ave hospital to see how I am feeling. 
si.................................................. (Patient) 
PLEASE FAX THIS FORM TO THE COPID AST H%MA O\'IE STUDY 
0 121 42-Ir 16' 54 AND THEN FILE IT RNTHE PATIE NT'S NIOýTES 
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Multi-Centre Intensive Care Outcome Study Coordinating Centre 
Heartlands Research Institute, 
Birmingham Heartlands Hospital 
Bordesley Green East, 
Birmingham 
B9 5SS 
Tel 0 121424 2644 
Dr Wildman Trial coordinator 07702 123764 
Consent Form 
Title of Project: Multi-centre study of outcomes after Intensive Care. 
Name of Researcher: Dr Martin Wildman Please initial box 
i) I confam that I have read and understood the 
information sheet for the above study. I am aware ofthe 
contact phone number to ring if I wish to ask questions 
and know that I am welcome to use it if I wish. 
2) 1 understand that my participation is voluntary and I am 
free not to take part withoht giving any reason, without 
my medical care or legal rights being affected. 
3) 1 understand that sections of any of my medical notes 
may be looked at by responsible members of the study 
team or from regulatory authorities where it is relevant to 
me taking part in research. I give permission for these 
individuals to have access to my records. 
4) 1 agree to take part in the study. 
5) 1 agree for information held by the NHS or records used by 
the General Register Office to be used in order to follow up 
my health status. 
Name of patient Date Signature 
Please return this copy of the Consent form with the questiommm m the FREEPOST envelope. 
Multi-Centre Intensive Care outcome Study 
Heartlands Research Institute, 
I" Floor Lincoln House 
Heartlands Hospital 
Bordesley Green East 
B9 5SS 
0121424 2644 
Dear 
Dr lead clinician at Hospital, let me know about your admission 
to Intensive Care Unit in this year. My name is Dr Martin Wildman and I 
am the Co-ordinator of the Multi-Centre Intensive outcome Study that is currently 
being carried out in England and Wales. As wen as carrying out this study I work as a 
Doctor in intensive care and look after patients with chest problems. 
I am writing to you because we are trying to understand more about the health of 
people admitted to intensive care with breathing problems. In the envelope I have sent 
to you I have included a full explanation of the study and how you can help with it if 
you wish to do so. I have also explained that taking part is entirely up to you and if 
you choose not to take part that will not affect your future care in any way. 
If you do wish to take part, the information from the questionnaire will have your 
personal details removed and it will than be analysed with information from other 
people who have been admitted to intensive care, to help us understand more about 
how people get on after they have been admitted to intensive care. This will help us 
talk to patients in the future who might need intensive care to explain what is likely to 
happen if they are admitted. Dr sent us some details about how ill you were 
when you entered Intensive Care and these details have been coded at the study centre 
so that they are anonymous and the data that you send back to us will be joined with 
this information. 
Once you have returned this questionnaire we will not need to contact you again. 
However if you agree we may use this information held by the NES or records used 
by the General Register Office in order to follow up your health status. 
If you have any questions about the study you can contact the co-ordinating centre 
using the contact details at the head of this letter. 
With best wishes, 
Yours sincerely, 
Martin Wildman 
LGJ 
Multimcentre 
M Intensive Care 
outcome study 
This booklet contains 
questions to help us 
to understand 
how you feel today 
Suppofted by. 
C Study 
L, A0 
HHC 
COPD & Asthma Outcome Study Medical Research Council 
There are 4 pages of questions, including this one. 
Please answer the questions on each page 
Today's date is: 
ýILII 
ddmmYYYY 
Please choose one of the descriptions that best describes you today 
Fully mobile and living without assistance 
,I 
Able to live on your own and get out of the house to do basic 
necessities, but severely limited in how far you can walk EI 
Cannot get out of the house unassisted or get out of the house 
rarely, able to perform self-care but unable to do heavy chores such 
as house cleaning, cannot live alone without help LA 
Bed or chair bound 
Thinking back to your admission to intensive care, under the same 
circumstances, would you be willing to undergo similar intensive 
care treatment again. 
Thinking back to how you were before you became ill and had to be 
admitted to intensive care 6 months ago. Please choose the one 
description that best describes how you are now compared to 
how you were 6 months ago. 
Please tick (. /) 
ONE box only 
Yes No 
7 
L 
My health today is much worse than it was when I was at home 6 months ago. 
My health today is a little worse than it was when I was at home 6 months ago. 
My health today is about the same as it was when I was at home 6 months ago. 
My health today is a little better than it was when I was at home 6 months ago. 
My health today is much better than it was when I was at home 6 months ago. 
Please tick (. /) 
ONE box only 
LI 
LI 
Page 1 of 4 
YOUR OWN HEALTH STATE TODAY 
By placing a tick (V) in one box in each group of questions below, please indicate 
which statement best describes your own health today 
Mobility 
I have no problems in walking about 
I have some problems in walking about 
I am confined to bed 
Self-care 
I have no problems with self-care 
I have some problems washing and dressing myself 
I am unable to wash and dress myself 
Usual activities (e. g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual duties 
I have some problems with performing my usual duties 
I am unable to perform my usual duties 
Pain/Discomfort 
I have no pain or discomfort 
I have moderate pain or discomfort 
I have extreme pain or discomfort 
Anxiety/ Depression 
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
Paae 2 of 4 
YOUR OWN HEALTH STATE TODAY 
To help people say how good 
or bad a health state 'is, we 
have drawn a scale on which 
the best state you can 
imagine is marked 100 and 
the worst is marked at 0 
We would like you to indicate 
on the scale how good or 
bad your own health is today, 
in your opinion. Please do 
this by drawing a fine line 
from the box below to which 
ever point on the scale 
indicates how good or bad 
your health state is 
9 
7 
2 
0 
Page 3 of 4 
Please tick (*/) one box per question - If it does not apply to you please tick Not applicable) 
Yes No Not 
applicable 
1 Do you cough often during the day? L- 
2 Does your chest trouble often make you feel restless? El 
3 Does gardening make you breathless? II F-I 
F7 
4 Do you worry when going to a friend's house that there might L be something there that will upset your chest? l 
5 Do you get chest problems when you come 'into contact with 
ll h f k f 
- 1 El 1: 1 
strong sme s, ex aust umes, cigarette smo e, per ume etc? - 
6 Does your partner find your chest trouble upsetting? L 
1: 1 
7 Do you feel breathless when trying to sleep? ý-A 
El 
8 Do you worry about the long term effects of the drugs you 
take for your chest trouble? 
F-7 
9 Does getting emotionally upset make your chest trouble worse? 
10 Are there times when you have difficulty getting around 
the house because of your chest trouble? LJ LJ 
11 Does your chest problem make you breathless when you do 
things at work? (paid employment) 
12 Does walking upstairs make you breathless? 
13 Do you get breathless doing housework? 
14 Does your chest trouble make you go home sooner than 
others after a night out? 
15 Do you suffer from breathlessness when you laugh? 
16 Does your chest trouble often make you feel impatient? 
17 Do you think the fullness of your life is limited by your 
chest trouble? 
18 Do you feel drained after a cold because of your chest trouble? 
19 Do you have a feeling of chest heaviness? 
20 Do you worry a lot about your chest trouble? 
-: 
1 El El 
A 1: 1 El 
ý7 F-I 77 
El 
F-7 
El 1: 1 
El 1: 1 
You have now answered all the questions 
Please put the completed booklet into the FREEPOST envelope and post back 
to us, there is no need to add a stamp 
W9 
F-, 
W- 
Co 
1 
-4 s3- 
ti 
ICNARC 
Intensive Care National Audit & Research Centre 
CAOS tudy 
COPD & Asthma Outcome Study 
A study to understand the prognosis of 
patients, 45 years and older, admitted to 
critical care unit with respiratory failure due 
to an exacerbation of COPD or asthma 
Please complete a patient data booklet 
for all non-surgical patients, aged 45 
years or older, admitted to your critical 
care with respiratory failure due to an 
exacerbation of COPD or asthma as 
their major reason for admission 
Supported by 
[MFEDý 
LMC 
CAOS Co-ordinating Centre 
Mrs Jayne Groves (Research Nurse): 0121424 2644 
Dr Martin Wildman (Study Co-ordinator): 0121424 1631/Mobile: 07702 123764 
Centre fax number: 0121424 1634 
CAOS/PQ/1/202 
CAOS tudy 
COPD & Asthma Outcome Study 
Study overview 
1) When a patient aged 45 years or older is admitted to your critical care unit with breathlessness, respiratory 
failure or change in mental status due to an exacerbation of COPID or asthma as the major reason for 
admission they must be recruited. 
2) If the patient has had surgery in the past ten days they should be excluded. 
3) If the patient was transferred from another hospital they should be excluded. 
4) Odd pages 1 to 13 (light blue) of the data booklet collect information available at or before admission to your 
critical care unit . It is important that the first seven odd pages are faxed to the CAOS Co-ordinating Centre (0121 424 1634) within 24 hours of the patient's admission to your critical care. This will enrol the patient in 
the Study and allow us to validate CAOS data during their critical care stay. Information for all pages 
(except page 15, yellow) should be available within the first 24 hours. Don't worry if you have a few 
pieces of missing data, we will chase these with you once the pages are faxed to us. 
5) After faxing the pages and enrolling the patient, file the CAOS patient data booklet with the patient's notes 
and the CAOS team will contact you to complete data validation. 
6) At discharge from your critical care unit please give the patient a Patient Information Booklet and fax page 15 
(yellow) to the CAOS Co-ordinatiung Centre. 
7) Six weeks after the patient has been discharged from your critical care we will contact you once more to 
determine the patient's hospital outcome. 
8) At 180 days following admission to your critical care unit, and before sending the 180 day follow-up 
questionnaire, the CAOS Co-ordinating Centre will contact the patient's GP to ensure the patient is still alive. 
Data collection in CAOS 
0 
Deciding on the clinical diagnosis of COPD or asthma (Q 1,2 & 3) 
Patients to be included are those who are aged 45 or older, admitted with breathlessness, respiratory failure or a change 
in mental status due to an exacerbation of COPID or asthma. It may be difficult to be sure to what extent the patient has 
pure COPID or pure asthma. The criteria below are for guidance, however, in the absense of the previous investigations, 
we ask that clinicians make a clinical categorisation. 
0 Patients with COPID will have airway obstruction with an FEV, <80% predicted and an FEVNC ratio <70% which 
does not change markedly over many months. For the purposes of this study COPID includes emphysema. 
0 Patients with asthma will have episodic airway obstruction that can be restored towards normal with treatment. 
0 Patients with a mixture of COPID and asthma may have marked variability in airway obstruction superimposed on 
fixed irreversible airway narrowing 
1. CAOS m., idv 
COPD & Asthma Outcome Study 
SPECIAL NOTE 
Please fax odd pages 1 to 13 
(light blue) 
of this questionnaire to the 
CAOS Co-ordinating Centre 
Fax: 0121 424 1634 
within 24 hours of the patient's 
admission to your critical care unit 
2389 
CAOSttl('ý- 
COPD & Asthma Outcome Study 
Please complete a patient data booklet for ALL non-surgical patients aged 45 years or older admitted to critical care 
with respiratory failure due to exacerbation of COPD or asthma as the major reason for admission 
Full inclusion and exclusion criteria can be found at the CAOS website www. caos. lshtmýv_uk. For further advice contact 07702 123764 (241hourý; ) 
INCLUSION CRITERIA 
Ple, ýý, (, tick (. /) Y(-,, '(-), ONLY ONE oý (ilwtiorv, I ýo 
1 is the clinical diagnosis breathlessness, respiratory failure or change in mental - 
status due to an exacerbation of COPD? Yes Include 
2 is the clinical diagnosis breathlessness, respiratory failure or change in mental - 
status due to an exacerbation of asthma? ; Yes Include 
3 is the clinical diagnosis breathlessness, respiratory failure or change in mental 
status due to an exacerbation of a mixture COPD and asthma? Yes Include 
E XCLU S 10 N CRITE R IA (The patient CANNOT be entered if any of the boxes below are t icked) 
4 Is the patient below 45 years of age? Yes[] Exclude 
5 Has the patient had surgery in the past 10 days? Yes Exclude 
6 Has the patient been transferred from another hospital? Yes Exclude 
DATE AND TIME OF ADMISSION 
7 a) Date of admission to your hospital ddMMyyyy 
b) Time of admission to your hospital 
[=: [: ]= 
(24 hr clock) 
8 a) Date of admission to your critical care unit 
1-F 
/F- 
Cl dMMYYYY 
b) Time of admission to your critical care unit (24 hr clock) 
PATIENT DETAILS 
9 Family name: 
(or attach a label with these details) 
Given name: Sex: Male[] Female[-] 
Address : 
Postcode: Date of birth: 
F-P LLYIýM 
ddMMY i- -YY 
NHS Number: 
GP DETAILS 
10 GP Details: name: 
(or attach a label with these details) 
Address: 
Postcode: Telephone No.: 
CAOS/PQ/1/202 page 1 
Guidance Notes 
0 
1Q 11.3 
A clinical diagnosis of congestive cardiac failure should be made when it is thought to be 
contributing to the patient's current illness 
2Q 12.1-4 
The most senior doctor involved in making the decision to admit the patient to your critical care 
unit should complete this section as early as possible after admission so that predictions reflect 
the doctor's view at the time the decision to admit was made. 
0 
CAOS/PQ/1/202 page 
2389 
CAO S I'- COPD & Asthma Outcome SILId\ 
11.1 is the patient in atrial fibrillation? Yes:, No 
F- 
11.2 Is there any abnormal shadowing on the pre-critical care unit chest x-ray? Yes L- No7 
11.2.1 If abnormal shadowing is present, are there any old x-rays available at 
the time of admission to aid interpretation of admission chest x-ray? Yes I No Not applicable, 
11.2.2 What, in yourjudgement (at the time of admission to your critical care unit), 
is responsible for the abnormal chest x-ray shadowing? 
Not applicable 
F-1 
infection heart failure 
Ll 
combined heart failure and infection 
other 
11 
please specify: 
11.3 Does the patient have congestive cardiac failure as a contibutory cause for this deterioration'? Yes, ---- No,: 
] 
12.1 What is your probability of this patient surviving to leave your critical care Un it2? 
12.2 What is your probability of this patient surviving to leave your hospital? 
12.3 What is your probability of this patient surviving for 180 days? 
12.4 Indicate your prediction of the patient's quality of life at 180 days if the patient survives for: 180 days. 
1 )0 90 80 70 60 50 40 30 20 10 0 
Date: 
EII -1 (24 hours) Date and time of prediction: dd Time: L-LIFF 
Speciality of clinician making prediction: 
Grade of clinician making prediction: 
Name of clinician making prediction: 
CAOS/PQ/1/202 page 3 
Guidance Notes 
This information is designed to indicate what the patient was able to do before they 
became acutely unwell. 
Some patients may have been unwell for many months and may not report a recent 
period of stability. For these patients fill in the data sheet to describe the best that the 
patient has been in the 2 weeks prior to admission to your hospital. 
0 
0 
CAOS/PQ/1/202 page 
I 
FAX BACK: 0121 424 1634 Patient No.: 
CAOS'Lidy 
COPD & Asthma Outcome Study 
13 Functional Score 
Choose the ONE description that best describes the patient in the period of stability TWO WEEKS prior to 
admission to your hospital 
Fully mobile and living without assistance 
Able to live on their own and get out of the house to do basic 
necessities but severely limited in exercise ability 
Cannot get out of the house unassisted or gets out of the house rarely, able to perform self-care 
but unable to do heavy chores such as house cleaning, cannot live alone, may be institutionalised 
Bed or chair bound 
El 
information source (tick W) all that apply) Clinical record Patient 
DJ Other witness 
LI 
14 How would the patient have rated their quality 
of life in the period of stability two weeks prior 
to the admission to your hospital 
Information source (tick (. /) all that apply) 
F1 FI El E FE 
Excellent Very good Fair Poor very poor 
Clinical record Patient 
II 
Other witness 
CAOS/PQ/1/202 page 
Guidance Notes 
" This information is designed to indicate what the patient was able to do before they 
became acutely unwell. 
" Some patients may have been unwell for many months and may not report a recent 
period of stability. For these patients fill in the data sheet to describe the best that the 
patient has been in the 2 weeks prior to admission to your hospital . 
'QI 5 
Activities of Daily Living scale 
For each activity choose one description/description pair that best describes the patient's activity in the 
period of stability prior to admission to your hospital. 
CAOS/PQ/1/202 page 6 
2389 
CAOSifldý 
COPD & Asthma Outcome Study 
15 Activities of Daily Living scale 2 
Tick (. /) ONE box per activity that corresponds to the description(s) that best describes the patient in the period 
of stability TWO WEEKS prior to admission to your hospital. 
(The word "assistance" means supervision, direction or personal assistance) 
177 I Bathing Receives no assistance (gets in and out I F-I Receives assistance in bathing more 
(Either sponge of tub by self if tub is usual means of bathing) bath, tub bath, or than one part of the body 
shower) OR OR 
Receives assistance in bathing only not bathed 
one part of the body (such as back or leg) 
Dressing Gets clothes and gets completely 
17 
Receives assistance in getting dressed, 
(Gets clothes from dressed without assistance or stays partly or completely undressed. closets and drawers- 
including 
OR 
underclothes, outer Gets clothes and gets dressed garments and using 
fasteners and braces if without assistance except for 
worn) assistance in tying shoes. 
Toilleting Goes to "toilet room, " cleans self, Receives assistance in going to 
IGoing to the "toilet 
" and arranges clothes without "toilet room" or in cleansing self or in room for bowel and 
urine elimination, assistance arranging clothes after elimination or in 
cleaning self after (may use object for support such as cane, walker, use of night bedpan or commode. elimination, and 
arranging clothes. ) or wheelchair and may manage night bedpan or OR 
commode, emptying same in morning) Doesn't go to room termed "toilet" for 
the elimination process. 
Transfer Moves in and out of bed as well as in LJ Moves in and out of bed or chair with 
El 
and out of chair without assistance assistance. 
(may be using object for support such as OR 
cane or walker) Doesn't get out of bed. 
Continence ý -i Controls urination and bowel I Has occasional "accidents" 
-1 
movement completely by self. OR 
Supervision helps keep urine or bowel 
control; catheter is used, or is incontinent . 
Feeding Feeds self without assistance 
El 
Receives assistance in feeding or is fed 
OR partly or completely by using tubes or 
Feeds self except for getting assistance intravenous fluids 
in cutting meat or buttering bread. 
Information source (tick (. /) all that apply) Clinical recordEl Patient 
El Other witness 
CAOS/PQ/1/202 paqe 
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'Evidence to assess co-morbiclities 
Evidence to assess medical history can be from hospital case notes, doctors' or nurses' 
case note, GP case notes, information from patient, the patient's relatives, friends or GP. 
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_PAST 
MEDICAL HISTORY 
16 About the patient's past medical history 
is there any evidence' available to assess past medical history/co-morbidity? Yes No 
Co-morbiclity Def inition Pl(-ase tick V) one box fo! EACH condition Rtýsent Absent 
Myocardial infarction History of medically documented myocardial infarction 
11 E 
Congestive heart failure Has the patient ever been treated for heart failure? 
1: 1 El 
Peripheral vascular disease Intermittent claudication, peripheral artery bypass for insuff iciency 
d 6 El aneurysm (> cm) gangrene, acute arterial insufficiency, untreate 
Cerebrovascular disease 
h i l i 
History of transient ischaemic attack (TIA), or 
ll i h (except em p eg a) nor seque ae no or m Cerebrovascular accident (CVA) wit 
Herniplegia Diff iculty in moving an arm or leg as a result of a stroke El 
or Cerebrovascular accident 
Dementia Chronic cognitive defect 
L] El 
Chronic pulmonary disease Symptomatic dyspnoea due to chronic respiratory 
conditions (including asthma) 
Connective tissue disease SLE, polymyositis, mixed connective tissue disease, polymyalgia 
i i i h El r t s d art rheumatica, moderate to severe rheumato 
Peptic ulcer disease Patients who have required treatment for peptic ulcer disease 
El 
Mild liver disease Cirrhosis without portal hypertension, chronic hepatitis El [I 
Moderate or severe liver disease Cirrhosis with portal hypertension ± variceal bleeding 
1: 1 El 
Moderate or severe renal disease Creatinine greater than 265 pmol/l or dialysis or transplantation 'El 
0 
Diabetes (without complications) Diabetes treated with insulin or medicabon, but without complicabons 
11 El 
Diabetes with end organ damage Retinopathy or neuropathy or nephropathy El 
Ca ncer (non-metastatic) Any cancer other than haematological cancer or skin cancer, 
without metastasis initially treated in past 5 years. Exclude 
l ki non-me anomatous s n cancers and in situ cervical cancer 
Cancer (metastatic) Any cancer other than haernatological cancer or skin 
i h i El E cancer, w t metastas s l 
Leukaemia Chronic myeloid leukaemia (CIVIL), chronic lymphoid leukaemia 
(CLL), Acute myeloid leukaemia, (AML), Acute lymphoblastic 
l k i ALL l eu aem a( ), po ycythemia rubra vera (PV) 
Lymphoma, multiple myeloma Non-Hodgkin's lymphorna (NHQ, Hodgkin's, Waldenstroms 
l b li i l l macrog o u neam a, mu tip e myeloma 
AIDS 
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'Q17 
Inhaled steroids are often described by patients or their families as a brown or orange or purple inhaler. 
Inhaled steroids include: Beclomethasone, Aerobec, Asmabec, Beclazone, Becodisks, Becotide, 
Qvar, AeroBec Forte, Becloforte, Venticle, Budesonicle, Pulmicort, 
Symbicort, Flixotide, Sereticle. 
2QI8 
This question refers to patients who have been assessed for home oxygen and prescribed an oxygen 
concentrator. Please do NOT tick "yes" for patients who have cylinders at home that they use on an as 
required basis. 
Measuring mid-arm circumference 
Why are we asking you to measure mid-arm circumference? 
There is strong evidence that Body Mass Index (BMI) predicts outcome for COPID patients admitted to critical 
care units. 
Weight can be difficult to measure in very sick patients, so BMI may be difficult to measure reliably. 
mid-arm circumference provides a readily obtained surrogate for BMI and can be obtained on all patients. 
How to measure mid-arm circumference. 
(1) Use the non-dominant arm. For most of the 
population who are right handed this will be the 
left arm. 
(2) Finding the mid-point of the upper arm. 
a) Bend the arm to 900 with the palm facing 
downwards in order to locate the landmarks 
and mark the mid-point of the upper arm. 
b) Locate the tip of the shoulder. (This is the 
acromiom process. ) 
C) Locate the bony tip of the elbow. 
(This is the olecranon). 
d) Mark the mid-point between the tip of the 
shoulder and the bony tip of the elbow. 
(3) Measuring the mid-arm circumference 
a) Now straighten the arm again. 
b) Measure the circumference of the arm at the 
mid-point that you have just marked. 
Locating the mid-point of the upper arm 
Acromion II 
P ocess at 
hroulder ttip ti i 
v"-mid-point 
j 
Forearm, 
] 
palm down I I 
across body Y Ol ec ra non 
O pr c 
of u of u 
process 
of ulna 
Having located the mid-point, straighten the arm before measuring 
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0 
(continued) 
17 Was the patient taking inhaled steroids prior to admission to your hospital' YeS L --j 
Noý i Don't know 
2 18 Does the patient use home oxygen via a prescribed oxygen concentrator Yes No 
19 Has the patient required intubation and ventilation before? Yes 
L] 
No Number of times 
Information source (tick W) all that apply) Clinical record 
IL. 
-J 
Patient 
El 
Other witness 
El 
20 How long ago was the last episode of intubation and ventilation in months? months 
21 Please record the patent's most recent lung function. FEV, and date performed 
Not available 
1-1 
22 How many admissions to hospital with breathing problems has the patient had in 
the past 6 months, excluding the current admission? (Please use old notes, informants, GP) admissions 
Information source (tick (. /) all that apply) Clinical record 
11 
Patient Other witness 
E 
23 About the patient's smoking history 
23.1 Is the patient a current smoker 
an ex-smoker 
a 'never' smoker 
23.2 For current and ex-smokers please state: 
Yes No 
Yes 
L 
No 
F-I 
Yes! No 
F T, 
cigarettes per day 
E= 
years 
a) Average number of cigarettes smoked per day over the years as a smoker 
b) Approximate total number of years smoked 
0 
1 ABOUT THE PATIENT'S WEIGHT AND HEIGHT I 
24 Please tick (V) the response that best represents the patient's body weight today? 
very underweight 
E 
mildly underweight[-] normalweightEl mildly overweight 
LI 
very overweight[] 
25 Has the patient lost any weight in the past six months? Yes No L_j 
Weight loss lbs or 
=LJ 
kg 
Information source (tick (. /) all that apply) Clinical record 
El 
Patient Other witness 
11 
26 How tall is the patient? either 
E feet inches or cmS 
Please tick (. /): estimated measured 
El 
27 How much does the patient weigh? either 
D kg or 
=stones = lbs 
Please tick (. /): estimated 
11 
measureclF 
28 What is the patients left mid-arm circumference'? 
Ll 
cmS 
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Guidance Notes 
I) This page collects physiological and laboratory data to describe the patient's condition immediately before 
admission to your critical care unit and should document the highest and lowest values from the 24 hours 
preceding critical care unit admission. For some patients, these will be the data from the clerking carried out 
in casualty immediately prior to admission to your critical care Unit . 
2) Some patients may only have had urea and electrolytes measured in the 24hours prior to admission and in 
these cases please phone the laboratory to request albumin, glucose, and bilirubin. 
3) We recognise that some patients will only have one set of results to choose from, in that case please record 
them all in the lowest column. 
4) Some patients may be transferred directly from casualty to critical care. These patients will have been in 
hospital much less than 24 hours prior to critical care. For these patients record the data from the tests done 
after the patient reached hospital but before critical care admission. 
2Q 29.1 
FIO 2 approximations 
Conversion table for FIO 2 when measured on nasal cannula or mask 
Nasal 
cannula 
Face 
Mask 
Face mask I 
with reservoir 
bag 
-Venturr type 
face mask e. g. 
Ventimask 
Aerosol face mask I 0 15 litres min-1 2 
via nebuliser 
Litres 
min-1 
RO 2 Litres 
min-1 
RO 2 Litres RO 2 
min-1 
Set %1 RO 2 Set % RO 2 
1 0.22 2 0.25 6 0.6 24 0.24 35 0.28 
2 0.25 3 0.27 7 0.7 28 0.28 40 0.30 
3 0.27 4 0.30 8 0.8 35 0.35 70 0.50 
4 0.30 5 0.35 910.85 40 0.40 100 0.60 
5 0.35 6 0.40 10+ 0.9 60 0.60 
7 0.45 
8+ 0.50 
Table taken from appendix page 169 CMP data collection programme. The CMP manual has references supporting the table findings 
3Q 29.3 and 29.4 
Centrall/non-centrall temperature 
e Tympanic membrane, nasopharyngeal, oesophageal, rectal, pulmonary artery, bladder are considered as central 
temperature measurement sites. 
4Q 29.17 
Assessment of Glasgow coma scale 
o Use the notes or interview clinical staff involved in the patients' pre-critical care management to asses the 
patients worst Glasgow coma score prior to critical care admission. 
The best eye opening response The best verbal response 
Spontaneous 4 Orientated and converses 5 
To verbal command 3 Disorientated and converses 4 
To pain 2 Inappropriate words 3 
No response 1 Incomprehensible sounds 2 
The best motor response No response I 
Obeys verbal command 6 
Localises pain 5 If an admission is intubated, use clinical judgement to score 
Flexion withdrawal 4 verbal response as follows: 
Flexion-abnormal/clecorticate rigidity 3 Appears orientated 5 
Exten s io n/clecereb rate rigidity 2 Responsive but ability to converse questionable 3 
No response 1 Generally unresponsive 1 
5 Q30 
Oedema is considered to be present if gentle pressure with a finger to the leg, around the 
ankle, produces an indentation that persists when the finger is removed. 
0 
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Please record the data below that describes the patient's condition after admission to 
your hospital but before admission to your critical care unit 
29 Did the patient receive non-invasive ventilation elsewhere 
in your hospital prior to admission to your critical care unit? Yes No 
29.1 Most acidic gases in the 24 hours 
2 I . prior to critical care admission Highest H 
Lowest pH 
FIO 2% 
2 
paO 2 
Kpa or mmHg 
PaCO 
2 
Kpa or mmHg 
Actual bicarbonate mmol l-, 
Base excess W El* FTI_ *Please indicate +ve or -ve 
29.2 Blood pressure (recorasystoitcand Systo Iic Diastolic 
diastolic from reading with lowest diastolic) 
Lowest Highest 
29.3 Central temperature (oC)3 OC OC 
29.4 Non-central temperature (oC)3 
FTI 1: 1 
oc =Ecic 
29.5 Heart rates (beats min-') beats min-' beats min-' 
29.6 Non-ventilated respiratory rate (breaths min-1) 
LDI breaths min- 1 1 Ibreaths min-1 
, 
29.7 Haematocrit L% -] 
% =[L 
29.8 Haemoglobin (g dl-1) 
=F 
g dl-1 
=Elg dl-1 
29.9 White blood cell count (xi 091-1) F_F=x1oqr1 E= x 1091-1 
29.10 Serum sodium (mmo 1-1) FT7= mmo 1-1 mmo 1-1 
29.11 Serum potassium (mmol 1-1) 
=Emmol 1-1 mmol 1-1 
29.12 Serum creatinine (Pmol 1-1) 
F-=E 
pmol 1-1 L-Ipmol 1-1 
29.13 Urea (mmol 1-1) 11 T-1 1: 1 mmol 1-1 mmol 1-1 
29.14 Albumin (g 1-1) =L: lg ri g 1-1 
29.15 Bilirubin (pmol 1-1) Pmol 1-1 
F 
pmol 1-1 
29.16 Glucose (mmol 1-1) =EI mmol 1-1 
=EI 
mmol 1-1 
29.17 Glasgow coma scale 4 I_T7 
30 Does the patient have bilateral ankle oedema'? _7 Yes No . ___I 
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'Q31 
About non-invasive respiratory support during the stay in your critical care unit 
We are only collecting information about non-invasive ventilation used as 
EITHER the sole means of respiratory support in critical care 
OR the respiratory support preceding intubation on the first occasion the patient is intubated 
during the critical care stay 
NOTE 
We realise some patients will receive non-invasive ventilation following extubation. 
We are NOT collecting information about this. 
0 
. 
Q32.2 
Did the patient receive a tracheostomy during the stay in your critical care unit? 
Answer yes if the patient received a tracheostomy that was at any time used as the airway. 
Answer no if the patient either only received a mini-tracheostomy for clearing secretions or 
did not receive any form of tracheostomy. 
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SPECIAL NOTE 
Please fax page 15 (yellow) 
of this questionnaire to the 
CAOS Co-ordinating Centre 
Fax: 0121 424 1634 
ONLY when the patient leaves 
your critical care unit 
FAX BACK: 0121 424 1634 Patient No.: 
CAOS"!, A 
COPD & Asthma Outcome Study 
ABOUT THE PATIENT'S TIME IN YOUR CRITICAL CARE UNIT 
This page to be faxed to the CAOS Co-ordinating Centre when the patient is 
discharged from your critical care unit 
31 About non-invasive respiratory support during the stay in your critical care unit' 
These questions ask about non-invasive ventilation either as the sole means of respiratory support or as the 
means of respiratory support preceding the initial intubation 1. 
31.1 Was the non-invasive ventilation: 
a) Bilevel non-invasive ventilation ie a different level of support 
during inspiration from that delivered during expiration Yes. . No. 
Not applicable 
b) CPAP (delivered by face mask) i. e. a constant level of support 
delivered during both inspiration and the same constant 
level of support delivered during expiration Yes, No Not applicable 
c) A mixture of Bilevel non-invasive ventilation and CPAP 
(delivered by face mask) Yes No. Not applicable 
31.2 Did the patient receive non-invasive ventilation in critical 
care as the sole assisted means of ventilatory support? Yes No 
31.2.1 For patients receiving non-invasive ventilation as the sole means 
of ventilatory support would the patient have been intubated 
if non-invasive ventilation had not been successful ? Yes No Not applicable 
31.3 Did the patient receive non-invasive ventilation in critical 
care prior to intubation? Yes No 
31.4 Did the patient only receive medical treatment (eg intensive nebullser treatment etc) 
without either non-invasive ventilatory support or invasive support as the sole 
means of treatment whilst in the critical care unit? Yes No' 
32 About intubation 
32.1 Was the patient intubated at any time in the critical care stay? Yes No 
If Yes: 
:E (24 hours) a) what date and time was the patient intubated? 
L 
ddMMYYYY 
b) how many hours was the patient intubated for 
hours during the first intubation of this admission 
32.2 Did the patient receive a tracheostomy during the critical care stay 2 Yes No 
If Yes: on what date and time was the -1 -I-I-! 
(24 hours) tracheostomy performed? 
I ILL I 
ddMMYYYY 
Thank you 
Please fax odd pages 1 to 13 (light blue) of this questionnaire to the CAOS Co-ordinating Centre 
within 24 hours of the patient's admission to your critical care unit. 
AND 
page 15 (yellow) when the patient leaves your critical care unit 
COAS Co-ordinating Centre Fax: 0121424 1634 
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